STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 134605

TO: Jennifer Kim
Location: 4b02 / 4b18
Thursday, October 07, 2004
Art Unit: 1617
Phone: 272-0628
Serial Number: 10 / 673121

From: Jan Delaval
Location: Biotech-Chem Library
Rem 1A51
Phone: 272-2504

jan.delaval@uspto.gov

Search Notes

— Jan Retrieval —

Access DB# 134605

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Jennifer Kim Examiner #: 77469 Date: 10/6/04
Art Unit: 1617 Phone Number: 20628 Serial Number: 10/673121
Mail Box and Bldg Room Location: Cem 4B02 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Indazole derivatives as JNK inhibitors + composition + methods related thereto

Inventors (please provide full names): Bhagwat et al.

Earliest Priority Filing Date: 9/31/2000

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

1) Please search claim 22.

2) Please search the cpd → (need not reg. #)



for the treatment of cancer { or as an antiproliferative Agent. antineoplastic Agent. etc.

3) Display all the hit structure of cpd in claim #22 with a method of treating cancer.

THX,

JW

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: 3	NA Sequence (#)	STN ✓
Searcher Phone #: 32504	AA Sequence (#)	Dialog
Searcher Location:	Structure (#) ✓	Questel/Orbit
Date Searcher Picked Up: 10/7	Bibliographic	Lexis/Nexis
Date Completed: 10/7	Litigation	Sequence Systems
Searcher Prep & Review Time:	Fulltext	WWW/Internet
Clerical Prep Time: 20	Patent Family	Other (specify)
Online Time: +30	Other	

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4
DICTIONARY FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

```
=> d sta que l51
L1             1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (US20040077877 OR US2002010322
                  9)/PN
L2                SEL  PLU=ON  L1 1- RN :    1161 TERMS
L3          1161 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2
L4            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 AND N2C3-C6/ES AND NC5/ES
                  AND N2CNC/ES AND 46.150.18/RID
L5            27 SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND 5/NR
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND C22H24N6O
L7             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  C22H24N6O/MF AND 5/NR AND
                  N2C3-C6/ES AND NC5/ES AND N2CNC/ES AND 46.150.18/RID
L8             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7)
L13               STR
```



Cy @34








```
VAR G1=34/11/14/23/24/33
REP G2=(0-5) CH2
REP G3=(0-4) CH2
REP G4=(0-3) CH2
NODE ATTRIBUTES:
CONNECT IS M1  RC AT   6
CONNECT IS M1  RC AT  13
CONNECT IS M1  RC AT  17
CONNECT IS M1  RC AT  21
CONNECT IS M1  RC AT  27
CONNECT IS M1  RC AT  31
CONNECT IS M1  RC AT  34
```

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 7
NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE
L14 28038 SEA FILE=REGISTRY ABB=ON PLU=ON 333.161.31/RID
L15 49149 SEA FILE=REGISTRY ABB=ON PLU=ON N2C3-C6/ES
L16 49149 SEA FILE=REGISTRY ABB=ON PLU=ON (L14 OR L15)
L18 2354 SEA FILE=REGISTRY SUB=L16 CSS FUL L13
L19 675 SEA FILE=REGISTRY ABB=ON PLU=ON L3 AND L18
L20 1679 SEA FILE=REGISTRY ABB=ON PLU=ON L18 NOT (L19 OR L8)
L49 STR



CH2—G2—Cy
@11 12 13

CH═CH—G3—Cy
@14 15 16 17

Cy @34

CH2—G4—CH═CH—G3—Cy
@23 22 18 19 20 21

C≡C—G3—Cy
@24 25 26 27

CH2—G4—C≡C—G3—Cy
@33 32 28 29 30 31

VAR G1=34/11/14/23/24/33
REP G2=(0-5) CH2
REP G3=(0-4) CH2
REP G4=(0-3) CH2
NODE ATTRIBUTES:
CONNECT IS M3 RC AT 6
CONNECT IS M1 RC AT 13
CONNECT IS M1 RC AT 17
CONNECT IS M1 RC AT 21
CONNECT IS M1 RC AT 27
CONNECT IS M1 RC AT 31
CONNECT IS M1 RC AT 34
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 7
NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE
L51 1039 SEA FILE=REGISTRY SUB=L20 SSS FUL L49

100.0% PROCESSED 1679 ITERATIONS 1039 ANSWERS
SEARCH TIME: 00.00.01

=> d his

```
     (FILE 'HOME' ENTERED AT 14:36:39 ON 07 OCT 2004)
                SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 14:36:54 ON 07 OCT 2004
L1             1 S (US20040077877 OR US20020103229)/PN

     FILE 'REGISTRY' ENTERED AT 14:37:27 ON 07 OCT 2004

     FILE 'HCAPLUS' ENTERED AT 14:37:28 ON 07 OCT 2004
                SET SMARTSELECT ON
L2           SEL L1 1- RN :    1161 TERMS
                SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 14:37:28 ON 07 OCT 2004
L3          1161 S L2
L4            37 S L3 AND N2C3-C6/ES AND NC5/ES AND N2CNC/ES AND 46.150.18/RID
L5            27 S L4 AND 5/NR
L6             1 S L5 AND C22H24N6O
                E C2H24N6O/MF
                E C22H24N6O/MF
L7             1 S E3 AND 5/NR AND N2C3-C6/ES AND NC5/ES AND N2CNC/ES AND 46.150
L8             1 S L6,L7
                SEL RN
L9             0 S E1/CRN

     FILE 'HCAOLD' ENTERED AT 14:39:09 ON 07 OCT 2004
L10            0 S L8

     FILE 'USPATFULL, USPAT2' ENTERED AT 14:39:15 ON 07 OCT 2004
L11            3 S L8

     FILE 'HCAPLUS' ENTERED AT 14:39:18 ON 07 OCT 2004
L12            2 S L8

     FILE 'REGISTRY' ENTERED AT 14:39:33 ON 07 OCT 2004

     FILE 'USPATFULL, USPAT2' ENTERED AT 14:39:44 ON 07 OCT 2004

     FILE 'HCAPLUS' ENTERED AT 14:39:52 ON 07 OCT 2004

     FILE 'REGISTRY' ENTERED AT 14:40:15 ON 07 OCT 2004
L13              STR
                 E 333.161.31/RID
L14         28038 S E3
                 E N2C3-C6/ES
L15         49149 S E3
L16         49149 S L14,L15
L17            50 S L13 CSS SAM SUB=L16
L18          2354 S L13 CSS FUL SUB=L16
                 SAV L18 JKIM673/A
L19           675 S L3 AND L18
L20          1679 S L18 NOT L19,L8
L21           674 S L19 NOT L8

     FILE 'HCAPLUS' ENTERED AT 14:47:48 ON 07 OCT 2004
L22            52 S L21

     FILE 'REGISTRY' ENTERED AT 14:49:10 ON 07 OCT 2004
L23             3 S 155215-87-5 OR 289899-93-0 OR 291756-39-3
L24           103 S KINASE(L)PHOSPHORYLATING(L)C()JUN (L) N()TERMINAL (L) GENE
L25             8 S L24 NOT SQL/FA
L26             8 S L23,L25
```

```
     FILE 'HCAPLUS' ENTERED AT 14:50:13 ON 07 OCT 2004
L27          5990 S L26
L28             7 S L22 AND L27
L29           220 S L20
L30             2 S L27 AND L29
L31             8 S L28,L30

     FILE 'REGISTRY' ENTERED AT 14:51:02 ON 07 OCT 2004
L32            95 S L24 NOT L26

     FILE 'HCAPLUS' ENTERED AT 14:51:05 ON 07 OCT 2004
L33            49 S L32
L34             0 S L22 AND L33
L35             0 S L29 AND L33
L36             8 S L22,L29 AND JNK
L37             8 S L31,L36
L38             2 S L37 AND (PD<=20000731 OR PRD<=20000731 OR AD<=20000731)
L39             2 S L1,L38
L40           197 S L22,L29 AND (PD<=20000731 OR PRD<=20000731 OR AD<=20000731)
L41             8 S L21 (L) (THU OR PKT OR PAC OR DMA)/RL
L42            85 S L20 (L) (THU OR PKT OR PAC OR DMA)/RL
L43             2 S L41 AND L40
L44            49 S L42 AND L40
L45             2 S L39,L43
L46            45 S L44 AND P/DT
L47             9 S L46 AND US/PC.B
                  SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 14:58:26 ON 07 OCT 2004
L48            44 S E1-E44
L49               STR L13
L50            43 S L49 SAM SUB=L20
L51          1039 S L49 FUL SUB=L20
                  SAV L51 JKIM673A/A
                  SAV L19 JKIM673B/A
L52             0 S L48 AND L51

     FILE 'HCAPLUS' ENTERED AT 15:00:17 ON 07 OCT 2004
L53            82 S L51
L54            59 S L53 AND (PD<=20000731 OR PRD<=20000731 OR AD<=20000731)
L55            10 S L51 (L) (THU OR PAC OR PKT OR DMA)/RL AND L54
L56            29 S L54 AND (PHARMACEUT? OR PHARMACOL?)/SC,SX
L57            29 S L55,L56
                  SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 15:01:48 ON 07 OCT 2004
L58           204 S E45-E248
L59           204 S L58 AND L14

     FILE 'REGISTRY' ENTERED AT 15:02:30 ON 07 OCT 2004

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:02:43 ON 07 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>

=> d all fhitstr tot l45

L45 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:533982 HCAPLUS
DN 141:89085
ED Entered STN: 02 Jul 2004
TI Preparation of indazole derivatives as **JNK** enzyme inhibitors
IN Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.; Buhr, Chris A.; Albers, Ronald; Sapienza, John; Plantevin, Veronique; Chao, Qi; Sahasrabudhe, Kiran; Ferri, Rachel
PA USA
SO U.S. Pat. Appl. Publ., 275 pp., Cont.-in-part of U.S. Ser. No. 910,950.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-416
ICS C07D231-56
NCL 514406000; 548362100
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004127536	A1	20040701	US 2003-414839	20030416 <--
	US 2002103229	A1	20020801	US 2001-910950	20010723 <--
	US 2004077877	A1	20040422	US 2003-673121	20030926 <--
PRAI	US 2000-221799P	P	20000731	<--	
	US 2001-910950	A2	20010723		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004127536	ICM	A61K031-416
	ICS	C07D231-56
	NCL	514406000; 548362100
US 2004127536	ECLA	C07D231/56B; C07D405/14; C07D405/14; C07D409/04; C07D409/12; C07D409/14; C07D409/14; C07D413/04; C07D417/12; C07D401/04; C07D401/06; C07D401/12; C07D401/14; C07D; C07D403/04; C07D403/04; C07D403/04; C07D403/04; C07D403/06; C07D403/14; C07D405/04; C07D405/04; C07D040/12; C07D405/14 <--
US 2004077877	ECLA	C07D231/56B; C07D401/14; C07D401/14; C07D403/04; C07D403/04; C07D403/04; C07D403/04; C07D403/06; C07D403/14; C07D405/04; C07D405/12; C07D405/14; C07D405/1; C07D405/14; C07D409/04; C07D409/12; C07D409/14; C07D409/14; C07D413/04; C07D417/12; C07D401/04; C07D401/06; C07D401/12 <--

OS MARPAT 141:89085
GI



I

AB Indazole derivs. I [A = a bond, (CH2)a, (CH2)bCH:CH(CH2)c, (CH2)bC.tplbond.C(CH2)c; R1 = (un)substituted aryl, heteroaryl or heterocycle fused to Ph; R2 = R3, R4, (CH2)bC(O)R5, (CH2)bC(:O)OR5, (CH2)bC(O)NR5R6, (CH2)bC(O)NR5(CH2)cC(O)R6, (CH2)bNR5C(O)R6, (CH2)bNR5C(O)NR6R7, (CH2)bNR5R6, (CH2)bOR5, (CH2)bSOdR5 or (CH2)bSO2NR5R6; a = 1-6; b, c = 0-4; d = 0-2; R3 = halo, OH, CO2H, carboxy, etc.; R4 = (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, or R4 = halo or OH; R5-R7 = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl; with the provisos] having activity as selective inhibitors of **JNK**, are disclosed. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to **JNK** inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds. Many of the claimed compds. have IC50 values ≤0.5 μM in the JNK2 assay, e.g. 5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole. Although the methods of preparation are not claimed, >400 example prepns. are included.

ST indazole prepn Jun N terminal kinase **JNK** inhibitor antiinflammatory

IT AIDS (disease)
(AIDS dementia complex; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT Mental disorder
(AIDS dementia; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT Intestine, disease
(Crohn's; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Respiratory distress syndrome
(acute; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT Nose, disease
(allergic rhinitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Bronchi, disease
(bronchitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Lung, disease
(chronic obstructive; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Intestine, disease
(colitis, mucous; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Esophagus, disease
(esophagitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Obesity
(exogenous; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT Lung, disease
(fibrosis, treating pulmonary interstitial fibrosis; preparation of indazole

derivs. as **JNK** enzyme inhibitors)
IT Kidney, disease
Liver, disease
(fibrosis; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Drug delivery systems
(for indazole derivs. useful as **JNK** enzyme inhibitors)
IT Stomach, disease
(gastritis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Obesity
(genetic; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Intestine, disease
(inflammatory; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Reperfusion
(injury; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Diabetes mellitus
(insulin-dependent; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Intestine, disease
(irritable bowel syndrome; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Hearing
(loss; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Heterocyclic compounds
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nitrogen, five-membered, indazoles; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Diabetes mellitus
(non-insulin-dependent; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Ear, disease
(otitis media, treating acute otitis media; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Ear, disease
(otitis, otitis externa; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Pancreas, disease
(pancreatitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Peritoneum, disease
(peritonitis; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Allergy
Allergy inhibitors
Anti-inflammatory agents
Antiobesity agents
Asthma
Diabetes insipidus
Gout
Inflammation
Kidney, disease
Multiple sclerosis
Osteoarthritis
Rheumatoid arthritis
Wound healing
(preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Anti-ischemic agents
Antiarthritics

Antiasthmatics
Antidiabetic agents
Antirheumatic agents
(preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Burn
Cystic fibrosis
Dermatitis
Eczema
Lupus erythematosus
Psoriasis
Transplant rejection
(preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Shock (circulatory collapse)
(septic; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT Spinal column, disease
(spondylitis, rheumatoid; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Anti-AIDS agents
(treating AIDS dementia complex; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT Diabetes mellitus
(treating diabetes mellitus, malnutrition-related diabetes, ketosis-prone diabetes or ketosis-resistant diabetes; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT Obesity
(treating hormone related obesity or obesity related to the administration of medication; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT Intestine, disease
(ulcerative colitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT **716321-04-9P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(del b,sprepn. of indazole derivs. as **JNK** enzyme inhibitors)

IT **155215-87-5**, **JNK 289899-93-0**, JNK2
291756-39-3, JNK3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **293758-67-5P**, 5-Nitro-3-phenyl-1H-indazole **395099-05-5P**, 5-Amino-3-phenyl-1H-indazole **395099-16-8P**, Methyl 4-[N-(3-phenyl-1H-indazol-5-yl)carbamoyl]benzoate **395099-28-2P**, 3-(4-Methoxyphenyl)-5-nitro-1H-indazole **395099-32-8P**, 3-(3,4-Dimethoxyphenyl)-5-nitro-1H-indazole **395099-59-9P**, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid **395099-86-2P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-hydroxybenzamide **395099-88-4P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-pyridinecarboxamide **395099-89-5P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-pyridinecarboxamide **395100-10-4P**, 3-(4-Fluorophenyl)-1H-indazole-5-carboxylic acid **395100-21-7P**, Methyl 4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzoate **395100-32-0P**, 3-[[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]propanoic acid **395100-33-1P**, N-(3-Nitrophenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-76-2P**, N-(Phenylmethoxy)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-93-3P**, N-[(tert-Butoxy)carbonylamino]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-95-5P**, N-Amino-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395101-17-4P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(4-nitrophenyl)-4H-1,2,4-

triazole **395101-18-5P**, 1-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]-4-methoxybenzene **395101-19-6P**, Ethyl 2-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]acetate **395101-25-4P**, 3-(4-Fluorophenyl)-5-(2-phenylethynyl)-1H-indazole **395101-30-1P**, 5-((1E)-2-Phenylvinyl)-3-(4-fluorophenyl)-1H-indazole **395101-32-3P**, 5-[(1E)-2-(2-Pyridyl)vinyl]-3-(4-fluorophenyl)-1H-indazole **395101-36-7P**, 4-[(1E)-2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]vinyl]benzoic acid **395101-38-9P**, 5-[(1E)-2-(3-Nitrophenyl)vinyl]-3-(4-fluorophenyl)-1H-indazole **395101-52-7P**, Ethyl (2E)-3-[3-(4-fluorophenyl)-1H-indazol-5-yl]prop-2-enoate **395101-66-3P**, 3-(4-Methoxyphenyl)-1H-indazole-5-carboxamide **395101-72-1P**, 3-(4-Hydroxyphenyl)-1H-indazole-5-carboxamide **395101-78-7P**, 3-(2-Naphthyl)-1H-indazole-5-carboxamide **395101-82-3P**, Methyl 3-benzo[b]thiophen-2-yl-1H-indazole-5-carboxylate **395101-92-5P**, 3-(Benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395101-97-0P**, 3-[4-(Dimethylamino)phenyl]-1H-indazole-5-carboxamide **395102-02-0P**, 3-(2-Phenylethynyl)-1H-indazole-5-carboxamide **395102-08-6P**, 3-[4-[2-(Dimethylamino)ethoxy]phenyl]-1H-indazole-5-carboxamide **395102-09-7P**, 1-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-2-methoxybenzene **395102-46-2P**, 1-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-3-methoxybenzene **395103-58-9P**, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]ethan-1-one **395103-83-0P**, Ethyl 3-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propanoate **395104-41-3P 395107-78-5P** **395107-84-3P**, 3-(3-Quinolyl)-1H-indazole-5-carboxamide **395107-88-7P**, 3-(6-Methoxy-2-naphthyl)-1H-indazole-5-carboxamide
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 55-85-6P, N-Amino-2-(dimethylamino)acetamide 770-17-2P, N-Amino-2-(morpholin-4-yl)acetamide 2644-33-9P, N-Amino-2-(diethylamino)acetamide 7408-09-5P, N-Amino-2-piperidinoacetamide 22636-79-9P, N-Amino-3-(dimethylamino)propanamide 24534-93-8P, 3-Hydroxybutyric acid hydrazide 24632-72-2P, 2-(4-Acetylpiperazino)-N-aminoacetamide 37115-47-2P, N-Amino-2-(methylamino)acetamide 40598-94-5P, 3-Bromo-1H-indazole 59776-89-5P, N-Amino-2-(2-oxopyrrolidinyl)acetamide 66544-68-1P 67400-25-3P, 3-Bromo-5-nitro-1H-indazole 74626-47-4P, 1H-Indazole-5-carbonitrile 146137-79-3P, 4-Fluoro-3-formylbenzenecarbonitrile 395098-99-4P, 3-Bromo-1-[(2-methoxyethoxy)methyl]-1H-indazole 395099-00-0P, 1-[(2-Methoxyethoxy)methyl]-3-(4-methoxyphenyl)-1H-indazole 395099-02-2P, 1-[(2-Methoxyethoxy)methyl]-3-(2-methoxyphenyl)-1H-indazole 395099-03-3P, 3-(4-Fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazole 395099-07-7P, N-[2-(Phenylcarbonyl)-4-(phenylmethoxy)phenyl]benzamide 395099-09-9P, 2-Amino-5-(phenylmethoxy)phenyl phenyl ketone 395099-14-6P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)-2-pyridinecarboxamide 395099-17-9P, Methyl 4-[N-(1-acetyl-3-phenyl-1H-indazol-5-yl)carbamoyl]benzoate 395099-20-4P, 2-[N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)carbamoyl]phenyl acetate 395099-21-5P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)acetamide 395099-24-8P, N-[1-Acetyl-3-phenyl-1H-indazol-5-yl]-4-nitrobenzamide 395099-25-9P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)-4-aminobenzamide 395099-27-1P, N-[1-Acetyl-3-phenyl-1H-indazol-5-yl]-3-nitrobenzamide 395099-29-3P, 3-Bromo-1-[(2-methoxyethoxy)methyl]-5-nitro-1H-indazole 395099-30-6P, 1-[(2-Methoxyethoxy)methyl]-3-(4-methoxyphenyl)-5-nitro-1H-indazole 395099-33-9P, 3-(3,4-Dimethoxyphenyl)-1-[(2-methoxyethoxy)methyl]-5-nitro-1H-indazole 395099-35-1P, 1-[(2-Methoxyethoxy)methyl]-5-nitro-3-(3-nitrophenyl)-1H-indazole 395099-62-4P, Methyl 4-[N-[3-(4-fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazol-5-yl]carbamoyl]benzoate 395099-63-5P, Methyl 4-[N-[3-(4-fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazol-5-yl]-N-

methylcarbamoyl]benzoate 395099-66-8P, Methyl 3-[N-[3-(4-fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-72-6P, 4-Methoxy-1-[5-nitro-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzene 395099-74-8P, 3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-ylamine **395099-75-9P**, Methyl 4-[N-[3-(4-methoxyphenyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-76-0P, Methyl 4-[N-[3-(4-methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-78-2P, 2-[5-Nitro-3-(4-pyridyl)-1H-indazol-1-yl]perhydro-2H-pyran 395099-79-3P, 1-(Perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazol-5-ylamine 395099-80-6P, Methyl 4-[N-[1-(perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazol-5-yl]carbamoyl]benzoate **395099-81-7P**, Methyl 4-[N-[3-(4-pyridyl)-1H-indazol-5-yl]carbamoyl]benzoate 395100-00-2P, 1-Acetyl-3-(4-fluorophenyl)-1H-indazole-5-carbonyl chloride 395100-11-5P, 4-Fluoro-3-[(4-fluorophenyl)carbonyl]benzenecarbonitrile **395100-12-6P**, 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile 395100-39-7P, Methyl 4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoate **395100-41-1P**, Methyl 4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoate 395100-43-3P, N-(3-Nitrophenyl)-1-acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-48-8P 395100-52-4P, Methyl 4-[[[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]methyl]benzoate 395100-56-8P, N-(4-Pyridylmethyl)-1-acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-59-1P, Ethyl 2-[4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetate **395100-60-4P**, Ethyl 2-[4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetate **395100-66-0P**, N-[2-[(tert-Butoxy)carbonylamino]ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-69-3P**, N-[3-[(tert-Butoxy)carbonylamino]propyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-73-9P, tert-Butyl 4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]piperazine-1-carboxylate 395100-74-0P, 1-Acetyl-3-(4-fluorophenyl)-5-(1-piperazinylcarbonyl)-1H-indazole 395100-84-2P, 1-Acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxylic acid 395100-98-8P, tert-Butyl 3-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]propanoate 395101-04-9P, N-[(1-Iminoethyl)amino]-3-(4-fluorophenyl)indene-5-carboxamide **395101-06-1P**, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine hydrochloride 395101-26-5P, 2-Amino-5-bromo-4'-fluorobenzophenone **395101-27-6P**, 5-Bromo-3-(4-fluorophenyl)-1H-indazole 395101-28-7P, 5-Bromo-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-29-8P, 3-(4-Fluorophenyl)-5-(2-phenylethynyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-31-2P, 5-((1E)-2-Phenylvinyl)-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-34-5P, 5-[(1E)-2-(2-Pyridyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-37-8P, 4-[(1E)-2-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]vinyl]benzoic acid 395101-44-7P, 5-[(1E)-2-(4-Aminophenyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-46-9P, 5-[(1E)-2-(4-Pyridyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-50-5P, Ethyl (2E)-3-[3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]prop-2-enoate 395101-61-8P, 1-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-2-phenylethan-1-ol 395101-64-1P, 1-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-2-phenylethan-1-one 395101-67-4P, 3-Bromo-1H-indazole-5-carbonitrile 395101-69-6P, 3-Bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-70-9P, 3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395101-71-0P**, 3-(4-Methoxyphenyl)-1H-indazole-5-carbonitrile 395101-74-3P, 3-(4-Hydroxyphenyl)-1-perhydro-2H-pyran-2-yl-1H-indazole-5-carbonitrile **395101-77-6P**, 3-(4-Hydroxyphenyl)-1H-indazole-5-carbonitrile 395101-79-8P, 3-(2-Naphthyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395101-80-1P**, 3-(2-Naphthyl)-1H-indazole-5-carbonitrile 395101-84-5P, 3-Bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide

395101-85-6P, 3-Benzo[b]thiophen-2-yl-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395101-89-0P, 3-Benzo[b]thiophen-2-yl-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395101-91-4P**, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carbonitrile 395101-94-7P, 3-(Benzo[d]furan-2-yl)-1-perhydro-2H-pyran-2-yl-1H-indazole-5-carbonitrile **395101-95-8P**, 3-(Benzo[d]furan-2-yl)-1H-indazole-5-carbonitrile 395101-98-1P, 3-[4-(Dimethylamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-00-8P**, 3-[4-(Dimethylamino)phenyl]-1H-indazole-5-carbonitrile 395102-04-2P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-phenylethynyl)-1H-indazole-5-carbonitrile **395102-06-4P**, 3-(2-Phenylethynyl)-1H-indazole-5-carbonitrile 395102-11-1P, 3-(2-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-12-2P**, 3-(2-Methoxyphenyl)-1H-indazole-5-carbonitrile 395102-14-4P, 3-((1E)-2-Phenylvinyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-15-5P**, 3-((1E)-2-Phenylvinyl)-1H-indazole-5-carbonitrile 395102-19-9P, 1-(Perhydro-2H-pyran-2-yl)-3-(3-pyridyl)-1H-indazole-5-carbonitrile **395102-20-2P**, 3-(3-Pyridyl)-1H-indazole-5-carbonitrile 395102-22-4P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-thienyl)-1H-indazole-5-carbonitrile 395102-24-6P, 3-[4-Isopropylphenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-27-9P, 3-(2-Furyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-29-1P, 3-(3-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-31-5P, 3-(2H-Benzo[d]-1,3-dioxolan-5-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-32-6P**, 3-(2H-Benzo[d]-1,3-dioxolan-5-yl)-1H-indazole-5-carbonitrile 395102-34-8P, 1-(Perhydro-2H-pyran-2-yl)-3-(3-thienyl)-1H-indazole-5-carbonitrile 395102-38-2P, 3-[4-(2-Methylpropoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-40-6P**, 3-[4-(2-Methylpropoxy)phenyl]-1H-indazole-5-carbonitrile 395102-44-0P, 3-(4-Chlorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-47-3P, 3-(3-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-50-8P, 1-(Perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazole-5-carbonitrile 395102-60-0P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-phenylethyl)-1H-indazole-5-carbonitrile 395102-75-7P, 3-(1-Naphthyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-77-9P**, 3-(1-Naphthyl)-1H-indazole-5-carbonitrile **395102-79-1P**, 3-(1-Naphthyl)-1H-indazole-5-carboxamide 395102-89-3P, 3-(3,4-Dichlorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-96-2P, (2E)-2-Aza-3-(dimethylamino)-1-[3-bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]prop-2-en-1-one 395102-97-3P, 2-[5-(1H-1,2,4-Triazol-3-yl)-3-bromo-1H-indazol-1-yl]perhydro-2H-pyran 395102-98-4P 395102-99-5P, 2-[3-(4-Methylphenyl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-03-4P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenylamine 395103-09-0P, 1-[(1E)-2-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]vinyl]-4-methoxybenzene 395103-13-6P, 2-[3-[(1E)-2-(4-Chlorophenyl)vinyl]-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-17-0P, 4-Methylthio-1-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzene 395103-19-2P, 2-[3-[(1E)-2-(4-Methylphenyl)vinyl]-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-23-8P, 5-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane 395103-31-8P, (Methylsulfonyl)[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]amine 395103-35-2P, 2-Methoxy-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395103-40-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395103-42-1P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-44-3P,

N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395103-52-3P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-3-bromo-1H-indazolyl]perhydro-2H-pyran 395103-53-4P, 2-[3-Bromo-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazolyl]perhydro-2H-pyran 395103-54-5P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazol-3-yl]phenylamine 395103-56-7P, 2-Methoxy-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazol-3-yl]phenyl]acetamide 395103-60-3P, 1-[3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]ethan-1-one **395103-65-8P**, 3-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]-1H-indazole-5-carbonitrile 395103-71-6P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395103-73-8P, 3-(3,4-Dimethoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395103-74-9P**, 3-(3,4-Dimethoxyphenyl)-1H-indazole-5-carbonitrile 395103-77-2P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-(1-piperidyl)propanamide 395103-80-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-82-9P, 3-(3-Hydroxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395103-87-4P, Ethyl 3-(N-aminocarbamoyl)propanoate 395103-88-5P, Ethyl 4-(N-aminocarbamoyl)butanoate 395103-92-1P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-methoxypropanamide 395103-94-3P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazole-3-yl]phenyl]-3-pyridinecarboxamide 395103-98-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide **395104-11-7P**, 3-[4-[3-(Dimethylamino)propoxy]phenyl]-1H-indazole-5-carbonitrile **395104-14-0P**, 3-[3-[3-(Dimethylamino)propoxy]phenyl]-1H-indazole-5-carbonitrile 395104-16-2P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenol **395104-26-4P**, 3-[4-[2-(Dimethylamino)ethoxy]phenyl]-1H-indazole-5-carbonitrile **395104-34-4P**, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(2-piperazinoethoxy)benzene 395104-50-4P, 4-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenylamine 395104-53-7P, Methyl 3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzoate 395104-55-9P, N-Benzyl-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-61-7P 395104-65-1P, N-(2,2-Dimethylpropyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-68-4P, N-(Cyclopropylmethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-72-0P, N-(3-Pyridylmethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-76-4P, N-[(4-Fluorophenyl)methyl]-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-78-6P, N-(Indan-2-yl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-81-1P, N-((1R)-Indanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-83-3P, N-((1S)-Indanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-85-5P, N-((1S,2R)-2-Hydroxyindanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazole-3-yl]benzamide 395104-87-7P, N-((1R,2S)-2-Hydroxyindanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-89-9P, N-(1-Methyl-1-phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-91-3P, N-(tert-Butyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazole-3-yl]benzamide 395104-93-5P, N-((1R)-1-Phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-94-6P, N-((1S)-1-Phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide

395104-96-8P, Isoindolin-2-yl 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl ketone 395105-01-8P, Ethyl 3-(benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylate 395105-03-0P, 3-(Benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylic acid 395105-04-1P, N-Isopropyl-3-(benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-13-2P, N-Amino-2-(4-hydroxypiperidyl)acetamide 395105-17-6P, (1S)-1-[N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-20-1P, 1-(Perhydro-2H-pyran-2-yl)-3-[3-(3-pyridylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-22-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-piperidylpropanamide 395105-25-6P, 1-[N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-27-8P, 3-(3-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-28-9P, 3-[3-(2-Methoxyacetamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-30-3P, tert-Butyl 4-[N-[3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]piperidine-1-carboxylate 395105-31-4P, tert-Butyl 4-[N-[3-(5-carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)phenyl]carbamoyl]piperidine-1-carboxylate 395105-33-6P, (1S)-1-[N-[3-[5-Carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-35-8P, 3-[3-[(2-Methoxyethyl)amino]phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-37-0P, 1-(Perhydro-2H-pyran-2-yl)-3-[3-(3-piperidylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395105-39-2P, 3-[3-(2-Furylcarbonylamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-41-6P, 2-(Dimethylamino)-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-44-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]butanamide 395105-46-1P, (2E)-N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-phenylprop-2-enamide 395105-48-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395105-51-8P, 3-[3-[2-(Dimethylamino)acetylamino]phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-54-1P, 3,3-Dimethyl-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]butanamide 395105-56-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]cyclopropanecarboxamide 395105-58-5P, 2-(Indol-3-yl)-2-oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-61-0P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-6-chloro-3-pyridinecarboxamide 395105-64-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]cyclopentanecarboxamide 395105-66-5P, Methyl[N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]formate 395105-69-8P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]benzo[b]thiophene-2-carboxamide 395105-72-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-pyridinecarboxamide 395105-74-5P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-furancarboxamide 395105-76-7P, [N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]phenylmethyl acetate 395105-79-0P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]isoxazole-5-carboxamide **395105-81-4P**, N-((1S)-1-Phenylethyl)-3-[5-(1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395105-82-5P, 2-(2-Furyl)-2-oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-84-7P, 2-Oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-

(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395105-86-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]pentanamide 395105-88-1P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-4-pyridinecarboxamide 395105-91-6P, 2-Cyclohexyl-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-93-8P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-phenylpropanamide 395105-95-0P, 2-(4-Fluorophenyl)-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-97-2P **395106-03-3P**, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine 395106-23-7P, N-Amino-2-(dimethylamino)propanamide 395106-25-9P, (1R)-[N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]phenylmethyl acetate **395106-27-1P**, (2R)-N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide hydrochloride 395106-31-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide **395106-32-8P**, N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide hydrochloride **395106-36-2P** 395106-38-4P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-methylbutanamide **395106-39-5P**, N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide hydrochloride 395106-70-4P, 3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395106-71-5P, 3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395106-79-3P, N-[(4-Fluorophenyl)methyl]-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-80-6P, N-[(4-Fluorophenyl)methyl]-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-82-8P, N-(tert-Butyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-83-9P, N-(tert-Butyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenylcarboxamide 395106-85-1P, N-((1R)-Indanyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-86-2P, N-((1R)-Indanyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-88-4P, [[3-[3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-91-9P, [[3-[3-(2H-Benzo[d]-1,3-dioxol-5-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-94-2P, [3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl](hydroxyimino)methylamine 395106-96-4P, 2-Amino-1-aza-2-[3-(4-fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]vinyl ethoxyformate 395106-97-5P, 3-[3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1,2,4-oxadiazolin-5-one **395106-99-7P**, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl](phenylmethoxy)methane 395107-03-6P, N-(2-Piperidinoethyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-05-8P**, N-(2-Piperidinoethyl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide trihydrochloride 395107-08-1P **395107-11-6P**, N-Phenyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 395107-13-8P, N-(4-Fluorophenyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-15-0P**, N-(4-Fluorophenyl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-17-2P, N-(Indan-2-yl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-18-3P**, N-(Indan-2-yl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride

395107-20-7P, N-Cyclopropyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-22-9P**, N-Cyclopropyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-25-2P, N-Cyclobutyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-26-3P**, N-Cyclobutyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-28-5P, 3-(4-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395107-29-6P, N-[4-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395107-30-9P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]-3-(2-methoxyethoxy)benzene 395107-46-7P, Methyl 3-(5-carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoate **395107-80-9P** 395107-86-5P, 3-(1,1-Dimethyl-1-stannaethyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395107-90-1P**, 3-(6-Methoxy-2-naphthyl)-1H-indazole-5-carbonitrile **395107-96-7P**, 3-(2,3-Dihydrobenzo[b]furan-5-yl)-1H-indazole-5-carbonitrile **395108-15-3P**, Ethoxy[3-(6-methoxy-2-naphthyl)-1H-indazol-5-yl]methanimine **395108-20-0P**, N-Phenyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide 395108-21-1P, N-Phenyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395108-24-4P** **395108-25-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **395100-29-5P**, tert-Butyl 3-[[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]propanoate
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **57614-16-1P**, 5-Methyl-3-phenyl-1H-indazole **57614-63-8P**, 5-Fluoro-3-phenyl-1H-indazole **395099-04-4P**, 3-Phenyl-5-trifluoromethyl-1H-indazole **395099-06-6P**, 3-Phenyl-5-(phenylmethoxy)-1H-indazole **395099-10-2P**, 3-Phenyl-1H-indazol-5-ol **395099-11-3P**, N-(3-Phenyl-1H-indazol-5-yl)benzamide **395099-12-4P**, N-(3-Phenyl-1H-indazol-5-yl)-2-pyridinecarboxamide **395099-18-0P**, 4-[N-(3-Phenyl-1H-indazol-5-yl)carbamoyl]benzoic acid **395099-19-1P**, N-(3-Phenyl-1H-indazol-5-yl)-2-Hydroxybenzamide **395099-22-6P**, N-[3-Phenyl-1H-indazol-5-yl]acetamide **395099-23-7P**, N-(3-Phenyl-1H-indazol-5-yl)-4-aminobenzamide **395099-26-0P**, N-(3-Phenyl-1H-indazol-5-yl)-3-aminobenzamide **395099-31-7P**, 5-Nitro-3-[3-(trifluoromethyl)phenyl]-1H-indazole **395099-34-0P**, 5-Nitro-3-(3-nitrophenyl)-1H-indazole **395099-36-2P**, 3-(1-Naphthyl)-5-nitro-1H-indazole **395099-37-3P**, 3-(2-Naphthyl)-5-nitro-1H-indazole **395099-38-4P**, 3-(5-Nitro-1H-indazol-3-yl)furan **395099-39-5P**, 3-Ethoxy-1-(5-nitro-1H-indazol-3-yl)benzene **395099-40-8P**, 3-[3-Isopropylphenyl]-5-nitro-1H-indazole **395099-41-9P**, 3-[4-Isopropylphenyl]-5-nitro-1H-indazole **395099-42-0P**, 5-Nitro-3-(3-phenylphenyl)-1H-indazole **395099-43-1P**, 5-Nitro-3-(4-phenylphenyl)-1H-indazole **395099-45-3P**, 5-Amino-3-(3,4-dimethoxyphenyl)-1H-indazole mono(trifluoroacetate) **395099-46-4P**, 5-Amino-3-(4-methoxyphenyl)-1H-indazole monohydrochloride **395099-47-5P**, 3-[3-(Trifluoromethyl)phenyl]-1H-indazol-5-ylamine **395099-48-6P**, 3-(4-Fluorophenyl)-1H-indazol-5-ylamine **395099-50-0P**, Ethyl[3-(4-fluorophenyl)-1H-indazol-5-yl]amine **395099-51-1P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methylbenzamide **395099-53-3P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methoxybenzamide **395099-54-4P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-phenylbenzamide **395099-55-5P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]benzo[b]thiophene-2-carboxamide **395099-56-6P**, [3-(4-Fluorophenyl)-1H-indazol-5-

yl](phenylsulfonyl)amine **395099-57-7P**, Methyl
4-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoate
395099-58-8P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-
pyridinecarboxamide **395099-60-2P**, N-[3-(4-Fluorophenyl)-1H-
indazol-5-yl]cyclopropanecarboxamide **395099-61-3P**, Methyl
4-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]-N-methylcarbamoyl]benzoate
395099-64-6P, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-N-
methylcarbamoyl]benzoic acid **395099-65-7P**, Methyl
3-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoate
395099-68-0P, 3-[N-[3-(4-Fluorophenyl)-1H-indazol-5-
yl]carbamoyl]benzoic acid **395099-69-1P**, N-[3-(4-Fluorophenyl)-1H-
indazol-5-yl]-4-(N-methylcarbamoyl)benzamide **395099-70-4P**,
4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzamide
395099-71-5P, 4-[N-[3-(4-Methoxyphenyl)-1H-indazol-5-
yl]carbamoyl]benzoic acid **395099-77-1P**, 4-[N-(3-(4-Pyridyl)-1H-
indazol-5-yl)carbamoyl]benzoic acid **395099-82-8P**,
N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]benzamide **395099-83-9P**,
N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3,5-Bis(trifluoromethyl)benzamide
395099-84-0P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-
furancarboxamide **395099-85-1P 395099-87-3P**,
[2-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]phenyl]methyl benzoate
395099-90-8P, [3-(4-Fluorophenyl)-1H-indazol-5-yl](4-
pyridylmethyl)amine **395099-91-9P**, [3-(4-Fluorophenyl)-1H-indazol-
5-yl](3-pyridylmethyl)amine **395099-92-0P**, N-[3-(4-Fluorophenyl)-
1H-indazol-5-yl]-2-thiophenecarboxamide **395099-94-2P**,
N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]morpholine-4-carboxamide
395099-96-4P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl][(4-
fluorophenyl)amino]carboxamide **395099-99-7P**,
3-(4-Fluorophenyl)-1H-indazole-5-carboxamide **395100-02-4P**,
5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole
395100-04-6P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-
triazole **395100-06-8P**, 3-(4-Fluorophenyl)-5-imidazol-2-yl-1H-
indazole **395100-08-0P**, 3-(4-Fluorophenyl)-5-pyrazol-3-yl-1H-
indazole **395100-13-7P**, Ethyl 3-(4-fluorophenyl)-1H-indazole-5-
carboxylate **395100-14-8P**, 5-Benzimidazol-2-yl-3-(4-fluorophenyl)-
1H-indazole **395100-16-0P**, N-Phenyl-3-(4-fluorophenyl)-1H-
indazole-5-carboxamide **395100-18-2P**, N-[2-(Dimethylamino)ethyl]-
3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-19-3P**, Ethyl
1-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]piperidine-4-carboxylate
395100-22-8P, 4-[[3-(4-Fluorophenyl)-1H-indazol-5-
yl]carbonylamino]benzoic acid **395100-23-9P**, 4-[[3-(4-
Fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzamide **395100-25-1P**
, 1-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonyl]piperidine-4-
carboxylicaci **395100-26-2P**, N-(2-Pyridyl)-3-(4-fluorophenyl)-1H-
indazole-5-carboxamide **395100-27-3P**, N-(3-Pyridyl)-3-(4-
fluorophenyl)-1H-indazole-5-carboxamide **395100-28-4P**,
N-(4-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide
395100-30-8P, N-(3-Hydroxyphenyl)-3-(4-fluorophenyl)-1H-indazole-5-
carboxamide **395100-35-3P 395100-37-5P**,
4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoic acid
395100-42-2P, N-(3-Aminophenyl)-3-(4-fluorophenyl)-1H-indazole-5-
carboxamide **395100-44-4P**, 2-[[3-(4-Fluorophenyl)-1H-indazol-5-
yl]carbonylamino]acetic acid **395100-46-6P**, 5-[[3-(4-
Fluorophenyl)-1H-indazol-5-yl]carbonylamino]pentanoic acid
395100-50-2P, 4-[[[3-(4-Fluorophenyl)-1H-indazol-5-
yl]carbonylamino]methyl]benzoic acid **395100-54-6P**,
N-(4-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide
395100-58-0P, 2-[4-[[3-(4-Fluorophenyl)-1H-indazol-5-
yl]carbonylamino]phenyl]acetic acid **395100-62-6P**,
N,N-Dimethyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide
395100-63-7P, N-Methyl-3-(4-fluorophenyl)-1H-indazole-5-
carboxamide **395100-65-9P**, N-(2-Aminoethyl)-3-(4-fluorophenyl)-1H-
indazole-5-carboxamide **395100-68-2P**, N-(3-Aminopropyl)-3-(4-

fluorophenyl)-1H-indazole-5-carboxamide **395100-70-6P**, 3-(4-Fluorophenyl)-1H-indazol-5-yl 1-pyrrolidinyl ketone **395100-72-8P**, 3-(4-Fluorophenyl)-1H-indazol-5-yl 1-piperazinyl ketone **395100-78-4P**, N-(2-Hydroxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-79-5P**, 3-(4-Fluorophenyl)-1H-indazole-5-carbohydroxamic acid **395100-81-9P**, N-(2H-1,2,3,4-Tetrazol-5-yl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-83-1P**, N-(3-(Morpholin-4-yl)propyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-86-4P**, N-(3-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-88-6P** **395100-89-7P**, N-[2-(1-Methylimidazol-5-yl)ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-91-1P**, N-(2-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-97-7P**, N-(2-Carbamoylethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395101-00-5P**, N-(3-Carbamoylpropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395101-02-7P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-methyl-4H-1,2,4-triazole **395101-05-0P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-isopropyl-4H-1,2,4-triazole **395101-07-2P**, 1-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propan-2-ol **395101-10-7P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-phenyl-4H-1,2,4-triazole **395101-12-9P**, 2-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]furan **395101-13-0P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(4-pyridyl)-4H-1,2,4-triazole **395101-14-1P**, 3-(4-Chlorophenyl)-5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazole **395101-15-2P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-propyl-4H-1,2,4-triazole **395101-20-9P**, 4-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]phenylamine **395101-21-0P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-benzyl-4H-1,2,4-triazole **395101-23-2P**, 2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-phenyl-1,3,4-oxadiazole **395101-24-3P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methyl-1,3,4-oxadiazole **395101-40-3P**, 5-((1Z)-2-Phenylvinyl)-3-(4-fluorophenyl)-1H-indazole **395101-42-5P**, 5-[(1E)-2-(4-Aminophenyl)vinyl]-3-(4-fluorophenyl)-1H-indazole **395101-45-8P**, 5-[(1E)-2-(4-Pyridyl)vinyl]-3-(4-fluorophenyl)-1H-indazole **395101-48-1P**, (2E)-3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]prop-2-enoic acid **395101-53-8P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]propanoic acid **395101-55-0P**, 5-[2-(3-Aminophenyl)ethyl]-3-(4-fluorophenyl)-1H-indazole **395101-57-2P**, 4-[2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]ethyl]benzoic acid **395101-58-3P**, 3-(4-Fluorophenyl)-5-[2-(2-pyridyl)ethyl]-1H-indazole **395101-59-4P** , 3-(4-Fluorophenyl)-5-(2-phenylethyl)-1H-indazole **395101-60-7P**, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-phenylethan-1-ol **395101-62-9P**, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-phenylethan-1-one **395101-86-7P**, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxylic acid **395101-88-9P**, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxamide **395101-96-9P**, 3-[3-Isopropylphenyl]-1H-indazole-5-carboxamide **395102-01-9P**, 3-(3-Furyl)-1H-indazole-5-carboxamide **395102-13-3P**, 5-[3-((1E)-2-Phenylvinyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-17-7P**, 5-[3-(3-Pyridyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-21-3P**, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]thiophene **395102-23-5P**, 5-[3-[4-Isopropylphenyl]-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-26-8P**, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]furan **395102-28-0P**, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenylamine **395102-30-4P**, 5-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane **395102-33-7P**, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]thiophene **395102-35-9P**, 5-[3-(2-Naphthyl)-1H-indazol-5-yl]-1H-1,2,3,4-tetrazole **395102-36-0P**, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-methoxybenzene **395102-37-1P**, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-(2-

methylpropoxy)benzene **395102-42-8P**, 5-[3-(4-Chlorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-48-4P**, 5-[3-(4-Pyridyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-52-0P**, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]benzo[b]furan **395102-55-3P**, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenol **395102-56-4P**, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenol **395102-57-5P**, 5-[3-(2-Phenylethynyl)-1H-indazol-5-yl]-1H-1,2,3,4-tetrazole **395102-59-7P**, 5-[3-(2-Phenylethyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-61-1P**, 5-[3-[3-Isopropylphenyl]-1H-indazol-5-yl]-1H-1,2,4-triazole **395102-63-3P**, 4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenol **395102-64-4P**, [4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl]dimethylamine **395102-66-6P**, 3-[3-((E)-2-Phenylvinyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395102-68-8P**, [2-[4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine **395102-70-2P**, 3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]furan **395102-72-4P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-methoxybenzene **395102-73-5P**, 5-(3-(1-Naphthyl)-1H-indazol-5-yl)-1H-1,2,4-triazole **395102-80-4P**, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]thiophene **395102-83-7P**, 5-[3-(2-Naphthyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395102-85-9P**, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenylamine **395102-87-1P**, 3-[3-(3,4-Dichlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395102-91-7P**, 3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzo[b]thiophene **395102-95-1P**, 3-[3-(4-Methylphenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-01-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]acetamide **395103-05-6P**, 5-[3-(3-Chlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-07-8P**, 1-[(1E)-2-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]vinyl]-4-methoxybenzene **395103-11-4P**, 3-[3-[(1E)-2-(4-Chlorophenyl)vinyl]-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-15-8P**, 2-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzo[b]furan **395103-16-9P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-(methylsulfonyl)benzene **395103-18-1P**, 3-[3-[(1E)-2-(4-Methylphenyl)vinyl]-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-20-5P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-(methylsulfinyl)benzene **395103-21-6P**, 5-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane **395103-25-0P**, 4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenylamine **395103-27-2P**, 5-[3-[4-(Trifluoromethyl)phenyl]-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-29-4P**, [3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl](methylsulfonyl)amine **395103-33-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide **395103-37-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenylacetamide **395103-41-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide **395103-43-2P**, 5-[3-(2-Phenylethynyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-45-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395103-46-5P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(3-pyridyl)-4H-1,2,4-triazole **395103-47-6P**, 4-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]phenol **395103-48-7P**, 2-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]aceticaci **395103-50-1P**, 1-[5-[3-(4-Fluorophenyl)1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]ethan-1-ol **395103-51-2P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide **395103-61-4P**, 2-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]benzo[b]thiophene **395103-63-6P**, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-(2-(morpholin-4-yl)ethoxy)benzene **395103-67-0P**, 4-[3-(4-Fluorophenyl)-1H-indazol-5-yl]pyrimidine-2-ylamine **395103-69-2P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide **395103-72-7P**, 3-(3,4-Dimethoxyphenyl)-1H-indazole-5-carboxamide

395103-76-1P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-(1-piperidyl)propanamide **395103-78-3P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide **395103-81-8P**, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene **395103-85-2P**, Ethyl 4-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]butanoate **395103-90-9P**, 4-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-1,2-dimethoxybenzene **395103-91-0P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-methoxypropanamide **395103-93-2P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395103-96-5P**, 3-(3-Aminophenyl)-1H-indazole-5-carboxamide **395104-02-6P**, 3-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propanoic acid **395104-04-8P**, 3-[2H-Benzo[d]-1,3-dioxol-5-yl]-1H-indazole-5-carboxamide **395104-06-0P**, 5-Methyl-3-(4-fluorophenyl)-1H-indazole **395104-09-3P**, [3-[4-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine trifluoroacetate **395104-13-9P**, [3-[3-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine trifluoroacetate **395104-15-1P**, [3-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine **395104-19-5P**, [2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine **395104-21-9P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene **395104-24-2P**, [2-[3-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine mono(trifluoroacetate) **395104-28-6P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-pyrrolidinoethoxy)benzene 395104-30-0P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene **395104-32-2P**, 1-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]pyrrolidin-2-one **395104-35-5P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperazinylethoxy)benzene bis(trifluoroacetate) **395104-37-7P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(3-piperidinopropoxy)benzene **395104-38-8P**, 4-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]-1-acetylpiperazine **395104-43-5P**, 2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethylamine mono(trifluoroacetate) **395104-45-7P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-cyclohexylethoxy)benzene **395104-47-9P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-hexahydroazepinoethoxy)benzene **395104-49-1P**, N-[4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide **395104-51-5P**, N-Benzyl-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-57-1P**, N-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]acetamide **395104-59-3P**, 5-[3-(2-Chlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395104-63-9P**, N-(2,2-Dimethylpropyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-67-3P**, N-(Cyclopropylmethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-70-8P**, N-(3-Pyridylmethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-74-2P**, [3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl] 4-methyl-1-piperazinyl ketone **395104-75-3P**, N-[(4-Fluorophenyl)methyl]-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-77-5P**, N-(Indan-2-yl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-79-7P**, N-((1R)-1-Indanyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-82-2P**, N-((1S)-Indanyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-84-4P**, N-((1S,2R)-2-Hydroxyindanyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-86-6P**, N-((2S,1R)-2-Hydroxyindanyl)3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-88-8P**, N-(1-Methyl-1-phenylethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-90-2P**, N-(tert-Butyl)-3-[5-(1H-1,2,4-triazol-

5-yl)-1H-indazol-3-yl]benzamide **395104-92-4P**, N-((1R)-1-Phenylethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-95-7P**, [3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl] isoindolin-2-yl ketone **395104-97-9P**, N-[2-(Dimethylamino)ethyl]-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-98-0P**, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]amine **395104-99-1P**, [[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]methyl]dimethylamine **395105-00-7P**, N-Isopropyl-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-05-2P**, N-(2-Methoxyethyl)-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-06-3P**, N-[2-(Dimethylamino)ethyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-07-4P**, N-[4-(Dimethylamino)butyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-08-5P**, N-[3-(Dimethylamino)propyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-10-9P**, N-(2-Methylpropyl)-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-11-0P**, N-Methyl-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-12-1P**, 1-[[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]methyl]piperidin-4-ol

RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **395105-14-3P**, 1-Acetyl-4-[[5-[3-(4-fluorophenyl)-1H-indazol-5-yl](4H-1,2,4-triazol-3-yl)]methyl]piperazine **395105-15-4P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-(2S)-2-hydroxypropanamide **395105-16-5P**, (1S)-1-[N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate **395105-19-8P**, 3-[3-(3-Pyridylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395105-21-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-piperidylpropanamide **395105-23-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-hydroxypropanamide **395105-26-7P**, 3-[3-(2-Methoxyacetylamino)phenyl]-1H-indazole-5-carboxamide **395105-29-0P**, 3-[3-(4-Piperidylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395105-32-5P**, (1S)-1-[N-[3-(5-Carbamoyl-1H-indazol-3-yl)phenyl]carbamoyl]ethyl acetate **395105-34-7P**, 3-[3-[(2-Methoxyethyl)amino]phenyl]-1H-indazole-5-carboxamide **395105-36-9P**, 3-[3-(3-Piperidylpropanoylamino)phenyl]-1H-indazole-5-carboxamide **395105-38-1P**, 3-[3-(2-Furylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395105-40-5P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(dimethylamino)acetamide **395105-43-8P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]butanamide **395105-45-0P**, (2E)-N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-phenylprop-2-enamide **395105-47-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide **395105-50-7P**, 3-[3-[2-(Dimethylamino)acetylamino]phenyl]-1H-indazole-5-carboxamide **395105-53-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide **395105-55-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]cyclopropanecarboxamide **395105-57-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-indol-3-yl-2-oxoacetamide **395105-59-6P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-6-chloro-3-pyridinecarboxamide **395105-63-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]cyclopentanecarboxamide **395105-65-4P**, [N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]carbamoyl]formic acid **395105-68-7P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]benzo[b]thiophen-2-carboxamide **395105-71-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-pyridinecarboxamide **395105-73-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-furancarboxamide **395105-75-6P**,

N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide **395105-78-9P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]isoxazole-5-carboxamide **395105-80-3P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(2-furyl)-2-oxoacetamide **395105-83-6P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-oxo-2-phenylacetamide **395105-85-8P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]pentanamide **395105-87-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-pyridinecarboxamide **395105-90-5P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-cyclohexylacetamide **395105-92-7P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-phenylpropanamide **395105-94-9P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(4-fluorophenyl)acetamide **395105-96-1P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-(2R)-2-hydroxy-2-phenylacetamide **395105-98-3P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-(2S)-2-hydroxy-2-phenylacetamide **395106-01-1P**, [2-[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl](1H-1,2,4-triazol-5-yl)]ethyl]dimethylamine **395106-04-4P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-(piperidinomethyl)-1H-1,2,4-triazole **395106-12-4P**, Diethyl[[3-[3-(4-fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]amine **395106-13-5P**, 4-[[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]morpholine **395106-16-8P**, 4-[[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1,3,4-oxadiazol-2-yl]methyl]morpholine **395106-17-9P**, 1-[[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]pyrrolidin-2-one **395106-20-4P**, [[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]methylamine **395106-21-5P**, [1-[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]ethyl]dimethylamine **395106-24-8P**, (2R)-N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide **395106-29-3P**, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide **395106-34-0P** **395106-35-1P**, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-methylbutanamide **395106-37-3P**, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395106-40-8P**, 3-[3-(2-Phenylacetylamino)phenyl]-1H-indazole-5-carboxamide **395106-41-9P**, 3-[3-[2-(4-Methoxyphenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-43-1P**, 3-[3-[2-(2-Methyl-1,3-thiazol-5-yl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-46-4P**, 3-[3-(Oxolan-3-ylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395106-48-6P**, 3-[3-[2-(3-Thienyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-50-0P**, 3-[3-(2-Thienylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395106-51-1P**, 3-[3-[2-(4-Pyridyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-52-2P**, 3-[3-[2-(2-Pyridyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-54-4P**, 3-[3-[2-(4-Fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-55-5P**, 3-[3-(Cyclopropylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395106-56-6P**, 3-[3-[(3-Hydroxyphenyl)carbonylamino]phenyl]-1H-indazole-5-carboxamide **395106-57-7P**, 3-[3-[2-(2,4-Dichlorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-58-8P**, 3-[3-[2-[4-(Trifluoromethyl)phenyl]acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-59-9P**, 3-[3-[2-[4-(Dimethylamino)phenyl]acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-60-2P**, 3-[3-[2-(2-Chloro-4-fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-62-4P**, 3-[3-[2-(4-Chlorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-63-5P**, 3-[3-(3-Phenylpropanoylamino)phenyl]-1H-indazole-5-carboxamide **395106-64-6P**, 3-[3-[3-(4-Fluorophenyl)propanoylamino]phenyl]-1H-indazole-5-carboxamide

395106-65-7P, 3-[3-[2-(3,4-Difluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-66-8P**, 3-[3-[2-(2-Fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-68-0P**, 3-[3-(2-Phenylpropanoylamino)phenyl]-1H-indazole-5-carboxamide **395106-69-1P**, 3-[3-(2-Piperidinoethoxy)phenyl]-1H-indazole-5-carboxamide **395106-73-7P**, N-Ethyl-3-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]propanamide **395106-74-8P**, N-[(4-Fluorophenyl)methyl]-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide **395106-81-7P**, N-tert-Butyl-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide **395106-84-0P**, N-((1R)-Indanyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide **395106-87-3P**, [[3-[3-(4-Methoxyphenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine **395106-90-8P**, [[3-[3-(2H-Benzo[d]-1,3-dioxol-5-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine **395106-92-0P**, N-(3-Methoxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395106-93-1P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1,2,4-oxadiazolin-5-one **395106-98-6P**, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]methan-1-ol **395107-01-4P**, N-(2-Piperidinoethyl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide **395107-07-0P**, [[5-[3-(Benzo[d]furan-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]methyl]dimethylamine **395107-09-2P**, N-Phenyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide **395107-12-7P**, N-(4-Fluorophenyl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide dihydrochloride **395107-16-1P**, N-(Indan-2-yl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide **395107-19-4P**, N-Cyclopropyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide **395107-24-1P**, N-Cyclobutyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide dihydrochloride **395107-27-4P**, N-[4-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395107-32-1P**, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(2-methoxyethoxy)benzene **395107-33-2P**, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(3-pyridylmethoxy)benzene **395107-34-3P**, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]benzoic acid **395107-35-4P**, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395107-36-5P**, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenylacetamide **395107-37-6P**, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide **395107-38-7P**, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(dimethylamino)acetamide **395107-39-8P**, [4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl](methylsulfonyl)amine **395107-40-1P**, N-(2-Methoxyethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-42-3P**, N-Phenyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-43-4P**, N-(2-Phenethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-44-5P**, N-(2-Piperidylethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-45-6P**, 3-[3-[N-(2-Piperidinoethyl)carbamoyl]phenyl]-1H-indazole-5-carboxamide **395107-47-8P**, N-[2-(Morpholin-4-yl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-48-9P**, N-Cyclohexyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-49-0P**, N-Cyclopentyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-51-4P**, N-(4-Fluorophenyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-53-6P**, N-[2-(1-Benzyl-4-piperidyl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-55-8P 395107-57-0P**, N-Cyclopropyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-59-2P**, N-(3-Pyridyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-61-6P**, N-(5,6,7,8-Tetrahydronaphthyl)-3-[5-(1H-1,2,4-

triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-63-8P**, N-[1-Benzyl-4-piperidyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-65-0P**, N-[1-Benzylpyrrolidin-3-yl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-67-2P**, N-Isopropyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-69-4P**, N-Cyclobutyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-70-7P**, N-(4-Pyridyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-72-9P**, N-(2-Hydroxyethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395107-73-0P**, N-(3-Hydroxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395107-74-1P**, N-(2-Methoxyethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395107-76-3P**, N-[(Oxolan-2-yl)methyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395107-82-1P** **395107-91-2P**, 6-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-2-methoxynaphthalene **395107-92-3P**, 3-[3-(3-Quinolyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395107-94-5P**, 3-[2,3-Dihydrobenzo[b]furan-5-yl]-1H-indazole-5-carboxamide **395107-98-9P**, 5-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-2,3-dihydrobenzo[b]furan **395107-99-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]benzamide **395108-01-7P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2,4-dichlorobenzamide **395108-03-9P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-methoxybenzamide **395108-05-1P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-methylbenzamide **395108-06-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-chlorobenzamide **395108-07-3P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methylpropanamide **395108-08-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-methylbutanamide **395108-10-8P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(morpholin-4-yl)acetamide **395108-11-9P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(4-methylpiperazino)acetamide **395108-12-0P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-[(4-pyrrolidinopiperidino)methyl]-1H-1,2,4-triazole **395108-14-2P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole **395108-16-4P**, [[3-[3-(6-Methoxy-2-naphthyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine **395108-17-5P**, 2-Methoxy-6-[5-[5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]naphthalene **395108-19-7P**, N-Phenyl-3-[5-[5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide **395108-23-3P** **395108-26-6P**, N-(3-Oxo-3-pyrrolidinopropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395108-28-8P**, 3-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]-N-methylpropanamide **395108-29-9P**, 3-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]-N,N-dimethylpropanamide **395108-30-2P** **716320-95-5P** **716320-96-6P** **716320-98-8P** **716320-99-9P** **716321-00-5P** **716321-01-6P** **716321-02-7P** **716321-03-8P** **716321-05-0P** **716321-06-1P** **716321-07-2P** **716321-08-3P** **716321-09-4P** **716321-10-7P** **716321-11-8P** **716321-12-9P** **716321-13-0P** **716321-14-1P** **716321-15-2P** **716321-16-3P** **716321-17-4P** **716321-18-5P** **716321-19-6P** **716321-20-9P** **716321-21-0P** **716321-22-1P** **716321-23-2P** **716321-24-3P** **716321-25-4P** **716321-26-5P** **716321-27-6P** **716321-28-7P** **716321-29-8P** **716321-30-1P** **716321-31-2P** **716321-32-3P** **716321-33-4P** **716321-34-5P** **716321-35-6P** **716321-36-7P** **716321-37-8P** **716321-38-9P** **716321-39-0P** **716321-40-3P** **716321-41-4P** **716321-42-5P** **716321-43-6P** **716321-44-7P** **716321-45-8P** **716321-46-9P** **716321-47-0P** **716321-48-1P** **716321-49-2P** **716321-50-5P** **716321-51-6P**

716321-52-7P 716321-53-8P 716321-54-9P
716321-55-0P 716321-56-1P 716321-57-2P
716321-58-3P 716321-59-4P 716321-60-7P
716321-61-8P 716321-62-9P 716321-63-0P
716321-64-1P 716321-65-2P 716321-66-3P
716321-67-4P 716321-68-5P 716321-69-6P
716321-70-9P 716321-71-0P 716321-72-1P
716321-73-2P 716321-74-3P 716321-75-4P **716321-76-5P**
716321-77-6P 716321-78-7P 716321-79-8P
716321-80-1P 716321-81-2P 716321-82-3P
716321-83-4P 716321-84-5P 716321-85-6P
716321-86-7P 716321-87-8P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **716321-88-9P 716321-89-0P 716321-90-3P**
716321-91-4P 716321-92-5P 716321-93-6P
716321-94-7P 716321-95-8P 716321-96-9P
716321-97-0P 716321-98-1P 716321-99-2P
716322-00-8P 716322-01-9P 716322-02-0P
716322-03-1P 716322-04-2P 716322-05-3P
716322-06-4P 716322-07-5P 716322-08-6P
716322-09-7P 716322-10-0P 716322-11-1P
716322-12-2P 716322-13-3P 716322-14-4P
716322-15-5P 716322-16-6P 716322-17-7P
716322-18-8P 716322-19-9P 716322-20-2P
716322-21-3P 716322-22-4P 716322-23-5P
716322-24-6P 716322-25-7P 716322-26-8P
716322-27-9P 716322-28-0P 716322-29-1P
716322-30-4P 716322-31-5P 716322-32-6P
716322-33-7P 716322-34-8P 716322-35-9P
716322-36-0P 716322-37-1P 716322-38-2P
716322-39-3P 716322-40-6P 716322-41-7P
716322-42-8P 716322-43-9P 716322-44-0P
716322-45-1P 716322-46-2P 716322-47-3P
716322-48-4P 716322-49-5P 716322-50-8P
716322-51-9P 716322-52-0P 716322-53-1P
716322-54-2P 716322-55-3P 716322-56-4P
716322-57-5P 716322-62-2P 716322-63-3P
716322-64-4P 716322-65-5P 716322-66-6P
716322-67-7P 716322-68-8P 716322-69-9P
716322-70-2P 716322-71-3P 716322-72-4P
716322-73-5P 716322-76-8P 716322-77-9P
716322-78-0P 716322-79-1P 716322-80-4P
716322-81-5P 716322-82-6P 716322-83-7P
716322-84-8P 716322-85-9P 716322-86-0P
716322-87-1P 716322-88-2P 716322-89-3P
716322-90-6P 716322-91-7P 716322-92-8P
716322-93-9P 716322-94-0P 716322-95-1P
716322-96-2P 716322-97-3P 716322-98-4P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 556-24-1 595-37-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 5856-77-9P 24310-18-7P **716320-97-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **13097-01-3P**, 3-Phenyl-1H-indazole **55271-06-2P**,

3-(4-Methoxyphenyl)-1H-indazole **155590-27-5P**,
3-(4-Fluorophenyl)-1H-indazole **395098-98-3P**,
3-(4-Hydroxyphenyl)-1H-indazole **395099-01-1P**,
3-(2-Methoxyphenyl)-1H-indazole
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 54-85-3, Isonicotinic acid hydrazide 64-04-0, Phenethylamine 67-51-6, 3,5-Dimethylpyrazole 75-31-0, Isopropylamine, reactions 75-64-9, tert-Butylamine, reactions 76-83-5, Triphenylmethyl chloride 78-77-3, 1-Bromo-2-methylpropane 78-81-9, Isobutylamine 78-96-6, 1-Amino-2-propanol 79-30-1, 2-Methylpropanoyl chloride 88-74-4, 2-Nitroaniline 89-75-8, 2,4-Dichlorobenzoyl chloride 96-32-2, Methyl bromoacetate 98-09-9, Phenylsulfonyl chloride 98-88-4, Benzoyl chloride 99-06-9, 3-Hydroxybenzoic acid, reactions 99-09-2, 3-Nitroaniline 100-07-2, 4-Methoxybenzoyl chloride 100-20-9, Terephthalic acid chloride 100-42-5, Styrene, reactions 100-43-6, 4-Vinylpyridine 100-55-0, 3-Pyridylcarbinol 100-69-6, 2-Vinylpyridine 103-80-0, Phenylacetyl chloride 103-82-2, Phenylacetic acid, reactions 104-01-8, 4-Methoxyphenylacetic acid 104-58-5, 3-Piperidinopropanol 106-40-1, 4-Bromoaniline 108-00-9, N,N-Dimethylethylenediamine 108-01-0, N,N-Dimethylethanolamine 108-12-3, 3-Methylbutanoyl chloride 108-91-8, Cyclohexylamine, reactions 109-01-3, N-Methylpiperazine 109-55-7, 3-Dimethylaminopropylamine 109-85-3, 2-Methoxyethylamine 121-90-4, 3-Nitrobenzoyl chloride 122-01-0, 4-Chlorobenzoyl chloride 122-04-3 122-78-1, Phenylacetaldehyde 123-00-2, 4-(3-Aminopropyl)morpholine 123-75-1, Pyrrolidine, reactions 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl acrylate 141-75-3, Butanoyl chloride 142-26-7, 2-N-Acetylaminoethanol 156-87-6, 3-Amino-1-propanol 271-44-3, 1H-Indazole 342-24-5, 2-Fluorobenzophenone 371-40-4, 4-Fluoroaniline 403-43-0, 4-Fluorobenzoyl chloride 405-50-5, 2-(4-Fluorophenyl)acetic acid 451-82-1, 2-Fluorophenylacetic acid 459-31-4, 3-(4-Fluorophenyl)propanoic acid 462-08-8, 3-Aminopyridine 488-93-7, Furan-3-carboxylic acid 492-37-5, 2-Phenylpropionic acid 496-12-8, Isoindoline 501-52-0, Hydrocinnamic acid 504-24-5, 4-Aminopyridine 504-29-0, 2-Aminopyridine 527-69-5, 2-Furoyl chloride 527-72-0, 2-Thiophenecarboxylic acid 535-17-1, 2-Acetoxypropionic acid 536-40-3, 4-Chlorobenzoic hydrazide 536-74-3, Phenylacetylene 547-64-8, Methyl lactate 553-53-7, Nicotinic hydrazide 585-32-0, Cumylamine 586-39-0, 3-Nitrostyrene 591-27-5, 3-Aminophenol 611-73-4, 2-Oxo-2-phenylacetic acid 613-94-5, Benzoic hydrazide 619-45-4, Methyl 4-aminobenzoate 622-40-2, 4-(2-Hydroxyethyl)morpholine 636-97-5, 4-Nitrobenzoic hydrazide 638-29-9, Pentanoyl chloride 644-42-8, 3-Methylhistamine 645-45-4, 3-Phenylpropanoyl chloride 658-93-5, 3,4-Difluorophenylacetic acid 661-69-8, Hexamethylditin 765-30-0, Cyclopropylamine 785-56-8, 3,5-Bis(trifluoromethyl)benzoyl chloride 870-46-2, tert-Butyl carbazate 874-60-2, 4-Methylbenzoyl chloride 937-39-3, Phenylacetic hydrazide 940-31-8, 2-Phenoxypropionic acid 1003-03-8, Cyclopentylamine 1075-49-6, 4-Vinylbenzoic acid 1126-09-6, Ethyl 4-piperidinecarboxylate 1194-02-1, 4-Fluorobenzonitrile 1195-45-5, 4-Fluorophenyl isocyanate 1423-26-3, 3-Trifluoromethylphenylboronic acid 1467-70-5, 2-(2-Furyl)-2-oxoacetic acid 1520-21-4, 4-Vinylaniline 1679-18-1, 4-Chlorophenylboronic acid 1679-64-7, Terephthalic acid monomethyl ester 1692-15-5, 4-Pyridylboronic acid 1692-25-7, 3-Pyridylboronic acid 1759-53-1, Cyclopropanecarboxylic acid 1765-93-1, 4-Fluorophenylboronic acid 1877-71-0, Isophthalic acid monomethyl ester 1986-47-6, trans-2-Phenylcyclopropylamine hydrochloride 2008-75-5, 1-(2-Chloroethyl)piperidine monohydrochloride 2038-03-1, 4-(2-Aminoethyl)morpholine 2133-40-6 2208-07-3, Ethyl acetimidate hydrochloride 2217-40-5, 1,2,3,4-Tetrahydro-1-naphthylamine 2338-18-3, 2-Aminoindan hydrochloride 2491-06-7, N,N-Dimethylglycine hydrochloride 2516-34-9, Cyclobutylamine 2516-47-4, Cyclopropylmethylamine 2544-06-1, 3-Methoxypropionic acid 2627-86-3, (S)-(-)-α-

Methylbenzylamine 2835-68-9, 4-Aminobenzamide 2955-88-6, 2-Pyrrolidinoethanol 2975-41-9, 2-Aminoindane 3024-72-4, 3,4-Dichlorobenzoyl chloride 3040-44-6, 2-Piperidinoethanol 3179-63-3, 3-N,N-Dimethylaminopropanol 3290-99-1, 4-Methoxybenzhydrazide 3326-71-4, 2-Furoic acid hydrazide 3445-11-2, 1-(2-Hydroxyethyl)pyrrolidin-2-one 3529-10-0, 4-Dimethylaminobutylamine 3538-65-6, Butyric acid hydrazide 3619-17-8, Isobutyric acid hydrazide 3731-51-9, 2-Aminomethylpyridine 3731-52-0, 3-Aminomethylpyridine 3731-53-1, 4-(Aminomethyl)pyridine 3853-06-3, Methyl 3-(dimethylamino)propanoate 3886-69-9, (R)-(+)-α-Methylbenzylamine 3900-89-8, 2-Chlorophenylboronic acid 3970-21-6, (2-Methoxyethoxy)methyl chloride 4023-34-1, Cyclopropylcarbonyl chloride 4442-79-9, 2-(Cyclohexyl)ethanol 4524-93-0, Cyclopentanecarbonyl chloride 4795-29-3, Tetrahydrofurfurylamine 5122-94-1, 4-Phenylphenylboronic acid 5122-95-2, 3-Phenylphenylboronic acid 5271-67-0, 2-Thiophenecarbonyl chloride 5292-21-7, 2-Cyclohexylacetic acid 5332-24-1, 3-Bromoquinoline 5332-73-0, 3-Methoxypropylamine 5382-16-1, 4-Hydroxypiperidine 5401-94-5, 5-Nitro-1H-indazole 5405-41-4, Ethyl 3-hydroxybutyrate 5438-70-0, Ethyl (4-aminophenyl)acetate 5445-17-0, Methyl 2-bromopropanoate 5538-51-2, Acetyl salicyloyl chloride 5691-09-8, trans-2-Aminomethyl-1-cyclohexanol 5720-05-8, 4-Methylphenylboronic acid 5720-06-9, 2-Methoxyphenylboronic acid 5720-07-0, 4-Methoxyphenylboronic acid 5781-53-3, Methyl (chlorocarbonyl)formate 5813-64-9, 2,2-Dimethylpropylamine 6034-46-4, (S)-(-)-2-Acetoxypropionic acid 6165-68-0, 2-Thiopheneboronic acid 6165-69-1, 3-Thiopheneboronic acid 6456-74-2, tert-Butyl glycinate 6482-24-2, 2-Bromo-1-methoxyethane 6622-91-9, 4-Pyridylacetic acid hydrochloride 6783-05-7, trans-2-Phenylethenylboronic acid 6964-21-2, 3-Thiopheneacetic acid 7065-46-5, 3,3-Dimethylbutanoyl chloride 7171-96-2, N-Amino-2-pyrrolidinoacetamide 7322-88-5, (2S)-2-Acetyloxy-2-phenylacetic acid 7377-26-6, Methyl 4-carboxybenzoyl chloride 10277-74-4, (R)-(-)-1-Aminoindane 10365-98-7, 3-Methoxyphenylboronic acid 10400-19-8, Pyridine-3-carbonyl chloride 13031-60-2, Methyl 4-aminobutyrate hydrochloride 13331-23-2, 2-Furanboronic acid 13331-27-6, 3-Nitrophenylboronic acid 13515-93-0, Methyl 2-(methylamino)acetate hydrochloride 13797-62-1, 2-(2-Methyl-1,3-thiazol-4-yl)acetic acid 13889-98-0, 1-Acetylpiperazine 13922-41-3, 1-Naphthylboronic acid 14002-51-8, 4-Phenylbenzoyl chloride 14794-31-1, Ethyl succinyl chloride 15159-40-7, Morpholine-4-carbonyl chloride 16152-51-5, 4-Isopropylphenylboronic acid 16179-97-8, 2-Pyridylacetic acid hydrochloride 17078-28-3, 4-(Dimethylamino)phenylacetic acid 17082-09-6, (2E)-3-Phenylprop-2-enoyl chloride 17852-28-7, 2-Amino-5-methylphenyl phenyl ketone 18469-52-8, Methyl 4-(aminomethyl)benzoate 18471-40-4, 1-Benzyl-3-aminopyrrolidine 18668-00-3, (R)-2-Acetoxypropionic acid 19335-11-6, 5-Aminoindazole 19719-28-9, 2,4-Dichlorophenylacetic acid 20260-53-1, Pyridine-3-carbonyl chloride hydrochloride 20603-00-3, 2-(Perhydroazepino)ethanol 21615-34-9, 2-Methoxybenzoyl chloride 22980-09-2, 2-(Indol-3-yl)-2-oxoacetyl chloride 26371-07-3, 1-Piperidinepropionic acid 27578-60-5, 1-(2-Aminoethyl)piperidine 28611-39-4, 4-(N,N-Dimethylamino)phenylboronic acid 29745-44-6, Pyridine-2-carbonyl chloride 30280-35-4, Methyl 2-(diethylamino)acetate 30418-59-8, 3-Aminophenylboronic acid 32316-92-0, 2-Naphthylboronic acid 32857-62-8, 4-(Trifluoromethyl)phenylacetic acid 34052-37-4, 2-Chloro-5-nitrobenzophenone 35855-10-8, Methyl 2-(morpholin-4-yl)acetate 38870-89-2, 2-Methoxyacetyl chloride 39178-35-3, Pyridine-4-carbonyl chloride hydrochloride 39256-35-4, N-Amino-2-(phenylmethoxy)acetamide 39827-11-7, 2-Benzo[b]thiophene-2-carbonyl chloride 39901-94-5, Picolinoyl chloride hydrochloride 50541-93-0, 4-Amino-1-benzylpiperidine 51019-43-3, (R)-2-Acetoxy-2-phenylacetic acid 55552-70-0, 3-Furanboronic acid 57260-71-6, tert-Butyl 1-piperazine carboxylate 57260-73-8, N-(2-Aminoethyl)carbamic acid tert-butyl ester 58249-87-9, [2-(Chlorocarbonyl)phenyl]methyl

benzoate 58583-90-7, Methyl 2-piperidinoacetate 58620-93-2, H-β-Ala-O-tert-butyl hydrochloride 58757-38-3, 6-Chloropyridine-3-carbonyl chloride 59776-88-4, Methyl 2-(2-oxopyrrolidinyl)acetate 61341-86-4, (S)-(+)-1-Aminoindane 62348-13-4, Isoxazole-5-carbonyl chloride 63984-02-1, Methyl 5-aminovalerate 71597-85-8, 4-Hydroxybenzeneboronic acid 72316-18-8 75178-96-0 76652-88-5, (S)-2-Acetylpropionic acid 77279-24-4, 2-[4-(tert-Butyloxycarbonyl)piperazino]ethanol 77987-49-6, 2-[N-(Benzyloxycarbonyl)amino]ethanol 84358-13-4, 1-[(tert-Butyl)oxycarbonyl]piperidine-4-carboxylic acid 85068-36-6, 2,5-Difluorobenzophenone 86945-25-7, 4-(2-Aminoethyl)-1-benzylpiperidine 87199-18-6, 3-Hydroxyphenylboronic acid 88443-78-1, 3-Acetoxyphenylacetyl chloride 89364-31-8, Tetrahydro-3-furoic acid 89415-43-0, 4-Aminophenylboronic acid 90555-66-1, 3-Ethoxyphenylboronic acid 91713-56-3, 2-Amino-5-methylphenyl 4-fluorophenyl ketone 94839-07-3, 3,4-(Methylenedioxy)phenylboronic acid 98431-09-5, Ethyl glutaryl chloride 98437-23-1, Benzo[b]thiophene-2-boronic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 98437-24-2 98546-51-1, 4-(Methylthio)phenylboronic acid 99769-19-4, 3-(Carbomethoxy)phenylboronic acid 122775-35-3, 3,4-Dimethoxyphenylboronic acid 126456-43-7, (1S,2R)-(-)-cis-1-Amino-2-indanol 128796-39-4, 4-Trifluoromethylphenylboronic acid 136030-00-7, (1R,2S)-(+)-cis-1-Amino-2-indanol 151169-75-4, 3,4-Dichlorophenylboronic acid 154230-29-2, trans-2-(4-Chlorophenyl)ethenylboronic acid 156641-98-4, 6-Methoxynaphthalene-2-boronic acid 164014-95-3 177985-32-9, 2-Chloro-4-fluorophenylacetic acid 199292-40-5, 2-Fluoro-5-trifluoromethylbenzophenone 214360-73-3, 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 216019-28-2, 3-Isopropylphenylboronic acid 227305-69-3, 2,3-Dihydrobenzo[b]furan-5-boronic acid 395099-08-8, N-[4-Hydroxy-2-(phenylcarbonyl)phenyl]benzamide 395099-15-7, 1-Acetyl-5-amino-3-phenyl-1H-indazole 395099-49-7, 1-[[3-(4-Fluorophenyl)-5-nitro-1H-indazol-1-yl]methoxy]-2-methoxyethane 395099-52-2, 1-[[3-(4-Fluorophenyl)-5-amino-1H-indazol-1-yl]methoxy]-2-methoxyethane 395099-67-9, 2-[3-(4-Fluorophenyl)-5-amino-1H-indazol-1-yl]perhydro-2H-pyran 395099-73-7, 2-(3-Bromo-5-nitro-1H-indazol-1-yl)perhydro-2H-pyran 395099-97-5, 3-(4-Fluorophenyl)-1-(2-methoxyethoxy)-1H-indazol-5-ylamine 395100-09-1, 3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-81-5**, 3-(3-Thienyl)-1H-indazole-5-carboxamide **395102-93-9**, 3-(Benzo[b]thiophen-3-yl)-1H-indazole-5-carboxamide **395103-84-1**, Ethoxy[[3-(4-fluorophenyl)-1H-indazol-5-yl]methyl]amine monohydrochloride 395105-02-9, Ethyl 3-bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylate 395106-75-9, Methyl 3-(5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoate 395106-77-1, 3-(5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoic acid **395107-00-3**, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine dihydrochloride 395107-31-0, 3-[5-(1H-1,2,4-Triazol-3-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenol 395108-13-1, Methyl 2-(4-pyrrolidinopiperidino)acetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **716321-04-9P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **THU (Therapeutic use)**; PREP (Preparation); USES (Uses)
(del b,sprepn. of indazole derivs. as **JNK** enzyme inhibitors)

RN 716321-04-9 HCAPLUS

CN Benzamide, N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



L45 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:107318 HCAPLUS
DN 136:151163
ED Entered STN: 10 Feb 2002
TI Preparation of indazole derivatives as **JNK** enzyme inhibitors
IN Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 412 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D231-00
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010137	A2	20020207	WO 2001-US23890	20010730 <--
	WO 2002010137	C2	20030206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1313711	A2	20030528	EP 2001-957332	20010730 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004513882	T2	20040513	JP 2002-516269	20010730 <--
	NZ 524045	A	20040730	NZ 2001-524045	20010730 <--
PRAI	US 2000-221799P	P	20000731 <--		
	WO 2001-US23890	W	20010730		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002010137	ICM	C07D231-00
JP 2004513882	FTERM	4C063/AA01; 4C063/AA03; 4C063/BB01; 4C063/BB02; 4C063/BB03; 4C063/BB09; 4C063/CC22; 4C063/CC25; 4C063/CC26; 4C063/CC29; 4C063/CC41; 4C063/CC47; 4C063/CC51; 4C063/CC58; 4C063/CC62; 4C063/CC75; 4C063/CC76; 4C063/CC81; 4C063/CC82; 4C063/CC92; 4C063/CC94; 4C063/DD10; 4C063/DD12; 4C063/DD14; 4C063/DD22; 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC37; 4C086/BC38; 4C086/BC39; 4C086/BC42; 4C086/BC50; 4C086/BC60; 4C086/BC62; 4C086/BC67; 4C086/BC71; 4C086/BC73; 4C086/BC82; 4C086/GA02; 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA09; 4C086/GA10; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA02; 4C086/ZA06; 4C086/ZA15; 4C086/ZA16; 4C086/ZA36; 4C086/ZA40; 4C086/ZA45;

4C086/ZA59; 4C086/ZA66; 4C086/ZA68; 4C086/ZA75;
4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB05;
4C086/ZB07; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15;
4C086/ZB26; 4C086/ZB27; 4C086/ZC31; 4C086/ZC35;
4C086/ZC54 <--

OS MARPAT 136:151163

AB Indazole derivs., 3-R1A-5-R2-1H-indazoles (1), having activity as selective inhibitors of **JNK** are disclosed. In 1: A is a direct bond, -(CH2)a-, -(CH2)bCH:CH(CH2)c-, or -(CH2)bC.tplbond.C(CH2)c-; R1 is aryl, heteroaryl or heterocycle fused to Ph, each being optionally substituted with 1-4 R3; R2 is -R3, -R4, -(CH2)bC(O)R5, -(CH2)bC(:O)OR5, -(CH2)bC(O)NR5R6, -(CH2)bC(O)NR5(CH2)cC(O)R6, -(CH2)bNR5C(O)R6, -(CH2)bNR5C(O)NR6R7, -(CH2)bNR5R6, -(CH2)bOR5, -(CH2)bSOdR5 or -(CH2)bSO2NR5R6. A is 1-6; b and c are the same or different and are 0-4; d is 0-2. R3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(O)OR8, -C(O)R8, -C(O)NR8R9, -C(O)NR8OR9, -SO2NR8R9, -NR8SO2R9, -CN, -NO2, -NR8R9, -NR8C(O)R9, -NR8C(O)(CH2)bOR9, -NR8C(O)(CH2)bR9, -O(CH2)bNR5R9, or heterocycle fused to Ph. R4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with 1-4 R3, or R4 is halogen or hydroxy. R5, R6and R7 are the same or different and are H, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R5, R6 and R7 are optionally substituted with 1-4 R3. R8 and R9 are the same or different and at each occurrence independently H, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R8 and R9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R8, R9, and R8 and R9 taken together to form a heterocycle are optionally substituted with 1-4 R3 with the proviso that: when A is a direct bond and R1 is Ph, R2 is not Me, methoxy, C(O)CH3 or C(O)H; when A is a direct bond and R1 is 4-Me-Ph, R2 is not Me; when A is a direct bond and R1 is 4-F-Ph, R2 is not trifluoromethyl; when A is a direct bond or -C.tplbond.C- and R1 is Ph, R2 is not -COOEt; and when A is a direct bond and R1 is 6,7-dimethoxyisoquinolin-1-yl, R2 is not hydroxy. Such compds. have utility in the treatment of a wide range of conditions that are responsive to **JNK** inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds. Many of the claimed compds. have IC50 values ≤0.5 μM in the JNK2 assay, e.g. 5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole. Although the methods of preparation are not claimed, >400 example prepns. are included.

ST indazole deriv prepn Jun N terminal kinase inhibitor; **JNK** enzyme inhibitor indazole deriv prepn

IT Intestine, disease
(Crohn's; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Nervous system, disease
(Huntington's chorea; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Antidiabetic agents
(Type II; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Nose, disease
(allergic rhinitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Antitumor agents
(bladder; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Antitumor agents
(blood; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Antitumor agents
(brain; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Antitumor agents
(bronchi; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Bronchi, disease
(bronchitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Uterus, neoplasm
(cervix, inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Antitumor agents
(cervix; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Lung, disease
(chronic obstructive; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Intestine, disease
(colitis, mucous; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Intestine, neoplasm
(colon, inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Antitumor agents
(colon; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Esophagus, disease
(esophagitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Antitumor agents
(esophagus; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Drug delivery systems
(for indazole derivs. useful as **JNK** enzyme inhibitors)
IT Stomach, disease
(gastritis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Transplant and Transplantation
(graft-vs.-host reaction; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Antitumor agents
(head; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Heart, disease
(infarction, therapeutic agents; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Intestine, disease
(inflammatory; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Brain, neoplasm
Kidney, neoplasm
Lung, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Skin, neoplasm
Stomach, neoplasm
Uterus, neoplasm
(inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Intestine, disease
(irritable bowel syndrome; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Antitumor agents
(kidney; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Antitumor agents
(larynx tumor inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Heart, disease
(left ventricle, hypertrophy; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Antitumor agents
(liver; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Antitumor agents
(lung; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Antitumor agents
(mouth; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Antitumor agents
(neck; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Bladder
Bronchi
Esophagus
Head
Mouth
Neck, anatomical
Prostate gland
(neoplasm, inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Kidney, disease
(nephritis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Heterocyclic compounds
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nitrogen, five-membered, indazoles; preparation of indazole derivs. as **JNK** enzyme inhibitors)
IT Antitumor agents
(ovary; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Antitumor agents
(pancreas; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Pancreas, disease
(pancreatitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)
IT Antitumor agents
(pharynx; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)
IT Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Anticonvulsants
Antiparkinsonian agents
Antirheumatic agents
Antitumor agents

Cytotoxic agents
(preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Organ preservation
(preparation of indazole derivs. as **JNK** enzyme inhibitors useful for)

IT Burn
Cachexia
Cystic fibrosis
Dermatitis
Eczema
Hepatitis
Lupus erythematosus
Multiple organ failure
Psoriasis
Transplant rejection
(preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Antitumor agents
(prostate gland; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Intestine, neoplasm
(rectum, inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Antitumor agents
(rectum; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Artery, disease
(restenosis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Shock (circulatory collapse)
(septic; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Antitumor agents
(skin; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Transplant and Transplantation
(skin; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Spinal column, disease
(spondylitis, rheumatoid; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Antitumor agents
(stomach; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Brain, disease
(stroke; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Multiple sclerosis
(therapeutic agents; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Skin
(transplant; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Larynx
(tumor inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT Intestine, disease
(ulcerative colitis; preparation of indazole derivs. as **JNK** enzyme inhibitors useful in treating)

IT Antitumor agents
(uterus; preparation of indazole derivs. as **JNK** enzyme inhibitors useful as)

IT **155215-87-5**, **JNK** **289899-93-0**, JNK2
291756-39-3, JNK3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **293758-67-5P**, 5-Nitro-3-phenyl-1H-indazole **395099-05-5P**, 5-Amino-3-phenyl-1H-indazole **395099-16-8P**, Methyl 4-[N-(3-phenyl-1H-indazol-5-yl)carbamoyl]benzoate **395099-28-2P**, 3-(4-Methoxyphenyl)-5-nitro-1H-indazole **395099-32-8P**, 3-(3,4-Dimethoxyphenyl)-5-nitro-1H-indazole **395099-59-9P**, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid **395099-86-2P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-hydroxybenzamide **395099-88-4P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-pyridinecarboxamide **395099-89-5P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-pyridinecarboxamide **395100-10-4P**, 3-(4-Fluorophenyl)-1H-indazole-5-carboxylic acid **395100-21-7P**, Methyl 4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzoate **395100-32-0P**, 3-[[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]propanoic acid **395100-33-1P**, N-(3-Nitrophenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-76-2P**, N-(Phenylmethoxy)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-93-3P**, N-[(tert-Butoxy)carbonylamino]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-95-5P**, N-Amino-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395101-17-4P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(4-nitrophenyl)-4H-1,2,4-triazole **395101-18-5P**, 1-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]-4-methoxybenzene **395101-19-6P**, Ethyl 2-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]acetate **395101-25-4P**, 3-(4-Fluorophenyl)-5-(2-phenylethynyl)-1H-indazole **395101-30-1P**, 5-((1E)-2-Phenylvinyl)-3-(4-fluorophenyl)-1H-indazole **395101-32-3P**, 5-[(1E)-2-(2-Pyridyl)vinyl]-3-(4-fluorophenyl)-1H-indazole **395101-36-7P**, 4-[(1E)-2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]vinyl]benzoic acid **395101-38-9P**, 5-[(1E)-2-(3-Nitrophenyl)vinyl]-3-(4-fluorophenyl)-1H-indazole **395101-52-7P**, Ethyl (2E)-3-[3-(4-fluorophenyl)-1H-indazol-5-yl]prop-2-enoate **395101-66-3P**, 3-(4-Methoxyphenyl)-1H-indazole-5-carboxamide **395101-72-1P**, 3-(4-Hydroxyphenyl)-1H-indazole-5-carboxamide **395101-78-7P**, 3-(2-Naphthyl)-1H-indazole-5-carboxamide **395101-82-3P**, Methyl 3-benzo[b]thiophen-2-yl-1H-indazole-5-carboxylate **395101-92-5P**, 3-(Benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395101-97-0P**, 3-[4-(Dimethylamino)phenyl]-1H-indazole-5-carboxamide **395102-02-0P**, 3-(2-Phenylethynyl)-1H-indazole-5-carboxamide **395102-08-6P**, 3-[4-[2-(Dimethylamino)ethoxy]phenyl]-1H-indazole-5-carboxamide **395102-09-7P**, 1-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-2-methoxybenzene **395102-46-2P**, 1-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-3-methoxybenzene **395103-58-9P**, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]ethan-1-one **395103-83-0P**, Ethyl 3-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propanoate **395104-41-3P** **395107-78-5P** **395107-84-3P**, 3-(3-Quinolyl)-1H-indazole-5-carboxamide **395107-88-7P**, 3-(6-Methoxy-2-naphthyl)-1H-indazole-5-carboxamide
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 55-85-6P, N-Amino-2-(dimethylamino)acetamide 770-17-2P, N-Amino-2-(morpholin-4-yl)acetamide 2644-33-9P, N-Amino-2-(diethylamino)acetamide 7408-09-5P, N-Amino-2-piperidinoacetamide 22636-79-9P, N-Amino-3-(dimethylamino)propanamide 24534-93-8P, 3-Hydroxybutyric acid hydrazide 24632-72-2P, 2-(4-Acetylpiperazino)-N-aminoacetamide 37115-47-2P, N-Amino-2-(methylamino)acetamide

40598-94-5P, 3-Bromo-1H-indazole 59776-89-5P, N-Amino-2-(2-oxopyrrolidinyl)acetamide 66544-68-1P 67400-25-3P, 3-Bromo-5-nitro-1H-indazole 74626-47-4P, 1H-Indazole-5-carbonitrile 146137-79-3P, 4-Fluoro-3-formylbenzenecarbonitrile 395098-99-4P, 3-Bromo-1-[(2-methoxyethoxy)methyl]-1H-indazole 395099-00-0P, 1-[(2-Methoxyethoxy)methyl]-3-(4-methoxyphenyl)-1H-indazole 395099-02-2P, 1-[(2-Methoxyethoxy)methyl]-3-(2-methoxyphenyl)-1H-indazole 395099-03-3P, 3-(4-Fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazole 395099-07-7P, N-[2-(Phenylcarbonyl)-4-(phenylmethoxy)phenyl]benzamide 395099-09-9P, 2-Amino-5-(phenylmethoxy)phenyl phenyl ketone 395099-14-6P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)-2-pyridinecarboxamide 395099-17-9P, Methyl 4-[N-(1-acetyl-3-phenyl-1H-indazol-5-yl)carbamoyl]benzoate 395099-20-4P, 2-[N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)carbamoyl]phenyl acetate 395099-21-5P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)acetamide 395099-24-8P, N-[1-Acetyl-3-phenyl-1H-indazol-5-yl]-4-nitrobenzamide 395099-25-9P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)-4-aminobenzamide 395099-27-1P, N-[1-Acetyl-3-phenyl-1H-indazol-5-yl]-3-nitrobenzamide 395099-29-3P, 3-Bromo-1-[(2-methoxyethoxy)methyl]-5-nitro-1H-indazole 395099-30-6P, 1-[(2-Methoxyethoxy)methyl]-3-(4-methoxyphenyl)-5-nitro-1H-indazole 395099-33-9P, 3-(3,4-Dimethoxyphenyl)-1-[(2-methoxyethoxy)methyl]-5-nitro-1H-indazole 395099-35-1P, 1-[(2-Methoxyethoxy)methyl]-5-nitro-3-(3-nitrophenyl)-1H-indazole 395099-62-4P, Methyl 4-[N-[3-(4-fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazol-5-yl]carbamoyl]benzoate 395099-63-5P, Methyl 4-[N-[3-(4-fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazol-5-yl]-N-methylcarbamoyl]benzoate 395099-66-8P, Methyl 3-[N-[3-(4-fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-72-6P, 4-Methoxy-1-[5-nitro-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzene 395099-74-8P, 3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-ylamine **395099-75-9P**, Methyl 4-[N-[3-(4-methoxyphenyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-76-0P, Methyl 4-[N-[3-(4-methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-78-2P, 2-[5-Nitro-3-(4-pyridyl)-1H-indazol-1-yl]perhydro-2H-pyran 395099-79-3P, 1-(Perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazol-5-ylamine 395099-80-6P, Methyl 4-[N-[1-(perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazol-5-yl]carbamoyl]benzoate **395099-81-7P**, Methyl 4-[N-[3-(4-pyridyl)-1H-indazol-5-yl]carbamoyl]benzoate 395100-00-2P, 1-Acetyl-3-(4-fluorophenyl)-1H-indazole-5-carbonyl chloride 395100-11-5P, 4-Fluoro-3-[(4-fluorophenyl)carbonyl]benzenecarbonitrile **395100-12-6P**, 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile 395100-39-7P, Methyl 4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoate **395100-41-1P**, Methyl 4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoate 395100-43-3P, N-(3-Nitrophenyl)-1-acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-48-8P 395100-52-4P, Methyl 4-[[[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]methyl]benzoate 395100-56-8P, N-(4-Pyridylmethyl)-1-acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-59-1P, Ethyl 2-[4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetate **395100-60-4P**, Ethyl 2-[4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetate **395100-66-0P**, N-[2-[(tert-Butoxy)carbonylamino]ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-69-3P**, N-[3-[(tert-Butoxy)carbonylamino]propyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-73-9P, tert-Butyl 4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]piperazine-1-carboxylate 395100-74-0P, 1-Acetyl-3-(4-fluorophenyl)-5-(1-piperazinylcarbonyl)-1H-indazole 395100-84-2P, 1-Acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxylic acid 395100-98-8P, tert-Butyl 3-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]propanoate 395101-04-9P, N-[(1-Iminoethyl)amino]-3-(4-fluorophenyl)indene-5-carboxamide **395101-06-1P**, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine hydrochloride 395101-26-5P, 2-Amino-5-bromo-4'-fluorobenzophenone **395101-27-6P**

, 5-Bromo-3-(4-fluorophenyl)-1H-indazole 395101-28-7P, 5-Bromo-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-29-8P, 3-(4-Fluorophenyl)-5-(2-phenylethynyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-31-2P, 5-((1E)-2-Phenylvinyl)-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-34-5P, 5-[(1E)-2-(2-Pyridyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-37-8P, 4-[(1E)-2-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]vinyl]benzoic acid 395101-44-7P, 5-[(1E)-2-(4-Aminophenyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-46-9P, 5-[(1E)-2-(4-Pyridyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-50-5P, Ethyl (2E)-3-[3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]prop-2-enoate 395101-61-8P, 1-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-2-phenylethan-1-ol 395101-64-1P, 1-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-2-phenylethan-1-one 395101-67-4P, 3-Bromo-1H-indazole-5-carbonitrile 395101-69-6P, 3-Bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-70-9P, 3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395101-71-0P**, 3-(4-Methoxyphenyl)-1H-indazole-5-carbonitrile 395101-74-3P, 3-(4-Hydroxyphenyl)-1-perhydro-2H-pyran-2-yl-1H-indazole-5-carbonitrile **395101-77-6P**, 3-(4-Hydroxyphenyl)-1H-indazole-5-carbonitrile 395101-79-8P, 3-(2-Naphthyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395101-80-1P**, 3-(2-Naphthyl)-1H-indazole-5-carbonitrile 395101-84-5P, 3-Bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395101-85-6P, 3-Benzo[b]thiophen-2-yl-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395101-89-0P, 3-Benzo[b]thiophen-2-yl-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395101-91-4P**, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carbonitrile 395101-94-7P, 3-(Benzo[d]furan-2-yl)-1-perhydro-2H-pyran-2-yl-1H-indazole-5-carbonitrile **395101-95-8P**, 3-(Benzo[d]furan-2-yl)-1H-indazole-5-carbonitrile 395101-98-1P, 3-[4-(Dimethylamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-00-8P**, 3-[4-(Dimethylamino)phenyl]-1H-indazole-5-carbonitrile 395102-04-2P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-phenylethynyl)-1H-indazole-5-carbonitrile **395102-06-4P**, 3-(2-Phenylethynyl)-1H-indazole-5-carbonitrile 395102-11-1P, 3-(2-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-12-2P**, 3-(2-Methoxyphenyl)-1H-indazole-5-carbonitrile 395102-14-4P, 3-((1E)-2-Phenylvinyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-15-5P**, 3-((1E)-2-Phenylvinyl)-1H-indazole-5-carbonitrile 395102-19-9P, 1-(Perhydro-2H-pyran-2-yl)-3-(3-pyridyl)-1H-indazole-5-carbonitrile **395102-20-2P**, 3-(3-Pyridyl)-1H-indazole-5-carbonitrile 395102-22-4P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-thienyl)-1H-indazole-5-carbonitrile 395102-24-6P, 3-[4-Isopropylphenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-27-9P, 3-(2-Furyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-29-1P, 3-(3-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-31-5P, 3-(2H-Benzo[d]-1,3-dioxolan-5-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-32-6P**, 3-(2H-Benzo[d]-1,3-dioxolan-5-yl)-1H-indazole-5-carbonitrile 395102-34-8P, 1-(Perhydro-2H-pyran-2-yl)-3-(3-thienyl)-1H-indazole-5-carbonitrile 395102-38-2P, 3-[4-(2-Methylpropoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-40-6P**, 3-[4-(2-Methylpropoxy)phenyl]-1H-indazole-5-carbonitrile 395102-44-0P, 3-(4-Chlorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-47-3P, 3-(3-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-50-8P, 1-(Perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazole-5-carbonitrile 395102-60-0P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-phenylethyl)-1H-indazole-5-carbonitrile 395102-75-7P, 3-(1-Naphthyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-77-9P**, 3-(1-Naphthyl)-1H-indazole-5-carbonitrile **395102-79-1P**, 3-(1-Naphthyl)-1H-indazole-5-carboxamide

395102-89-3P, 3-(3,4-Dichlorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-96-2P, (2E)-2-Aza-3-(dimethylamino)-1-[3-bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]prop-2-en-1-one 395102-97-3P, 2-[5-(1H-1,2,4-Triazol-3-yl)-3-bromo-1H-indazol-1-yl]perhydro-2H-pyran 395102-98-4P 395102-99-5P, 2-[3-(4-Methylphenyl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-03-4P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenylamine 395103-09-0P, 1-[(1E)-2-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]vinyl]-4-methoxybenzene 395103-13-6P, 2-[3-[(1E)-2-(4-Chlorophenyl)vinyl]-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-17-0P, 4-Methylthio-1-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzene 395103-19-2P, 2-[3-[(1E)-2-(4-Methylphenyl)vinyl]-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-23-8P, 5-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane 395103-31-8P, (Methylsulfonyl)[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]amine 395103-35-2P, 2-Methoxy-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395103-40-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395103-42-1P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-44-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395103-52-3P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-3-bromo-1H-indazolyl]perhydro-2H-pyran 395103-53-4P, 2-[3-Bromo-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazolyl]perhydro-2H-pyran 395103-54-5P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazol-3-yl]phenylamine 395103-56-7P, 2-Methoxy-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazol-3-yl]phenyl]acetamide 395103-60-3P, 1-[3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]ethan-1-one **395103-65-8P**, 3-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]-1H-indazole-5-carbonitrile 395103-71-6P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395103-73-8P, 3-(3,4-Dimethoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395103-74-9P**, 3-(3,4-Dimethoxyphenyl)-1H-indazole-5-carbonitrile 395103-77-2P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-(1-piperidyl)propanamide 395103-80-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-82-9P, 3-(3-Hydroxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395103-87-4P, Ethyl 3-(N-aminocarbamoyl)propanoate 395103-88-5P, Ethyl 4-(N-aminocarbamoyl)butanoate 395103-92-1P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-methoxypropanamide 395103-94-3P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazole-3-yl]phenyl]-3-pyridinecarboxamide 395103-98-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide **395104-11-7P**, 3-[4-[3-(Dimethylamino)propoxy]phenyl]-1H-indazole-5-carbonitrile **395104-14-0P**, 3-[3-[3-(Dimethylamino)propoxy]phenyl]-1H-indazole-5-carbonitrile 395104-16-2P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenol **395104-26-4P**, 3-[4-[2-(Dimethylamino)ethoxy]phenyl]-1H-indazole-5-carbonitrile **395104-34-4P**, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(2-piperazinoethoxy)benzene 395104-50-4P, 4-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenylamine 395104-53-7P, Methyl 3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzoate 395104-55-9P, N-Benzyl-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-61-7P 395104-65-1P, N-(2,2-Dimethylpropyl)-3-[1-(perhydro-2H-

pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-68-4P, N-(Cyclopropylmethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-72-0P, N-(3-Pyridylmethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-76-4P, N-[(4-Fluorophenyl)methyl]-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-78-6P, N-(Indan-2-yl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-81-1P, N-((1R)-Indanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-83-3P, N-((1S)-Indanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-85-5P, N-((1S,2R)-2-Hydroxyindanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazole-3-yl]benzamide 395104-87-7P, N-((1R,2S)-2-Hydroxyindanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-89-9P, N-(1-Methyl-1-phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-91-3P, N-(tert-Butyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazole-3-yl]benzamide 395104-93-5P, N-((1R)-1-Phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-94-6P, N-((1S)-1-Phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-96-8P, Isoindolin-2-yl 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl ketone 395105-01-8P, Ethyl 3-(benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylate 395105-03-0P, 3-(Benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylic acid 395105-04-1P, N-Isopropyl-3-(benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-13-2P, N-Amino-2-(4-hydroxypiperidyl)acetamide 395105-17-6P, (1S)-1-[N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-20-1P, 1-(Perhydro-2H-pyran-2-yl)-3-[3-(3-pyridylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-22-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-piperidylpropanamide 395105-25-6P, 1-[N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-27-8P, 3-(3-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-28-9P, 3-[3-(2-Methoxyacetamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-30-3P, tert-Butyl 4-[N-[3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]piperidine-1-carboxylate 395105-31-4P, tert-Butyl 4-[N-[3-(5-carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)phenyl]carbamoyl]piperidine-1-carboxylate 395105-33-6P, (1S)-1-[N-[3-[5-Carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate
395105-35-8P, 3-[3-[(2-Methoxyethyl)amino]phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-37-0P, 1-(Perhydro-2H-pyran-2-yl)-3-[3-(3-piperidylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395105-39-2P, 3-[3-(2-Furylcarbonylamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-41-6P, 2-(Dimethylamino)-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-44-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]butanamide 395105-46-1P, (2E)-N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-phenylprop-2-enamide 395105-48-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395105-51-8P, 3-[3-[2-(Dimethylamino)acetylamino]phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-54-1P, 3,3-Dimethyl-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-

triazol-3-yl]-1H-indazol-3-yl]phenyl]butanamide 395105-56-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]cyclopropanecarboxamide 395105-58-5P, 2-(Indol-3-yl)-2-oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-61-0P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-6-chloro-3-pyridinecarboxamide 395105-64-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]cyclopentanecarboxamide 395105-66-5P, Methyl[N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]formate 395105-69-8P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]benzo[b]thiophene-2-carboxamide 395105-72-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-pyridinecarboxamide 395105-74-5P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-furancarboxamide 395105-76-7P, [N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]phenylmethyl acetate 395105-79-0P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]isoxazole-5-carboxamide **395105-81-4P**, N-((1S)-1-Phenylethyl)-3-[5-(1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395105-82-5P, 2-(2-Furyl)-2-oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-84-7P, 2-Oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395105-86-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]pentanamide 395105-88-1P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-4-pyridinecarboxamide 395105-91-6P, 2-Cyclohexyl-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-93-8P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-phenylpropanamide 395105-95-0P, 2-(4-Fluorophenyl)-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-97-2P **395106-03-3P**, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine 395106-23-7P, N-Amino-2-(dimethylamino)propanamide 395106-25-9P, (1R)-[N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]phenylmethyl acetate **395106-27-1P**, (2R)-N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide hydrochloride 395106-31-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide **395106-32-8P**, N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide hydrochloride **395106-36-2P** 395106-38-4P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-methylbutanamide **395106-39-5P**, N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide hydrochloride 395106-70-4P, 3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395106-71-5P, 3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395106-79-3P, N-[(4-Fluorophenyl)methyl]-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-80-6P, N-[(4-Fluorophenyl)methyl]-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-82-8P, N-(tert-Butyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-83-9P, N-(tert-Butyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenylcarboxamide 395106-85-1P, N-((1R)-Indanyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-86-2P, N-((1R)-Indanyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-88-4P,

[[3-[3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-91-9P, [[3-[3-(2H-Benzo[d]-1,3-dioxol-5-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-94-2P, [3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl](hydroxyimino)methylamine 395106-96-4P, 2-Amino-1-aza-2-[3-(4-fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]vinyl ethoxyformate 395106-97-5P, 3-[3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1,2,4-oxadiazolin-5-one **395106-99-7P**, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl](phenylmethoxy)methane 395107-03-6P, N-(2-Piperidinoethyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-05-8P**, N-(2-Piperidinoethyl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide trihydrochloride 395107-08-1P **395107-11-6P**, N-Phenyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 395107-13-8P, N-(4-Fluorophenyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-15-0P**, N-(4-Fluorophenyl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-17-2P, N-(Indan-2-yl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-18-3P**, N-(Indan-2-yl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-20-7P, N-Cyclopropyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-22-9P**, N-Cyclopropyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-25-2P, N-Cyclobutyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395107-26-3P**, N-Cyclobutyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-28-5P, 3-(4-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395107-29-6P, N-[4-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395107-30-9P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]-3-(2-methoxyethoxy)benzene 395107-46-7P, Methyl 3-(5-carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoate **395107-80-9P** 395107-86-5P, 3-(1,1-Dimethyl-1-stannaethyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395107-90-1P**, 3-(6-Methoxy-2-naphthyl)-1H-indazole-5-carbonitrile **395107-96-7P**, 3-(2,3-Dihydrobenzo[b]furan-5-yl)-1H-indazole-5-carbonitrile **395108-15-3P**, Ethoxy[3-(6-methoxy-2-naphthyl)-1H-indazol-5-yl]methanimine **395108-20-0P**, N-Phenyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide 395108-21-1P, N-Phenyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide **395108-24-4P** **395108-25-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **395100-29-5P**, tert-Butyl 3-[[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]propanoate
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **57614-16-1P**, 5-Methyl-3-phenyl-1H-indazole **57614-63-8P**, 5-Fluoro-3-phenyl-1H-indazole **395099-04-4P**, 3-Phenyl-5-trifluoromethyl-1H-indazole **395099-06-6P**, 3-Phenyl-5-(phenylmethoxy)-1H-indazole **395099-10-2P**, 3-Phenyl-1H-indazol-5-ol **395099-11-3P**, N-(3-Phenyl-1H-indazol-5-yl)benzamide **395099-12-4P**, N-(3-Phenyl-1H-indazol-5-yl)-2-pyridinecarboxamide **395099-18-0P**, 4-[N-(3-Phenyl-1H-indazol-5-yl)carbamoyl]benzoic

acid **395099-19-1P**, N-(3-Phenyl-1H-indazol-5-yl)-2-Hydroxybenzamide **395099-22-6P**, N-[3-Phenyl-1H-indazol-5-yl]acetamide **395099-23-7P**, N-(3-Phenyl-1H-indazol-5-yl)-4-aminobenzamide **395099-26-0P**, N-(3-Phenyl-1H-indazol-5-yl)-3-aminobenzamide **395099-31-7P**, 5-Nitro-3-[3-(trifluoromethyl)phenyl]-1H-indazole **395099-34-0P**, 5-Nitro-3-(3-nitrophenyl)-1H-indazole **395099-36-2P**, 3-(1-Naphthyl)-5-nitro-1H-indazole **395099-37-3P**, 3-(2-Naphthyl)-5-nitro-1H-indazole **395099-38-4P**, 3-(5-Nitro-1H-indazol-3-yl)furan **395099-39-5P**, 3-Ethoxy-1-(5-nitro-1H-indazol-3-yl)benzene **395099-40-8P**, 3-[3-Isopropylphenyl]-5-nitro-1H-indazole **395099-41-9P**, 3-[4-Isopropylphenyl]-5-nitro-1H-indazole **395099-42-0P**, 5-Nitro-3-(3-phenylphenyl)-1H-indazole **395099-43-1P**, 5-Nitro-3-(4-phenylphenyl)-1H-indazole **395099-45-3P**, 5-Amino-3-(3,4-dimethoxyphenyl)-1H-indazole mono(trifluoroacetate) **395099-46-4P**, 5-Amino-3-(4-methoxyphenyl)-1H-indazole monohydrochloride **395099-47-5P**, 3-[3-(Trifluoromethyl)phenyl]-1H-indazol-5-ylamine **395099-48-6P**, 3-(4-Fluorophenyl)-1H-indazol-5-ylamine **395099-50-0P**, Ethyl[3-(4-fluorophenyl)-1H-indazol-5-yl]amine **395099-51-1P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methylbenzamide **395099-53-3P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methoxybenzamide **395099-54-4P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-phenylbenzamide **395099-55-5P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]benzo[b]thiophene-2-carboxamide **395099-56-6P**, [3-(4-Fluorophenyl)-1H-indazol-5-yl](phenylsulfonyl)amine **395099-57-7P**, Methyl 4-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoate **395099-58-8P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-pyridinecarboxamide **395099-60-2P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]cyclopropanecarboxamide **395099-61-3P**, Methyl 4-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]-N-methylcarbamoyl]benzoate **395099-64-6P**, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-N-methylcarbamoyl]benzoic acid **395099-65-7P**, Methyl 3-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoate **395099-68-0P**, 3-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid **395099-69-1P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-(N-methylcarbamoyl)benzamide **395099-70-4P**, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzamide **395099-71-5P**, 4-[N-[3-(4-Methoxyphenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid **395099-77-1P**, 4-[N-(3-(4-Pyridyl)-1H-indazol-5-yl)carbamoyl]benzoic acid **395099-82-8P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]benzamide **395099-83-9P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3,5-Bis(trifluoromethyl)benzamide **395099-84-0P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-furancarboxamide **395099-85-1P 395099-87-3P**, [2-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]phenyl]methyl benzoate **395099-90-8P**, [3-(4-Fluorophenyl)-1H-indazol-5-yl](4-pyridylmethyl)amine **395099-91-9P**, [3-(4-Fluorophenyl)-1H-indazol-5-yl](3-pyridylmethyl)amine **395099-92-0P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-thiophenecarboxamide **395099-94-2P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]morpholine-4-carboxamide **395099-96-4P**, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl][(4-fluorophenyl)amino]carboxamide **395099-99-7P**, 3-(4-Fluorophenyl)-1H-indazole-5-carboxamide **395100-02-4P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395100-04-6P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395100-06-8P**, 3-(4-Fluorophenyl)-5-imidazol-2-yl-1H-indazole **395100-08-0P**, 3-(4-Fluorophenyl)-5-pyrazol-3-yl-1H-indazole **395100-13-7P**, Ethyl 3-(4-fluorophenyl)-1H-indazole-5-carboxylate **395100-14-8P**, 5-Benzimidazol-2-yl-3-(4-fluorophenyl)-1H-indazole **395100-16-0P**, N-Phenyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-18-2P**, N-[2-(Dimethylamino)ethyl]-

3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-19-3P**, Ethyl 1-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]piperidine-4-carboxylate **395100-22-8P**, 4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzoic acid **395100-23-9P**, 4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzamide **395100-25-1P**, 1-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonyl]piperidine-4-carboxylic acid **395100-26-2P**, N-(2-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-27-3P**, N-(3-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-28-4P**, N-(4-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-30-8P**, N-(3-Hydroxyphenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-35-3P 395100-37-5P**, 4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoic acid **395100-42-2P**, N-(3-Aminophenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-44-4P**, 2-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]acetic acid **395100-46-6P**, 5-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]pentanoic acid **395100-50-2P**, 4-[[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]methyl]benzoic acid **395100-54-6P**, N-(4-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-58-0P**, 2-[4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetic acid **395100-62-6P**, N,N-Dimethyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-63-7P**, N-Methyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-65-9P**, N-(2-Aminoethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-68-2P**, N-(3-Aminopropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-70-6P**, 3-(4-Fluorophenyl)-1H-indazol-5-yl 1-pyrrolidinyl ketone **395100-72-8P**, 3-(4-Fluorophenyl)-1H-indazol-5-yl 1-piperazinyl ketone **395100-78-4P**, N-(2-Hydroxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-79-5P**, 3-(4-Fluorophenyl)-1H-indazole-5-carbohydroxamic acid **395100-81-9P**, N-(2H-1,2,3,4-Tetrazol-5-yl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-83-1P**, N-(3-(Morpholin-4-yl)propyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-86-4P**, N-(3-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-88-6P 395100-89-7P**, N-[2-(1-Methylimidazol-5-yl)ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-91-1P**, N-(2-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395100-97-7P**, N-(2-Carbamoylethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395101-00-5P**, N-(3-Carbamoylpropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395101-02-7P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-methyl-4H-1,2,4-triazole **395101-05-0P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-isopropyl-4H-1,2,4-triazole **395101-07-2P**, 1-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propan-2-ol **395101-10-7P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-phenyl-4H-1,2,4-triazole **395101-12-9P**, 2-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]furan **395101-13-0P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(4-pyridyl)-4H-1,2,4-triazole **395101-14-1P**, 3-(4-Chlorophenyl)-5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazole **395101-15-2P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-propyl-4H-1,2,4-triazole **395101-20-9P**, 4-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]phenylamine **395101-21-0P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-benzyl-4H-1,2,4-triazole **395101-23-2P**, 2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-phenyl-1,3,4-oxadiazole **395101-24-3P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methyl-1,3,4-oxadiazole **395101-40-3P**, 5-((1Z)-2-Phenylvinyl)-3-(4-fluorophenyl)-1H-indazole **395101-42-5P**, 5-[(1E)-2-(4-Aminophenyl)vinyl]-3-(4-fluorophenyl)-1H-indazole **395101-45-8P**, 5-[(1E)-2-(4-Pyridyl)vinyl]-3-(4-fluorophenyl)-1H-indazole **395101-48-1P**, (2E)-3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]prop-2-enoic acid **395101-53-8P**, 3-[3-(4-Fluorophenyl)-1H-

indazol-5-yl]propanoic acid **395101-55-0P**, 5-[2-(3-Aminophenyl)ethyl]-3-(4-fluorophenyl)-1H-indazole **395101-57-2P**, 4-[2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]ethyl]benzoic acid **395101-58-3P**, 3-(4-Fluorophenyl)-5-[2-(2-pyridyl)ethyl]-1H-indazole **395101-59-4P**, 3-(4-Fluorophenyl)-5-(2-phenylethyl)-1H-indazole **395101-60-7P**, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-phenylethan-1-ol **395101-62-9P**, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-phenylethan-1-one **395101-86-7P**, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxylic acid **395101-88-9P**, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxamide **395101-96-9P**, 3-[3-Isopropylphenyl]-1H-indazole-5-carboxamide **395102-01-9P**, 3-(3-Furyl)-1H-indazole-5-carboxamide **395102-13-3P**, 5-[3-((1E)-2-Phenylvinyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-17-7P**, 5-[3-(3-Pyridyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-21-3P**, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]thiophene **395102-23-5P**, 5-[3-[4-Isopropylphenyl]-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-26-8P**, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]furan **395102-28-0P**, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenylamine **395102-30-4P**, 5-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane **395102-33-7P**, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]thiophene **395102-35-9P**, 5-[3-(2-Naphthyl)-1H-indazol-5-yl]-1H-1,2,3,4-tetrazole **395102-36-0P**, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-methoxybenzene **395102-37-1P**, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-(2-methylpropoxy)benzene **395102-42-8P**, 5-[3-(4-Chlorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-48-4P**, 5-[3-(4-Pyridyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-52-0P**, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]benzo[b]furan **395102-55-3P**, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenol **395102-56-4P**, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenol **395102-57-5P**, 5-[3-(2-Phenylethynyl)-1H-indazol-5-yl]-1H-1,2,3,4-tetrazole **395102-59-7P**, 5-[3-(2-Phenylethyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole **395102-61-1P**, 5-[3-[3-Isopropylphenyl]-1H-indazol-5-yl]-1H-1,2,4-triazole **395102-63-3P**, 4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenol **395102-64-4P**, [4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl]dimethylamine **395102-66-6P**, 3-[3-((E)-2-Phenylvinyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395102-68-8P**, [2-[4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine **395102-70-2P**, 3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]furan **395102-72-4P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-methoxybenzene **395102-73-5P**, 5-(3-(1-Naphthyl)-1H-indazol-5-yl)-1H-1,2,4-triazole **395102-80-4P**, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]thiophene **395102-83-7P**, 5-[3-(2-Naphthyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395102-85-9P**, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenylamine **395102-87-1P**, 3-[3-(3,4-Dichlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395102-91-7P**, 3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzo[b]thiophene **395102-95-1P**, 3-[3-(4-Methylphenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-01-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]acetamide **395103-05-6P**, 5-[3-(3-Chlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-07-8P**, 1-[(1E)-2-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]vinyl]-4-methoxybenzene **395103-11-4P**, 3-[3-[(1E)-2-(4-Chlorophenyl)vinyl]-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-15-8P**, 2-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzo[b]furan **395103-16-9P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-(methylsulfonyl)benzene **395103-18-1P**, 3-[3-[(1E)-2-(4-Methylphenyl)vinyl]-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-20-5P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-(methylsulfinyl)benzene **395103-21-6P**, 5-[5-(1H-1,2,4-Triazol-5-

yl)-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane **395103-25-0P**, 4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenylamine **395103-27-2P**, 5-[3-[4-(Trifluoromethyl)phenyl]-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-29-4P**, [3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl](methylsulfonyl)amine **395103-33-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide **395103-37-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenylacetamide **395103-41-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide **395103-43-2P**, 5-[3-(2-Phenylethynyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395103-45-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395103-46-5P**, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(3-pyridyl)-4H-1,2,4-triazole **395103-47-6P**, 4-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]phenol **395103-48-7P**, 2-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]acetic acid **395103-50-1P**, 1-[5-[3-(4-Fluorophenyl)1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]ethan-1-ol **395103-51-2P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide **395103-61-4P**, 2-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]benzo[b]thiophene **395103-63-6P**, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-(2-(morpholin-4-yl)ethoxy)benzene **395103-67-0P**, 4-[3-(4-Fluorophenyl)-1H-indazol-5-yl]pyrimidine-2-ylamine **395103-69-2P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide **395103-72-7P**, 3-(3,4-Dimethoxyphenyl)-1H-indazole-5-carboxamide **395103-76-1P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-(1-piperidyl)propanamide **395103-78-3P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide **395103-81-8P**, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene **395103-85-2P**, Ethyl 4-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]butanoate **395103-90-9P**, 4-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-1,2-dimethoxybenzene **395103-91-0P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-methoxypropanamide **395103-93-2P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395103-96-5P**, 3-(3-Aminophenyl)-1H-indazole-5-carboxamide **395104-02-6P**, 3-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propanoic acid **395104-04-8P**, 3-[2H-Benzo[d]-1,3-dioxol-5-yl]-1H-indazole-5-carboxamide **395104-06-0P**, 5-Methyl-3-(4-fluorophenyl)-1H-indazole **395104-09-3P**, [3-[4-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine trifluoroacetate **395104-13-9P**, [3-[3-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine trifluoroacetate **395104-15-1P**, [3-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine **395104-19-5P**, [2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine **395104-21-9P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene **395104-24-2P**, [2-[3-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine mono(trifluoroacetate) **395104-28-6P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-pyrrolidinoethoxy)benzene 395104-30-0P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene **395104-32-2P**, 1-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]pyrrolidin-2-one **395104-35-5P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperazinylethoxy)benzene bis(trifluoroacetate) **395104-37-7P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(3-piperidinopropoxy)benzene **395104-38-8P**, 4-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]-1-acetylpiperazine **395104-43-5P**, 2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethylamine mono(trifluoroacetate) **395104-45-7P**,

1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-cyclohexylethoxy)benzene **395104-47-9P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-hexahydroazepinoethoxy)benzene **395104-49-1P**, N-[4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide **395104-51-5P**, N-Benzyl-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-57-1P**, N-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]acetamide **395104-59-3P**, 5-[3-(2-Chlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395104-63-9P**, N-(2,2-Dimethylpropyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-67-3P**, N-(Cyclopropylmethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-70-8P**, N-(3-Pyridylmethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-74-2P**, [3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl] 4-methyl-1-piperazinyl ketone **395104-75-3P**, N-[(4-Fluorophenyl)methyl]-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-77-5P**, N-(Indan-2-yl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-79-7P**, N-((1R)-1-Indanyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-82-2P**, N-((1S)-Indanyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-84-4P**, N-((1S,2R)-2-Hydroxyindanyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-86-6P**, N-((2S,1R)-2-Hydroxyindanyl)3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-88-8P**, N-(1-Methyl-1-phenylethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-90-2P**, N-(tert-Butyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-92-4P**, N-((1R)-1-Phenylethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-95-7P**, [3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl] isoindolin-2-yl ketone **395104-97-9P**, N-[2-(Dimethylamino)ethyl]-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide **395104-98-0P**, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]amine **395104-99-1P**, [[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]methyl]dimethylamine **395105-00-7P**, N-Isopropyl-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-05-2P**, N-(2-Methoxyethyl)-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-06-3P**, N-[2-(Dimethylamino)ethyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-07-4P**, N-[4-(Dimethylamino)butyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-08-5P**, N-[3-(Dimethylamino)propyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-10-9P**, N-(2-Methylpropyl)-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-11-0P**, N-Methyl-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide **395105-12-1P**, 1-[[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]methyl]piperidin-4-ol

RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **395105-14-3P**, 1-Acetyl-4-[[5-[3-(4-fluorophenyl)-1H-indazol-5-yl](4H-1,2,4-triazol-3-yl)]methyl]piperazine **395105-15-4P**, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-(2S)-2-hydroxypropanamide **395105-16-5P**, (1S)-1-[N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate **395105-19-8P**, 3-[3-(3-Pyridylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395105-21-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-piperidylpropanamide **395105-23-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-hydroxypropanamide **395105-26-7P**, 3-[3-(2-Methoxyacetylamino)phenyl]-1H-indazole-5-carboxamide **395105-29-0P**, 3-[3-(4-Piperidylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395105-32-5P**, (1S)-1-[N-[3-(5-Carbamoyl-1H-indazol-3-yl)phenyl]carbamoyl]ethyl acetate **395105-34-7P**,

3-[3-[(2-Methoxyethyl)amino]phenyl]-1H-indazole-5-carboxamide **395105-36-9P**, 3-[3-(3-Piperidylpropanoylamino)phenyl]-1H-indazole-5-carboxamide **395105-38-1P**, 3-[3-(2-Furylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395105-40-5P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(dimethylamino)acetamide **395105-43-8P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]butanamide **395105-45-0P**, (2E)-N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-phenylprop-2-enamide **395105-47-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide **395105-50-7P**, 3-[3-[2-(Dimethylamino)acetylamino]phenyl]-1H-indazole-5-carboxamide **395105-53-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide **395105-55-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]cyclopropanecarboxamide **395105-57-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-indol-3-yl-2-oxoacetamide **395105-59-6P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-6-chloro-3-pyridinecarboxamide **395105-63-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]cyclopentanecarboxamide **395105-65-4P**, [N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]carbamoyl]formic acid **395105-68-7P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]benzo[b]thiophen-2-carboxamide **395105-71-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-pyridinecarboxamide **395105-73-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-furancarboxamide **395105-75-6P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide **395105-78-9P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]isoxazole-5-carboxamide **395105-80-3P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(2-furyl)-2-oxoacetamide **395105-83-6P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-oxo-2-phenylacetamide **395105-85-8P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]pentanamide **395105-87-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-pyridinecarboxamide **395105-90-5P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-cyclohexylacetamide **395105-92-7P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-phenylpropanamide **395105-94-9P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(4-fluorophenyl)acetamide **395105-96-1P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-(2R)-2-hydroxy-2-phenylacetamide **395105-98-3P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-(2S)-2-hydroxy-2-phenylacetamide **395106-01-1P**, [2-[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl](1H-1,2,4-triazol-5-yl)]ethyl]dimethylamine **395106-04-4P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-(piperidinomethyl)-1H-1,2,4-triazole **395106-12-4P**, Diethyl[[3-[3-(4-fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]amine **395106-13-5P**, 4-[[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]morpholine **395106-16-8P**, 4-[[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1,3,4-oxadiazol-2-yl]methyl]morpholine **395106-17-9P**, 1-[[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]pyrrolidin-2-one **395106-20-4P**, [[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]methylamine **395106-21-5P**, [1-[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]ethyl]dimethylamine **395106-24-8P**, (2R)-N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide **395106-29-3P**, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide **395106-34-0P** **395106-35-1P**, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-methylbutanamide **395106-37-3P**, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395106-40-8P**,

3-[3-(2-Phenylacetylamino)phenyl]-1H-indazole-5-carboxamide **395106-41-9P**, 3-[3-[2-(4-Methoxyphenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-43-1P**, 3-[3-[2-(2-Methyl-1,3-thiazol-5-yl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-46-4P**, 3-[3-(Oxolan-3-ylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395106-48-6P**, 3-[3-[2-(3-Thienyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-50-0P**, 3-[3-(2-Thienylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395106-51-1P**, 3-[3-[2-(4-Pyridyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-52-2P**, 3-[3-[2-(2-Pyridyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-54-4P**, 3-[3-[2-(4-Fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-55-5P**, 3-[3-(Cyclopropylcarbonylamino)phenyl]-1H-indazole-5-carboxamide **395106-56-6P**, 3-[3-[(3-Hydroxyphenyl)carbonylamino]phenyl]-1H-indazole-5-carboxamide **395106-57-7P**, 3-[3-[2-(2,4-Dichlorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-58-8P**, 3-[3-[2-[4-(Trifluoromethyl)phenyl]acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-59-9P**, 3-[3-[2-[4-(Dimethylamino)phenyl]acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-60-2P**, 3-[3-[2-(2-Chloro-4-fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-62-4P**, 3-[3-[2-(4-Chlorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-63-5P**, 3-[3-(3-Phenylpropanoylamino)phenyl]-1H-indazole-5-carboxamide **395106-64-6P**, 3-[3-[3-(4-Fluorophenyl)propanoylamino]phenyl]-1H-indazole-5-carboxamide **395106-65-7P**, 3-[3-[2-(3,4-Difluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-66-8P**, 3-[3-[2-(2-Fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide **395106-68-0P**, 3-[3-(2-Phenylpropanoylamino)phenyl]-1H-indazole-5-carboxamide **395106-69-1P**, 3-[3-(2-Piperidinoethoxy)phenyl]-1H-indazole-5-carboxamide **395106-73-7P**, N-Ethyl-3-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]propanamide **395106-74-8P**, N-[(4-Fluorophenyl)methyl]-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide **395106-81-7P**, N-tert-Butyl-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide **395106-84-0P**, N-((1R)-Indanyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide **395106-87-3P**, [[3-[3-(4-Methoxyphenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine **395106-90-8P**, [[3-[3-(2H-Benzo[d]-1,3-dioxol-5-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine **395106-92-0P**, N-(3-Methoxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395106-93-1P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1,2,4-oxadiazolin-5-one **395106-98-6P**, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]methan-1-ol **395107-01-4P**, N-(2-Piperidinoethyl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide **395107-07-0P**, [[5-[3-(Benzo[d]furan-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]methyl]dimethylamine **395107-09-2P**, N-Phenyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide **395107-12-7P**, N-(4-Fluorophenyl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide dihydrochloride **395107-16-1P**, N-(Indan-2-yl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide **395107-19-4P**, N-Cyclopropyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide **395107-24-1P**, N-Cyclobutyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide dihydrochloride **395107-27-4P**, N-[4-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395107-32-1P**, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(2-methoxyethoxy)benzene **395107-33-2P**, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(3-pyridylmethoxy)benzene **395107-34-3P**, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]benzoic acid **395107-35-4P**,

N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide **395107-36-5P**, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenylacetamide **395107-37-6P**, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide **395107-38-7P**, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(dimethylamino)acetamide **395107-39-8P**, [4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl](methylsulfonyl)amine **395107-40-1P**, N-(2-Methoxyethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-42-3P**, N-Phenyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-43-4P**, N-(2-Phenethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-44-5P**, N-(2-Piperidylethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-45-6P**, 3-[3-[N-(2-Piperidinoethyl)carbamoyl]phenyl]-1H-indazole-5-carboxamide **395107-47-8P**, N-[2-(Morpholin-4-yl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-48-9P**, N-Cyclohexyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-49-0P**, N-Cyclopentyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-51-4P**, N-(4-Fluorophenyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-53-6P**, N-[2-(1-Benzyl-4-piperidyl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-55-8P 395107-57-0P**, N-Cyclopropyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-59-2P**, N-(3-Pyridyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-61-6P**, N-(5,6,7,8-Tetrahydronaphthyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-63-8P**, N-[1-Benzyl-4-piperidyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-65-0P**, N-[1-Benzylpyrrolidin-3-yl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-67-2P**, N-Isopropyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-69-4P**, N-Cyclobutyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-70-7P**, N-(4-Pyridyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide **395107-72-9P**, N-(2-Hydroxyethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395107-73-0P**, N-(3-Hydroxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395107-74-1P**, N-(2-Methoxyethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395107-76-3P**, N-[(Oxolan-2-yl)methyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395107-82-1P** **395107-91-2P**, 6-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-2-methoxynaphthalene **395107-92-3P**, 3-[3-(3-Quinolyl)-1H-indazol-5-yl]-1H-1,2,4-triazole **395107-94-5P**, 3-[2,3-Dihydrobenzo[b]furan-5-yl]-1H-indazole-5-carboxamide **395107-98-9P**, 5-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-2,3-dihydrobenzo[b]furan **395107-99-0P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]benzamide **395108-01-7P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2,4-dichlorobenzamide **395108-03-9P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-methoxybenzamide **395108-05-1P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-methylbenzamide **395108-06-2P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-chlorobenzamide **395108-07-3P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methylpropanamide **395108-08-4P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-methylbutanamide **395108-10-8P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(morpholin-4-yl)acetamide **395108-11-9P**, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(4-methylpiperazino)acetamide **395108-12-0P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-[(4-pyrrolidinopiperidino)methyl]-1H-1,2,4-triazole **395108-14-2P**, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole **395108-16-4P**, [[3-[3-(6-Methoxy-2-naphthyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine **395108-17-5P**, 2-Methoxy-6-[5-[5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]naphthalene

395108-19-7P, N-Phenyl-3-[5-[5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide **395108-23-3P** **395108-26-6P**, N-(3-Oxo-3-pyrrolidinopropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide **395108-28-8P**, 3-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]-N-methylpropanamide **395108-29-9P**, 3-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]-N,N-dimethylpropanamide **395108-30-2P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **13097-01-3P**, 3-Phenyl-1H-indazole **55271-06-2P**, 3-(4-Methoxyphenyl)-1H-indazole **155590-27-5P**, 3-(4-Fluorophenyl)-1H-indazole **395098-98-3P**, 3-(4-Hydroxyphenyl)-1H-indazole **395099-01-1P**, 3-(2-Methoxyphenyl)-1H-indazole
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 54-85-3, Isonicotinic acid hydrazide 64-04-0, Phenethylamine 67-51-6, 3,5-Dimethylpyrazole 75-31-0, Isopropylamine, reactions 75-64-9, tert-Butylamine, reactions 76-83-5, Triphenylmethyl chloride 78-77-3, 1-Bromo-2-methylpropane 78-81-9, Isobutylamine 78-96-6, 1-Amino-2-propanol 79-30-1, 2-Methylpropanoyl chloride 88-74-4, 2-Nitroaniline 89-75-8, 2,4-Dichlorobenzoyl chloride 96-32-2, Methyl bromoacetate 98-09-9, Phenylsulfonyl chloride 98-88-4, Benzoyl chloride 99-06-9, 3-Hydroxybenzoic acid, reactions 99-09-2, 3-Nitroaniline 100-07-2, 4-Methoxybenzoyl chloride 100-20-9, Terephthalic acid chloride 100-42-5, Styrene, reactions 100-43-6, 4-Vinylpyridine 100-55-0, 3-Pyridylcarbinol 100-69-6, 2-Vinylpyridine 103-80-0, Phenylacetyl chloride 103-82-2, Phenylacetic acid, reactions 104-01-8, 4-Methoxyphenylacetic acid 104-58-5, 3-Piperidinopropanol 106-40-1, 4-Bromoaniline 108-00-9, N,N-Dimethylethylenediamine 108-01-0, N,N-Dimethylethanolamine 108-12-3, 3-Methylbutanoyl chloride 108-91-8, Cyclohexylamine, reactions 109-01-3, N-Methylpiperazine 109-55-7, 3-Dimethylaminopropylamine 109-85-3, 2-Methoxyethylamine 121-90-4, 3-Nitrobenzoyl chloride 122-01-0, 4-Chlorobenzoyl chloride 122-04-3 122-78-1, Phenylacetaldehyde 123-00-2, 4-(3-Aminopropyl)morpholine 123-75-1, Pyrrolidine, reactions 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl acrylate 141-75-3, Butanoyl chloride 142-26-7, 2-N-Acetylaminoethanol 156-87-6, 3-Amino-1-propanol 271-44-3, 1H-Indazole 342-24-5, 2-Fluorobenzophenone 371-40-4, 4-Fluoroaniline 403-43-0, 4-Fluorobenzoyl chloride 405-50-5, 2-(4-Fluorophenyl)acetic acid 451-82-1, 2-Fluorophenylacetic acid 459-31-4, 3-(4-Fluorophenyl)propanoic acid 462-08-8, 3-Aminopyridine 488-93-7, Furan-3-carboxylic acid 492-37-5, 2-Phenylpropionic acid 496-12-8, Isoindoline 501-52-0, Hydrocinnamic acid 504-24-5, 4-Aminopyridine 504-29-0, 2-Aminopyridine 527-69-5, 2-Furoyl chloride 527-72-0, 2-Thiophenecarboxylic acid 535-17-1, 2-Acetoxypropionic acid 536-40-3, 4-Chlorobenzoic hydrazide 536-74-3, Phenylacetylene 547-64-8, Methyl lactate 553-53-7, Nicotinic hydrazide 585-32-0, Cumylamine 586-39-0, 3-Nitrostyrene 591-27-5, 3-Aminophenol 611-73-4, 2-Oxo-2-phenylacetic acid 613-94-5, Benzoic hydrazide 619-45-4, Methyl 4-aminobenzoate 622-40-2, 4-(2-Hydroxyethyl)morpholine 636-97-5, 4-Nitrobenzoic hydrazide 638-29-9, Pentanoyl chloride 644-42-8, 3-Methylhistamine 645-45-4, 3-Phenylpropanoyl chloride 658-93-5, 3,4-Difluorophenylacetic acid 661-69-8, Hexamethylditin 765-30-0, Cyclopropylamine 785-56-8, 3,5-Bis(trifluoromethyl)benzoyl chloride 870-46-2, tert-Butyl carbazate 874-60-2, 4-Methylbenzoyl chloride 937-39-3, Phenylacetic hydrazide 940-31-8, 2-Phenoxypropionic acid 1003-03-8, Cyclopentylamine 1075-49-6, 4-Vinylbenzoic acid 1126-09-6, Ethyl 4-piperidinecarboxylate 1194-02-1, 4-Fluorobenzonitrile 1195-45-5, 4-Fluorophenyl isocyanate 1423-26-3, 3-Trifluoromethylphenylboronic acid 1467-70-5, 2-(2-Furyl)-2-oxoacetic

acid 1520-21-4, 4-Vinylaniline 1679-18-1, 4-Chlorophenylboronic acid 1679-64-7, Terephthalic acid monomethyl ester 1692-15-5, 4-Pyridylboronic acid 1692-25-7, 3-Pyridylboronic acid 1759-53-1, Cyclopropanecarboxylic acid 1765-93-1, 4-Fluorophenylboronic acid 1877-71-0, Isophthalic acid monomethyl ester 1986-47-6, trans-2-Phenylcyclopropylamine hydrochloride 2008-75-5, 1-(2-Chloroethyl)piperidine monohydrochloride 2038-03-1, 4-(2-Aminoethyl)morpholine 2133-40-6 2208-07-3, Ethyl acetimidate hydrochloride 2217-40-5, 1,2,3,4-Tetrahydro-1-naphthylamine 2338-18-3, 2-Aminoindan hydrochloride 2491-06-7, N,N-Dimethylglycine hydrochloride 2516-34-9, Cyclobutylamine 2516-47-4, Cyclopropylmethylamine 2544-06-1, 3-Methoxypropionic acid 2627-86-3, (S)-(-)-α-Methylbenzylamine 2835-68-9, 4-Aminobenzamide 2955-88-6, 2-Pyrrolidinoethanol 2975-41-9, 2-Aminoindane 3024-72-4, 3,4-Dichlorobenzoyl chloride 3040-44-6, 2-Piperidinoethanol 3179-63-3, 3-N,N-Dimethylaminopropanol 3290-99-1, 4-Methoxybenzhydrazide 3326-71-4, 2-Furoic acid hydrazide 3445-11-2, 1-(2-Hydroxyethyl)pyrrolidin-2-one 3529-10-0, 4-Dimethylaminobutylamine 3538-65-6, Butyric acid hydrazide 3619-17-8, Isobutyric acid hydrazide 3731-51-9, 2-Aminomethylpyridine 3731-52-0, 3-Aminomethylpyridine 3731-53-1, 4-(Aminomethyl)pyridine 3853-06-3, Methyl 3-(dimethylamino)propanoate 3886-69-9, (R)-(+)-α-Methylbenzylamine 3900-89-8, 2-Chlorophenylboronic acid 3970-21-6, (2-Methoxyethoxy)methyl chloride 4023-34-1, Cyclopropylcarbonyl chloride 4442-79-9, 2-(Cyclohexyl)ethanol 4524-93-0, Cyclopentanecarbonyl chloride 4795-29-3, Tetrahydrofurfurylamine 5122-94-1, 4-Phenylphenylboronic acid 5122-95-2, 3-Phenylphenylboronic acid 5271-67-0, 2-Thiophenecarbonyl chloride 5292-21-7, 2-Cyclohexylacetic acid 5332-24-1, 3-Bromoquinoline 5332-73-0, 3-Methoxypropylamine 5382-16-1, 4-Hydroxypiperidine 5401-94-5, 5-Nitro-1H-indazole 5405-41-4, Ethyl 3-hydroxybutyrate 5438-70-0, Ethyl (4-aminophenyl)acetate 5445-17-0, Methyl 2-bromopropanoate 5538-51-2, Acetyl salicyloyl chloride 5691-09-8, trans-2-Aminomethyl-1-cyclohexanol 5720-05-8, 4-Methylphenylboronic acid 5720-06-9, 2-Methoxyphenylboronic acid 5720-07-0, 4-Methoxyphenylboronic acid 5781-53-3, Methyl (chlorocarbonyl)formate 5813-64-9, 2,2-Dimethylpropylamine 6034-46-4, (S)-(-)-2-Acetoxypropionic acid 6165-68-0, 2-Thiopheneboronic acid 6165-69-1, 3-Thiopheneboronic acid 6456-74-2, tert-Butyl glycinate 6482-24-2, 2-Bromo-1-methoxyethane 6622-91-9, 4-Pyridylacetic acid hydrochloride 6783-05-7, trans-2-Phenylethenylboronic acid 6964-21-2, 3-Thiopheneacetic acid 7065-46-5, 3,3-Dimethylbutanoyl chloride 7171-96-2, N-Amino-2-pyrrolidinoacetamide 7322-88-5, (2S)-2-Acetyloxy-2-phenylacetic acid 7377-26-6, Methyl 4-carboxybenzoyl chloride 10277-74-4, (R)-(-)-1-Aminoindane 10365-98-7, 3-Methoxyphenylboronic acid 10400-19-8, Pyridine-3-carbonyl chloride 13031-60-2, Methyl 4-aminobutyrate hydrochloride 13331-23-2, 2-Furanboronic acid 13331-27-6, 3-Nitrophenylboronic acid 13515-93-0, Methyl 2-(methylamino)acetate hydrochloride 13797-62-1, 2-(2-Methyl-1,3-thiazol-4-yl)acetic acid 13889-98-0, 1-Acetylpiperazine 13922-41-3, 1-Naphthylboronic acid 14002-51-8, 4-Phenylbenzoyl chloride 14794-31-1, Ethyl succinyl chloride 15159-40-7, Morpholine-4-carbonyl chloride 16152-51-5, 4-Isopropylphenylboronic acid 16179-97-8, 2-Pyridylacetic acid hydrochloride 17078-28-3, 4-(Dimethylamino)phenylacetic acid 17082-09-6, (2E)-3-Phenylprop-2-enoyl chloride 17852-28-7, 2-Amino-5-methylphenyl phenyl ketone 18469-52-8, Methyl 4-(aminomethyl)benzoate 18471-40-4, 1-Benzyl-3-aminopyrrolidine 18668-00-3, (R)-2-Acetoxypropionic acid 19335-11-6, 5-Aminoindazole 19719-28-9, 2,4-Dichlorophenylacetic acid 20260-53-1, Pyridine-3-carbonyl chloride hydrochloride 20603-00-3, 2-(Perhydroazepino)ethanol 21615-34-9, 2-Methoxybenzoyl chloride 22980-09-2, 2-(Indol-3-yl)-2-oxoacetyl chloride 26371-07-3, 1-Piperidinepropionic acid 27578-60-5, 1-(2-Aminoethyl)piperidine 28611-39-4, 4-(N,N-Dimethylamino)phenylboronic acid 29745-44-6,

Pyridine-2-carbonyl chloride 30280-35-4, Methyl 2-(diethylamino)acetate 30418-59-8, 3-Aminophenylboronic acid 32316-92-0, 2-Naphthylboronic acid 32857-62-8, 4-(Trifluoromethyl)phenylacetic acid 34052-37-4, 2-Chloro-5-nitrobenzophenone 35855-10-8, Methyl 2-(morpholin-4-yl)acetate 38870-89-2, 2-Methoxyacetyl chloride 39178-35-3, Pyridine-4-carbonyl chloride hydrochloride 39256-35-4, N-Amino-2-(phenylmethoxy)acetamide 39827-11-7, 2-Benzo[b]thiophene-2-carbonyl chloride 39901-94-5, Picolinoyl chloride hydrochloride 50541-93-0, 4-Amino-1-benzylpiperidine 51019-43-3, (R)-2-Acetoxy-2-phenylacetic acid 55552-70-0, 3-Furanboronic acid 57260-71-6, tert-Butyl 1-piperazine carboxylate 57260-73-8, N-(2-Aminoethyl)carbamic acid tert-butyl ester 58249-87-9, [2-(Chlorocarbonyl)phenyl]methyl benzoate 58583-90-7, Methyl 2-piperidinoacetate 58620-93-2, H-β-Ala-O-tert-butyl hydrochloride 58757-38-3, 6-Chloropyridine-3-carbonyl chloride 59776-88-4, Methyl 2-(2-oxopyrrolidinyl)acetate 61341-86-4, (S)-(+)-1-Aminoindane 62348-13-4, Isoxazole-5-carbonyl chloride 63984-02-1, Methyl 5-aminovalerate 71597-85-8, 4-Hydroxybenzeneboronic acid 72316-18-8 75178-96-0 76652-88-5, (S)-2-Acetylpropionic acid 77279-24-4, 2-[4-(tert-Butyloxycarbonyl)piperazino]ethanol 77987-49-6, 2-[N-(Benzyloxycarbonyl)amino]ethanol 84358-13-4, 1-[(tert-Butyl)oxycarbonyl]piperidine-4-carboxylic acid 85068-36-6, 2,5-Difluorobenzophenone 86945-25-7, 4-(2-Aminoethyl)-1-benzylpiperidine 87199-18-6, 3-Hydroxyphenylboronic acid 88443-78-1, 3-Acetoxyphenylacetyl chloride 89364-31-8, Tetrahydro-3-furoic acid 89415-43-0, 4-Aminophenylboronic acid 90555-66-1, 3-Ethoxyphenylboronic acid 91713-56-3, 2-Amino-5-methylphenyl 4-fluorophenyl ketone 94839-07-3, 3,4-(Methylenedioxy)phenylboronic acid 98431-09-5, Ethyl glutaryl chloride 98437-23-1, Benzo[b]thiophene-2-boronic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT 98437-24-2 98546-51-1, 4-(Methylthio)phenylboronic acid 99769-19-4, 3-(Carbomethoxy)phenylboronic acid 122775-35-3, 3,4-Dimethoxyphenylboronic acid 126456-43-7, (1S,2R)-(-)-cis-1-Amino-2-indanol 128796-39-4, 4-Trifluoromethylphenylboronic acid 136030-00-7, (1R,2S)-(+)-cis-1-Amino-2-indanol 151169-75-4, 3,4-Dichlorophenylboronic acid 154230-29-2, trans-2-(4-Chlorophenyl)ethenylboronic acid 156641-98-4, 6-Methoxynaphthalene-2-boronic acid 164014-95-3 177985-32-9, 2-Chloro-4-fluorophenylacetic acid 199292-40-5, 2-Fluoro-5-trifluoromethylbenzophenone 214360-73-3, 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 216019-28-2, 3-Isopropylphenylboronic acid 227305-69-3, 2,3-Dihydrobenzo[b]furan-5-boronic acid 395099-08-8, N-[4-Hydroxy-2-(phenylcarbonyl)phenyl]benzamide 395099-15-7, 1-Acetyl-5-amino-3-phenyl-1H-indazole 395099-49-7, 1-[[3-(4-Fluorophenyl)-5-nitro-1H-indazol-1-yl]methoxy]-2-methoxyethane 395099-52-2, 1-[[3-(4-Fluorophenyl)-5-amino-1H-indazol-1-yl]methoxy]-2-methoxyethane 395099-67-9, 2-[3-(4-Fluorophenyl)-5-amino-1H-indazol-1-yl]perhydro-2H-pyran 395099-73-7, 2-(3-Bromo-5-nitro-1H-indazol-1-yl)perhydro-2H-pyran 395099-97-5, 3-(4-Fluorophenyl)-1-(2-methoxyethoxy)-1H-indazol-5-ylamine 395100-09-1, 3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile **395102-81-5**, 3-(3-Thienyl)-1H-indazole-5-carboxamide **395102-93-9**, 3-(Benzo[b]thiophen-3-yl)-1H-indazole-5-carboxamide **395103-84-1**, Ethoxy[[3-(4-fluorophenyl)-1H-indazol-5-yl]methyl]amine monohydrochloride 395105-02-9, Ethyl 3-bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylate 395106-75-9, Methyl 3-(5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoate 395106-77-1, 3-(5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoic acid **395107-00-3**, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine dihydrochloride 395107-31-0, 3-[5-(1H-1,2,4-Triazol-3-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenol 395108-13-1, Methyl 2-(4-pyrrolidinopiperidino)acetate
RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of indazole derivs. as **JNK** enzyme inhibitors)

IT **155215-87-5, JNK**
RL: **PAC (Pharmacological activity)**; BIOL (Biological study); **THU (Therapeutic use)**; **THU (Therapeutic use)**
(inhibitors; preparation of indazole derivs. as **JNK** enzyme inhibitors)
RN 155215-87-5 HCAPLUS
CN Kinase (phosphorylating), gene c-jun protein N-terminal (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:03:24 ON 07 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4
DICTIONARY FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> => d scan l21

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole, 5-(5-ethyl-1H-1,2,4-triazol-3-yl)-3-(4-fluorophenyl)- (9CI)
MF C17 H14 F N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole-5-carboxamide, 3-(4-chlorophenyl)- (9CI)
MF C14 H10 Cl N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole, 3-(3-fluorophenyl)-5-[5-(2-methylpropyl)-1H-1,2,4-triazol-3-yl]- (9CI)
MF C19 H18 F N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole, 3-(3,4-difluorophenyl)-5-[5-(2-methylpropyl)-1H-1,2,4-triazol-3-yl]- (9CI)
MF C19 H17 F2 N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-phenyl-3-[5-[5-(1-pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]- (9CI)

MF C27 H25 N7 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-cyclopentyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]- (9CI)
MF C21 H20 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole-5-carboxamide, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI)
MF C21 H24 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, α-hydroxy-N-[3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl]-, (αR)- (9CI)

MF C23 H18 N6 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole-5-carboxamide, 3-(2-benzofuranyl)-N-[4-(dimethylamino)butyl]-(9CI)
MF C22 H24 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Propanamine, N,N-dimethyl-3-[3-[5-(1H-tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]-, trifluoroacetate (9CI)
MF C19 H21 N7 O . x C2 H F3 O2

CM 1



CM 2



L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole, 3-(2-benzofuranyl)-5-(1H-1,2,4-triazol-3-yl)- (9CI)
MF C17 H11 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole, 5-(1H-tetrazol-5-yl)-3-(2-thienyl)- (9CI)
MF C12 H8 N6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole, 3-(4-fluorophenyl)-5-[(1E)-2-phenylethenyl]- (9CI)
MF C21 H15 F N2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetic acid, 4-[[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]- (9CI)
MF C22 H16 F N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 3,4-dichloro-N-[3-(4-fluorophenyl)-1H-indazol-5-yl]- (9CI)
MF C20 H12 Cl2 F N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 4-amino-N-(3-phenyl-1H-indazol-5-yl)- (9CI)
MF C20 H16 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole-5-carboxamide, 3-(4-fluoro-3-methoxyphenyl)- (9CI)
MF C15 H12 F N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole, 3-(2,4-difluoro-3-methoxyphenyl)-5-(1H-1,2,4-triazol-3-yl)- (9CI)
MF C16 H11 F2 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole, 3-(4-fluorophenyl)-5-(1-methyl-1H-1,2,4-triazol-3-yl)- (9CI)

MF C16 H12 F N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazole, 3-[3-(1,3-benzodioxol-5-yl)phenyl]-5-[5-(2-methylpropyl)-1H-1,2,4-triazol-3-yl]- (9CI)
MF C26 H23 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 674 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]- (9CI)
MF C23 H24 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 15:03:47 ON 07 OCT 2004

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d l57 all fhitstr tot

L57 ANSWER 1 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:816656 HCAPLUS
DN 135:357932
ED Entered STN: 09 Nov 2001
TI Preparation of heterocyclic pharmaceutical compositions as muscarinic agonists
IN Andersson, Carl-magnus A.; Friberg, Bo Lennart M.; Skjaerbaek, Niels; Spalding, Tracy; Uldam, Allan K.
PA Acadia Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D401-06
ICS C07D413-06; C07D405-06; C07D417-06; C07D409-06; A61K031-454; A61P025-28; A61P027-06; A61P025-18; A61P025-04; C07D471-04
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 2001083472	A1	20011108	WO 2001-US13561	20010427	<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2002037886	A1	20020328	US 2001-844685	20010427	<--
US 6627645	B2	20030930			
EP 1278741	A1	20030129	EP 2001-932682	20010427	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001010420	A	20030701	BR 2001-10420	20010427	<--
JP 2003531901	T2	20031028	JP 2001-580900	20010427	<--

ZA 2002008504	A	20040122	ZA 2002-8504	20021021	<--
NO 2002005115	A	20021219	NO 2002-5115	20021024	<--
PRAI US 2000-200791P	P	20000428	<--		
WO 2001-US13561	W	20010427			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001083472	ICM	C07D401-06
	ICS	C07D413-06; C07D405-06; C07D417-06; C07D409-06; A61K031-454; A61P025-28; A61P027-06; A61P025-18; A61P025-04; C07D471-04
US 2002037886	ECLA	C07D401/06; C07D401/06; C07D401/06; C07D401/06; C07D405/06; C07D409/06; C07D413/06; C07D413/06; C07D417/06; C07D; C07D471/04 <--

OS MARPAT 135:357932

GI





AB Heterocyclic pharmaceutical compns. I (Z1-Z4 = N or carbon substituted with H, NH2, OH, halo, alkyl, alkenyl, heteroalkyl, haloalkyl, CN, CF3, etc. and no more than two of Z1-Z4 = N; W1 = O, S, N; W2 and W3 = N or CR6 or CG where R6 = H, alkyl, CHO, cycloalkyl, (un)substituted aryl; Y = O, S, CHOH, NHC(O), C(O)NH, C(O), OC(O), (O)CO, CH=N or absent; p = 1-5; Z (un)substituted carbon or absent; n = 1-3; R10 = R11 = H, straight/branched (un)substituted alkyl, alkenyl, alkynyl, alkylidene, alkoxy, alkylthio, etc.) or pharmaceutically acceptable salt, ester or prodrug were prepared for treating disease conditions where modification of cholinergic, especially muscarinic M1, M4, or both M1 and M4, receptor activity has a beneficial effect. Thus 35AKU-21 (II) was prepared from 4-butylpiperidine and 1-(3-bromopropyl)-1H-indazole and tested for ocular hypotensive effect in glaucomatous monkeys and had a -29.2% IOP change in 6 h. Data is provided for the screening of test compds. I demonstrating the selective agonist activity using muscarinic receptor subtypes M1, M2, M3, M4 and M5.

ST piperidinyl substituted indazole indole benzimidazole benzotriazole prepn muscarinic agonist; ocular hypotensive prepn; heterocyclization antiglaucoma antiAlzheimer agent prepn

IT Muscarinic receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(M1; preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT Muscarinic receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(M4; preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT Mental disorder
(attention deficit disorder; preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT Heterocyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(bicyclic; preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT Nervous system
(degeneration; preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT Bicyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(heterocyclic; preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT Alzheimer's disease
Anti-Alzheimer's agents
Antiglaucoma agents
Antihypertensives
Digestive tract
Heterocyclization
Muscarinic agonists
(preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT 372195-79-4P 372195-80-7P 372195-89-6P 372196-05-9P 372196-09-3P
372196-15-1P 372196-19-5P 372196-24-2P 372196-30-0P 372196-35-5P
372196-41-3P 372196-47-9P 372196-53-7P 372196-58-2P 372196-61-7P
372196-65-1P 372196-70-8P 372196-76-4P 372196-82-2P 372197-02-9P
372197-07-4P 372197-17-6P 372197-21-2P 372197-28-9P 372197-81-4P
372197-85-8P 372197-91-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT 372195-64-7P 372195-65-8P 372195-66-9P 372195-67-0P 372195-68-1P
372195-69-2P 372195-70-5P 372195-71-6P 372195-72-7P 372195-73-8P
372195-74-9P 372195-75-0P 372195-76-1P 372195-77-2P 372195-78-3P
372195-84-1P 372195-86-3P 372195-87-4P 372195-88-5P 372195-91-0P
372195-92-1P 372195-94-3P 372196-01-5P 372196-07-1P 372196-13-9P
372196-17-3P 372196-22-0P 372196-28-6P 372196-33-3P 372196-39-9P
372196-42-4P 372196-48-0P 372196-56-0P 372196-60-6P 372196-64-0P
372196-68-4P 372196-74-2P 372196-80-0P 372196-86-6P 372196-92-4P
372196-94-6P 372196-98-0P 372197-04-1P 372197-09-6P 372197-13-2P
372197-15-4P 372197-19-8P 372197-22-3P 372197-30-3P 372197-33-6P
372197-39-2P 372197-41-6P 372197-45-0P 372197-47-2P 372197-49-4P
372197-51-8P 372197-53-0P 372197-56-3P 372197-58-5P 372197-60-9P
372197-62-1P 372197-64-3P 372197-67-6P **372197-74-5P**
372197-76-7P 372197-83-6P **372197-89-2P** 372197-95-0P
372197-99-4P 372198-01-1P **372198-03-3P** 372198-05-5P
372198-07-7P 372198-09-9P 372518-00-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT 51-17-2, 1H-Benzimidazole 54-96-6, Pyridine-3,4-diamine 83-34-1, 3-Methyl-1H-indole 89-73-6, Salicylhydroxamic acid 95-15-8, Benzo[b]thiophene 95-20-5, 2-Methyl-1H-indole 95-54-5, 1,2-Diaminobenzene, reactions 95-55-6, 2-Aminophenol 99-56-9, 1,2-Diamino-4-nitrobenzene 106-95-6, Allylbromide, reactions 107-04-0, 1-Bromo-2-chloroethane 109-64-8, 1,3-Dibromopropane 118-93-4 120-72-9, 1H-Indole, reactions 137-07-5, 2-AminobenzENEthiol 271-44-3, Indazole 271-89-6, Benzofuran 273-02-9, 2H-Benzotriazole 312-73-2, 2-Trifluoromethyl-1H-benzimidazole 487-89-8, 1H-Indole-3-carboxaldehyde 582-60-5, 5,6-Dimethylbenzimidazole 614-97-1, 5-Methylbenzimidazole 615-72-5, 1,2-Diamino-4-hydroxybenzene 626-58-4, 4-Methylpiperidine 694-83-7, Cyclohexane-1,2-diamine 703-80-0, 1-(1H-Indol-3-yl)ethanone 716-79-0, 2-Phenylbenzimidazole 771-51-7, 1H-Indole-3-acetonitrile 830-96-6, 3-Indolepropionic acid 1066-45-1, Trimethyltin chloride 1779-51-7, Butyltriphenylphosphonium bromide 2687-25-4, 1,2-Diamino-3-methylbenzene 3389-21-7, 3-(2-Bromoethyl)indole 3422-01-3, Phenylcarbamic acid tert-butyl ester 3612-20-2, 1-Benzyl-4-piperidone 3694-52-8, 1,2-Diamino-3-nitrobenzene 4498-67-3, 1H-Indazole-3-carboxylic acid 4635-59-0, 4-Chlorobutanoyl chloride 4760-34-3, N-Methylbenzene-1,2-diamine 4856-97-7, 1H-Benzimidazole-2-methanol 4887-80-3, 5-Methoxybenzimidazole 4897-84-1, 4-Bromobutyric acid methyl ester 5401-94-5, 5-Nitroindazole 5457-28-3, 1H-Indole-3-carbonitrile 5470-11-1, Hydroxylammonium chloride 6940-76-7, 1-Chloro-3-iodopropane 7342-82-7, 3-Bromobenzo[b]thiophene 7597-18-4, 6-Nitroindazole 10075-50-0, 5-Bromo-1H-indole 13754-19-3, Pyrimidine-4,5-diamine 17514-63-5 19614-16-5, 2-Bromothioanisole 21535-97-7, 3-Methylbenzofuran 22306-36-1, 1-Bromo-3-iodopropane 22398-09-0, 4-Propylpiperidine 24152-40-7 29110-74-5, 3-Chloroindazole 31252-42-3, 4-Benzylpiperidine 36238-83-2 51417-51-7, 7-Bromo-1H-indole 58333-75-8, 4-(2-Methoxyphenyl)piperidine 63155-04-4 68176-57-8, 4-tert-Butyl-1,2-diaminobenzene 113269-06-0 127491-00-3, 1H-Benzotriazole-4,5-diamine 153505-39-6 358625-95-3, 4-Pentylidenepiperidine 372195-85-2, 4-Butylpiperidine hydrochloride 372196-26-4 372196-37-7, 4-Propylidenepiperidine 372196-44-6 372197-43-8 372197-87-0 372197-93-8 372197-97-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

IT 1196-29-8P 2369-29-1P, 1,2-Diamino-3,5-difluorobenzene 3569-21-9P, 1H-Indole-3-propanol 4825-75-6P 21725-69-9P, 1,2-Benzisoxazol-3(2H)-one 24152-39-4P 31909-07-6P 62781-36-6P 90562-04-2P 114552-32-8P 116578-61-1P 132439-21-5P 321656-05-7P 372195-81-8P 372195-82-9P 372195-83-0P, 1,2-Benzisoxazole-3-propanal 372195-96-5P 372195-99-8P 372196-03-7P 372196-72-0P 372196-78-6P 372196-84-4P 372196-88-8P 372197-26-7P 372197-72-3P 372197-78-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Glaser, T; US 4870085 A 1989 HCAPLUS
(2) Koninklijke Pharmaceutische Fabrieken VH Brocades-Steehman & Pharmaci; NL 6511642 A 1966 HCAPLUS
(3) Lounasmaa; TETRAHEDRON 1989, V45(12), P3975 HCAPLUS
(4) Lounasmaa; TETRAHEDRON 1991, V47(32), P6371 HCAPLUS
(5) Lounasmaa, M; TETRAHEDRON 1997, V53(14), P5349 HCAPLUS
(6) Troponwerke Gmbh & Co Kg; DE 4039631 A 1992 HCAPLUS

IT **372197-85-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); **THU (Therapeutic use)**;

THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic pharmaceutical compns. with agonist activity at the M1/M4 muscarinic receptors)

RN 372197-85-8 HCAPLUS
CN 1H-Indazole, 3-[3-(4-butyl-1-piperidinyl)propyl]-5-methoxy- (9CI) (CA INDEX NAME)



L57 ANSWER 2 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:545668 HCAPLUS
DN 135:137505
ED Entered STN: 27 Jul 2001
TI Synthesis of disubstituted indazole compounds as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation
IN Reich, Siegfried Heinz; Bleckman, Ted Michael; Kephart, Susan Elizabeth; Romines, William Henry, III; Wallace, Michael B.
PA Agouron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D231-56
ICS C07D403-04; C07D401-04; C07D401-14; A61K031-416; A61K031-4184; A61K031-4439; A61P035-00
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001053268	A2	20010726	WO 2001-US1477	20010118 <--
WO 2001053268	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1250326	A2	20021023	EP 2001-942620	20010118 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002161022	A1	20021031	US 2001-761656	20010118 <--
US 6555539	B2	20030429		
BR 2001007783	A	20021119	BR 2001-7783	20010118 <--
JP 2003520273	T2	20030702	JP 2001-553270	20010118 <--
EE 200200398	A	20031015	EE 2002-398	20010118 <--
ZA 2002003040	A	20030811	ZA 2002-3040	20020417 <--
NO 2002002117	A	20020916	NO 2002-2117	20020503 <--
BG 107011	A	20030430	BG 2002-107011	20020816 <--
US 2003139463	A1	20030724	US 2002-291158	20021108 <--
PRAI US 2000-176484P	P	20000118 <--		

US 2001-761656	A3	20010118
WO 2001-US1477	W	20010118

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 2001053268	ICM	C07D231-56	
	ICS	C07D403-04; C07D401-04; C07D401-14; A61K031-416; A61K031-4184; A61K031-4439; A61P035-00	
US 2002161022	ECLA	C07D231/56B; C07D401/04; C07D401/04; C07D401/04; C07D401/04; C07D401/14; C07D401/14; C07D401/14; C07D401/14; C07D401/14; C07D401/14; C07D401/14R; C07D403/04; C07D403/04; C07D471/04; C07D521/00B1C8	<--
US 2003139463	ECLA	C07D231/56B; C07D401/04; C07D401/04; C07D401/04; C07D401/04; C07D401/14; C07D401/14; C07D401/14; C07D401/14; C07D401/14; C07D401/14; C07D401/14; C07D401/14R; C07D403/04; C07D403/04; C07D471/04; C07D521/00B1C8	<--

OS MARPAT 135:137505

GI



I

AB Title compds. I [R1 = alkyl, aryl, heteroaryl, carbocycle, heterocycle, etc.; R2 = alkyl, aryl, heteroaryl, carbocycle, heterocycle, etc.] were prepared Examples include over 90 synthetic examples and 8 bioassays. For instance, 5-amino-1H-indazole was converted to 5-chloro-3-iodo-1H-indazole by diazotization/chlorination (NaNO2, HCl, 0°C/CuCl, 60°C) followed by iodination (I2, NaOHaq). Protection as the N-SEM derivative and sequential Suzuki coupling with (E)-β-styreneboronic acid to the 3 position and phenylboronic acid to the 5-position yielded N-SEM derivative I (R1 = (E)-β-styrenyl; R2 = Ph). Deprotection with 3M HCl in EtOH at reflux afforded I (R1 = (E)-β-styrenyl; R2 = Ph; II). II had Ki = 1.7 μM for cdk4/cyclin D3 complex and Ki = 6.7 μM for chk1 protein kinase. Selected examples of I were also assayed for cytotoxicity (HCT 116 cell line, 69 examples). The invention is also directed to methods of treating cancer and disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis.

ST indazole cyclin dependent kinase inhibitor prepn; styrene benzimidazole pyridine phenol kinase inhibitor prepn; angiogenesis quinoline pyridazine pyrrole kinase inhibitor prepn

IT Proliferation inhibition
(proliferation inhibitors; synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

IT Angiogenesis inhibitors
Antitumor agents
Cyclin dependent kinase inhibitors
Cytotoxicity
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

IT **351454-76-7P 351454-82-5P 351456-19-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

IT **351454-59-6P 351454-61-0P 351454-64-3P**
351454-67-6P 351454-70-1P 351454-73-4P
351454-79-0P 351454-85-8P 351454-88-1P
351454-91-6P 351454-94-9P 351454-97-2P
351455-00-0P 351455-03-3P 351455-06-6P
351455-09-9P 351455-12-4P 351455-15-7P
351455-18-0P 351455-21-5P 351455-23-7P
351455-26-0P 351455-28-2P 351455-30-6P
351455-32-8P 351455-34-0P 351455-36-2P
351455-38-4P 351455-40-8P 351455-42-0P
351455-44-2P 351455-45-3P 351455-46-4P
351455-47-5P 351455-49-7P 351455-51-1P
351455-53-3P 351455-55-5P 351455-57-7P
351455-59-9P 351455-61-3P 351455-63-5P
351455-65-7P 351455-67-9P 351455-69-1P
351455-71-5P 351455-73-7P 351455-75-9P
351455-77-1P 351455-79-3P 351455-81-7P
351455-83-9P 351455-85-1P 351455-87-3P
351455-89-5P 351455-91-9P 351455-93-1P
351455-95-3P 351455-97-5P 351455-99-7P
351456-01-4P 351456-03-6P 351456-05-8P
351456-07-0P 351456-09-2P 351456-11-6P
351456-13-8P 351456-15-0P 351456-17-2P
351456-21-8P 351456-23-0P 351456-25-2P
351456-27-4P 351456-28-5P 351456-29-6P
351456-30-9P **351456-31-0P 351456-32-1P**
351456-33-2P 351456-34-3P 351456-35-4P
351456-36-5P 351456-37-6P 351456-38-7P
351456-39-8P 351456-40-1P 351456-41-2P
351456-42-3P 351456-43-4P 351456-44-5P
351458-50-9P 351458-51-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

IT 144114-16-9 146279-88-1 150977-45-0D, Δ50 construct of 153190-75-1 154907-65-0 208996-51-4
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

IT 74-89-5, Methylamine, reactions 75-04-7, Ethylamine, reactions 75-31-0, Isopropylamine, reactions 75-64-9, tert-Butylamine, reactions 95-54-5, 1,2-Phenylenediamine, reactions 98-80-6, Phenylboronic acid 100-46-9, Benzylamine, reactions 100-52-7, Benzaldehyde, reactions 106-95-6, Allyl bromide, reactions 109-89-7, Diethylamine, reactions 109-97-7, Pyrrole 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 141-43-5, 2-Aminoethanol, reactions 288-32-4, Imidazole, reactions 302-01-2, Hydrazine, reactions 367-27-1, 2,4-Difluorophenol 462-08-8, 3-Aminopyridine 579-07-7, 1-Phenyl-1,2-propanedione 606-18-8, 3-Nitroanthranilic acid 611-35-8, 4-Chloroquinoline 625-92-3, 3,5-Dibromopyridine 661-69-8, Hexamethylditin 765-39-9, 1-Aminopyrrole 765-87-7, 1,2-Cyclohexanedione 824-94-2, 4-Methoxybenzyl chloride 1003-03-8, Cyclopentylamine 1071-46-1 1118-02-1, Trimethylsilylisocyanate 1423-27-4, 2-Trifluoromethylphenyl boronic acid 1532-97-4, 4-Bromoisoquinoline 1692-15-5, 4-Pyridinyl boronic acid 1692-25-7, 3-Pyridinyl boronic acid 1993-03-9, 2-Fluorophenyl boronic acid 2516-47-4, Aminomethylcyclopropane 2713-34-0, 3,5-Difluorophenol

3430-22-6, 3-Bromo-4-methylpyridine 3430-23-7 4498-67-3,
1H-Indazole-3-carboxylic acid 4837-88-1, 2-Methyl-3-nitroanisole
5382-16-1, 4-Hydroxypiperidine 5401-94-5, 5-Nitroindazole 5460-31-1,
2-Methyl-3-nitrophenol 5720-07-0, 4-Methoxyphenyl boronic acid
6638-79-5, Methoxy methyl amine hydrochloride 6783-05-7 6859-99-0,
3-Hydroxypiperidine 7304-32-7, 2-Fluoro-5-nitrobenzoic acid 7651-83-4,
7-Hydroxyisoquinoline 10168-00-0, 4-Bromo-3-methylpyridine 10365-98-7,
3-Methoxyphenyl boronic acid 10400-19-8, Nicotinoyl chloride
16552-65-1, 5-Amino-4-bromoisoquinoline 17997-47-6, 2-Tributylstannyl
pyridine 19335-11-6, 5-Amino-1H-indazole 23491-48-7 34052-37-4,
2-Chloro-5-nitrobenzophenone 36635-61-7, Tosylmethyl isocyanide
41018-86-4 52488-36-5, 4-Bromoindole 59280-69-2, 3-Bromo-4-
methylquinoline 59483-54-4, 3-Chloro-2-nitroaniline 59649-56-8
73183-34-3 76320-87-1 76345-48-7 76513-69-4 87199-15-3,
3-(Hydroxymethyl)phenyl boronic acid 89167-34-0 95067-35-9
106018-85-3 162101-25-9, 2,6-Difluorophenylboronic acid 192182-56-2
319473-23-9 319473-70-6 351458-46-3 351458-49-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

IT 709-46-6P, 2-Fluoro-5-nitrobenzoyl chloride 13958-99-1P 19500-02-8P
20864-49-7P 21093-09-4P 21745-41-5P, 3-Chlorobenzene-1,2-diamine
27063-98-5P 53222-92-7P, 3-Amino-2-methylphenol 55919-82-9P
97231-91-9P 101226-37-3P, 1-[2-(Trimethylsilylethoxy)methyl]-1H-
benzimidazole 116529-75-0P 125419-80-9P 135361-30-7P 139743-08-1P
154544-53-3P 159724-49-9P 193694-04-1P 194784-10-6P 273749-25-0P
293758-67-5P 319473-09-1P 351456-45-6P 351456-46-7P 351456-47-8P
351456-48-9P 351456-49-0P 351456-50-3P 351456-51-4P 351456-52-5P
351456-53-6P 351456-55-8P 351456-57-0P 351456-59-2P 351456-61-6P
351456-63-8P 351456-65-0P 351456-69-4P 351456-71-8P 351456-74-1P
351456-76-3P 351456-78-5P 351456-80-9P 351456-82-1P 351456-84-3P
351456-86-5P 351456-88-7P 351456-90-1P **351456-92-3P**
351456-94-5P 351456-96-7P 351456-98-9P 351457-00-6P 351457-02-8P
351457-04-0P 351457-06-2P 351457-08-4P **351457-10-8P**
351457-12-0P 351457-14-2P 351457-16-4P 351457-18-6P 351457-20-0P
351457-22-2P 351457-23-3P 351457-24-4P 351457-25-5P 351457-26-6P
351457-27-7P 351457-28-8P 351457-29-9P 351457-30-2P
351457-31-3P 351457-32-4P 351457-33-5P 351457-34-6P 351457-35-7P
351457-36-8P 351457-37-9P 351457-38-0P 351457-39-1P 351457-40-4P
351457-41-5P 351457-42-6P 351457-43-7P 351457-44-8P 351457-45-9P
351457-46-0P 351457-47-1P 351457-48-2P 351457-49-3P 351457-50-6P
351457-51-7P 351457-52-8P 351457-53-9P 351457-54-0P 351457-55-1P
351457-56-2P 351457-57-3P 351457-58-4P 351457-59-5P 351457-60-8P
351457-61-9P 351457-62-0P 351457-63-1P 351457-64-2P 351457-65-3P
351457-66-4P 351457-67-5P 351457-68-6P 351457-69-7P 351457-70-0P
351457-71-1P 351457-72-2P 351457-73-3P 351457-74-4P 351457-75-5P
351457-76-6P 351457-77-7P 351457-78-8P 351457-79-9P 351457-80-2P
351457-81-3P 351457-82-4P 351457-83-5P 351457-84-6P 351457-85-7P
351457-86-8P 351457-87-9P 351457-88-0P 351457-89-1P 351457-90-4P
351457-91-5P 351457-92-6P 351457-93-7P 351457-94-8P 351457-95-9P
351457-96-0P 351457-97-1P 351457-98-2P 351457-99-3P 351458-00-9P
351458-01-0P 351458-02-1P 351458-03-2P 351458-04-3P 351458-05-4P
351458-06-5P 351458-07-6P 351458-08-7P 351458-09-8P 351458-10-1P
351458-11-2P 351458-12-3P 351458-13-4P 351458-14-5P 351458-15-6P
351458-16-7P 351458-17-8P 351458-18-9P 351458-19-0P 351458-20-3P
351458-21-4P 351458-22-5P 351458-23-6P 351458-24-7P 351458-25-8P
351458-26-9P 351458-27-0P 351458-28-1P 351458-29-2P 351458-30-5P
351458-31-6P 351458-32-7P 351458-33-8P 351458-34-9P 351458-35-0P
351458-36-1P 351458-37-2P 351458-38-3P 351458-52-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

IT **351454-76-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); **THU (Therapeutic use)**; **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)
RN 351454-76-7 HCAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L57 ANSWER 3 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:208282 HCAPLUS
DN 134:237472
ED Entered STN: 22 Mar 2001
TI Preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists
IN Fink, David M.; Freed, Brian S.; Hrib, Nicholas J.; Kosley, Raymond W., Jr.; Lee, George E.; Merriman, Gregory H.; Rauckman, Barbara S.
PA Aventis Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D498-04
ICS C07D519-00; A61K031-40; A61K031-55; A61K031-501; A61K031-42; A61K031-44; A61K031-506; A61P025-18; C07D498-04; C07D333-00; C07D261-00; C07D519-00; C07D498-00; C07D451-00; C07D519-00; C07D498-00; C07D495-00
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019833	A1	20010322	WO 2000-US24962	20000913 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000014515	A	20020625	BR 2000-14515	20000913 <--
EP 1216250	A1	20020626	EP 2000-964969	20000913 <--
EP 1216250	B1	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EE 200200135	A	20030415	EE 2002-135	20000913 <--
AT 254621	E	20031215	AT 2000-964969	20000913 <--
PT 1216250	T	20040430	PT 2000-964969	20000913 <--
ES 2209995	T3	20040701	ES 2000-964969	20000913 <--

	TW 530060	B	20030501	TW 2000-89118850	20000914 <--
	NO 2002001251	A	20020510	NO 2002-1251	20020313 <--
	ZA 2002001762	A	20030602	ZA 2002-1762	20020321 <--
PRAI	US 1999-396081	A1	19990914 <--		
	WO 2000-US24962	W	20000913		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001019833	ICM	C07D498-04
	ICS	C07D519-00; A61K031-40; A61K031-55; A61K031-501; A61K031-42; A61K031-44; A61K031-506; A61P025-18; C07D498-04; C07D333-00; C07D261-00; C07D519-00; C07D498-00; C07D451-00; C07D519-00; C07D498-00; C07D495-00

OS MARPAT 134:237472

AB RZOCH2CR1R2CH2NR3R4 [I; R = e.g., thieno[2,3-d]isoxazol-3-yl; R1 = OH or alkoxy; R2,R4 = H or alkyl; R3 = CH2R5, CH2CH(OH)R5, indanyl, etc.; R5 = cyclohex(en)yl, (hetero)aryl, etc.; Z = phenylene] were prepared Thus, 3-bromothiophene was acylated by 3-(MeO)C6H4COCl and the oximated product cyclized to give, after O-demethylation, 3-RC6H4OH [R = thieno[2,3-d]isoxazol-3-yl] which was etherified by (R)-glycidyl tosylate and the product aminated by PhCHMeNH2 to give (R)-3-RC6H4OCH2CH(OH)CH2NMeCH2Ph (R as above). Data for biol. activity of I were given.

ST thienoisoxazolylphenoxypropanol prepn dopamine D4 antagonist; psychotropic thienoisoxazolylphenoxypropanol prepn

IT Dopamine receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(D4, mediated disorders; treatment; preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)

IT Dopamine antagonists
Psychotropics
(preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)

IT 330650-04-9P 330650-05-0P 330650-06-1P 330650-07-2P
330650-08-3P 330650-09-4P 330650-10-7P 330650-11-8P
330650-12-9P 330650-13-0P 330650-14-1P 330650-15-2P 330650-16-3P
330650-17-4P 330650-18-5P 330650-19-6P 330650-20-9P 330650-21-0P
330650-22-1P 330650-23-2P 330650-24-3P 330650-25-4P 330650-26-5P
330650-27-6P 330650-28-7P 330650-29-8P 330650-30-1P 330650-31-2P
330650-32-3P 330650-33-4P 330650-34-5P 330650-35-6P 330650-36-7P
330650-37-8P 330650-38-9P 330650-39-0P 330650-40-3P 330650-41-4P
330650-42-5P 330650-43-6P 330650-44-7P 330650-45-8P 330650-46-9P
330650-47-0P 330650-48-1P 330650-49-2P 330650-50-5P 330650-51-6P
330650-52-7P 330650-53-8P 330650-54-9P 330650-55-0P 330650-56-1P
330650-57-2P 330650-58-3P 330650-59-4P 330650-60-7P 330650-61-8P
330650-62-9P 330650-63-0P 330650-64-1P 330650-65-2P 330650-66-3P
330650-67-4P 330650-68-5P 330650-69-6P 330650-70-9P 330650-71-0P
330650-72-1P 330650-73-2P 330650-74-3P 330650-75-4P 330650-76-5P
330650-77-6P 330650-78-7P 330650-79-8P 330650-82-3P 330650-83-4P
330650-84-5P 330650-85-6P 330650-86-7P 330650-87-8P 330650-88-9P
330650-89-0P 330650-90-3P 330650-91-4P 330650-92-5P 330650-93-6P
330650-94-7P 330650-95-8P 330650-96-9P 330650-97-0P 330650-98-1P
330650-99-2P 330651-00-8P 330651-01-9P 330651-02-0P 330651-03-1P
330651-04-2P 330651-05-3P 330651-06-4P 330651-07-5P 330651-08-6P
330651-09-7P 330651-10-0P 330651-11-1P 330651-12-2P 330651-13-3P
330651-14-4P 330651-15-5P 330651-16-6P 330651-17-7P 330651-18-8P
330651-19-9P 330651-20-2P 330651-21-3P 330651-22-4P 330651-23-5P
330651-24-6P 330672-14-5P 330672-15-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)

IT 89-97-4, 2-Chlorobenzylamine 89-99-6, 2-Fluorobenzylamine 91-21-4, 1,2,3,4-Tetrahydroisoquinoline 92-54-6, 1-Phenylpiperazine 98-59-9, Tosyl chloride 100-07-2, p-Methoxybenzoyl chloride 100-46-9, Benzylamine, reactions 100-82-3, 3-Fluorobenzylamine 102-49-8, 3,4-Dichlorobenzylamine 103-67-3, N-Methylbenzylamine 104-84-7, 4-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine 110-89-4, Piperidine, reactions 118-31-0, 1-Naphthalenemethylamine 140-75-0, 4-Fluorobenzylamine 617-89-0, Furfurylamine 768-94-5, 1-Adamantanamine 872-31-1, 3-Bromothiophene 1011-15-0, 1-(2-Fluorophenyl)piperazine 1711-05-3, 3-Methoxybenzoyl chloride 2217-40-5, 1,2,3,4-Tetrahydro-1-naphthylamine 2252-63-3, 1-(4-Fluorophenyl)piperazine 2328-12-3, 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 2338-18-3, 2-Aminoindan hydrochloride 2393-23-9, 4-Methoxybenzylamine 2627-86-3, (S)-α-Methylbenzylamine 3218-02-8, Cyclohexanemethylamine 3300-51-4, 4-Trifluoromethylbenzylamine 3731-51-9, 2-Aminomethylpyridine 3731-52-0, 3-Aminomethylpyridine 3731-53-1, 4-Aminomethylpyridine 3886-69-9 5446-02-6, Methyl 4-methoxysalicylate 5993-91-9, 2-Aminomethylbenzimidazole dihydrochloride 6850-57-3, 2-Methoxybenzylamine 7568-93-6, 2-Amino-1-phenylethanol 13078-15-4, 1-(3-Chlorophenyl)piperazine hydrochloride 16502-01-5, 1,2,3,4-Tetrahydro-β-carboline 20662-53-7 27757-86-4, 3-Thiophenemethanamine 30433-91-1, 2-Thiopheneethanamine 31252-42-3, 4-Benzylpiperidine 32231-06-4 34698-41-4, 1-Aminoindan 34803-66-2, 1-(2-Pyridinyl)piperazine 35386-24-4, 1-(2-Methoxyphenyl)piperazine 35947-12-7, 1-(4-Methoxyphenyl)-2-methylpiperazine 38212-33-8, 1-(4-Chlorophenyl)piperazine 38869-47-5, 1-(4-Methoxyphenyl)piperazine dihydrochloride 39512-49-7, 4-(4-Chlorophenyl)-4-hydroxypiperidine 41202-32-8 56346-57-7, 4-(4-Fluorobenzoyl)piperidine 63854-31-9, 1-(2-Trifluoromethylphenyl)piperazine 72235-53-1, 3,4-Difluorobenzylamine 84163-13-3 84163-77-9 87691-87-0 87757-07-1 94021-22-4, 1-(2-Pyrimidinyl)piperazine dihydrochloride 97840-40-9, 4-(3-Chlorophenoxy)piperidine 111373-03-6, 2-(1-Piperazinyl)benzonitrile 113826-06-5 115132-84-8, 3-Thiophenemethanamine hydrochloride 115314-17-5 118200-96-7 128520-83-2 **131634-54-3** 143697-74-9 145759-43-9 150555-95-6 152535-43-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)

IT 28783-41-7P 89942-57-4P 110894-88-7P 110894-89-8P 110894-90-1P 110894-91-2P 110894-93-4P 110894-94-5P 110894-95-6P 110894-97-8P 110895-01-7P 157368-62-2P 179820-83-8P 330651-26-8P 330651-27-9P 330651-28-0P 330651-29-1P 330651-30-4P 330651-31-5P 330651-32-6P 330651-33-7P 330651-34-8P 330651-35-9P 330651-36-0P 330651-37-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Duphar International Research B V; WO 9940067 A 1999 HCAPLUS

(2) Hoechst-Roussel Pharmaceuticals Inc; EP 0221414 A 1987 HCAPLUS

IT **330650-08-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)

RN 330650-08-3 HCAPLUS

CN 1-Piperazineethanol, 4-(5-methoxy-1H-indazol-3-yl)-α-[(3-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 4 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:115143 HCAPLUS
DN 134:163054
ED Entered STN: 15 Feb 2001
TI Preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists
IN Clark, Robin Douglas; O'Yang, Counde
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D401-14
ICS C07D471-04; A61K031-517; A61P013-00
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**, **63**

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010860	A2	20010215	WO 2000-EP7336	20000728 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6258819	B1	20010710	US 2000-626806	20000727 <--
	US 2001051627	A1	20011213	US 2001-803078	20010308 <--
	US 6376500	B2	20020423		
PRAI	US 1999-147537P	P	19990805 <--		
	US 2000-191342P	P	20000322 <--		
	US 2000-626806	A3	20000727 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001010860	ICM	C07D401-14
	ICS	C07D471-04; A61K031-517; A61P013-00

OS MARPAT 134:163054
GI



I



II

AB The title compds. [I; AB = NHC, NHN, OC, SC; Z = benzene, pyridine; R1-R4 = H, halo, alkyl, etc.; m = 0-3; n = 1-6] and their pharmaceutically acceptable salts which are generally alpha1A/B-receptor antagonists, and are useful for the treatment of disorders of the urinary tract such as benign prostatic hypertrophy (BPH) and for analgesic/antihyperalgesic therapies for treating pain, were prepared and formulated. E.g., a multi-step synthesis of the quinazolinone II which showed pKi of 8.79 and 8.5 in assays for [3H]prazosin binding at adrenoceptors alpha1A and alpha1B, resp., was given.

ST adrenoceptor alpha 1A 1B antagonist quinazolinone azaquinazolinone prepn formulation; benign prostatic hypertrophy quinazolinone azaquinazolinone prepn formulation; prostate gland benign hyperplasia quinazolinone azaquinazolinone prepn formulation; analgesic quinazolinone azaquinazolinone prepn formulation; urinary tract disorder quinazolinone azaquinazolinone prepn formulation

IT Prostate gland
(benign hyperplasia, treatment of; preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists)

IT Urinary tract
(disease, treatment of; preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists)

IT Analgesics
(preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(α1A; preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(α1B; preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists)

IT 325772-33-6P 325772-34-7P 325772-35-8P 325772-37-0P 325772-38-1P
325772-39-2P 325772-40-5P 325772-42-7P 325772-44-9P 325772-45-0P
325772-46-1P 325772-47-2P 325772-49-4P 325772-51-8P 325772-53-0P
325772-55-2P 325772-57-4P 325772-59-6P 325772-61-0P 325772-63-2P
325772-65-4P 325772-67-6P 325772-69-8P 325772-71-2P 325772-73-4P

325772-75-6P 325772-77-8P 325772-79-0P 325772-80-3P 325772-81-4P
325772-82-5P 325772-83-6P 325772-84-7P 325772-85-8P 325772-86-9P
325772-87-0P 325772-88-1P 325772-89-2P 325772-90-5P 325772-91-6P
325772-92-7P 325772-93-8P 325772-94-9P 325772-95-0P
325772-97-2P 325772-99-4P 325773-01-1P
325773-03-3P 325773-05-5P 325773-07-7P
325773-09-9P 325773-11-3P 325773-13-5P 325773-14-6P
325773-15-7P 325773-16-8P 325773-17-9P 325773-18-0P 325773-19-1P
325773-20-4P 325773-21-5P 325773-22-6P 325773-23-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists)

IT 118-92-3, 2-Aminobenzoic acid 3389-21-7, 3-(2-Bromoethyl)indole 13438-65-8, 2-Aminonicotinamide 84358-13-4, N-(tert-Butoxycarbonyl)-4-piperidinecarboxylic acid 127561-10-8, 3-(2-Bromoethyl)-5-fluoroindole 325773-39-5, 3-(2-Bromoethyl)-5-chloroindole 325773-40-8, 3-(2-Bromoethyl)-6-chloroindole 325773-41-9, 3-(2-Bromoethyl)-6-fluoroindole 325773-42-0, 3-(2-Bromoethyl)-5-chloro-1H-indazole 325773-43-1, 3-(2-Bromoethyl)-6-fluoro-1H-indazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists)

IT 325773-24-8P 325773-25-9P 325773-26-0P 325773-27-1P 325773-28-2P
325773-29-3P 325773-30-6P 325773-31-7P 325773-32-8P 325773-33-9P
325773-34-0P 325773-35-1P 325773-36-2P 325773-37-3P 325773-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists)

IT **325772-97-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolinones and azaquinazolinones as α1A/B-receptor antagonists)

RN 325772-97-2 HCAPLUS
CN 4(1H)-Quinazolinone, 2-[1-[2-(5-chloro-1H-indazol-3-yl)ethyl]-4-piperidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 325772-96-1
CMF C22 H22 Cl N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L57 ANSWER 5 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:900647 HCAPLUS
DN 134:56657
ED Entered STN: 22 Dec 2000
TI Preparation of substituted heterocycle fused gamma-carbolines
IN Robichaud, Albert J.; Lee, Taekyu; Deng, Wei; Mitchell, Ian S.; Haydar, Simon; Chen, Wenting; McClung, Christopher D.; Calvello, Emilie J. B.; Zawrotny, David M.
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 764 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D513-16
ICS C07D519-00; C07D495-06; C07D491-06; A61K031-55; A61K031-4353; A61P025-00; C07D513-16; C07D281-00; C07D221-00; C07D209-00; C07D519-00; C07D513-00; C07D471-00; C07D519-00; C07D513-00; C07D473-00; C07D495-06; C07D337-00; C07D223-00
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000077010	A2	20001221	WO 2000-US16373	20000615	<--
	WO 2000077010	A3	20010628			
	W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	EP 1192165	A2	20020403	EP 2000-942807	20000615	<--
	EP 1192165	B1	20040922			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	BR 2000012411	A	20020416	BR 2000-12411	20000615	<--
	TR 200103658	T2	20020621	TR 2001-200103658	20000615	<--
	JP 2003502336	T2	20030121	JP 2001-503867	20000615	<--
	US 6548493	B1	20030415	US 2000-594008	20000615	<--
	US 6552017	B1	20030422	US 2000-595250	20000615	<--
	US 6713471	B1	20040330	US 2000-594954	20000615	<--
	ZA 2001009735	A	20040127	ZA 2001-9735	20011127	<--
	NO 2001006128	A	20020211	NO 2001-6128	20011214	<--
	US 2004034015	A1	20040219	US 2003-370878	20030220	<--
	US 2004127482	A1	20040701	US 2003-370872	20030220	<--
PRAI	US 1999-139321P	P	19990615	<--		
	US 2000-594008	A3	20000615	<--		
	US 2000-595250	A3	20000615	<--		
	WO 2000-US16373	W	20000615	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000077010	ICM	C07D513-16
	ICS	C07D519-00; C07D495-06; C07D491-06; A61K031-55; A61K031-4353; A61P025-00; C07D513-16; C07D281-00; C07D221-00; C07D209-00; C07D519-00; C07D513-00;

C07D471-00; C07D519-00; C07D513-00; C07D473-00;
C07D495-06; C07D337-00; C07D223-00
US 2004034015 ECLA C07D221/18; C07D223/32; C07D471/06; C07D471/06;
C07D471/06; C07D071/16; C07D471/16; C07D471/16;
C07D471/16; C07D471/16; C07D487/16; C07D491/06;
C07D491/06; C07D491/06; C07D495/06; C07D495/06;
C07D495/06; C07D495/06; C07D495/06; C07D495/06;
C07D513/16; C07D519/00; C07D519/00 <--
US 2004127482 ECLA C07D221/18; C07D223/32; C07D471/06; C07D471/06;
C07D471/06; C07D071/16; C07D471/16; C07D471/16;
C07D471/16; C07D471/16; C07D487/16; C07D491/06;
C07D491/06; C07D491/06; C07D495/06; C07D495/06;
C07D495/06; C07D495/06; C07D495/06; C07D495/06;
C07D513/16; C07D519/00; C07D519/00 <--
OS MARPAT 134:56657
GI



I



II

AB Novel γ-carboline compds. of formula I [R1, R2 = H, acyl, alkyl, cycloalkyl, etc.; R3, R4 = H, OH, amino, CF3, alkyl, etc.; R5-R7 = H, halo, CF3, OH, CN, alkyl, aryl, heterocycle, etc.; X = (substituted) NH, (substituted) CONH, (substituted) NHCO, S; A, B, C = (CH2)n, n = 0-3] are prepared The invention is also concerned with pharmaceutical formulations comprising these novel compds. as active ingredients and the use of the novel compds. and their formulations in the treatment of certain disorders. The compds. of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility. Thus, II is prepared starting from p-fluorophenol, β-propiolactone and 1-carbethoxy-4-piperidone. Pharmaceutical compns. containing I are described.

ST carboline gamma prepn serotonin agonist antagonist; central nervous system disorder gamma carboline prepn

IT Nervous system
(central; preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT Pain
(cephalic; preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT Mental disorder
(depression; preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT Sleep
(disorder; preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT Headache
(migraine; preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)
IT 5-HT agonists
5-HT antagonists
Analgesics
Anxiety
Obesity
Schizophrenia
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)
IT Mental disorder
(psychosis; preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)
IT 76133-81-8P 313368-75-1P 313538-36-2P 313538-37-3P 313538-40-8P
313538-42-0P 313538-43-1P 313538-44-2P 313538-45-3P 313538-46-4P
313539-09-2P 313539-10-5P 313539-11-6P 313539-12-7P 313539-13-8P
313539-14-9P 313539-18-3P 313539-19-4P 313540-62-4P 313542-19-7P
313643-27-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)
IT 51512-12-0P 76133-74-9P 76133-77-2P 313368-91-1P 313368-92-2P
313369-37-8P 313538-35-1P 313538-38-4P 313538-39-5P 313538-41-9P
313538-47-5P 313538-48-6P 313538-49-7P 313538-50-0P 313538-51-1P
313538-52-2P 313538-53-3P 313538-54-4P 313538-55-5P 313538-56-6P
313538-57-7P 313538-58-8P 313538-59-9P 313538-60-2P 313538-61-3P
313538-62-4P 313538-63-5P 313538-64-6P 313538-65-7P 313538-66-8P
313538-67-9P 313538-68-0P 313538-69-1P 313538-70-4P 313538-71-5P
313538-72-6P 313538-73-7P 313538-74-8P 313538-75-9P 313538-76-0P
313538-77-1P 313538-78-2P 313538-79-3P 313538-80-6P 313538-81-7P
313538-82-8P 313538-83-9P 313538-84-0P 313538-85-1P 313538-86-2P
313538-87-3P 313538-88-4P 313538-89-5P 313538-90-8P 313538-91-9P
313538-92-0P 313538-93-1P 313538-94-2P 313538-95-3P 313538-96-4P
313538-97-5P 313538-98-6P 313538-99-7P 313539-00-3P 313539-01-4P
313539-02-5P 313539-03-6P 313539-04-7P 313539-05-8P 313539-06-9P
313539-07-0P 313539-08-1P 313539-15-0P 313539-16-1P 313539-17-2P
313539-20-7P 313539-21-8P 313539-22-9P 313539-23-0P 313539-24-1P
313539-25-2P 313539-26-3P 313539-27-4P 313539-28-5P 313539-29-6P
313539-30-9P 313539-31-0P 313539-32-1P 313539-33-2P 313539-34-3P
313539-35-4P 313539-36-5P 313539-37-6P 313539-38-7P 313539-39-8P
313539-40-1P 313539-41-2P 313539-42-3P 313539-43-4P 313539-44-5P
313539-45-6P 313539-46-7P 313539-47-8P 313539-48-9P 313539-49-0P
313539-50-3P 313539-51-4P 313539-52-5P 313539-53-6P 313539-54-7P
313539-55-8P 313539-56-9P 313539-57-0P 313539-58-1P 313539-59-2P
313539-60-5P 313539-61-6P 313539-62-7P 313539-63-8P 313539-64-9P
313539-65-0P 313539-66-1P 313539-67-2P 313539-68-3P 313539-69-4P
313539-70-7P 313539-71-8P 313539-72-9P 313539-73-0P 313539-74-1P
313539-75-2P 313539-76-3P 313539-77-4P 313539-78-5P 313539-79-6P
313539-80-9P 313539-81-0P 313539-82-1P 313539-83-2P 313539-84-3P
313539-85-4P 313539-86-5P 313539-87-6P 313539-88-7P 313539-89-8P
313539-90-1P 313539-91-2P 313539-92-3P 313539-93-4P 313539-94-5P
313539-95-6P 313539-96-7P 313539-97-8P 313539-98-9P 313539-99-0P
313540-00-0P 313540-01-1P 313540-02-2P 313540-03-3P 313540-04-4P
313540-05-5P 313540-06-6P 313540-07-7P 313540-08-8P 313540-09-9P
313540-10-2P 313540-12-4P 313540-13-5P 313540-14-6P 313540-15-7P
313540-16-8P 313540-17-9P 313540-18-0P 313540-19-1P 313540-20-4P
313540-21-5P 313540-22-6P 313540-23-7P 313540-24-8P 313540-25-9P
313540-26-0P 313540-27-1P 313540-28-2P 313540-29-3P 313540-30-6P
313540-31-7P 313540-32-8P 313540-33-9P 313540-34-0P 313540-35-1P

313540-36-2P 313540-37-3P 313540-38-4P 313540-39-5P 313540-40-8P
313540-41-9P 313540-42-0P 313540-43-1P 313540-44-2P 313540-45-3P
313540-46-4P 313540-47-5P 313540-48-6P 313540-49-7P 313540-50-0P
313540-51-1P 313540-52-2P 313540-53-3P 313540-54-4P 313540-56-6P
313540-57-7P 313540-58-8P 313540-59-9P 313540-60-2P 313540-61-3P
313540-63-5P 313540-64-6P 313540-65-7P 313540-66-8P 313540-67-9P
313540-68-0P 313540-69-1P 313540-70-4P 313540-71-5P 313540-72-6P
313540-73-7P 313540-74-8P 313540-75-9P 313540-76-0P 313540-77-1P
313540-78-2P 313540-79-3P 313540-80-6P 313540-81-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT 313540-82-8P 313540-83-9P 313540-84-0P 313540-85-1P 313540-86-2P
313540-87-3P 313540-88-4P 313540-89-5P **313540-90-8P**
313540-91-9P 313540-92-0P 313540-93-1P 313540-94-2P 313540-95-3P
313540-96-4P 313540-97-5P 313540-98-6P 313540-99-7P 313541-00-3P
313541-01-4P 313541-02-5P 313541-03-6P 313541-04-7P 313541-05-8P
313541-06-9P 313541-07-0P 313541-09-2P 313541-11-6P 313541-13-8P
313541-15-0P 313541-16-1P 313541-18-3P 313541-20-7P 313541-22-9P
313541-24-1P 313541-26-3P 313541-28-5P 313541-30-9P 313541-31-0P
313541-32-1P 313541-33-2P 313541-34-3P 313541-35-4P 313541-36-5P
313541-37-6P 313541-38-7P 313541-39-8P 313541-40-1P 313541-41-2P
313541-42-3P 313541-43-4P 313541-44-5P 313541-45-6P 313541-46-7P
313541-47-8P 313541-48-9P 313541-49-0P 313541-50-3P 313541-51-4P
313541-52-5P 313541-53-6P 313541-54-7P 313541-55-8P 313541-56-9P
313541-57-0P 313541-58-1P 313541-59-2P 313541-60-5P 313541-61-6P
313541-62-7P 313541-63-8P 313541-64-9P 313541-65-0P 313541-66-1P
313541-67-2P 313541-68-3P 313541-69-4P 313541-70-7P 313541-71-8P
313541-72-9P 313541-73-0P 313541-74-1P 313541-75-2P 313541-76-3P
313541-77-4P 313541-78-5P 313541-79-6P 313541-80-9P 313541-81-0P
313541-83-2P 313541-85-4P 313541-86-5P 313541-87-6P 313541-88-7P
313541-90-1P 313541-91-2P 313541-92-3P 313541-93-4P 313541-94-5P
313541-95-6P 313541-96-7P 313541-97-8P 313541-98-9P 313541-99-0P
313542-00-6P 313542-01-7P 313542-02-8P 313542-03-9P 313542-04-0P
313542-05-1P 313542-06-2P 313542-07-3P 313542-08-4P 313542-09-5P
313542-10-8P 313542-11-9P 313542-12-0P 313542-13-1P 313542-14-2P
313542-15-3P 313542-16-4P 313542-17-5P 313542-18-6P 313542-20-0P
313542-21-1P 313542-22-2P 313542-23-3P 313542-24-4P 313542-25-5P
313542-26-6P 313542-27-7P 313542-28-8P 313542-29-9P 313542-30-2P
313542-31-3P 313542-32-4P 313542-33-5P 313542-34-6P 313542-35-7P
313542-36-8P 313542-37-9P 313542-38-0P 313542-39-1P 313542-40-4P
313542-41-5P 313542-42-6P 313542-43-7P 313542-44-8P 313542-45-9P
313542-46-0P 313542-47-1P 313542-48-2P 313542-49-3P 313542-50-6P
313542-52-8P 313542-54-0P 313542-56-2P 313542-58-4P 313542-60-8P
313542-62-0P 313542-64-2P 313542-66-4P 313542-68-6P 313542-70-0P
313542-72-2P 313542-73-3P 313542-74-4P 313542-75-5P 313542-76-6P
313542-77-7P 313542-78-8P 313542-79-9P 313542-80-2P 313542-81-3P
313542-82-4P 313542-83-5P 313542-84-6P 313542-85-7P 313542-86-8P
313542-87-9P 313542-88-0P 313542-89-1P 313542-90-4P 313542-91-5P
313542-92-6P 313542-93-7P 313542-94-8P 313542-95-9P 313542-96-0P
313542-97-1P 313542-98-2P 313542-99-3P 313543-00-9P 313543-01-0P
313543-02-1P 313543-03-2P 313543-04-3P 313543-05-4P 313543-06-5P
313543-07-6P 313543-08-7P 313543-09-8P 313543-10-1P 313543-11-2P
313543-12-3P 313543-13-4P 313543-14-5P 313543-15-6P 313543-16-7P
313543-17-8P 313543-18-9P 313543-19-0P 313543-20-3P 313543-21-4P
313543-22-5P 313543-23-6P 313543-24-7P 313543-25-8P 313543-26-9P
313543-27-0P 313543-28-1P 313543-29-2P 313543-30-5P 313543-31-6P
313543-32-7P 313543-33-8P 313543-34-9P 313543-35-0P 313543-36-1P
313543-37-2P 313543-38-3P 313543-39-4P 313543-40-7P 313543-41-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic**

use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT 313543-42-9P 313543-43-0P 313543-44-1P 313543-45-2P 313543-46-3P
313543-47-4P 313543-48-5P 313543-49-6P 313543-50-9P 313543-51-0P
313543-52-1P 313543-53-2P 313543-54-3P 313543-55-4P 313543-56-5P
313543-57-6P 313543-58-7P 313543-59-8P 313543-60-1P 313543-61-2P
313543-62-3P 313543-63-4P 313543-64-5P 313543-65-6P 313543-66-7P
313543-67-8P 313543-68-9P 313543-69-0P 313543-70-3P 313543-71-4P
313543-72-5P 313543-73-6P 313543-74-7P 313543-75-8P 313543-76-9P
313543-77-0P 313543-78-1P 313543-79-2P 313543-80-5P 313543-81-6P
313543-82-7P 313543-83-8P 313543-84-9P 313543-85-0P 313543-86-1P
313543-87-2P 313543-88-3P 313543-89-4P 313543-90-7P 313543-91-8P
313543-92-9P 313543-93-0P 313544-88-6P 313544-89-7P 313643-28-6P
313643-29-7P 313643-30-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT 51-17-2, 1H-Benzimidazole 57-57-8, β-Propiolactone 75-26-3,
2-Bromopropane 78-76-2, 2-Bromobutane 78-77-3, 1-Bromo-2-methylpropane
79-10-7, Acrylic acid, reactions 86-51-1, 2,3-Dimethoxybenzaldehyde
86-81-7, 3,4,5-Trimethoxybenzaldehyde 87-41-2, 1(3H)-Isobenzofuranone
89-92-9, 2-Methylbenzyl bromide 91-16-7 95-14-7, 1H-Benzotriazole
98-80-6, Phenylboronic acid 98-88-4, Benzoyl chloride 100-39-0, Benzyl
bromide 100-58-3, Phenyl magnesium bromide 100-61-8, reactions
103-63-9, (2-Bromoethyl)benzene 104-81-4, 4-Methylbenzyl bromide
105-30-6, 2-Methyl-1-pentanol 106-45-6, p-Thiocresol 106-94-5,
1-Bromopropane 106-95-6, Allyl bromide, reactions 107-04-0,
1-Bromo-2-chloroethane 107-81-3, 2-Bromopentane 107-82-4,
1-Bromo-3-methylbutane 108-37-2, 1-Bromo-3-chlorobenzene 108-42-9
108-95-2, Phenol, reactions 109-65-9, 1-Bromobutane 109-70-6,
1-Bromo-3-chloropropane 109-83-1, 2-(Methylamino)ethanol 110-52-1
110-53-2, 1-Bromopentane 111-25-1, 1-Bromohexane 120-14-9,
3,4-Dimethoxybenzaldehyde 120-72-9, 1H-Indole, reactions 120-73-0,
Purine 137-06-4, o-Thiocresol 141-43-5, reactions 347-93-3,
3-Chloro-4'-fluoropropiophenone 348-54-9 352-13-6 369-36-8
371-40-4 371-42-6, p-Fluorothiophenol 372-19-0, 3-Fluoroaniline
372-20-3, 3-Fluorophenol 393-52-2 394-28-5, 2-Bromo-5-fluorobenzoic
acid 399-51-9, 6-Fluoroindole 399-52-0, 5-Fluoroindole 403-43-0
452-62-0 452-63-1, 1-Bromo-4-fluoro-2-methylbenzene 458-50-4
496-15-1 534-00-9, (S)-1-Bromo-2-methylbutane 536-90-3 541-41-3,
Ethyl chloroformate 574-98-1 576-23-8 589-35-5, 3-Methyl-1-pentanol
591-19-5 613-45-6, 2,4-Dimethoxybenzaldehyde 615-13-4 620-13-3,
3-Methylbenzyl bromide 626-89-1, 4-Methyl-1-pentanol 626-93-7,
2-Hexanol 628-20-6 635-46-1 694-80-4, 1-Bromo-2-chlorobenzene
768-35-4 772-31-6 830-96-6, 1H-Indole-3-propanoic acid 870-63-3,
4-Bromo-2-methyl-2-butene 873-77-8, 4-Chlorophenyl magnesium bromide
877-88-3, 3,5-Dimethoxybenzyl bromide 928-51-8 932-31-0,
2-Methylphenylmagnesium bromide 1015-53-8 1119-51-3, 5-Bromo-1-pentene
1212-08-4 1422-53-3 1423-27-4, 2-(Trifluoromethyl)benzeneboronic acid
1458-98-6, 3-Bromo-2-methylpropene 1585-16-6, 2,4,6-Trimethylbenzyl
chloride 1589-82-8 1667-11-4, 4-Phenylbenzyl chloride 1679-47-6
1716-42-3 1735-53-1 1765-40-8, Pentafluorobenzyl bromide 1765-93-1,
4-Fluorobenzene boronic acid 2043-61-0, Cyclohexanecarboxaldehyde
2103-57-3, 2,3,4-Trimethoxybenzaldehyde 2114-39-8, 2-Bromo-1-
phenylpropane 2270-59-9, 5-Bromo-2-methyl-2-pentene 2323-81-1, Ethyl
5-chlorovalerate 2550-36-9, (Bromomethyl)cyclohexane 2557-77-9,
3-Fluorothiophenol 2567-14-8, 1,1,3-Trichloropropene 2605-67-6, Methyl
(triphenylphosphoranylidene)acetate 3017-96-7 3153-36-4, Ethyl
4-chlorobutanoate 3209-22-1, 2,3-Dichloronitrobenzene 3240-34-4,
Iodobenzene diacetate 3312-04-7 3360-41-6, 4-Phenyl-1-butanol

3384-04-1 3389-21-7 3392-97-0, 2,6-Dimethoxybenzaldehyde 3460-18-2, 2,5-Dibromonitrobenzene 3535-37-3, 3,4-Dimethoxybenzoyl chloride 3569-21-9, 1H-Indole-3-propanol 3814-34-4, 1-Bromo-2-ethylbutane 3874-54-2 3900-89-8, (2-Chlorophenyl)boronic acid 3970-35-2 4441-57-0, Cyclohexanebutanol 4460-86-0, 2,4,5-Trimethoxybenzaldehyde 4635-59-0, 4-Chlorobutyryl chloride 4894-61-5, trans-1-Chloro-2-butene 5162-44-7, 4-Bromo-1-butene 5322-56-5 5325-20-2, 2H-1,4-Benzothiazin-3(4H)-one 5556-86-5, 2,3,6-Trimethoxybenzaldehyde 5698-74-8 5720-05-8, 4-Methylbenzeneboronic acid 5720-06-9, 2-Methoxybenzeneboronic acid 5785-66-0 6783-05-7 6969-71-7, [1,2,4]-Triazolo[4,3-a]pyridin-3(2H)-one 6971-51-3, 3-Methoxybenzyl alcohol 7051-34-5, (Bromomethyl)cyclopropane 7348-71-2, trans-1-Bromo-2-pentene 7348-78-9, cis-1-Bromo-2-pentene 7565-57-3 7589-27-7, 4-Fluorophenethyl alcohol 10365-98-7 13331-27-6, 3-Nitrophenylboronic acid 13631-21-5, 4-Bromo-3-chlorophenol 13922-41-3 16308-92-2, 2,4-Dimethylbenzyl alcohol 16419-60-6, 2-Methylphenylboronic acid 17213-57-9, 3,5-Dimethoxybenzoyl chloride 17247-58-4, (Bromomethyl)cyclobutane 17318-06-8 17481-19-5, 3-Chloro-1-propanethiol 17918-14-8, 2,5-Dimethoxybenzoyl chloride 19853-09-9, 2-Phenylbenzyl bromide 23356-96-9 24850-33-7, Allyltributyltin 26146-77-0 27060-75-9 27129-87-9, 3,5-Dimethylbenzyl alcohol 29976-53-2, 1-Carbethoxy-4-piperidone 32316-92-0, 2-Naphthaleneboronic acid 34737-83-2, 1-Methyl-4-piperidone hydrochloride 35450-36-3 36942-56-0, 3-Bromo-4-methylanisole 38425-26-2, 4-Chloro-4'-methylbutyrophenone 39093-62-4 39512-46-4 40138-16-7 40877-19-8, 4-Chloro-4'-methoxybutyrophenone 41661-47-6, 4-Piperidone 41979-39-9, 4-Piperidone hydrochloride 50492-22-3 50837-53-1, 2,5-Dimethylbenzyl bromide 51511-27-4 54013-89-7 55204-78-9 55204-79-0 55204-80-3 55717-04-9 58121-92-9 59020-06-3, 4-Trimethylstannylpyridine 59564-59-9 62673-31-8, Benzylzinc bromide 63488-10-8, 4-tert-Butylphenyl magnesium bromide 64248-56-2 64465-53-8 68716-47-2, 2,4-Dichlorobenzene boronic acid 68832-13-3 69963-21-9 70336-24-2 72482-64-5, 2,4-Difluorobenzoyl chloride 73852-17-2, 2,6-Dichlorobenzene boronic acid 73852-18-3, 2,4,6-Trichlorobenzeneboronic acid 75694-39-2, 3-Bromo-1-propanethiol 82297-89-0 84243-02-7 87199-16-4 90897-92-0, 3,4-Difluorophenyl magnesium bromide 101335-11-9 104255-56-3 104605-81-4 117258-56-7 121905-60-0, m-Tolyl magnesium chloride 122775-35-3 124929-81-3 125367-04-6 128796-39-4 131379-39-0 133730-34-4 135145-90-3 135579-86-1 139301-27-2, 4-(Trifluoromethoxy)benzeneboronic acid 139911-29-8, 4-Fluoro-2-methylphenylboronic acid 139962-95-1 144432-85-9 145240-28-4 145349-62-8 150255-96-2 151169-74-3, 2,3-Dichlorophenyl boronic acid 151169-75-4, 3,4-Dichlorophenyl boronic acid 153254-09-2 156545-07-2 160591-91-3 162101-25-9, 2,6-Difluorophenyl boronic acid 168267-41-2 168618-42-6 171860-68-7 175676-65-0, 2-(Trifluoromethoxy)phenylboronic acid 182163-96-8 182344-16-7 182482-25-3 188132-02-7 193065-68-8 208399-66-0 214210-21-6 216393-63-4 219735-99-6 223761-28-2 254993-59-4 265330-98-1 309977-93-3 313369-66-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT 313544-17-1 313544-25-1 313544-26-2 313544-27-3 313544-28-4 313544-29-5 313544-97-7 313545-31-2 313545-32-3 313545-33-4 313545-34-5 313545-35-6 313545-36-7 313545-37-8 313545-38-9 313545-39-0 313545-40-3 313545-41-4 313545-42-5 313546-12-2 313546-13-3 313546-14-4 313546-15-5 313546-16-6 313546-17-7 313546-18-8 313546-19-9 313546-20-2 313546-56-4 313546-57-5 313547-20-5 313547-21-6 313547-22-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT 658-28-6P 827-88-3P 1006-33-3P 3080-99-7P 3311-94-2P 3312-08-1P

3970-37-4P 4551-08-0P 5334-06-5P 5746-95-2P 6139-84-0P
6692-64-4P 6948-34-1P 7160-97-6P, 2,3,4,5-Tetrahydro-1,5-benzoxazepine
7239-60-3P, Diacetatotriphenylbismuth 7394-78-7P 13633-25-5P,
1-Bromo-4-phenylbutane 13739-35-0P 18838-10-3P 18845-22-2P
19543-85-2P 21243-18-5P 27129-86-8P, 3,5-Dimethylbenzyl bromide
29373-02-2P 29957-90-2P 40759-47-5P 41575-23-9P 42923-82-0P
51511-34-3P 51511-44-5P 51511-54-7P 52200-03-0P 52989-39-6P
57728-63-9P 57901-08-3P 58029-83-7P 59280-48-7P 61053-78-9P
62356-27-8P, 2-Bromo-6-chlorotoluene 63169-11-9P 64605-33-0P
72132-79-7P 76699-29-1P 78831-87-5P, 2,4-Dimethylbenzyl bromide
96437-60-4P 98546-01-1P 111904-31-5P 116578-61-1P 118511-94-7P
121900-00-3P, Diacetatotris(4-fluorophenyl)bismuth 134186-51-9P
134186-71-3P 137540-94-4P 141071-78-5P 141071-80-9P 143356-10-9P
147372-83-6P 160420-53-1P 161194-92-9P 162101-31-7P 163517-62-2P
166328-16-1P 179897-94-0P 183158-34-1P 223567-67-7P 313369-12-9P
313369-13-0P 313369-14-1P 313369-21-0P 313543-94-1P 313543-95-2P
313543-96-3P 313543-97-4P 313543-98-5P 313543-99-6P 313544-00-2P
313544-01-3P 313544-02-4P 313544-03-5P 313544-04-6P 313544-05-7P
313544-06-8P 313544-07-9P 313544-08-0P 313544-09-1P 313544-10-4P
313544-11-5P 313544-12-6P 313544-13-7P 313544-14-8P 313544-15-9P
313544-16-0P 313544-18-2P 313544-19-3P 313544-20-6P 313544-21-7P
313544-22-8P 313544-23-9P 313544-24-0DP, resin-bound 313544-30-8P
313544-31-9P 313544-32-0P 313544-33-1P 313544-34-2P 313544-35-3P
313544-36-4P 313544-66-0P 313544-72-8P 313544-73-9P 313544-74-0P
313544-75-1P 313544-76-2P 313544-77-3P 313544-78-4P 313544-79-5P
313544-80-8P 313544-81-9P 313544-82-0P 313544-83-1P 313544-84-2P
313544-85-3P 313544-86-4P 313544-87-5P 313544-90-0P 313544-91-1P
313544-92-2P 313544-93-3P 313544-94-4P 313544-95-5P 313544-96-6P
313544-98-8P 313544-99-9P 313545-00-5P 313545-01-6P 313545-02-7P
313545-03-8P 313545-04-9P 313545-05-0P 313545-06-1P 313545-07-2P
313545-08-3P 313545-09-4P 313545-10-7P 313545-11-8P 313545-12-9P
313545-13-0P 313545-14-1P 313545-15-2P 313545-16-3P 313545-17-4P
313545-18-5P 313545-19-6P 313545-20-9P 313545-21-0P 313545-22-1P
313545-23-2P 313545-24-3P 313545-25-4P 313545-26-5P 313545-27-6P
313545-28-7P 313545-29-8P 313545-30-1P 313545-43-6P 313545-44-7P
313545-45-8P 313545-46-9P 313545-47-0P 313545-48-1P 313545-49-2P
313545-50-5P 313545-51-6P 313545-52-7P 313545-53-8P 313545-54-9P
313545-55-0P 313545-56-1P 313545-57-2P 313545-58-3P 313545-59-4P
313545-60-7P 313545-61-8P 313545-62-9P 313545-63-0P 313545-64-1P
313545-65-2P 313545-66-3P 313545-67-4P 313545-68-5P 313545-69-6P
313545-70-9P 313545-71-0P 313545-72-1P 313545-73-2P 313545-74-3P
313545-75-4P 313545-76-5P 313545-77-6P 313545-78-7P 313545-79-8P
313545-80-1P 313545-81-2P 313545-82-3P 313545-83-4P 313545-84-5P
313545-85-6P 313545-86-7P 313545-87-8P 313545-88-9P 313545-89-0P
313545-90-3P 313545-91-4P 313545-92-5P 313545-93-6P 313545-94-7P
313545-95-8P 313545-96-9P 313545-97-0P 313545-98-1P 313545-99-2P
313546-00-8P 313546-01-9P 313546-02-0P 313546-03-1P 313546-04-2P
313546-05-3P 313546-06-4P 313546-07-5P 313546-08-6P 313546-09-7P
313546-10-0P 313546-21-3P 313546-22-4P 313546-23-5P 313546-24-6P
313546-25-7P 313546-26-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT 313546-27-9P 313546-28-0P 313546-29-1P 313546-30-4P 313546-31-5P
313546-32-6P 313546-33-7P 313546-34-8P 313546-35-9P 313546-36-0P
313546-37-1P 313546-38-2P 313546-39-3P 313546-40-6P 313546-41-7P
313546-42-8P 313546-43-9P 313546-44-0P 313546-45-1P 313546-46-2P
313546-47-3P 313546-48-4P 313546-49-5P 313546-50-8P 313546-51-9P
313546-52-0P 313546-53-1P 313546-54-2P 313546-55-3P 313546-58-6P
313546-59-7P 313546-60-0P 313546-61-1P 313546-62-2P 313546-63-3P
313546-64-4P 313546-65-5P 313546-66-6P 313546-67-7P 313546-68-8P
313546-69-9P 313546-70-2P 313546-72-4P 313546-73-5P 313546-74-6P

313546-75-7P 313546-76-8P 313546-77-9P 313546-78-0P 313546-79-1P
313546-80-4P 313546-81-5P 313546-82-6P 313546-83-7P 313546-84-8P
313546-85-9P 313546-86-0P 313546-87-1P 313546-88-2P 313546-89-3P
313546-90-6P 313546-91-7P 313546-92-8P 313546-93-9P 313546-94-0P
313546-95-1P 313546-96-2P 313546-97-3P 313546-98-4P 313546-99-5P
313547-00-1P 313547-01-2P 313547-02-3P 313547-03-4P 313547-04-5P
313547-05-6P 313547-06-7P 313547-07-8P 313547-08-9P 313547-09-0P
313547-10-3P 313547-11-4P 313547-12-5P 313547-13-6P 313547-14-7P
313547-15-8P 313547-16-9P 313547-17-0P 313547-18-1P 313547-19-2P
313547-23-8P 313547-24-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT 313546-71-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

IT **313540-90-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocycle fused γ-carbolines as serotonin agonists and antagonists)

RN 313540-90-8 HCAPLUS
CN 5H-Pyrido[3',4':4,5]pyrrolo[1,2,3-ef][1,5]benzothiazepine, 11-[3-(5-fluoro-1H-indazol-3-yl)propyl]-6,7,8a,9,10,11,12,12a-octahydro-, (8aS,12aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 6 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:854415 HCAPLUS
DN 133:362769
ED Entered STN: 07 Dec 2000
TI Preparation of 6-(thiomorpholinomethylfuranyl)-4-quinazolinamines as protein tyrosine kinase inhibitors
IN Carter, Malcolm Clive; Cockerill, George Stuart; Guntrip, Stephen Barry; Lackey, Karen Elizabeth; Smith, Kathryn Jane
PA Glaxo Group Ltd., UK
SO Brit. UK Pat. Appl., 151 pp.
CODEN: BAXXDU
DT Patent
LA English
IC ICM C07D471-04
ICS A61K031-517; A61K031-519; A61K031-54; C07D417-14
ICA A61P011-00; A61P017-06; A61P019-02; A61P035-00
ICI C07D471-04, C07D221-00, C07D239-00; C07D417-14, C07D239-94
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2345486	A1	20000712	GB 1999-29973	19991217 <--
PRAI	GB 1999-518	A	19990111 <--		
	GB 1999-15510	A	19990703 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
GB 2345486	ICM	C07D471-04
	ICS	A61K031-517; A61K031-519; A61K031-54; C07D417-14
	ICA	A61P011-00; A61P017-06; A61P019-02; A61P035-00
	ICI	C07D471-04, C07D221-00, C07D239-00; C07D417-14, C07D239-94

OS MARPAT 133:362769

GI



I



II

AB The title compds. (I) [wherein X = N or CH; V and Y = independently CR1, CR2, or N; and V ≠ Y; R1 = Q(CH2)qAr; m = 1 or 2; p = 1 or 2; q = 1-4; Ar = (un)substituted Ph, furanyl, thiophenyl, pyrrolyl, or thiazolyl; R2 = H, halo, OH, alkyl(amino) alkoxy, or dialkylamino; U = (un)substituted Ph, pyridyl, (benz)imidazolyl, (iso)indolyl, (iso)indolinyl, indazolyl, or benzotriazolyl] were prepared as protein tyrosine kinase inhibitors for the treatment of cancer and other disorders mediated by aberrant protein tyrosine kinase activity. For example, II•2HCl was formed in a multi-step sequence involving (1) reaction of 5-(1,3-dioxolan-2-yl)-2-(tributylstannyl)furan with (4-benzyloxyphenyl)(6-bromoquinazolin-4-yl)amine using Pd(PPh3)2Cl2 in dioxane, (2) conversion of the cyclic acetal to the aldehyde with HCl in THF, (3) addition of thiomorpholine-S-oxide in CH2Cl2 and conversion to the HCl salt. I inhibited EGFR and c-erbB-2 tyrosine kinase with IC50 < 0.10 μM and suppressed cell proliferation against a range of tumor cell lines.

ST thiomorpholinomethylfuranyl quinazoline prepn protein tyrosine kinase inhibitor; quinazolinamine thiomorpholinomethylfuranyl prepn anticancer

IT Antitumor agents
(preparation of thiomorpholinomethylfuranyl quinazolinamines and pyrido[3,4-d]pyrimidinamines as protein tyrosine kinase inhibitors for treatment of cancer)

IT Epidermal growth factor receptors
Tyrosine kinase receptors

neu (receptor)
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of thiomorpholinomethylfuranyl quinazolinamines and pyrido[3,4-d]pyrimidinamines as protein tyrosine kinase inhibitors for treatment of cancer)

IT 307327-34-0P, (1-Benzyl-1H-indazol-5-yl)(6-(5-(thiazolidin-3-ylmethyl)furan-2-yl)quinazolin-4-yl)amine 307328-02-5P, (4-Benzyloxyphenyl)-[6-[5-(1-oxothiomorpholin-4-ylmethyl)furan-2-yl]quinazolin-4-yl]amine dihydrochloride 307328-04-7P, (4-Benzyloxyphenyl)-[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]amine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addition of thiomorpholine (oxides))

IT 307327-99-7P 307328-06-9P, (4-Benzyloxyphenyl)-[6-[5-(thiomorpholin-4-ylmethyl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]amine 307328-08-1P, (4-Benzyloxyphenyl)-[6-[5-((1,1-dioxothiomorpholin-4-yl)methyl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]amine hydrochloride 307328-11-6P, [4-(3-Fluorobenzyloxy)phenyl]-[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]amine dihydrochloride 307328-13-8P, [4-(3-Fluorobenzyloxy)phenyl]-[6-[4-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]amine dihydrochloride 307328-15-0P, (4-Benzyloxyphenyl)-[6-[2-((1-oxothiomorpholin-4-yl)methyl)thiazol-4-yl]quinazolin-4-yl]amine dihydrochloride 307328-18-3P 307328-20-7P, (4-Benzyloxyphenyl)-[6-[5-((1,1-dioxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine dihydrochloride 307328-22-9P, (4-Benzenesulphonylphenyl)-[6-[5-(1,1-dioxothiomorpholin-4-ylmethyl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]amine dihydrochloride 307328-24-1P, (4-Benzyloxy-3-fluorophenyl)-(6-(5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl)quinazolin-4-yl)amine 307328-27-4P, [4-((3-Fluorobenzyl)oxy)-3-(trifluoromethyl)phenyl]-[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine 307328-31-0P, (4-((3-Fluorobenzyl)oxy)-3-chlorophenyl)-(6-(5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl)quinazolin-4-yl)amine **307328-34-3P**, 1-(3-Fluorobenzyl-1H-indazol-5-yl)[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine 307328-38-7P, (4-Benzyloxy-3-chlorophenyl)-[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine 307328-41-2P, (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-((5-(thiazolidin-3-yl)methyl)furan-2-yl)quinazolin-4-yl)amine dihydrochloride
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addition of thiomorpholine (oxides))

IT 99-56-9, 4-Nitro-o-phenylene diamine 100-39-0, Benzyl bromide 103-82-2, Phenylacetic acid, reactions 123-90-0, Thiomorpholine 139-59-3, 4-Phenoxyaniline 504-78-9, Thiazolidine 5326-23-8, 6-Chloronicotinic acid 5401-94-5, 5-Nitroindazole 6146-52-7, 5-Nitroindole 7019-01-4, 4-(Benzenesulphonyl)phenylamine 18542-42-2, 2-(Methylthio)ethylamine 20570-96-1, Benzyl hydrazine dihydrochloride 22200-50-6, 4-Chloro-7-iodoquinoline 38267-96-8, 4-Chloro-6-bromoquinazoline 39213-13-3, Thiomorpholine-S-oxide 51388-20-6, 4-Benzyloxyaniline hydrochloride 70338-47-5, 4-(Benzyloxy)-3-trifluoromethylaniline 79110-05-7 90004-09-4, 7-Aminoquinazolin-4-one 93631-55-1, [4-(3-Bromobenzyloxy)phenyl]amine 94012-20-1,

3-Benzenesulphonyl-6-nitroindole 98556-31-1, 4-Chloro-6-iodoquinazoline 118505-28-5, 2-(Tributylstannyl)-5-(1,3-dioxolan-2-yl)furan 124434-65-7, 3-(1,3-Dioxolan-2-yl)phenyltributylstannane 130493-24-2, 5-(Tributylstannyl)furan-3-carbaldehyde 139696-74-5, 5-Formyl-1-methyl-2-(tri-n-butylstannyl)pyrrole 144968-78-5, 5-(Tributylstannyl)furan-2-carbaldehyde 168268-00-6, (4-Benzyloxy-3-fluorophenyl)amine 171178-48-6, 4,6-Dichloropyrido[3,4-d]pyrimidine 173978-98-8, 4-Bromo-2-(tributylstannyl)thiazole 179248-66-9, (4-Benzyloxyphenyl)-(6-bromoquinazolin-4-yl)amine 189680-75-9, (4-Benzenesulphonylphenyl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)amine 202196-54-1, 5-[4-(1-Benzyl-1H-indazol-5-ylamino)quinazolin-6-yl]furan-2-carbaldehyde 202198-16-1, (4-Benzyloxyphenyl)-(6-iodoquinazolin-4-yl)amine 202272-67-1, (1-Benzyl-1H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)amine 231278-11-8, 4-Chloro-6-iodo-7-fluoroquinazoline hydrochloride 231278-13-0, 4-(1,3-Dioxolan-2-yl)-5-(tributylstannyl)thiazole 231278-56-1 231278-64-1, 4-Chloro-6-iodo-7-fluoroquinazoline 231278-65-2, [4-(3-Fluorobenzyloxy)-3-fluorophenyl]amine 231278-66-3, [4-(3-Fluorobenzyloxy)-3-methoxyphenyl]amine 231278-67-4, [4-(3-Trifluoromethylbenzyloxy)phenyl]amine 231278-68-5, (4-Benzyloxyphenyl)-(7-methoxy-6-(trifluoromethanesulphonyl)quinazolin-4-yl)amine 231278-69-6 231278-70-9, (1-Benzyl-1H-indazol-5-yl)(7-methoxy-6-(trifluoromethanesulphonyl)quinazolin-4-yl)amine 231278-82-3 231278-83-4, [5-[4-[4-(Benzyloxy)-3-chloroanilino]-6-quinazolinyl]-2-furancarboxaldehyde 231278-84-5, [5-[4-[4-[(3-Fluorobenzyl)oxy]-3-chloroanilino]-6-quinazolinyl]-2-furancarboxaldehyde 307326-69-8, 1-Benzyl-1H-indol-5-ylamine 307327-22-6, 4-(4-Benzyloxyphenylamino)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine 307327-67-9, (1-Benzyl-1H-indazol-5-ylamino)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-fluoroquinazolin-4-yl]amine 307328-29-6, [5-[4-[4-[(3-Fluorobenzyl)oxy]-3-(trifluoromethyl)anilino]-6-quinazolinyl]-2-furancarboxaldehyde 307328-36-5, [[5-(4-[[1-(3-Fluorobenzyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-furancarboxaldehyde

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addition of thiomorpholine (oxides))

IT 7189-72-2P, 2-Benzyl-5-nitro-1H-benzimidazole 23856-20-4P, 1-Benzyl-5-nitroindazole 23856-21-5P, 5-Amino-1-benzyl-1H-indazole 26807-73-8P, 5-Amino-1-benzyl-1H-indole 53234-85-8P, 4-(4-Fluorobenzyloxy)aniline 57181-83-6P, 4-(2-Fluorobenzyloxy)aniline 59404-86-3P, 4-Benzyloxy-3-chloroaniline 65795-95-1P, 1-Benzyl-5-nitro-1H-indole 102137-46-2P, 4-(Pyridyl-2-methoxy)aniline 105350-42-3P, 4-(Pyridyl-4-methoxy)aniline 105350-44-5P, 4-(Pyridyl-3-methoxy)aniline 108281-61-4P, 5-Amino-2-benzyl-1H-benzimidazole 171178-45-3P, 5-[N-(tert-Butoxycarbonyl)amino]-2-chloropyridine 179246-45-8P, 3-Chloro-4-(2-fluorobenzyloxy)aniline 179246-97-0P, (4-Benzyloxyphenyl)-(6-bromoquinazolin-4-yl)amine hydrochloride 179246-99-2P, (4-Benzyloxyphenyl)-(6-iodoquinazolin-4-yl)amine hydrochloride 187668-23-1P, 2-N-Benzyl-5-nitro-2H-indazole 189680-34-0P, 5-[4-(4-Benzyloxyphenylamino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde 189680-73-7P, (4-Benzyloxyphenyl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)amine 202196-42-7P, (4-Benzyloxyphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine 202196-46-1P, 5-[4-(4-Benzyloxyphenylamino)quinazolin-6-yl]furan-2-carbaldehyde 202196-53-0P, (1-Benzyl-1H-indazol-5-yl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine 202197-01-1P 202197-25-9P, 4-(3-Fluorobenzyloxy)aniline 202197-26-0P, 3-Chloro-4-(3-fluorobenzyloxy)aniline 202197-27-1P, 3-Chloro-4-(4-fluorobenzyloxy)aniline 202197-28-2P, 1-Benzyl-3-methyl-5-nitro-1H-indazole 202197-29-3P, 1-Benzyl-3-methyl-1H-indazol-5-ylamine 202197-30-6P, 5-Amino-1-(2-fluorobenzyl)-1H-indazole 202197-31-7P,

5-Amino-1-(3-fluorobenzyl)-1H-indazole 202197-32-8P,
5-Amino-1-(4-fluorobenzyl)-1H-indazole 202197-33-9P,
5-Amino-1-(2-pyridylmethyl)-1H-indazole 202197-34-0P,
5-Amino-1-(3-pyridylmethyl)-1H-indazole 202197-35-1P,
5-Amino-1-(4-pyridylmethyl)-1H-indazole 202197-36-2P,
5-Amino-1-(2,3-difluorobenzyl)-1H-indazole 202197-37-3P,
5-Amino-1-(3,5-difluorobenzyl)-1H-indazole 202197-38-4P,
3-Benzenesulphonylindol-6-ylamine 202197-39-5P, (1-Benzyl-1H-indazol-5-yl)(6-bromoquinazolin-4-yl)amine 202197-40-8P, (1-Benzyl-1H-indazol-5-yl)(6-iodoquinazolin-4-yl)amine hydrochloride 202197-77-1P,
7-Iodoquinazolin-4-one 202197-78-2P, 4-Chloro-7-iodoquinazoline 202197-79-3P, (1-Benzyl-1H-indazol-5-yl)(7-iodoquinazolin-4-yl)amine hydrochloride 202197-80-6P, 5-[4-(4-Benzyloxyphenylamino)quinazolin-6-yl]furan-2-carbaldehyde hydrochloride 202197-83-9P, 5-[4-(1-Benzyl-1H-indazol-5-ylamino)quinazolin-6-yl]furan-2-carbaldehyde hydrochloride 202198-15-0P, (1-Benzyl-1H-indazol-5-yl)-[7-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine hydrochloride 202271-32-7P,
(4-Benzyloxyphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]amine 202272-71-7P, (2-Benzyl-1H-benzimidazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)amine 202272-74-0P,
(1-Benzyl-1H-indazol-5-yl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]amine 202272-75-1P, 5-[4-(1-Benzyl-1H-indazol-5-ylamino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde 202273-09-4P,
(1-Benzyl-1H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)amine hydrochloride 202273-20-9P, (1-Benzyl-1H-indol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)amine hydrochloride 230955-62-1P, (6-Chloropyrido[3,4-d]pyrimidin-4-yl)(4-(3-fluorobenzyloxy)phenyl)amine 230955-63-2P,
[4-(Benzenesulphonyl)phenyl](6-iodoquinazolin-4-yl)amine 231278-14-1P,
4-(Tributylstannyl)thiazole-2-carbaldehyde 231278-15-2P,
5-[4-(1-Benzyl-1H-indazol-5-ylamino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde hydrochloride 231278-16-3P, (4-Phenoxyphenyl)-(7-iodoquinolin-4-yl)amine 231278-17-4P, (4-Benzyloxyphenyl)(6-iodo-7-fluoroquinazolin-4-yl)amine hydrochloride 231278-18-5P,
(1-Benzyl-1H-indazol-5-yl)(6-iodo-7-fluoroquinazolin-4-yl)amine hydrochloride 231278-19-6P, (4-(Benzenesulphonyl)phenyl)(6-iodo-7-fluoroquinazolin-4-yl)amine hydrochloride 231278-20-9P 231278-21-0P 231278-22-1P 231278-23-2P 231278-24-3P 231278-25-4P 231278-26-5P 231278-28-7P, (4-Benzyloxyphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-fluoroquinazolin-4-yl]amine 231278-29-8P, (1-Benzyl-1H-indazol-5-yl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-fluoroquinazolin-4-yl]amine 231278-30-1P 231278-31-2P, (4-Benzyloxy-3-trifluoromethylphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine 231278-32-3P,
5-[4-(4-Benzyloxy-3-trifluoromethylphenylamino)quinazolin-6-yl]furan-2-carbaldehyde 231278-33-4P, (4-Benzyloxyphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-methoxyquinazolin-4-yl]amine 231278-34-5P,
4-[4-(4-Phenoxyphenylamino)quinolin-7-yl]thiazole-2-carbaldehyde 231278-36-7P, 5-[4-(4-Benzyloxyphenylamino)-7-methoxyquinazolin-6-yl]furan-2-carbaldehyde hydrochloride 231278-37-8P, [6-[5-(1,3-Dioxolan-2-yl)furan-2-yl]-7-methoxyquinazolin-4-yl](4-(benzenesulphonyl)phenyl)amine 231278-38-9P, 5-[4-(4-Phenoxyphenylamino)quinolin-7-yl]furan-2-carbaldehyde 231278-39-0P, 5-[7-Methoxy-4-((4-(benzenesulphonyl)phenyl)amino)quinazolin-6-yl]furan-2-carbaldehyde hydrochloride 231278-40-3P, 5-[4-(4-Benzyloxyphenylamino)-7-fluoroquinazolin-6-yl]furan-2-carboxaldehyde hydrochloride 231278-41-4P,
5-[4-(1-Benzyl-1H-indazol-5-ylamino)-7-fluoroquinazolin-6-yl]furan-2-carbaldehyde hydrochloride 231278-42-5P 231278-43-6P,
(4-Phenoxyphenyl)-[7-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinolin-4-yl]amine 231278-44-7P, (1-Benzyl-1H-indazol-5-yl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-methoxyquinazolin-4-yl]amine 231278-45-8P 231278-46-9P 231278-50-5P, [6-[5-(1,3-Dioxolan-2-yl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]-[4-(3-fluorobenzyloxy)phenyl]amine 231278-51-6P,
5-[4-[4-(3-Fluorobenzyloxy)phenylamino]pyrido[3,4-d]pyrimidin-6-yl]furan-3-carbaldehyde 231278-52-7P, 5-[4-[4-(3-Fluorobenzyloxy)phenylamino]pyrido

[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde 231278-54-9P, (4-Benzenesulphonylphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl]amine 231278-55-0P, 5-[4-(4-Benzenesulphonylphenylamino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde hydrochloride 231278-59-4P, (4-Benzyloxyphenyl)-[6-[3-(1,3-dioxolan-2-yl)phenyl]pyrido[3,4-d]pyrimidin-4-yl]amine 231278-60-7P, 3-[4-[(4-Benzyloxyphenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]benzaldehyde 307326-79-0P, [4-(3-Fluorobenzyloxy)phenyl]-[6-[5-(thiomorpholin-4-ylmethyl)furan-2-yl]pyrido-[3,4-d]pyrimidin-4-yl]amine dihydrochloride 307326-84-7P, [6-[5-(1,3-Dioxolan-2-yl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-yl](4-phenoxyphenyl)amine 307326-86-9P, (6-Chloropyrido[3,4-d]pyrimidin-4-yl)(4-Phenoxyphenyl)amine 307326-88-1P, 5-[4-(4-Phenoxyphenylamino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde 307326-92-7P, (4-Benzenesulphonylphenyl)[6-(5-(thiomorpholin-4-ylmethyl)furan-2-yl)pyrido[3,4-d]pyrimidin-4-yl]amine dihydrochloride 307327-30-6P, 4-[4-[(4-Benzyloxyphenyl)amino]quinazolin-6-yl]thiazole-2-carbaldehyde 307327-37-3P, (1-Benzyl-1H-indazol-5-yl)(6-(5-(thiomorpholin-4-ylmethyl)furan-2-yl)quinazolin-4-yl)amine 307327-40-8P, (4-Benzyloxyphenyl)(6-(5-(thiomorpholin-4-ylmethyl)furan-2-yl)quinazolin-4-yl)amine hydrochloride 307327-44-2P, [4-(Benzenesulphonyl)phenyl]-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine 307327-47-5P, 5-[4-((4-(Benzenesulphonyl)phenyl)amino)quinazolin-6-yl]furan-2-carbaldehyde 307327-53-3P 307327-71-5P, 4-Chloro-6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinoline 307327-73-7P, 5-(4-Chloroquinolin-6-yl)furan-2-carbaldehyde 307327-76-0P, 4-Chloro-6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinoline 307327-82-8P, [1-N-(3-Pyridylmethyl)-1H-indazol-5-yl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine 307327-85-1P, [4-(3-Fluorobenzyloxy)phenyl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine 307327-87-3P, (1-Benzyl-1H-indazol-5-yl)-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine 307327-89-5P, [1-N-(2-Pyridylmethyl)-1H-indazol-5-yl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine 307327-91-9P, [1-(2,6-Difluorobenzyl)-1H-indazol-5-yl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine 307327-93-1P, [4-(3,4-Difluorobenzyloxy)phenyl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine 307327-95-3P, [1-(2,3-Difluorobenzyl)-1H-indazol-5-yl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine 307327-97-5P, (4-Phenoxyphenyl)-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addition of thiomorpholine (oxides))

IT 65340-70-7, 6-Bromo-4-chloroquinoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of the (haloheterocyclyl)furancarboxaldehyde with anilines followed by addition of thiomorpholine (oxides))

IT 79079-06-4, EGFR kinase 103171-49-9, Ras tyrosine kinase 137632-09-8, Protein tyrosine kinase erbB-2
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of thiomorpholinomethylfuranyl quinazolinamines and pyrido[3,4-d]pyrimidinamines as protein tyrosine kinase inhibitors for treatment of cancer)

IT **307328-34-3P**, 1-(3-Fluorobenzyl-1H-indazol-5-yl)[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addition of thiomorpholine (oxides))

RN 307328-34-3 HCAPLUS

CN 4-Quinazolinamine, N-[3-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



L57 ANSWER 7 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:98104 HCAPLUS

DN 132:151815

ED Entered STN: 11 Feb 2000

TI Preparation of indazoles as 5-HT1F agonists.

IN Krushinski, Joseph Herman, Jr.; Schaus, John Mehnert

PA Eli Lilly and Company, USA

SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW

DT Patent

LA English

IC ICM C07D401-04
ICS A61K031-445; C07D471-04; C07D455-02

ICI C07D471-04, C07D221-00, C07D209-00; C07D471-04, C07D223-00, C07D221-00

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 978514	A1	20000209	EP 1999-305915	19990726 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6133290	A	20001017	US 1999-334157	19990616 <--
	WO 2000006173	A1	20000210	WO 1999-US13834	19990622 <--
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9946961	A1	20000221	AU 1999-46961	19990622 <--
PRAI	US 1998-94940P	P	19980731 <--		
	WO 1999-US13834	W	19990622 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 978514	ICM	C07D401-04
	ICS	A61K031-445; C07D471-04; C07D455-02
	ICI	C07D471-04, C07D221-00, C07D209-00; C07D471-04, C07D223-00, C07D221-00

OS MARPAT 132:151815
GI



I

AB Title compds. (I; AD = CHCH2, C:CH; R = NO2, amino, halo, OH, acylamino; R1 = H, alkyl, R2 = H; R1R2 = atoms to form a fused 5-7 membered ring), were prepared as 5-HT1F agonists (no data). Thus, 4-(2-amino-5-nitrobenzoyl)-1-methylpiperidine (preparation given) in aqueous HCl at -5° was treated with aqueous NaNO2; the resulting diazonium salt solution was added to a -5° solution of SnCl2 in aqueous HCl followed by 2 h stirring at -3° to give 31.4% 5-nitro-3-(1-methylpiperidin-4-yl)-1H-indazole.

ST indazole prepn serotonin agonist; piperidinylindazole prepn serotonin antagonist; neuronal protein extravasation inhibitor indazole prepn

IT 5-HT agonists
(5-HT1; preparation of indazoles as 5-HT1F agonists)

IT Nerve
(neuron, neuronal protein extravasation inhibitors; preparation of indazoles as 5-HT1F agonists)

IT **253436-74-7P 253436-75-8P 253436-76-9P**
253436-77-0P 257637-10-8P 257637-12-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazoles as 5-HT1F agonists)

IT 78-94-4, Methyl vinyl ketone, reactions 1445-73-4, 1-Methyl-4-piperidone 6146-52-7, 5-Nitroindole 6346-09-4, 4,4-Diethoxybutylamine 10075-50-0, 5-Bromoindole 16686-11-6 17422-32-1, 5-Chloroindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indazoles as 5-HT1F agonists)

IT 2407-99-0P 6138-17-6P, 1,3-Dioxolane-2-butanenitrile 23581-42-2P 49552-70-7P, 1,3-Dioxolane-2-butanamine 116480-53-6P 121206-76-6P 214626-11-6P 214626-14-9P 214626-17-2P 220380-07-4P 253436-67-8P 253436-72-5P 253436-73-6P 257637-18-6P 257637-20-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazoles as 5-HT1F agonists)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Eli, L; EP 0733628 A 1996 HCAPLUS
(2) Eli, L; EP 0842934 A 1998 HCAPLUS
(3) Eli, L; EP 0875513 A 1998 HCAPLUS
(4) Hoechst Roussel Pharma; EP 0135781 A 1985 HCAPLUS
(5) Merck Sharp & Dohme; EP 0494774 A 1992 HCAPLUS

IT **253436-74-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazoles as 5-HT1F agonists)

RN 253436-74-7 HCAPLUS
CN 1H-Indazole, 3-(1-methyl-4-piperidinyl)-5-nitro- (9CI) (CA INDEX NAME)



L57 ANSWER 8 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:15205 HCAPLUS
DN 132:64178
ED Entered STN: 07 Jan 2000
TI Preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists
IN Krushinski, Joseph Herman, Jr.; Rocco, Vincent Patrick; Schaus, John Mehnert
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D471-00
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): **1**, **63**

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000000490	A2	20000106	WO 1999-US14502	19990624 <--
	WO 2000000490	A3	20030417		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9949614	A1	20000117	AU 1999-49614	19990624 <--
PRAI	US 1998-90872P	P	19980626	<--	
	US 1998-94957P	P	19980731	<--	
	WO 1999-US14502	W	19990624	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000000490	ICM	C07D471-00

OS MARPAT 132:64178
GI



I

AB The title compds. [I; A = N, C; D = O, S, NH; E = C, N; GJ = CH2CH, CH:C; R = (un)substituted Ph, naphthyl, heteroaryl; R1, R2 = H, halo, alkyl, alkoxy; R3 = H, alkyl; R4 = H, alkyl; R5 = H or R4 and R5 combine, together with the 6-membered ring to which they are attached, to form a 6:5, 6:6, or 6:7 fused bicyclic ring; provided that: A may be N only when D = NH and E = C; E may be N only when D = NH and A = C; when E = N, R3 is not a substituent], useful for activating 5-HT1F receptors and inhibiting neuronal protein extravasation in a mammal, and therefore useful in the treatment of migraine and associated disorders, were prepared and formulated. Thus, reacting 5-bromo-3-(1-methylpiperidin-4-yl)-1H-indole with 4-chlorostyrene in the presence of tri-o-tolylphosphine, Pd(OAc)2 and ET3N in DMF afforded 53.5% I [D = NH; E = C; A = C; GJ = CH2CH; R5 = H; R4 = Me; R1 = R2 = H; R = 4-ClC6H4]. Compds. I are effective at 0.1-15 mg/kg/day.

ST methylpiperidinylindole prepn hydroxytryptamine selective agonist; piperidinylindole prepn hydroxytryptamine selective agonist; indole piperidinyl prepn hydroxytryptamine selective agonist; neuronal protein extravasation methylpiperidinylindole prepn; migraine methylpiperidinylindole prepn

IT 5-HT receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(5-HT1F; preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists)

IT Proteins, general, biological studies
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(inhibitors of neuronal protein extravasation; preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists)

IT Headache
(migraine, treatment of; preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists)

IT Nerve
(neuron, inhibitors of neuronal protein extravasation; preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists)

IT 253436-53-2P 253436-54-3P 253436-55-4P 253436-56-5P 253436-57-6P 253436-58-7P 253436-59-8P 253436-60-1P 253436-61-2P 253436-62-3P 253436-63-4P 253436-64-5P 253436-65-6P 253436-66-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists)

IT 2407-99-0P
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists)

IT 78-94-4, 3-Buten-2-one, reactions 274-07-7, Catecholborane 350-51-6, 3-Fluorostyrene 394-46-7, 2-Fluorostyrene 402-50-6, 4-Trifluoromethylstyrene 405-99-2, 4-Fluorostyrene 459-57-4, 4-Fluorobenzaldehyde 536-74-3, Phenylacetylene 622-97-9, 4-Methylstyrene 637-69-4 762-04-9, Diethyl phosphite 1073-67-2, 4-Chlorostyrene 1080-32-6, Benzyl diethyl phosphonate 1445-73-4, 1-Methyl-4-piperidone 2039-85-2, 3-Chlorostyrene 2039-87-4, 2-Chlorostyrene 4637-24-5, Dimethylformamide dimethylacetal 6146-52-7, 5-Nitro-1H-indole 6346-09-4, 4,4-Diethoxybutylamine 10075-50-0, 5-Bromo-1H-indole 16686-11-6, 2-(3-Chloropropyl)-1,3-dioxolane 20369-41-9, Diethyl (α-fluorobenzyl)phosphonate 20532-33-6, 5-Chlorobenzothiophene 22280-62-2, 2-Amino-5-nitro-6-methylpyridine 80522-42-5 106516-27-2
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists)

IT 5467-69-6P 6138-17-6P, 1,3-Dioxolane-2-butanenitrile 17288-40-3P
21386-00-5P 22280-60-0P 23581-42-2P 28489-45-4P 32969-26-9P
49552-70-7P, 1,3-Dioxolane-2-butanamine 55556-41-7P 57477-39-1P
96794-40-0P 111963-87-2P 116480-53-6P 121206-76-6P 209627-04-3P
214626-11-6P 214626-13-8P 214626-14-9P 214626-17-2P 215601-92-6P
220380-07-4P 253436-67-8P 253436-68-9P 253436-69-0P 253436-70-3P
253436-71-4P 253436-72-5P 253436-73-6P **253436-74-7P**
253436-75-8P 253436-76-9P 253436-77-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists)

IT **253436-74-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles as 5-HT1F agonists)

RN 253436-74-7 HCAPLUS
CN 1H-Indazole, 3-(1-methyl-4-piperidinyl)-5-nitro- (9CI) (CA INDEX NAME)



L57 ANSWER 9 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:15199 HCAPLUS
DN 132:64177
ED Entered STN: 07 Jan 2000
TI Preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists
IN Filla, Sandra Ann; Koch, Daniel James; Mathes, Brian Michael; Rocco, Vincent Patrick
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D401-04
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): **1, 63**

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000000487	A1	20000106	WO 1999-US14400	19990625 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2336254	AA	20000106	CA 1999-2336254	19990625 <--
AU 9948318	A1	20000117	AU 1999-48318	19990625 <--
EP 1089993	A1	20010411	EP 1999-931907	19990625 <--
EP 1089993	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO
JP 2002519348 T2 20020702 JP 2000-557248 19990625 <--
AT 252572 E 20031115 AT 1999-931907 19990625 <--
US 6358972 B1 20020319 US 2000-701934 20001205 <--
PRAI US 1998-91198P P 19980630 <--
WO 1999-US14400 W 19990625 <--
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000000487	ICM	C07D401-04
WO 2000000487	ECLA	C07D401/04; C07D401/14; C07D401/14; C07D405/14; C07D405/14; C07D409/14; C07D417/14; C07D417/14; C07D471/04; C07D401/14; C07D401/14; C07D401/14 <--

OS MARPAT 132:64177
GI



I



II

AB The title compds. [I; A = N, C; D = O, S, NH; E = C, N; GJ = CH2CH, CH:C; R = (un)substituted Ph, naphthyl, heteroaryl; R1, R2 = H, alkyl; R3 = H or R2 and R3 combine, together with the 6-membered ring to which they are attached, to form a 6:5, 6:6, or 6:7 fused bicyclic ring; with the provisos that: A may be N only when D = NH and E = C; E may be N only when D = NH and A = C; E = N, R1 is not a substituent] which are useful for activating 5-HT1F receptors (no data) and inhibiting neuronal protein extravasation in a mammal, and therefore useful for the treatment of migraine, were prepared and formulated. Thus, reacting O-trifluoromethanesulfonyl-3-(1-methylpiperidin-4-yl)-5-hydroxy-4-aza-1H-indole with 4-fluorophenylboronic acid in the presence of Pd(PPh3)4 and aqueous NaHCO3 in THF afforded 79% the title compound II. Compds. I are effective at 0.1-15 mg/kg/day.

ST methylpiperidinylindole prepn serotonin agonist selective; piperidinylindole prepn serotonin agonist selective; indole methylpiperidinyl prepn serotonin agonist selective; migraine methylpiperidinylindole prepn; headache migraine methylpiperidinylindole prepn; neuronal protein extravasation methylpiperidinylindole prepn

IT 5-HT receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(5-HT1F; preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

IT Proteins, general, biological studies
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(inhibitors of neuronal protein extravasation; preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

IT Headache

(migraine, treatment of; preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

IT Nerve
(neuron, inhibitors of neuronal protein extravasation; preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

IT 22280-60-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(chiral; preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

IT 253439-61-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

IT 163104-91-4P 163104-98-1P 253439-38-2P 253439-39-3P 253439-40-6P
253439-41-7P 253439-42-8P 253439-43-9P 253439-44-0P 253439-45-1P
253439-46-2P 253439-47-3P 253439-48-4P 253439-49-5P 253439-50-8P
253439-51-9P 253439-52-0P 253439-53-1P 253439-54-2P 253439-55-3P
253439-56-4P 253439-57-5P 253439-58-6P 253439-59-7P 253439-60-0P
253439-62-2P 253439-63-3P 253439-64-4P 253439-65-5P 253439-66-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

IT 78-94-4, 3-Buten-2-one, reactions 95-83-0, 4-Chloro-o-phenylenediamine
98-80-6, Phenylboronic acid 99-90-1, 1-Bromo-4-acetylbenzene 103-88-8,
1-Bromo-4-acetamidobenzene 367-31-7, 4-Fluoro-o-phenylenediamine
611-35-8, 4-Chloroquinoline 615-20-3, 2-Chlorobenzothiazole 626-55-1,
3-Bromopyridine 671-15-8 698-67-9, 4-Bromobenzamide 1445-73-4,
1-Methyl-4-piperidone 1679-18-1, 4-Chlorophenylboronic acid 1765-93-1,
4-Fluorophenylboronic acid 3034-53-5, 2-Bromothiazole 4637-24-5,
Dimethylformamide dimethylacetal 4857-06-1, 2-Chlorobenzimidazole
5332-24-1, 3-Bromoquinoline 5720-07-0, 4-Methoxyphenylboronic acid
6146-52-7, 5-Nitro-1H-indole 6165-68-0, 2-Thiopheneboronic acid
6165-69-1, 3-Thiopheneboronic acid 6346-09-4, 4,4-Diethoxybutylamine
10075-50-0, 5-Bromo-1H-indole 16686-11-6, 2-(3-Chloropropyl)-1,3-dioxolane 17422-32-1, 5-Chloro-1H-indole 17997-47-6,
2-Tributylstannylpyridine 20532-33-6, 5-Chlorobenzothiophene
22280-62-2, 2-Amino-5-nitro-6-methylpyridine 32316-92-0,
2-Naphthylboronic acid 58050-53-6 73852-19-4, 3,5-Bis(trifluoromethyl)phenylboronic acid 80360-14-1 80522-42-5,
Triisopropylsilyl trifluoromethanesulfonate 98437-23-1,
Benzo[b]thiophene-2-boronic acid 99275-44-2 106516-27-2 182344-25-8
182344-54-3 214147-60-1, 1-tert-Butoxycarbonyl-2-chlorobenzimidazole
224573-20-0 253439-75-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

IT 2407-99-0P 5467-69-6P 6138-17-6P, 1,3-Dioxolane-2-butanenitrile
17288-40-3P 23581-42-2P 28489-45-4P 32969-26-9P 49552-70-7P,
1,3-Dioxolane-2-butanamine 55556-41-7P 57477-39-1P 111963-87-2P
116480-53-6P 121206-76-6P 214626-11-6P 214626-13-8P 214626-14-9P
214626-17-2P 215601-92-6P 220380-07-4P 253436-67-8P 253436-71-4P
253436-72-5P 253436-73-6P **253436-74-7P 253436-75-8P**
253436-76-9P 253436-77-0P 253439-67-7P 253439-68-8P
253439-69-9P 253439-70-2P 253439-71-3P 253439-72-4P 253439-73-5P
253439-74-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Agarwal, A; Journal of Medicinal Chemistry V36(25), P4006 HCAPLUS
(2) Glaxo; WO 9528400 A 1995 HCAPLUS
(3) Merck Sharp & Dohme; EP 0438230 A 1991 HCAPLUS
(4) Merck Sharp & Dohme; EP 0494774 A 1992 HCAPLUS
(5) Pfizer; WO 9213856 A 1992 HCAPLUS
(6) Smithkline Beecham; WO 9414771 A 1994 HCAPLUS

IT **253436-74-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)-4-aza-1H-indoles as 5-HT1F agonists)

RN 253436-74-7 HCAPLUS
CN 1H-Indazole, 3-(1-methyl-4-piperidinyl)-5-nitro- (9CI) (CA INDEX NAME)



L57 ANSWER 10 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:769083 HCAPLUS
DN 132:122591
ED Entered STN: 06 Dec 1999
TI Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents
AU Patel, Mona; Rodgers, James D.; McHugh, Robert J., Jr.; Johnson, Barry L.; Cordova, Beverly C.; Klabe, Ronald M.; Bacheler, Lee T.; Erickson-Viitanen, Susan; Ko, Soo S.
CS DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA
SO Bioorganic & Medicinal Chemistry Letters (**1999**), 9(22), 3217-3220
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
CC 28-21 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**
OS CASREACT 132:122591
GI



I

AB The preparation of unsym. cyclic ureas bearing novel biaryl indazoles as P2/P2' substituents was undertaken, utilizing a Suzuki coupling reaction as the key step. Compound I (R = 4-MeOC6H4) was equipotent to the lead compound of the series SE063 I (R = H).

ST urea cyclic prepn HIV protease inhibitor; diazepinone indazolylmethyl prepn HIV protease inhibitor; indazolylmethyldiazepinone prepn HIV protease inhibitor; triflate aryl boronic acid Suzuki coupling

IT Anti-AIDS agents
Human immunodeficiency virus 1
Suzuki coupling reaction
(preparation and biol. activity of indazolylmethyldiazepinones as HIV-1 protease inhibitors)

IT 209804-40-0P
RL: PNU (Preparation, unclassified); PREP (Preparation)
(lead compound for series; preparation and biol. activity of indazolylmethyldiazepinones as HIV-1 protease inhibitors)

IT **256345-77-4P 256345-78-5P 256345-79-6P**
256345-80-9P 256345-81-0P 256345-82-1P
256345-83-2P 256345-84-3P 256345-85-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of indazolylmethyldiazepinones as HIV-1 protease inhibitors)

IT 1423-26-3 1765-93-1 5720-07-0 6165-68-0 6165-69-1 10365-98-7
13331-27-6 87199-17-5 128796-39-4 256345-51-4 256345-56-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and biol. activity of indazolylmethyldiazepinones as HIV-1 protease inhibitors)

IT 709-45-5P 256345-52-5P 256345-53-6P 256345-54-7P 256345-55-8P
256345-57-0P 256345-58-1P 256345-59-2P 256345-60-5P 256345-61-6P
256345-62-7P 256345-63-8P 256345-64-9P 256345-65-0P 256345-66-1P
256345-67-2P 256345-68-3P 256345-69-4P 256345-70-7P 256345-71-8P
256345-72-9P 256345-73-0P 256345-74-1P 256345-75-2P 256345-76-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and biol. activity of indazolylmethyldiazepinones as HIV-1 protease inhibitors)

IT 64113-84-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of bromomethylfluorobenzoate from fluoromethylbenzonitrile via esterification and bromination)

IT 2967-93-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bromomethylfluorobenzoate from fluoromethylbenzonitrile via esterification and bromination)

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Bacheler, L; Antiviral Chem Chemother 1994, V5, P111 HCAPLUS
(2) Baiocchi, L; Synthesis 1978, P633 HCAPLUS
(3) Collot, V; Tetrahedron 1999, V55, P6917 HCAPLUS
(4) De Lucca, G; J Med Chem 1998, V41, P2411 HCAPLUS
(5) Erickson-Viitanen, S; Antimicrob Agents Chemother 1994, V38, P1628 HCAPLUS
(6) Jadhav, P; J Med Chem 1997, V40, P181 HCAPLUS
(7) Miyaura, N; Chem Rev 1995, V95, P2457 HCAPLUS
(8) Ritter, K; Synthesis 1993, P735 HCAPLUS
(9) Rodgers, J; Bioorg Med Chem Lett 1996, V6, P2919 HCAPLUS
(10) Rodgers, J; Bioorg Med Chem Lett 1998, V8, P715 HCAPLUS
(11) Rodgers, J; Chem Biol 1998, V5, P597 HCAPLUS
(12) Simon, U; Liebigs Ann Chem 1966, V697, P17 HCAPLUS
(13) Walser, A; Heterocyclic Chem 1974, V11, P863 HCAPLUS
(14) Walser, A; Heterocyclic Chem 1991, V28, P1121 HCAPLUS
(15) Wong, M; Tetrahedron Lett 1993, V34, P8237 HCAPLUS
(16) Zenchoff, G; J Heterocyclic Chem 1976, V13, P33 HCAPLUS

IT **256345-77-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of indazolylmethyldiazepinones as HIV-1 protease inhibitors)

RN 256345-77-4 HCAPLUS

CN 2H-1,3-Diazepin-2-one, 1-[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-3-[[3-(2-thienyl)-1H-indazol-5-yl]methyl]-, (4R,5S,6S,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 11 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:148062 HCAPLUS
DN 130:276243
ED Entered STN: 08 Mar 1999
TI Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1a serotonin and dopamine D1 receptors
AU Andronati, S.; Sava, Vassil; Makan, S.; Kolodeev, G.
CS Bogatsky Physico-Chemical Institute, Nat. Acad. Sci. Ukraine, Odessa, 270086, Ukraine
SO Pharmazie (**1999**), 54(2), 99-101
CODEN: PHARAT; ISSN: 0031-7144
PB Govi-Verlag Pharmazeutischer Verlag
DT Journal
LA English
CC 1-3 (**Pharmacology**)

AB Eight 3-arylindazole derivs. were synthesized and their affinity to 5-HT1A serotonin and D1 dopamine receptors was investigated by radioligand anal. Quant. structure-activity relationships were studied using the Free-Wilson model. An increase in affinity to dopamine D1 receptors within substituents Br>Cl>CH3 at the 5-position of the 3-arylindazole mol. was observed Addition of a Cl2 atom to the ortho-position the of Ph ring let to even higher activity. Replacement of the H2 atom at the 1st position of the 3-arylindazole on the (phenylpiperazine)butyl substituent caused an increase of affinity and did not change the trends of affinity dependence on structure. An inverse dependence on the structure of the studied compds. was observed for the serotonin 5-HT1A receptors. Compds. containing a Me group at the 5-position of mol. were more active than compds. containing halogens. A Cl2 atom at the ortho-position of the Ph ring decreased affinity. Replacement of the H2 atom at the 1st position of the mol. on the (phenylpiperazine)butyl substituent led to an increase in affinity. Selectivity of the studied compds. varied within a wide range. Generally, the presence of the 3-arylindazole fragment in the new buspirone analogs increased their affinity to dopamine receptors and reduced their affinity to serotonin receptors. Compds. containing a Br2 atom in the 3-arylindazole moiety may be promising ligands for D1 receptors.

ST arylindazole phenylpiperazine deriv prepn serotonin receptor; dopamine receptor anxiolytic arylindazole phenylpiperazine deriv

IT 5-HT receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(5-HT1A; synthesis of 3-arylindazole derivs. and their affinity to 5-HT1a serotonin and dopamine D1 receptors)

IT Dopamine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(D1; synthesis of 3-arylindazole derivs. and their affinity to 5-HT1a serotonin and dopamine D1 receptors)

IT Anxiolytics
QSAR (structure-activity relationship)
(synthesis of 3-arylindazole derivs. and their affinity to 5-HT1a serotonin and dopamine D1 receptors)

IT 271-44-3P, Indazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(3-aryl derivs.; synthesis of 3-arylindazole derivs. and their affinity to 5-HT1a serotonin and dopamine D1 receptors)

IT 92-54-6P, Phenylpiperazine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(derivs.; synthesis of 3-arylindazole derivs. and their affinity to 5-HT1a serotonin and dopamine D1 receptors)

IT **13097-03-5P** 57614-16-1P **57639-16-4P** 163434-05-7P 163434-06-8P 163434-07-9P 163434-08-0P **163434-09-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of 3-arylindazole derivs. and their affinity to 5-HT1a serotonin and dopamine D1 receptors)

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; JP 83030383
(2) Anon; JP 8436628
(3) Bogatsky, A; SU 729192 1979 HCAPLUS
(4) Cimino, M; Biochem Pharmacol 1983, V32, P1069 HCAPLUS
(5) Fajimura, Y; US 39948890 1974
(6) Fajimura, Y; JP 58030383 1983 HCAPLUS
(7) Fajimura, Y; JP 59036628 1984 HCAPLUS

(8) Free, S; J Med Chem 1964, V7, P394
(9) Glennon, R; J Med Chem 1988, V31, P1968 HCAPLUS
(10) Hibert, M; J Med Chem 1983, V31, P1087
(11) Misztal, S; J Med Chem Res 1992, V2, P82 HCAPLUS
(12) New, J; Med Res Rev 1990, V10, P283 HCAPLUS
(13) O'Boyle, K; Neuropharmacol 1992, V31, P177 HCAPLUS
(14) Paul, S; Arch Gen Psychiatry 1987, V38, P1315
(15) Peroutka, S; Brain Res 1985, V344, P167 HCAPLUS
(16) Sims, J; US 4417049 1983 HCAPLUS
(17) Xiao, Z; Japan J Pharmacol 1989, V50, P333

IT **13097-03-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of 3-arylindazole derivs. and their affinity to 5-HT1a serotonin and dopamine D1 receptors)

RN 13097-03-5 HCAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



L57 ANSWER 12 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:682242 HCAPLUS
DN 129:290152
ED Entered STN: 28 Oct 1998
TI Preparation of N-indazolylmethyl cyclic ureas as HIV protease inhibitors
IN Rodgers, James David; Johnson, Barry Laine; Wang, Haisheng
PA Dupont Pharmaceuticals Co., USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D403-06
ICS A61K031-55; C07D403-14; C07D401-06; C07D417-14; C07D405-14
CC 28-21 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843969	A1	19981008	WO 1998-US5901	19980326 <--
	W: AU, CA, IL, JP, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9868700	A1	19981022	AU 1998-68700	19980326 <--
	EP 973767	A1	20000126	EP 1998-914311	19980326 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2001518094	T2	20011009	JP 1998-541787	19980326 <--
	US 5985867	A	19991116	US 1998-52350	19980330 <--
PRAI	US 1997-42219P	P	19970331 <--		
	WO 1998-US5901	W	19980326 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9843969	ICM	C07D403-06
	ICS	A61K031-55; C07D403-14; C07D401-06; C07D417-14; C07D405-14

OS MARPAT 129:290152
GI



I

AB Title compds. (I; R1 = CH2Z1Z2R3; Z1 = indazole-5,3-diyl)[II; R = H; R2 = CH2C6H4(NH2)-3 or -4; R3 = OH, (ar)alkoxy, (di)(alkyl)amino, alkoxycarbonyl, heterocyclyl, etc.; Z2 = bond, (CH2)1-3, CH:CHCH2, CH(OH)] were prepared as HIV protease inhibitors (no data). Thus, O-methyl-I-isourea (RR = CMe2, R1 = H) was N-alkylated by Me 5-bromo-1-tritylindazole-3-carboxylate (preparation given) and the product refluxed with 3-(O2N)C6H4CH2Cl/KI to give, in 2 addnl. steps, trityl-protected II [RR = CMe2, R2 = CH2C6H4(NO2)-3, Z2R3 = CH2Cl] which was etherified by 6-hydroxyquinoline to give, in 2 addnl. steps, II [R = H, R2 = CH2C6H4(NH2)-3, Z2R3 = 6-quinolyloxymethyl].

ST indazolylmethyl cyclic urea HIV protease inhibitor

IT 144114-21-6, Retropepsin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; N-indazolylmethyl cyclic ureas)

IT 214346-59-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-indazolylmethyl cyclic ureas as HIV protease inhibitors)

IT
214346-21-1P 214346-22-2P 214346-23-3P 214346-24-4P 214346-26-6P
214346-28-8P 214346-29-9P 214346-30-2P 214346-31-3P 214346-32-4P
214346-33-5P 214346-34-6P 214346-35-7P 214346-36-8P 214346-37-9P
214346-38-0P 214346-39-1P 214346-40-4P 214346-41-5P 214346-42-6P
214346-43-7P 214346-45-9P 214346-47-1P 214346-49-3P 214346-51-7P
214346-53-9P 214346-55-1P 214346-57-3P 214346-61-9P 214346-63-1P
214346-65-3P 214346-67-5P 214346-69-7P **214346-72-2P**
214346-74-4P 214346-76-6P 214346-78-8P 214346-80-2P
214346-81-3P **214346-82-4P** 214346-83-5P 214346-84-6P
214346-85-7P 214346-86-8P 214346-87-9P 214346-88-0P 214346-90-4P
214346-91-5P **214346-92-6P** 214346-93-7P 214346-94-8P
214346-95-9P **214346-96-0P** **214346-97-1P**
214346-98-2P **214346-99-3P** 214347-00-9P 214347-01-0P
214347-02-1P **214347-03-2P** 214347-04-3P
214347-05-4P **214347-06-5P** 214347-07-6P 214347-08-7P
214347-09-8P **214347-11-2P** **214347-12-3P**
214347-13-4P 214347-14-5P 214347-15-6P 214347-16-7P 214347-17-8P
214347-18-9P 214347-19-0P 214347-20-3P **214347-21-4P**
214347-22-5P 214347-23-6P 214347-24-7P 214347-25-8P 214347-26-9P
214347-27-0P 214347-28-1P 214347-29-2P 214347-30-5P 214347-31-6P
214347-33-8P **214347-34-9P** 214347-36-1P 214347-38-3P
214347-40-7P 214347-42-9P 214347-44-1P 214347-46-3P 214347-48-5P
214347-51-0P 214347-52-1P 214347-53-2P 214347-55-4P 214347-56-5P
214347-57-6P 214347-58-7P 214347-59-8P 214347-60-1P 214347-61-2P
214347-62-3P **214347-63-4P** 214347-64-5P 214347-65-6P
214347-66-7P 214347-67-8P 214347-68-9P 214347-69-0P 214347-70-3P
214347-71-4P 214347-72-5P 214347-73-6P 214347-76-9P 214347-78-1P
214347-80-5P 214347-82-7P 214347-84-9P 214347-85-0P 214347-86-1P

214347-88-3P 214347-89-4P 214347-90-7P 214347-91-8P 214347-92-9P
214347-93-0P 214347-94-1P 214347-95-2P 214347-96-3P 214347-97-4P
214347-98-5P 214347-99-6P 214348-00-2P 214348-01-3P
214348-02-4P 214348-03-5P 214348-04-6P
214348-05-7P 214348-07-9P 214348-09-1P **214348-11-5P**
214348-12-6P 214348-13-7P 214348-14-8P
214348-15-9P 214348-16-0P 214348-17-1P
214348-18-2P 214348-19-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-indazolylmethyl cyclic ureas as HIV protease inhibitors)

IT 76-83-5, Trityl chloride 77-76-9, 2,2-Dimethoxypropane 580-16-5, 6-Hydroxyquinoline 608-05-9, 5-Methylisatin 619-23-8, 3-Nitrobenzyl chloride 15190-10-0, 2-(1-Morpholinyl)benzeneacetonitrile 101226-33-9 170028-72-5 180302-25-4 214348-50-2 214348-51-3 **214348-52-4**
214348-53-5 214348-54-6 214348-55-7 214348-56-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-indazolylmethyl cyclic ureas as HIV protease inhibitors)

IT 1201-24-7P, 5-Methyl-1H-indazole-3-carboxylic acid 51941-85-6P, 5-Methyl-1H-indazole-3-carboxylic acid methyl ester 214348-20-6P
214348-21-7P 214348-22-8P 214348-23-9P 214348-24-0P 214348-25-1P
214348-26-2P 214348-27-3P 214348-28-4P 214348-29-5P 214348-30-8P
214348-32-0P 214348-33-1P 214348-34-2P 214348-35-3P 214348-36-4P
214348-38-6P 214348-39-7P 214348-41-1P 214348-47-7P 214348-48-8P
214348-49-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-indazolylmethyl cyclic ureas as HIV protease inhibitors)

IT **214348-43-3P** 214348-44-4P 214348-45-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of N-indazolylmethyl cyclic ureas as HIV protease inhibitors)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Du Pont Merck Pharma; WO 9820008 A 1998 HCAPLUS
(2) Du Pont Merck Pharma; WO 9820009 A 1998 HCAPLUS
(3) Jadhav, P; US 5683999 A 1997 HCAPLUS
(4) Jadhav, P; J MED CHEM 1997, V40(2), P181 HCAPLUS
(5) Lam, P; US 5610294 A 1997 HCAPLUS
(6) Rodgers, J; BIOORG MED CHEM LETT 1996, V6(24), P2919 HCAPLUS
(7) Smyser, T; US 5532356 A 1996 HCAPLUS
(8) Wilkerson, W; J MED CHEM 1997, V40(25), P4079 HCAPLUS

IT **214346-72-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-indazolylmethyl cyclic ureas as HIV protease inhibitors)

RN 214346-72-2 HCAPLUS
CN 2H-1,3-Diazepin-2-one, 1-[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-3-[[3-[(5-methyl-1H-indazol-1-yl)methyl]-1H-indazol-5-yl]methyl]-4,7-bis(phenylmethyl)-, (4R,5S,6S,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 13 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:366891 HCAPLUS
DN 129:41125
ED Entered STN: 17 Jun 1998
TI Preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists
IN Jadhav, Prabhakar Kondaji; Petraitis, Joseph James; Batt, Douglas Guy
PA Dupont Merck Pharmaceutical Co., USA
SO U.S., 119 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D403-14
ICS C07D401-14; A61K031-54; A61K031-535
NCL 514211000
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5760028	A	19980602	US 1996-770538	19961220 <--
PRAI US 1996-770538		19961220 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5760028	ICM	C07D403-14
	ICS	C07D401-14; A61K031-54; A61K031-535
	NCL	514211000

OS MARPAT 129:41125
GI



I



II



III

AB The title compds. [I; X1-X4 = N, C (at least two of X1-X4 = C); R1 = 2-aminopyridin-6-yl(CH2)2, pyridin-2-ylamino(CH2)3, imidazol-2-ylamino(CH2)3, etc.; R10 = H, halo, No2, etc.; R11 = H, halo, CF3, etc.; W = [C(R12)2]qC(O)NR13 (wherein R12 = H, halo, C1-6 alkyl, etc.; R13 = H, C1-6 alkyl, C3-7 cycloalkylmethyl, etc.; q = 0-2), C(O)NR13[C(R12)2]q; X = C(R12)(R14)C(R12)(R15) (R14 = H, C1-10 alkyl, C2-10 alkenyl, etc.; R15 = H, C1-10 alkyl, C1-10 alkoxyalkyl, etc.); WX = II (R18 = H, C(O)OR17, C(O)R17, etc.; R17 = C1-10 alkyl, C3-11 cycloalkyl, etc.); Y = SO3H, PO3H, tetrazolyl, etc.] including 3-{1-[3-(imidazolin-2-ylamino)propyl]indazol-5-ylcarbonylamino}-2-(benzyloxycarbonylamino)propionic acid, useful as antagonists of the αvβ3 integrin and related cell surface adhesive protein receptors, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis, were prepared Thus, e.g., multi-step synthesis of the title compound 2(S)-III.CF3COOH is described. Compds. I are effective at 0.001-10 mg/kg/day.

ST integrin antagonist indazolylcarbonylaminoaminopropionic acid prepn; cell adhesion inhibitor indazolylcarbonylaminoaminopropionic acid prepn; protein receptor adhesive indazolylcarbonylaminoaminopropionic acid prepn; antiinflammatory indazolylcarbonylaminoaminopropionic acid prepn; osteoporosis indazolylcarbonylaminoaminopropionic acid prepn; cancer metastasis indazolylcarbonylaminoaminopropionic acid prepn; antitumor agent metastasis indazolylcarbonylaminoaminopropionic acid prepn; diabetic retinopathy indazolylcarbonylaminoaminopropionic acid prepn; thrombosis indazolylcarbonylaminoaminopropionic acid prepn; restenosis indazolylcarbonylaminoaminopropionic acid prepn; macular degeneration indazolylcarbonylaminoaminopropionic acid prepn; angiogenesis indazolylcarbonylaminoaminopropionic acid prepn

IT Protein receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(adhesive, inhibitors; preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT Eye, disease
(diabetic retinopathy; preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT Eye, disease

(macula, degeneration; preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT Neoplasm
(metastasis, treatment of; preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT Anti-inflammatory agents
Antitumor agents
Thrombosis
(preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT Artery, disease
(restenosis; preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT Angiogenesis
(treatment of conditions mediated by cell adhesion and/or cell migration and/or angiogenesis; preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT Osteoporosis
(treatment of; preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT Integrins
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
($\alpha v\beta 3$; preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT 192944-48-2P 192944-58-4P 192944-68-6P 192944-72-2P 192944-75-5P
192944-81-3P 192944-84-6P 192944-91-5P 192944-94-8P 192944-95-9P
192944-97-1P 192945-04-3P 192945-08-7P 192945-12-3P 192945-15-6P
192945-23-6P 192945-32-7P 192945-40-7P 192945-47-4P 192945-54-3P
192945-66-7P 192945-70-3P 192945-80-5P 192945-81-6P 192945-82-7P
192945-83-8P 192945-84-9P 192945-85-0P 192945-86-1P 192945-87-2P
192945-88-3P 192945-89-4P 192945-90-7P 192945-91-8P 192945-92-9P
192945-93-0P 192945-94-1P 192945-95-2P 192945-96-3P 192945-97-4P
192945-98-5P 192945-99-6P 192946-00-2P 192946-01-3P 192946-02-4P
192946-03-5P 192946-04-6P 192946-05-7P 192946-06-8P 192946-07-9P
192946-08-0P 192946-09-1P 192946-10-4P 192946-11-5P 192946-12-6P
192946-13-7P 192946-14-8P 192946-15-9P 192946-16-0P 192946-17-1P
192946-18-2P 192946-19-3P 192946-20-6P 192946-21-7P 192946-22-8P
192946-23-9P 192946-24-0P 192946-25-1P 192946-26-2P 192946-27-3P
192946-28-4P 192946-29-5P 192946-30-8P 192946-31-9P 192946-32-0P
192946-33-1P 192946-34-2P 192946-35-3P 192946-36-4P 192946-37-5P
192946-38-6P 192946-40-0P 192946-41-1P 192946-42-2P 192946-43-3P
192946-44-4P 192946-45-5P 192946-46-6P 192946-47-7P 192946-48-8P
192946-49-9P 192946-50-2P 192946-51-3P 192946-52-4P 192946-53-5P
192946-54-6P 192946-55-7P 192946-56-8P 192946-57-9P 192946-58-0P
192946-59-1P 192946-60-4P 192946-61-5P 192946-62-6P 192946-63-7P
192946-64-8P 192946-65-9P 192946-66-0P 192946-67-1P 192946-68-2P
192946-69-3P 192946-70-6P 192946-71-7P 208446-06-4P 208446-07-5P
208446-08-6P 208446-09-7P 208446-10-0P 208446-11-1P 208446-12-2P
208446-13-3P 208446-14-4P 208446-15-5P 208446-16-6P 208446-17-7P
208446-18-8P 208446-19-9P 208446-20-2P 208446-21-3P 208446-22-4P
208446-23-5P 208446-24-6P 208446-25-7P 208446-26-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT 70-47-3, L-Asparagine, reactions 76-83-5, Triphenylmethyl chloride
85-44-9, 1,3-Isobenzofurandione 85-46-1, 1-Naphthalenesulfonyl chloride
98-80-6, Phenylboronic acid 103-71-9, Phenyl isocyanate, reactions
107-13-1, 2-Propenenitrile, reactions 115-11-7, reactions 140-10-3, trans-Cinnamic acid, reactions 501-53-1, Benzyl chloroformate
504-29-0, 2-Aminopyridine 536-74-3, Phenylacetylene 543-27-1, Isobutyl

chloroformate 773-64-8, Mesitylenesulfonyl chloride 1623-93-4, [1,1'-Biphenyl]-4-sulfonyl chloride 1663-39-4 2719-27-9, Cyclohexylcarbonyl chloride 2905-29-5, 2,6-Dimethylbenzenesulfonyl chloride 3113-71-1, 3-Methyl-4-nitrobenzoic acid 3144-16-9 4786-20-3, 2-Butenenitrile 5394-18-3, N-(4-Bromobutyl)phthalimide 5445-73-8, 2-Methylthio-3,4,5,6-tetrahydropyrimidine hydroiodide 5460-29-7, N-(3-Bromopropyl)phthalimide 5464-11-9 10160-87-9 18595-18-1, Methyl 3-amino-4-methylbenzoate 18742-02-4, 2-(2-Bromoethyl)-1,3-dioxolane 20295-64-1, 2-Chloropyridine-N-oxide hydrochloride 35761-26-3 42383-61-9, 2-Aminoimidazole sulfate 56379-96-5, N-Benzylsulfamoyl chloride 59382-59-1, Methyl 2-methyl-3-nitrobenzoate 77215-55-5 192945-11-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

IT 7720-39-0P, 1H-Imidazol-2-amine 18583-89-6P 30650-90-9P 35761-27-4P 40800-65-5P 58457-98-0P 77087-60-6P 170487-40-8P 185563-91-1P 185563-92-2P 185563-93-3P 185563-97-7P 185563-98-8P 192944-46-0P 192944-47-1P 192944-50-6P 192944-51-7P 192944-52-8P 192944-53-9P 192944-54-0P 192944-55-1P 192944-60-8P 192944-62-0P 192944-63-1P 192944-64-2P 192944-65-3P 192944-66-4P 192944-67-5P 192944-70-0P 192944-71-1P 192944-74-4P 192944-77-7P 192944-78-8P 192944-79-9P 192944-80-2P 192944-83-5P 192944-86-8P 192944-87-9P 192944-88-0P 192944-89-1P 192944-90-4P 192944-93-7P 192944-96-0P 192944-99-3P 192945-00-9P 192945-01-0P 192945-02-1P 192945-06-5P 192945-07-6P 192945-10-1P 192945-14-5P 192945-17-8P 192945-18-9P 192945-19-0P 192945-20-3P 192945-21-4P 192945-22-5P 192945-25-8P **192945-26-9P** 192945-27-0P 192945-28-1P 192945-29-2P 192945-30-5P 192945-31-6P **192945-34-9P** 192945-35-0P 192945-36-1P 192945-37-2P 192945-38-3P 192945-39-4P 192945-42-9P 192945-43-0P 192945-44-1P 192945-45-2P 192945-46-3P 192945-49-6P 192945-50-9P 192945-51-0P 192945-52-1P 192945-53-2P 192945-56-5P 192945-57-6P 192945-58-7P 192945-59-8P 192945-60-1P 192945-61-2P 192945-62-3P 192945-64-5P 192945-65-6P 192945-68-9P 192945-69-0P 192945-72-5P 192945-73-6P 192945-74-7P 192945-75-8P 192945-76-9P 192945-77-0P 208446-27-9P 208446-28-0P 208446-29-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; WO 9309795 1993 HCAPLUS
(2) Anon; WO 9408962 1994 HCAPLUS
(3) Anon; EP 0655439 1995 HCAPLUS
(4) Anon; WO 9504531 1995 HCAPLUS
(5) Anon; WO 9514683 1995 HCAPLUS
(6) Anon; WO 9517397 1995 HCAPLUS
(7) Anon; WO 9620192 1996 HCAPLUS
(8) Anon; WO 9637492 1996 HCAPLUS
(9) James; US 5444038 1995 HCAPLUS
(10) Kettner; US 5187157 1993 HCAPLUS
(11) Metternich; US 5288707 1994 HCAPLUS
(12) Nakamura; US 4950764 1990 HCAPLUS
(13) Smith; US 4808405 1989 HCAPLUS

IT **192945-26-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(indazol-5-ylcarbonylamino)-2-aminopropionic acids as integrin receptor antagonists)

RN 192945-26-9 HCAPLUS

CN 1H-Indazole-5-carboxylic acid, 3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 14 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:42394 HCAPLUS
DN 128:102084
ED Entered STN: 24 Jan 1998
TI Preparation of 4-heterocyclyl-1-piperidineacetates as glycoprotein IIb/IIIa receptor antagonists
IN Allen, David George; Eldred, Colin David; Judkins, Brian David; Mitchell, William Leonard; Scopes, David Ian Carter
PA Glaxo Group Ltd., UK; Allen, David George; Eldred, Colin David; Judkins, Brian David; Mitchell, William Leonard; Scopes, David Ian Carter
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D401-14
ICS A61K031-415; A61K031-41; A61K031-445; C07D413-14; C07D453-02
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9749698	A1	19971231	WO 1997-EP3194	19970619 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9732610	A1	19980114	AU 1997-32610	19970619 <--
	ZA 9705431	A	19981221	ZA 1997-5431	19970619 <--
	CN 1222153	A	19990707	CN 1997-195652	19970619 <--
PRAI	GB 1996-13017	A	19960621 <--		
	GB 1996-13018	A	19960621 <--		
	GB 1996-13026	A	19960621 <--		
	GB 1996-13095	A	19960621 <--		
	WO 1997-EP3194	W	19970619 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9749698	ICM	C07D401-14
	ICS	A61K031-415; A61K031-41; A61K031-445; C07D413-14; C07D453-02

OS MARPAT 128:102084
GI



I II

AB Title compds. [I; R = Z2R2; R1 = Z3CHR3CO2H; R2 = piperidinyl, piperazinyl, quinuclidinyl; R3 = H, alkyl, (hetero)aryl, etc.; Z1 = atoms to complete an (un)substituted R1-substituted heterocyclic ring; Z2 = CH2CH2, CH:CH, C.tplbond.C; Z3 = piperidine-4,1-diyl] were prepared Thus, 3-BrC6H4Br was acylated by 1-acetylpiperidine-4-carbonyl chloride and the hydrazone of the deprotected product cyclized to give I (R = Br, R1 = 4-piperidinyl, Z1 = C:NNH) which was N-alkylated by BrCH2CO2CMe3 to give, in 2 addnl. steps, title compound II. Data for biol. activity of I were given.

ST piperidineacetate glycoprotein IIb IIIa receptor antagonist; antithrombotic piperidineacetate prepn

IT Anticoagulants
Platelet aggregation inhibitors
(preparation of 4-heterocyclyl-1-piperidineacetates as glycoprotein IIb/IIIa receptor antagonists)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(αIIbβ3, mediated disorders; treatment; preparation of 4-heterocyclyl-1-piperidineacetates as glycoprotein IIb/IIIa receptor antagonists)

IT 201227-06-7P 201227-07-8P 201227-08-9P 201227-09-0P 201227-10-3P
201227-12-5P 201227-29-4P 201482-18-0P 201482-19-1P 201482-20-4P
201482-21-5P 201482-22-6P 201482-23-7P 201482-24-8P 201482-25-9P
201482-27-1P 201482-28-2P 201482-29-3P 201482-30-6P 201482-31-7P
201482-32-8P 201482-33-9P 201482-34-0P 201482-35-1P 201482-36-2P
201482-37-3P 201482-38-4P 201482-39-5P 201482-40-8P 201482-41-9P
201482-42-0P 201482-43-1P 201482-44-2P 201482-45-3P 201482-46-4P
201482-47-5P 201482-48-6P 201482-49-7P 201482-50-0P 201482-51-1P
201482-52-2P 201482-53-3P 201482-54-4P 201482-55-5P 201482-56-6P
201482-57-7P 201482-58-8P 201482-59-9P 201482-60-2P 201482-61-3P
201482-62-4P 201482-63-5P 201482-64-6P 201482-65-7P 201482-67-9P
201482-69-1P 201482-70-4P 201482-71-5P 201482-72-6P 201482-73-7P
201482-74-8P 201482-75-9P 201482-76-0P 201482-77-1P 201482-78-2P
201482-79-3P 201482-80-6P 201482-81-7P 201482-82-8P 201482-83-9P
201482-84-0P 201482-85-1P 201482-86-2P 201482-87-3P 201482-88-4P
201482-89-5P 201482-90-8P 201482-91-9P 201482-92-0P 201482-93-1P
201482-94-2P 201482-95-3P 201482-96-4P 201482-97-5P 201482-98-6P
201482-99-7P 201483-00-3P 201483-01-4P 201483-03-6P 201483-05-8P
201483-06-9P 201483-07-0P 201483-08-1P 201483-09-2P 201483-10-5P
201483-12-7P 201483-13-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-heterocyclyl-1-piperidineacetates as glycoprotein IIb/IIIa

receptor antagonists)

IT 96-32-2, Methyl bromoacetate 106-40-1, 4-Bromoaniline 108-36-1, 1,3-Dibromobenzene 110-91-8, Morpholine, reactions 459-46-1, 4-Fluorobenzyl bromide 501-53-1, Benzyl chloroformate 628-17-1, 1-Iodopentane 3622-76-2, N,N-Dimethyl-2-vinyloxyethylamine 5292-43-3, tert-Butyl bromoacetate 5445-25-0, α-Bromo-4-chlorobenzeneacetic acid ethyl ester 24850-33-7, Allyltributyl tin 51069-09-1, 4-Vinyl-1-azabicyclo[2.2.2]octane 53857-57-1, 5-Bromoindazole 58914-40-2, 4-Bromomethylbenzamide 59084-16-1, 1-Acetylpiperidine-4-carbonyl chloride 78155-74-5, Methyl 5-bromo-1H-indazole-3-carboxylate 138646-94-3, α-Bromo-4-chlorobenzeneacetic acid tert-butyl ester 141699-59-4, tert-Butyl 4-methylsulfonyloxy-1-piperidinecarboxylate 150849-43-7, 3-Cyclohexylpropyl methanesulfonate 180307-56-6, tert-Butyl 4-vinylpiperidine-1-carboxylate 201483-69-4, 5-Bromo-3-chloromethyl-1H-indazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 4-heterocyclyl-1-piperidineacetates as glycoprotein IIb/IIIa receptor antagonists)

IT 34774-91-9P 180307-50-0P 180307-51-1P 180307-52-2P 180307-54-4P 180307-58-8P 180307-61-3P 201227-16-9P, 5-Bromo-2-nitro-1H-indazole 201227-17-0P 201227-18-1P 201227-19-2P 201227-20-5P 201227-21-6P 201227-25-0P 201227-31-8P 201227-35-2P 201227-36-3P 201227-37-4P 201227-38-5P 201227-39-6P 201227-40-9P 201227-41-0P 201227-42-1P 201227-43-2P 201227-44-3P 201227-45-4P 201227-50-1P 201483-23-0P 201483-24-1P 201483-25-2P 201483-26-3P 201483-27-4P 201483-28-5P 201483-29-6P 201483-30-9P 201483-31-0P 201483-32-1P 201483-34-3P 201483-35-4P 201483-36-5P 201483-37-6P 201483-38-7P 201483-39-8P 201483-40-1P 201483-41-2P 201483-42-3P 201483-43-4P 201483-44-5P 201483-45-6P 201483-46-7P 201483-47-8P 201483-48-9P 201483-49-0P 201483-50-3P 201483-51-4P 201483-52-5P 201483-53-6P 201483-54-7P 201483-55-8P 201483-56-9P 201483-57-0P 201483-58-1P **201483-59-2P** 201483-60-5P 201483-62-7P 201483-63-8P 201483-64-9P 201483-66-1P 201483-67-2P 201483-68-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-heterocyclyl-1-piperidineacetates as glycoprotein IIb/IIIa receptor antagonists)

IT **201483-59-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-heterocyclyl-1-piperidineacetates as glycoprotein IIb/IIIa receptor antagonists)

RN 201483-59-2 HCAPLUS
CN 1H-Indazole, 5-bromo-3-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



L57 ANSWER 15 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:506247 HCAPLUS
DN 127:136075
ED Entered STN: 11 Aug 1997
TI Annelated pyrazoles as novel integrin receptor antagonists
IN Jadhav, Prabhakar Kondaji; Petraitis, Joseph James; Batt, Douglas Guy
PA Du Pont Merck Pharmaceutical Company, USA; Jadhav, Prabhakar Kondaji; Petraitis, Joseph James; Batt, Douglas Guy

SO PCT Int. Appl., 419 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D403-12
ICS A61K031-415; C07D401-12; C07D405-14; C07D409-14; C07D413-14; C07D417-14
CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9723480	A1	19970703	WO 1996-US20523	19961218 <--
	W: AM, AU, AZ, BA, BR, BY, CA, CN, CU, CZ, EE, HU, IL, JP, KG, KR, KZ, LC, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2240439	AA	19970703	CA 1996-2240439	19961218 <--
	AU 9713456	A1	19970717	AU 1997-13456	19961218 <--
	EP 939757	A1	19990908	EP 1996-944984	19961218 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000501105	T2	20000202	JP 1997-523845	19961218 <--
	ZA 9610873	A	19980623	ZA 1996-10873	19961223 <--
PRAI	US 1995-9088P	P	19951222 <--		
	US 1996-646663	A	19960508 <--		
	US 1996-25699P	P	19960909 <--		
	WO 1996-US20523	W	19961218 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9723480	ICM	C07D403-12
	ICS	A61K031-415; C07D401-12; C07D405-14; C07D409-14; C07D413-14; C07D417-14

OS MARPAT 127:136075
AB This invention relates to novel heterocycles including 3-[1-[3-(imidazolin-2-ylamino)propyl]indazol-5-ylcarbonylamino]-2-(benzyloxycarbonylamino)propionic acid (I), which are useful as antagonists of the αvβ3 integrin and related cell surface adhesive protein receptors (no data). Thus, I was prepared from 3-methyl-4-nitrobenzoic acid by conversion to Et 5-indazolecarboxylate and reaction with 2-methylthio-4,5-dihydroimidazole-HI, followed by (S)-H2NCH2CH(NHCO2CH2Ph)CO2Et.
ST pyrazole annelated prepn integrin receptor antagonist; imidazolinylaminopropylindazolylcarbonylaminopropionate prepn integrin receptor antagonist
IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(αvβ3, antagonists; preparation of annelated pyrazoles as integrin receptor antagonists)
IT 70-47-3, L-Asparagine, reactions 107-13-1, 2-Propenenitrile, reactions 140-10-3, trans-Cinnamic acid, reactions 504-29-0, 2-Aminopyridine 1450-93-7 1623-93-4, [1,1'-Biphenyl]-4-sulfonyl chloride 2905-29-5, 2,6-Dimethylbenzenesulfonyl chloride 3113-71-1, 3-Methyl-4-nitrobenzoic acid 4360-63-8, Bromoacetaldehyde ethyleneacetal 5460-29-7, N-(3-Bromopropyl)phthalimide 5464-11-9 18583-89-6, Methyl 2-methyl-3-aminobenzoate 18595-18-1, Methyl 3-amino-4-methylbenzoate 20295-64-1, 2-Chloropyridine N-oxide hydrochloride 35761-26-3 40322-87-0, 2-Methylthioimidazoline hydriodide 77215-55-5 192944-56-2 192945-11-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of annelated pyrazoles as integrin receptor antagonists)
IT 30650-90-9P, Ethyl 3-methyl-4-nitrobenzoate 33334-11-1P, 2-Aminoindazole 35761-27-4P 40800-65-5P 58457-98-0P 59382-59-1P 77087-60-6P

170487-40-8P 185563-91-1P 185563-92-2P 185563-93-3P 185563-96-6P
185563-97-7P 185563-98-8P 192944-46-0P 192944-47-1P 192944-50-6P
192944-51-7P 192944-52-8P 192944-53-9P 192944-54-0P 192944-55-1P
192944-57-3P 192944-60-8P 192944-61-9P 192944-62-0P 192944-63-1P
192944-64-2P 192944-65-3P 192944-66-4P 192944-67-5P 192944-70-0P
192944-71-1P 192944-74-4P 192944-77-7P 192944-78-8P 192944-79-9P
192944-80-2P 192944-83-5P 192944-86-8P 192944-87-9P 192944-88-0P
192944-89-1P 192944-90-4P 192944-93-7P 192944-96-0P 192944-99-3P
192945-00-9P 192945-01-0P 192945-02-1P 192945-03-2P 192945-06-5P
192945-07-6P 192945-10-1P 192945-14-5P 192945-17-8P 192945-18-9P
192945-19-0P 192945-20-3P 192945-21-4P 192945-22-5P 192945-25-8P
192945-26-9P 192945-27-0P 192945-28-1P 192945-29-2P
192945-30-5P 192945-31-6P **192945-34-9P** 192945-35-0P
192945-36-1P 192945-37-2P 192945-38-3P 192945-39-4P 192945-42-9P
192945-43-0P 192945-44-1P 192945-45-2P 192945-46-3P 192945-49-6P
192945-50-9P 192945-51-0P 192945-52-1P 192945-53-2P 192945-56-5P
192945-57-6P 192945-58-7P 192945-59-8P 192945-60-1P 192945-61-2P
192945-62-3P 192945-64-5P 192945-65-6P 192945-68-9P 192945-69-0P
192945-72-5P 192945-73-6P 192945-74-7P 192945-75-8P 192945-76-9P
192945-77-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of annelated pyrazoles as integrin receptor antagonists)

IT 192944-49-3P 192944-59-5P 192944-69-7P 192944-73-3P 192944-76-6P
192944-82-4P 192944-85-7P 192944-92-6P 192944-95-9P 192944-98-2P
192945-05-4P 192945-09-8P 192945-13-4P 192945-16-7P 192945-24-7P
192945-33-8P 192945-41-8P 192945-48-5P 192945-55-4P 192945-67-8P
192945-71-4P 192945-79-2P 192945-80-5P 192945-81-6P 192945-82-7P
192945-83-8P 192945-84-9P 192945-85-0P 192945-86-1P 192945-87-2P
192945-88-3P 192945-89-4P 192945-90-7P 192945-91-8P 192945-92-9P
192945-93-0P 192945-94-1P 192945-95-2P 192945-96-3P 192945-97-4P
192945-98-5P 192945-99-6P 192946-00-2P 192946-01-3P 192946-02-4P
192946-03-5P 192946-04-6P 192946-05-7P 192946-06-8P 192946-07-9P
192946-08-0P 192946-09-1P 192946-10-4P 192946-11-5P 192946-12-6P
192946-13-7P 192946-14-8P 192946-15-9P 192946-16-0P 192946-17-1P
192946-18-2P 192946-19-3P 192946-20-6P 192946-21-7P 192946-22-8P
192946-23-9P 192946-24-0P 192946-25-1P 192946-26-2P 192946-27-3P
192946-28-4P 192946-29-5P 192946-30-8P 192946-31-9P 192946-32-0P
192946-33-1P 192946-34-2P 192946-35-3P 192946-36-4P 192946-37-5P
192946-38-6P 192946-39-7P 192946-40-0P 192946-41-1P 192946-42-2P
192946-43-3P 192946-44-4P 192946-45-5P 192946-46-6P 192946-47-7P
192946-48-8P 192946-49-9P 192946-50-2P 192946-51-3P 192946-52-4P
192946-53-5P 192946-54-6P 192946-55-7P 192946-56-8P 192946-57-9P
192946-58-0P 192946-59-1P 192946-60-4P 192946-61-5P 192946-62-6P
192946-63-7P 192946-64-8P 192946-65-9P 192946-66-0P 192946-67-1P
192946-68-2P 192946-69-3P 192946-70-6P 192946-71-7P 192946-72-8P
192946-73-9P 192946-74-0P 192946-75-1P 192946-76-2P 192946-77-3P
192946-78-4P 192946-79-5P 192946-80-8P 192946-81-9P 192946-82-0P
192946-83-1P 192946-84-2P 192946-85-3P 192946-86-4P 192946-87-5P
192946-88-6P 192946-89-7P 192946-90-0P 192946-91-1P 192946-92-2P
192946-93-3P 192946-94-4P 192946-95-5P 192946-96-6P 192946-97-7P
192946-98-8P 192946-99-9P 192947-00-5P 192947-01-6P 192947-02-7P
192947-03-8P 192947-04-9P 192947-05-0P 192947-06-1P 192947-07-2P
192947-08-3P 192947-09-4P 192947-10-7P 192947-11-8P 192947-12-9P
192947-13-0P 192947-14-1P 192947-15-2P 192947-16-3P 192947-17-4P
192947-18-5P 192947-19-6P 192947-20-9P 192947-21-0P 192947-22-1P
192947-23-2P 192947-24-3P 192947-25-4P 192947-26-5P 192947-27-6P
192947-28-7P 192947-29-8P 192947-30-1P 192947-31-2P 192947-32-3P
192947-33-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of annelated pyrazoles as integrin receptor antagonists)

IT **192945-26-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of annelated pyrazoles as integrin receptor antagonists)
RN 192945-26-9 HCAPLUS
CN 1H-Indazole-5-carboxylic acid, 3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 16 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:483988 HCAPLUS
DN 127:190716
ED Entered STN: 04 Aug 1997
TI Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists
AU Henke, Brad R.; Aquino, Christopher J.; Birkemo, Larry S.; Croom, Dallas K.; Dougherty, Robert W. Jr.; Ervin, Gregory N.; Grizzle, Mary K.; Hirst, Gavin C.; James, Michael K.; Johnson, Michael F.; Queen, Kennedy L.; Sherrill, Ronald G.; Sugg, Elizabeth E.; Suh, Edward M.; Szewczyk, Jerzy W.; Unwalla, Rayomand J.; Yingling, Jeff; Willson, Timothy M.
CS Glaxo Wellcome Research and Development, Five Moore Drive, Research Triangle Park, NC, 27709, USA
SO Journal of Medicinal Chemistry (**1997**), 40(17), 2706-2725
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
CC 28-21 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**
GI



I

AB We previously described a series of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepine CCK-A agonists exemplified by compound I (GW 5823), which is the first reported binding selective CCK-A full agonist demonstrating oral efficacy in a rat feeding model. In this report we describe analogs of I designed to explore changes to the C3 and N1 pharmacophores and their effect on agonist activity and receptor selectivity. Agonist efficacy in

this series was affected by stereoelectronic factors within the C3 moiety. Binding affinity for the CCK-A vs. CCK-B receptor showed little dependence on the structure of the C3 moiety but was affected by the nature of the second substituent at C3. Structure-activity relationships at the N1-anilidoacetamide trigger moiety within the C3 indazole series were also investigated. Both agonist efficacy and binding affinity within this series were modulated by variation of substituents on the N1-anilidoacetamide moiety. Evaluation of several analogs in an in vivo mouse gallbladder emptying assay revealed compound I to be the most potent and efficacious of all the analogs tested. The pharmacokinetic and pharmacodynamic profile of I in rats is also discussed.

ST benzodiazepinedione indazolylmethyl prepn CCK A agonist; indazolylmethylbenzodiazepinedione prepn CCK A agonist; structure activity indazolylmethylbenzodiazepinedione CCK A agonist

IT Pharmacokinetics
Structure-activity relationship
(optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists)

IT 174181-69-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists)

IT 174181-80-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists)

IT 174180-37-1P 174181-60-3P 174181-61-4P 174181-62-5P 174181-68-1P
174181-70-5P 174181-75-0P 174181-81-8P 174181-82-9P 174181-84-1P
174181-88-5P 174181-92-1P 174181-94-3P 174181-98-7P 174181-99-8P
174182-02-6P 174182-05-9P 174182-14-0P 174182-15-1P 174182-16-2P
194278-32-5P 194278-33-6P 194278-34-7P 194278-35-8P
194278-36-9P 194278-37-0P 194278-38-1P 194278-39-2P
194278-40-5P 194278-41-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists)

IT 9011-97-6, Cholecystokinin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists)

IT 194278-30-3P 194278-31-4P
RL: PUR (Purification or recovery); PREP (Preparation)
(optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists)

IT 87-52-5, Gramine 95-56-7, 2-Bromophenol 119-75-5 302-01-2, Hydrazine, reactions 450-95-3, 2-Fluoroacetophenone 534-85-0, 1,2-Benzenediamine, N-phenyl- 623-47-2, Ethyl propiolate 4492-02-8, 1H-Indazole-3-carboxylic acid, 4,5,6,7-tetrahydro-, ethyl ester 4498-67-3, 1H-Indazole-3-carboxylic acid 5018-30-4, Dimethyl methoxymalonate 19060-10-7, Malonaldehyde dimethyl acetal 20577-61-1 31230-17-8, 3-Amino-5-methylpyrazole 39619-07-3, Methylmalonyl chloride 109216-60-6 112713-84-5 154447-01-5 174180-33-7, 1H-Indazole, 3-(bromomethyl)-1-(phenylmethyl)-
RL: RCT (Reactant); RACT (Reactant or reagent)
(optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as

potent, orally active CCK-A agonists)

IT 1578-96-7P 3176-62-3P, 3-Methylindazole 4687-23-4P, 3-Benzofuranmethanol 10368-14-6P 13210-25-8P 16495-67-3P 22316-50-3P 25016-17-5P 31143-05-2P 37924-85-9P 38281-49-1P 59057-83-9P 64856-16-2P 82071-69-0P, 1H-Indazole-3-methanol, 4,5,6,7-tetrahydro-1-(phenylmethyl)- 96551-21-2P 116834-96-9P, 1H-Pyrazolo[3,4-b]pyridine, 3-methyl- 131427-21-9P, 1H-Indazole-3-methanol, 1-(phenylmethyl)- 145324-80-7P 161455-90-9P 161455-95-4P 161455-96-5P 161455-97-6P 174180-28-0P 174180-38-2P 174180-39-3P 174180-40-6P 174180-42-8P 174180-45-1P 174180-54-2P, 1H-Indazole-3-carboxylic acid, 1-(phenylmethyl)-, phenylmethyl ester 174180-56-4P 174180-57-5P 174180-72-4P 174180-76-8P 174180-77-9P, 1H-Pyrazolo[3,4-b]pyridine-1-carboxylic acid, 3-methyl-, 1,1-dimethylethyl ester 174180-78-0P, 1H-Indazole-3-carboxylic acid, 4,5,6,7-tetrahydro-1-(phenylmethyl)-, ethyl ester 174180-79-1P 174180-80-4P 174180-81-5P 174180-84-8P 174180-85-9P 174180-89-3P 174180-95-1P 174180-98-4P 174181-01-2P 174181-02-3P 174181-03-4P 174181-07-8P 174181-08-9P 174181-22-7P 174181-23-8P 174181-25-0P 174181-26-1P 174181-27-2P 174181-29-4P 174181-30-7P 174181-31-8P 174181-40-9P 174181-79-4P 194278-14-3P 194278-28-9P 194278-29-0P 194278-42-7P 194278-43-8P 194278-44-9P 194278-45-0P 194278-46-1P 194278-48-3P 194278-49-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists)

IT **194278-36-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists)

RN 194278-36-9 HCAPLUS

CN 1H-1,5-Benzodiazepine-1-acetamide, 3-[(5-fluoro-1H-indazol-3-yl)methyl]-2,3,4,5-tetrahydro-N-(4-methoxyphenyl)-N-(1-methylethyl)-2,4-dioxo-5-phenyl- (9CI) (CA INDEX NAME)



L57 ANSWER 17 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:69730 HCAPLUS
DN 126:89354

ED Entered STN: 31 Jan 1997
TI Preparation of indole, indazole, and benzisoxazole derivatives for the treatment of schizophrenia
IN Lavielle, Gilbert; Muller, Olivier; Millan, Mark; Audinot, Valerie
PA Adir Et Compagnie, Fr.
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA French
IC ICM C07D403-06
ICS A61K031-40; C07D413-06
CC 28-1 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 27
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 747379	A1	19961211	EP 1996-401208	19960606 <--
	EP 747379	B1	19990811		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2735129	A1	19961213	FR 1995-6663	19950607 <--
	FR 2735129	B1	19970711		
	JP 08333362	A2	19961217	JP 1996-141436	19960604 <--
	CA 2178302	AA	19961208	CA 1996-2178302	19960605 <--
	CA 2178302	C	20020226		
	AU 9654735	A1	19961219	AU 1996-54735	19960605 <--
	AU 702285	B2	19990218		
	CN 1143642	A	19970226	CN 1996-107985	19960605 <--
	CN 1060772	B	20010117		
	NO 9602360	A	19961209	NO 1996-2360	19960606 <--
	US 5703070	A	19971230	US 1996-663464	19960606 <--
	AT 183183	E	19990815	AT 1996-401208	19960606 <--
	ES 2137638	T3	19991216	ES 1996-401208	19960606 <--
	ZA 9604842	A	19970107	ZA 1996-4842	19960607 <--
PRAI	FR 1995-6663	A	19950607 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 747379	ICM	C07D403-06
	ICS	A61K031-40; C07D413-06

OS MARPAT 126:89354
GI



I

AB I [R1 = H, halo, alkyl, alkoxy, trihalomethyl, OH; R2 = H, alkyl, (un)substituted Ph; R2XY = R2NCH, R2NN, ON; R3 = nitrogen heterocyclyl; n = 1-6] were prepared E.g., (5-methoxyindol-3-yl)acetic acid was reduced with LiAlH4, brominated (PPh3, CBr4), and reacted with 3-(4-fluorobenzoylmethyl)pyrrolidine to give 3-{2-[3-(4-fluorobenzoylmethyl)pyrrolidin-1-yl]ethyl}-5-methoxyindole hydrochloride. I showed strong affinity for 5-HT1A, 5-HT2A, and 5-HT2C receptors. Antipsychotic activities of I were also investigated.
ST indole prepn schizophrenia treatment; indazole prepn schizophrenia treatment; benzisoxazole prepn schizophrenia treatment; antipsychotic indole indazole benzisoxazole

IT 5-HT receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(5-HT1A; preparation and serotoninergic receptor affinity of indole, indazole, and benzisoxazole derivs.)

IT 5-HT receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(5-HT2A; preparation and serotoninergic receptor affinity of indole, indazole, and benzisoxazole derivs.)

IT 5-HT receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(5-HT2C; preparation and serotoninergic receptor affinity of indole, indazole, and benzisoxazole derivs.)

IT Antipsychotics
(preparation of indole, indazole, and benzisoxazole derivs. for the treatment of schizophrenia)

IT 185557-94-2P 185557-95-3P 185557-96-4P 185557-97-5P 185557-99-7P
185558-01-4P 185558-03-6P 185558-06-9P 185558-09-2P
185558-12-7P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole, indazole, and benzisoxazole derivs. for the treatment of schizophrenia)

IT 141-82-2, Malonic acid, reactions 823-85-8, 4-Fluorophenylhydrazine hydrochloride 3471-31-6 6581-66-4, 2-Methoxytetrahydropyran 6628-86-0, 5-Chloro-2-nitrobenzaldehyde 19501-58-7, 4-Methoxyphenylhydrazine hydrochloride 56565-20-9 131952-79-9 169168-04-1 169168-05-2 169168-06-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indole, indazole, and benzisoxazole derivs. for the treatment of schizophrenia)

IT 27328-68-3P 146818-71-5P 185558-16-1P 185558-18-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indole, indazole, and benzisoxazole derivs. for the treatment of schizophrenia)

IT **185558-12-7P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole, indazole, and benzisoxazole derivs. for the treatment of schizophrenia)

RN 185558-12-7 HCAPLUS

CN Ethanone, 2-[1-[2-(5-chloro-1H-indazol-3-yl)ethyl]-3-pyrrolidinyl]-1-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L57 ANSWER 18 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:490642 HCAPLUS
DN 122:314528
ED Entered STN: 15 Apr 1995
TI Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]-1,2-dihydro-3H-1,4-benzodiazepin-2-ones and -1H-indazoles and their affinity for benzodiazepine receptors
AU Andronati, S. A.; Kolodeyev, G. Ye.; Makan, S. Yu.; Sava, V. M.; Yavorsky, A. S.
CS Fiz.-Khim. Inst. im. A.V. Bogatskogo, Odessa, Ukraine
SO Dopovidi Akademii Nauk Ukraini (**1994**), (8), 126-31
CODEN: DNUKEM
PB Naukova Dumka
DT Journal
LA Russian
CC 28-21 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**
GI



I



II



III

AB Title compds. I (R = H, Cl) and II (R1 = Cl, Br, Me, R2 = H; R1 = Br, R2 = Cl) were prepared by reaction of spiro compound III with 1-unsubstituted benzodiazepinones and indazoles. The effect of the (phenylpiperazinyl)butyl group on the affinity to benzodiazepine receptors was examined
ST benzodiazepine receptor affinity phenylpiperazinylbutyl benzodiazepinone indazole
IT Receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(benzodiazepine, effect of (phenylpiperazinyl)butyl group on

benzodiazepine receptor affinity of benzodiazepinones and indazoles)

IT 163434-03-5P 163434-04-6P 163434-05-7P 163434-06-8P 163434-07-9P 163434-08-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(effect of (phenylpiperazinyl)butyl group on benzodiazepine receptor affinity of benzodiazepinones and indazoles)

IT 719-59-5, 2-Amino-5-chlorobenzophenone 17852-28-7, 2-Amino-5-methylbenzophenone 39859-36-4, 2-Amino-5-bromobenzophenone 60773-49-1 136312-82-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(effect of (phenylpiperazinyl)butyl group on benzodiazepine receptor affinity of benzodiazepinones and indazoles)

IT 2894-61-3P **13097-03-5P** 51753-57-2P 57614-16-1P **57639-16-4P 163434-09-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(effect of (phenylpiperazinyl)butyl group on benzodiazepine receptor affinity of benzodiazepinones and indazoles)

IT **13097-03-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(effect of (phenylpiperazinyl)butyl group on benzodiazepine receptor affinity of benzodiazepinones and indazoles)

RN 13097-03-5 HCAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



L57 ANSWER 19 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:134360 HCAPLUS
DN 120:134360
ED Entered STN: 19 Mar 1994
TI Synthesis and antiinflammatory activity of some indazole derivatives. Part 36. Azoles
AU Wrzeciono, U.; Linkowska, E.; Majewska, K.; Gzella, A.; Stochla, K.
CS Med. Acad., Poznan, Pol.
SO Pharmazie (**1993**), 48(8), 582-4
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**
GI



I

AB The indazole derivs. I (R = Ac, R1 = morpholino, piperidino, pyrrolidino, 4-methylpiperazino, R2 = 5-, 6-NHAc; R = H, R1 = morpholino, R2 = 5-NH2; R = H, R1 = 4-methylpiperazino, R2 = 5-Cl) were prepared from I (R2 = NO2). I (R = H, R1 = thiomorpholino, NO2, R2 = 5-NO2) were obtained by treating 2,5-dinitroindazole with thiomorpholine. The known indazole derivs. I (R = H, R1 = morpholino, R2 = 5-NO2; R = H, R1 = NEt2, R2 = 6-NO2) as well as I.HCl (R = H, R1 = morpholino, R2 = NH2; R = H, R1 = 4-methylpiperazino, R2 = 6-AcNH, 5-Cl) are less toxic than benzydamine hydrochloride (II). The same compds. show comparable or greater antiinflammatory effect than II in the carrageenin-induced edema test.

ST indazole prepn antiinflammatory

IT Inflammation inhibitors
(indazoles)

IT 80838-25-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory activity of)

IT 121879-77-4P 121879-78-5P **124673-62-7P 124673-63-8P 126596-47-2P 131875-38-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)

IT 31164-28-0P 126596-48-3P 153097-40-6P 153097-41-7P 153097-42-8P 153097-43-9P 153097-44-0P **153097-45-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 109-01-3, N-Methylpiperazine 123-90-0, Thiomorpholine
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with dinitroindazole)

IT 31163-68-5, 2,6-Dinitroindazole 98083-45-5, 5-Chloro-2-nitroindazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with methylpiperazine)

IT 31164-29-1, 2,5-Dinitroindazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with thiomorpholine)

IT **67400-26-4 68159-12-6 68159-15-9** 68159-18-2 68159-21-7 68159-25-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)

IT **124673-62-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)

RN 124673-62-7 HCAPLUS

CN 1H-Indazole, 5-chloro-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L57 ANSWER 20 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:517118 HCAPLUS
DN 119:117118
ED Entered STN: 18 Sep 1993
TI 4-(phenylalkyl)piperidines, e.g. spiro[isobenzofuran-1(3H),4'-piperidine] derivatives, and their use for the treatment of mental disorders
IN Moltzen, Ejner K.; Perregaard, Jens Kristian
PA Lundbeck, H., A/S, Den.
SO Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07D221-20
ICS C07D401-06; C07D471-08; C07D491-20; C07D495-10; A61K031-445
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 518805	A1	19921216	EP 1992-610044	19920612 <--
	R: PT				
	ZA 9204274	A	19930331	ZA 1992-4274	19920611 <--
	WO 9222554	A1	19921223	WO 1992-DK183	19920612 <--
	W: AU, CA, CS, FI, JP, KR, NO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	AU 9219848	A1	19930112	AU 1992-19848	19920612 <--
	AU 664557	B2	19951123		
	EP 593511	A1	19940427	EP 1992-912044	19920612 <--
	EP 593511	B1	19980902		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	JP 06508360	T2	19940922	JP 1992-500747	19920612 <--
	JP 2834577	B2	19981209		
	EP 853085	A1	19980715	EP 1998-101728	19920612 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT				
	EP 859004	A1	19980819	EP 1998-101729	19920612 <--
	EP 859004	B1	20030502		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT				
	AT 170523	E	19980915	AT 1992-912044	19920612 <--
	JP 11001475	A2	19990106	JP 1998-139146	19920612 <--
	ES 2123557	T3	19990116	ES 1992-912044	19920612 <--
	RU 2142952	C1	19991220	RU 1993-58600	19920612 <--
	SK 280899	B6	20000912	SK 1993-1409	19920612 <--
	CA 2111204	C	20010227	CA 1992-2111204	19920612 <--
	SK 281747	B6	20010710	SK 1999-1004	19920612 <--
	SK 281748	B6	20010710	SK 1999-1005	19920612 <--
	CZ 289479	B6	20020116	CZ 1993-2726	19920612 <--
	AT 239022	E	20030515	AT 1998-101729	19920612 <--
	NO 9304494	A	19940211	NO 1993-4494	19931209 <--
	US 5665725	A	19970909	US 1993-166647	19931213 <--
	US 5807871	A	19980915	US 1995-478563	19950607 <--
	US 6031099	A	20000229	US 1995-486510	19950607 <--
	JP 10316659	A2	19981202	JP 1998-139183	19980506 <--
	JP 3203230	B2	20010827		
	HK 1009272	A1	20000428	HK 1998-109879	19980812 <--
	US 6207677	B1	20010327	US 1999-391290	19990907 <--
	NO 9904487	A	19940211	NO 1999-4487	19990916 <--
	NO 9904488	A	19940211	NO 1999-4488	19990916 <--
	FI 9902134	A	19991004	FI 1999-2134	19991004 <--
	FI 9902135	A	19991004	FI 1999-2135	19991004 <--
PRAI	DK 1991-1129	A	19910613 <--		
	DK 1991-1131	A	19910613 <--		
	DK 1992-157	A	19920210 <--		
	EP 1992-912044	A3	19920612 <--		

JP 1992-500747	A3	19920612	<--
WO 1992-DK183	A	19920612	<--
US 1993-166647	A3	19931213	<--
US 1995-486510	A1	19950607	<--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
EP 518805	ICM	C07D221-20	
	ICS	C07D401-06; C07D471-08; C07D491-20; C07D495-10; A61K031-445	
US 5665725	ECLA	C07D221/20C; C07D401/06; C07D401/06; C07D401/12; C07D413/06; C07D417/12; C07D491/10; C07D491/10; C07D491/10; C07D495/1	<--
US 5807871	ECLA	C07D221/20C; C07D401/06; C07D401/06; C07D401/12; C07D413/06; C07D417/12; C07D491/10; C07D491/10; C07D491/10; C07D495/1	<--
US 6031099	ECLA	C07D221/20C; C07D491/10; C07D491/10; C07D491/10; C07D495/10; C07D401/06; C07D401/06; C07D401/12; C07D413/06; C07D	<--

OS MARPAT 119:117118

GI



I



II



III

AB The use of some 4-(phenylalkyl)piperidines, e.g. spiro[isobenzofuran-1(3H),4'-piperidine derivs., is claimed for the treatment of anxiety, psychosis, epilepsy, convulsions, movement disorders, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease. Bromination of spiro[isobenzofuran-1(3H),4'-piperidine] gave 1'-butylspiro[isobenzofuran-1(3H),4'-piperidine] (I) which was isolated as the I-oxalate. I inhibited binding of 1,3-di-o-tolyl guanidine to σ-receptors. Also prepared and tested were 3,4-dihydro-1'-(4-phenylbutyl)spiro[1H-2-benzopyran-1,3'-piperidine] (II) as the II-oxalate and 1'-(4-phenylbutyl)spiro[benzo[c]thiophene-1(3H),4'-piperidine] (III) as the III maleate.

ST phenylalkyl piperidine prepn mental disorder; spiroisobenzofuran piperidine prepn; Alzheimer disease spiroisobenzofuran piperidine prepn; anxiolytic antidepressant spiroisobenzofuran piperidine prepn; anticonvulsant spiroisobenzofuran piperidine prepn; amnesia spiroisobenzofuran piperidine prepn

IT Anticonvulsants and Antiepileptics
Antidepressants
Anxiolytics
([(phenylindazolyl)alkyl]spiro[isobenzofuranpiperidines]

(σ-receptor antagonists))
IT Parkinsonism
(treatment of, [(phenylindazolyl)alkyl]spiro[isobenzofuranpiperidines] (σ-receptor antagonists) for)
IT Mental disorder
(Alzheimer's disease, treatment of, [(phenylindazolyl)alkyl]spiro[isobenzofuranpiperidines] (σ-receptor antagonists) for)
IT Tranquilizers and Neuroleptics
(antipsychotics, [(phenylindazolyl)alkyl]spiro[isobenzofuranpiperidines] (σ-receptor antagonists))
IT 147372-76-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 147373-17-9P 147373-18-0P 147373-19-1P 147373-20-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for [(benzofuryl)alkyl]spiro[isobenzofuranpiperidine] σ-receptor antagonist))
IT 3133-87-7P, Benzo[b]thiophene-3-ethanol 147373-06-6P 147373-07-7P, Benzo[b]thiophene-3-butanol
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for [(benzothienyl)alkyl]spiro[benzopyranpiperidine] (σ-receptor antagonist))
IT 131084-28-1P 147373-28-2P 147373-29-3P 147373-30-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for [(phenylindazolyl)alkyl]spiro[isobenzofuranpiperidine] σ-receptor antagonist))
IT 3364-37-2P, 1H-Indole-3-butanol
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for [(phenylindolyl)alkyl]spiro[benzopyranpiperidine] (σ-receptor antagonist))
IT 147372-96-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for [(phenylindolyl)alkyl]spiro[isobenzofuranpiperidine] (σ-receptor antagonist))
IT 147373-10-2P 147373-11-3P 147373-12-4P 147373-13-5P 147373-14-6P 147373-15-7P 147373-16-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for [(phenylpiperidinyl)alkyl]benzofuran (σ-receptor antagonist))
IT 147372-92-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for [[(phenylindolyl)oxy]alkyl]spiro[isobenzofuranpiperidine] (σ-receptor antagonist))
IT 147373-22-6P 147373-23-7P 147373-24-8P 147373-25-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for [[(phenylindolyl)oxy]alkyl]spiro[isobenzofuranpiperidine] σ-receptor antagonist))
IT 65512-08-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for alkylspiro[isobenzofuranpiperidine] (σ-receptor antagonist))
IT 143682-52-4P 147359-18-0P 147359-19-1P 147359-20-4P 147359-21-5P
147359-22-6P 147359-23-7P 147372-50-7P 147372-51-8P 147372-52-9P
147372-53-0P, 1'-[3-(Phenylsulfonyl)propyl]spiro[isobenzofuran-1(3H),4'-piperidine] 147372-54-1P 147372-55-2P 147372-56-3P 147372-57-4P
147372-58-5P 147372-59-6P 147372-60-9P 147372-61-0P 147372-62-1P
147372-63-2P 147372-64-3P 147372-65-4P 147372-66-5P 147372-67-6P
147372-68-7P 147372-69-8P 147372-70-1P 147372-71-2P 147372-72-3P
147372-73-4P 147372-74-5P 147372-75-6P **147372-77-8P**
147372-78-9P 147372-79-0P 147372-80-3P 147372-81-4P 147372-82-5P
147816-99-7P, 1'-Butylspiro[isobenzofuran-1(3H),4'-piperidine] oxalate
147817-01-4P, 1'-Pentylspiro[isobenzofuran-1(3H),4'-piperidine] oxalate
147817-03-6P, 1'-(4-Cycloehexylbutyl)spiro[isobenzofuran-1(3H),4'-

piperidine] oxalate 147817-05-8P 147817-07-0P 147817-09-2P
147817-11-6P 147817-13-8P 147817-15-0P 147817-17-2P 147817-19-4P
147817-21-8P, 1'-[3-(Methylthio)propyl]spiro[isobenzofuran-1(3H),4'-
piperidine] oxalate 147817-23-0P 147817-25-2P, 1'-[3-
(Phenylthio)propyl]spiro[isobenzofuran-1(3H),4'-piperidine] oxalate
147817-26-3P 147817-28-5P 147817-30-9P 147817-32-1P 147817-34-3P
147817-36-5P, 1'-(4-Phenylbutyl)spiro[isobenzofuran-1(3H),4'-piperidine]
fumarate 147817-38-7P 147817-40-1P 147817-41-2P 147817-43-4P
147817-45-6P 147817-47-8P 147817-49-0P 147817-51-4P 147817-53-6P
147817-55-8P 147817-57-0P 147817-59-2P 147817-61-6P 147817-63-8P
147817-65-0P 147817-67-2P 147817-69-4P 147817-71-8P 147817-73-0P
147817-75-2P 147817-77-4P 147817-79-6P 147817-81-0P 147817-83-2P
147817-85-4P 147817-87-6P 147817-89-8P 147817-91-2P 147817-93-4P
147817-95-6P 147817-97-8P 147817-99-0P 147818-01-7P 147818-03-9P
147818-05-1P 147818-07-3P 147818-09-5P 147818-11-9P 147818-13-1P
147818-15-3P 147818-17-5P 147818-19-7P 147818-21-1P 147818-23-3P
147818-25-5P 147818-27-7P 147818-29-9P 147818-31-3P 147818-33-5P
147818-35-7P 147818-37-9P 147818-39-1P 147818-41-5P 147818-43-7P
147818-45-9P 147818-47-1P 147818-49-3P 147818-51-7P 147818-53-9P
147818-55-1P 147818-57-3P 147818-59-5P 147818-61-9P 147818-63-1P
147818-65-3P 147818-67-5P 147818-69-7P 147818-71-1P 147818-73-3P
147818-75-5P 147835-14-1P 147835-16-3P 147835-18-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as σ-receptor antagonist)

IT 147373-26-0 147373-27-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [(benzofuryl)alkyl]spiro[isobenzofuranpiperidine]
σ-receptor antagonist))

IT 7597-67-3 147373-08-8, 5-Methylbenzo[b]thiophene-3-butanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [(benzothienyl)alkyl]spiro[benzopyranpiperidine]
(σ-receptor antagonist))

IT 328-87-0, 2-Chloro-5-(trifluoromethyl)benzonitrile 928-51-8,
4-Chloro-1-butanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [(phenylindazolyl)alkyl]spiro[isobenzofuranpiperidine]
σ-receptor antagonist))

IT 15591-70-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [(phenylindolyl)alkyl]spiro[benzopyranfuranpiperidine]
(σ-receptor antagonist))

IT 147373-02-2 147373-05-5, 2,3-Dihydrospiro[4H-1-benzopyran-4,4'-
piperidine]
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [(phenylindolyl)alkyl]spiro[benzopyranpiperidine]
(σ-receptor antagonist))

IT 352-34-1, 1-Fluoro-4-iodobenzene 3437-95-4, 2-Iodothiophene
10486-61-0, 3-Iodothiophene 147372-97-2, 6-Fluorospiro[isobenzofuran-
1(3H),4'-piperidine] 147372-98-3, 6-Isopropylspiro[isobenzofuran-
1(3H),4'-piperidine] 147372-99-4, 5-Methylspiro[isobenzofuran-1(3H),4'-
piperidine] 147373-00-0 147373-03-3, 7-Fluorospiro[isobenzofuran-
1(3H),4'-piperidine] 147373-04-4, 4-Fluorospiro[isobenzofuran-1(3H),4'-
piperidine]
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [(phenylindolyl)alkyl]spiro[isobenzofuranpiperidine]
(σ-receptor antagonist))

IT 37656-48-7, 4-(4-Fluorophenyl)piperidine 147373-09-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [(phenylpiperidinyl)alkyl]benzofuran (σ-receptor
antagonist))

IT 3364-37-2, 1H-Indole-3-butanol 147372-88-1, 4-(1-Methanesulfonyl-3-
indolyl)-1-butyl methanesulfonate 147372-89-2, 4-(1-(4-Toluenesulfonyl)-
3-indolyl)-1-butyl methanesulfonate 147372-90-5, 4-(1-(2-

Thienylsulfonyl)-3-indolyl)-1-butyl methanesulfonate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [[(methansulfonyl)indolyl]alkyl]spiro[isobenzofuranpiperidine] (σ-receptor antagonist))

IT 147372-91-6 147372-93-8 147372-94-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [[(phenylindolyl)oxy]alkyl]spiro[isobenzofuranpiperidine] (σ-receptor antagonist))

IT 147373-21-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [[(phenylindolyl)oxy]alkyl]spiro[isobenzofuranpiperidine] σ-receptor antagonist))

IT 63303-29-7, 3,4-Dihydrospiro[1H-2-benzopyran-4,4'-piperidine]
147372-84-7, 1,4-Dihydrospiro[3H-2-benzopyran-3,4'-piperidine]
147372-85-8, 3,4-Dihydrospiro[2H-1-benzopyran-2,4'-piperidine]
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for alkylspiro[benzopyranpiperidine] (σ-receptor antagonist))

IT 59350-81-1, Spiro[benzo[c]thiophene-1(3H),4'-piperidine]
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for alkylspiro[benzothiophenepiperidine] (σ-receptor antagonist))

IT 33042-66-9, Spiro[1H-indene-1,4'-piperidine]
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for alkylspiro[indenepiperidine] (σ-receptor antagonist))

IT 147372-86-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for alkylspiro[isobenzofuranazabicyclopctane] (σ-receptor antagonist))

IT 79-03-8, Propionyl chloride 103-80-0, Benzeneacetyl chloride 109-65-9, 1-Bromobutane 110-53-2, 1-Bromopentane 645-45-4, 3-Phenylpropanoyl chloride 2003-42-1 3360-41-6, Benzenebutanol 3367-05-3 3367-20-2 5699-78-5, 5-Methylhexanoyl chloride 20371-41-9, 5-Phenylpentanoyl chloride 21389-46-8, 6-Phenylhexanoyl chloride 38309-60-3, Spiro[isobenzofuran-1(3H),4'-piperidine] 147372-83-6, 4-Cyclohexyl-1-butyl methanesulfonate 147372-87-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for alkylspiro[isobenzofuranpiperidine] (σ-receptor antagonist))

IT 134697-64-6, 3,4-Dihydrospiro[naphthalene-1(2H),4'-piperidine]
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for alkylspiro[naphthalenepiperidine] (σ-receptor antagonist))

IT 147373-01-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for1 [(phenylindolyl)alkyl]spiro[isobenzofuranpiperidine] (σ-receptor antagonist))

IT **147372-77-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as σ-receptor antagonist)

RN 147372-77-8 HCAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine], 1'-[4-[5-(trifluoromethyl)-1H-indazol-3-yl]butyl]- (9CI) (CA INDEX NAME)



L57 ANSWER 21 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:591847 HCAPLUS
DN 117:191847
ED Entered STN: 15 Nov 1992
TI 5-[(oxadiazolyl)alkyl]- and 5-[(thiadiazolyl)alkyl]-1H-indazole-3-ethanamines, a method for their preparation and their use as 5-HT1 receptor agonists (selective vasoconstrictors)
IN Baker, Raymond; Chambers, Mark S.; Street, Leslie J.
PA Merck Sharp and Dohme Ltd., UK
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07D413-04
ICS A61K031-415; C07D417-04; C07D231-56
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 494774	A1	19920715	EP 1992-300160	19920108 <--
	R: CH, DE, FR, GB, IT, LI, NL				
	US 5208248	A	19930504	US 1991-730751	19910716 <--
	CA 2058805	AA	19920712	CA 1992-2058805	19920106 <--
	JP 05039290	A2	19930219	JP 1992-3293	19920110 <--
	JP 2539127	B2	19961002		
PRAI	GB 1991-648		19910111 <--		
	GB 1991-15017		19910711 <--		
	US 1991-665047		19910306 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 494774	ICM	C07D413-04
	ICS	A61K031-415; C07D417-04; C07D231-56

OS CASREACT 117:191847; MARPAT 117:191847
GI



I

AB Certain pyridine, pyrazole and indazole derivs., their salts and prodrug forms are claimed. More specifically, 5-[(oxadiazolyl)alkyl]- and 5-[(thiadiazolyl)alkyl]-3-indazoleethanamine derivs. are claimed. These compds. are 5-HT1 receptor agonists; i.e. these compds. are selective vasoconstrictors and are hence potentially useful for the treatment of migraines and headaches associated with vascular disorders. A mixture of Me acetamide oxime (228 mg) and sodium (64 mg) in ethanol (10 mL) was added to Et 3-(2-aminoethyl)-1H-indazole-5-carboxylate (218 mg) to give 5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indazole-3-ethanamine (I) in 28% yield. I had activity as 5-HT1 receptor agonist.

ST oxadiazolyl indazoleethanamine hydroxytrypamine receptor agonist; vasoconstrictor oxadiazolyl indazoleethanamine HT receptor agonist; migraine vasoconstrictor oxadiazolyl indazoleethanamine; HT receptor agonist oxadiazol indazoleethanamine; aminoethylindazole oxadiazolyl hydroxytrypamine receptor agonist

IT Neurotransmitter agonists
(S1, [(oxadiazolyl)alkyl]- and [thiadiazolyl)alkyl]indazoleethanamines)

IT Vasoconstrictors
([(oxadiazolyl)alkyl]- and [thiadiazolyl)alkyl]indazoleethanamines)

IT Headache
(treatment of, [(oxadiazolyl)alkyl]- and [thiadiazolyl)alkyl]indazoleet hanamines for)

IT Headache
(migraine, treatment of, [(oxadiazolyl)alkyl]- and [thiadiazolyl)alkyl]indazoleethanamines for)

IT 105-13-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(benzylation with, of (aminoethyl)indazoleacetate)

IT 94-09-7 5438-70-0
RL: PROC (Process)
(conversion of, to hydrazine derivative)

IT 62626-11-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation reaction of, with (aminoethyl)indazolecarboxamide, (oxadiazolyl)indazoleethanamine from)

IT 29882-07-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation reaction of, with Et hydrazinobenzoate)

IT 144056-04-2 144056-05-3 **144056-06-4 144056-07-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydroxytrypamine receptor agonist)

IT 144055-96-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)

IT 144055-99-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and alkylation of)

IT 144056-00-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and benzylation of)

IT 144055-88-9P 144055-97-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reaction of)

IT 144055-90-3P 144055-92-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reaction of, with Me acetamide oxime, (oxadiazolyl)indazoleethanamine from)

IT 40566-85-6P 137402-61-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reaction of, with chlorobutanal di-Me acetal)

IT 144055-89-0P 144055-95-8P 144055-98-1P 144056-03-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of)

IT 144055-85-6P 144055-93-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and formylation of)

IT 144056-08-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

IT 144055-86-7P 144055-94-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oximation of)

IT 7272-54-0P 144055-87-8P 144056-01-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and protection of)

IT 144056-02-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with chlorothiadiazolamine)

IT 144055-91-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 144055-79-8P 144055-80-1P 144055-81-2P 144055-82-3P 144055-83-4P 144055-84-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hydroxytrypamine receptor agonist)

IT 50988-13-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with protected (aminoethyl)indazoleacetate)

IT **144056-06-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydroxytrypamine receptor agonist)

RN 144056-06-4 HCAPLUS

CN 1H-Indazole, 5-(1,2,4-oxadiazol-5-yl)-3-(4-piperidinyl)- (9CI) (CA INDEX NAME)



L57 ANSWER 22 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:235509 HCAPLUS
DN 116:235509
ED Entered STN: 13 Jun 1992
TI Azoles. Part 33. 5-Fluoroindazole derivatives
AU Wrzeciono, U.; Majewska, K.; Buege, A.; Koehler, T.; Rickinger, O.; Nuhn, P.
CS Karol Marcinkowski Med. Akad., Poznan, 60-780, Pol.
SO Pharmazie (**1992**), 47(1), 22-4
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**
AB Nitration of 5-fluoroindazole gave the 1-, 2-, and 3-nitro derivs. which were converted to amines. 5-Fluoro-3-nitroindazole caused 32.9% inhibition of phospholipase A2 at 5 + 10-4 mol/L. and 5-chloro-3-nitroindazole gave 52.6% inhibition at the same concentration The fluoroindazoles and related chloroindazoles were inactive against 15-lipoxygenase.
ST fluoronitroindazole prepn antiinflammatory; aminofluoroindazole; phospholipase inhibitor fluoronitroindazole; lipoxygenase inhibitor haloindazole
IT Inflammation inhibitors
(fluoro- and chloroindazoles)
IT 98083-46-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory activity of)
IT 326-65-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of)
IT 9001-84-7, Phospholipase A2 82249-77-2, 15-Lipoxygenase
RL: USES (Uses)
(inhibitors, fluoro- and chloroindazoles)
IT 107823-90-5 **124673-62-7 124673-63-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(lipoxygenase-inhibiting activity of)
IT 141071-13-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)
IT 348-26-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitration of)
IT 141071-11-6P 141071-12-7P 141071-15-0P 141071-16-1P
141071-17-2P 141071-18-3P 141071-19-4P
141071-20-7P 141071-21-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **141071-14-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, acetylation, and antiinflammatory activity of)
IT **124673-62-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(lipoxygenase-inhibiting activity of)
RN 124673-62-7 HCAPLUS
CN 1H-Indazole, 5-chloro-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L57 ANSWER 23 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:235431 HCAPLUS
DN 116:235431
ED Entered STN: 13 Jun 1992
TI Preparation of 3-arylindole and 3-arylindazole derivatives as 5-HT2 antagonists
IN Perregaard, Jens Kristian; Andersen, Kim
PA Lundbeck, H., A/S, Den.
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07D209-08
ICS C07D209-10; C07D231-56; C07D401-04; C07D401-12; C07D401-14; C07D405-04; C07D405-14; C07D409-04; C07D409-14; A61K031-40
ICI A61K031-415
CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): **1**, 28, **63**
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 470039	A2	19920205	EP 1991-610058	19910722 <--
	EP 470039	A3	19920527		
	EP 470039	B1	19941207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	NO 9102739	A	19920131	NO 1991-2739	19910712 <--
	NO 178192	B	19951030		
	NO 178192	C	19960207		
	IL 98829	A1	19960618	IL 1991-98829	19910715 <--
	ES 2064974	T3	19950201	ES 1991-610058	19910722 <--
	ZA 9105805	A	19920429	ZA 1991-5805	19910724 <--
	CA 2048027	AA	19920131	CA 1991-2048027	19910729 <--
	CA 2048027	C	20011030		
	FI 9103613	A	19920131	FI 1991-3613	19910729 <--
	FI 99111	B	19970630		
	FI 99111	C	19971010		
	AU 9181411	A1	19920206	AU 1991-81411	19910729 <--
	AU 646679	B2	19940303		
	JP 04368367	A2	19921221	JP 1991-188923	19910729 <--
	JP 3165181	B2	20010514		
	US 5393761	A	19950228	US 1993-131438	19931004 <--
PRAI	DK 1990-1811	A	19900730 <--		
	US 1991-734299	B1	19910718 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 470039	ICM	C07D209-08
	ICS	C07D209-10; C07D231-56; C07D401-04; C07D401-12; C07D401-14; C07D405-04; C07D405-14; C07D409-04; C07D409-14; A61K031-40

ICI A61K031-415
OS MARPAT 116:235431
GI



I

AB Title compds I [Ar = (substituted) Ph, 2-, 3-thienyl, 2-, 3-furyl, 2-, 3-, 4-pyridyl; R1-R4 = H, halo, alkyl, alkoxy, HO, O2N, etc.; X = N, R6C wherein R6 = H, halo, F3C, alkyl, H2C; Y = N, HC, C; R5 = H, cycloalkylalkyl, (substituted) alkyl, (substituted) alkenyl, etc.] salt and prodrugs thereof, are prepared I are useful for treatment of anxiety, aggression, depression, migraine, etc. A mixture of 6-chloro-3-(4-fluorophenyl-1-(piperidyl)-1H-indole (preparation given), 1-(2-chloroethyl)-3-methyl-2-imidazolinone, K2CO3, KI and Me2CHCH2COMe was refluxed for 18 h to give an oil which was purified by column chromatog. and precipitated as I [R1 = R2 = R4 = H, R3 = Cl, X = HC, Y = N, Ar = 4-ClC6H4, R5 = 2-(3-methylimidazolidin-2-on-1-yl)ethyl].maleate (II). In a pharmacol. test II inhibited 3H-ketanserin binding to serotonin S2 receptor in rat cortex in vitro with IC50 of 1.5 μM. Pharmaceutical formulations comprising I are given.

ST indole aryl prepn 5HT2 antagonist; indazole aryl prepn 5HT2 antagonist; serotonin antagonist arylindole arylidazole; imidazolidinonylethylindole prepn 5HT2 antagonist; anxiolytic arylindole arylindazole; antidepressant arylindole arylindazole

IT Antidepressants
Anxiolytics
(arylindole and arylindazole derivs.)

IT Parkinsonism
Schizophrenia
(treatment of, arylindoles and arylindazoles for)

IT Behavior
(aggressive, treatment of, arylindoles and arylindazoles for)

IT Sleep
(disorder, treatment of, arylindoles and arylindazoles for)

IT Headache
(migraine, treatment of, arylindoles and arylindazoles for)

IT Neurotransmitter antagonists
(serotoninergic S2, arylindole and arylindazole derivs.)

IT 22072-89-5P 34837-84-8P 101125-32-0P 141306-08-3P 141306-09-4P
141306-10-7P 141306-11-8P 141306-12-9P 141306-13-0P 141306-14-1P
141306-15-2P 141306-16-3P 141306-17-4P 141306-18-5P 141306-19-6P
141306-20-9P 141306-21-0P 141306-22-1P 141306-23-2P 141306-24-3P
141306-25-4P 141306-26-5P 141306-27-6P 141306-65-2P 141306-66-3P
141306-67-4P 141306-69-6P 141306-70-9P 141306-71-0P 141306-73-2P
141306-74-3P 141327-47-1P 141327-53-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of 5-HT2 antagonists)

IT 141306-29-8P 141306-30-1P 141306-31-2P 141306-32-3P 141306-33-4P
141306-34-5P 141306-35-6P 141306-36-7P 141306-37-8P 141306-39-0P
141306-41-4P 141306-42-5P 141306-43-6P 141306-44-7P 141306-45-8P
141306-46-9P 141306-47-0P 141306-48-1P 141306-50-5P 141306-51-6P
141306-52-7P 141306-53-8P 141306-54-9P 141306-55-0P 141306-56-1P
141306-57-2P 141306-58-3P 141306-59-4P 141306-60-7P 141306-62-9P
141306-63-0P 141306-64-1P 141327-48-2P 141327-49-3P 141327-51-7P
141327-52-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as 5-HT2 antagonist)

IT 30843-37-9P 141306-88-9P 141306-90-3P 141306-91-4P
141306-92-5P 141306-93-6P 141306-94-7P 141306-95-8P
141306-96-9P 141306-97-0P 141306-98-1P 141306-99-2P 141307-00-8P
141307-01-9P 141307-02-0P 141307-04-2P 141307-06-4P 141307-07-5P
141307-08-6P 141307-09-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as HT2 antagent)

IT 141306-75-4P 141306-76-5P 141306-77-6P 141306-78-7P 141306-79-8P
141306-80-1P 141306-81-2P 141306-82-3P 141306-83-4P 141306-84-5P
141306-85-6P 141306-86-7P 141327-54-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for HT2 antagonist)

IT 51-75-2 75-36-5, Acetyl chloride 79-22-1, Methyl chloroformate
96-32-2, Methyl 2-bromoacetate 105-36-2, Ethyl bromoacetate 106-49-0,
p-Toluidine, reactions 107-14-2, Chloroacetonitrile 459-03-0,
4-Fluorophenylacetone 539-44-6, 4-Tolylhydrazine 624-83-9, Methyl
isocyanate 3363-69-7 7379-35-3, 4-Chloropyridine hydrochloride
16420-13-6, N,N-Dimethylthiocarbamoyl chloride 19524-06-2,
4-Bromopyridine hydrochloride 122255-02-1 141306-68-5 141306-72-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of 5-HT2 antagonists)

IT **141306-92-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as HT2 antagent)

RN 141306-92-5 HCAPLUS
CN 1H-Indazole, 3-(4-fluorophenyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L57 ANSWER 24 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:62120 HCAPLUS
DN 114:62120
ED Entered STN: 23 Feb 1991
TI Preparation of 3-(1-substituted-4-piperazinyl)-1H-indazoles as analgesics and antipsychotics
IN Strupczewski, Joseph T.; Bordeau, Kenneth J.
PA Hoechst-Roussel Pharmaceuticals, Inc., USA
SO U.S., 27 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-495
ICS C07D401-14; C07D403-04; C07D403-14

NCL 514254000
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4954503	A	19900904	US 1989-405161	19890911 <--
	US 5077405	A	19911231	US 1990-526154	19900521 <--
	EP 417653	A1	19910320	EP 1990-117251	19900907 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2024996	AA	19910312	CA 1990-2024996	19900910 <--
	NO 9003925	A	19910312	NO 1990-3925	19900910 <--
	AU 9062298	A1	19910314	AU 1990-62298	19900910 <--
	ZA 9007174	A	19910626	ZA 1990-7174	19900910 <--
	JP 03167175	A2	19910719	JP 1990-237300	19900910 <--
PRAI	US 1989-405161		19890911 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4954503	ICM	A61K031-495
	ICS	C07D401-14; C07D403-04; C07D403-14
	NCL	514254000

OS CASREACT 114:62120; MARPAT 114:62120
GI



I



Q2



Q1



II

AB Title compds. I [R1 = H, (cycloalkyl- or aryl)alkyl, PhSO2; R2 = H, (hydroxy- or aryl- or cycloalkyl)alkyl, acyl, Q1, Q2 (G = lower alkylene, Z = H, halo, alkoxy, CF3, NO2, NH2), etc.; X = H, alkyl, OH, halo, alkoxy, CF3, NO2, NH2; n = 1-4; R2 ≠ alkyl when R1 = H or acyl and X = Cl], useful as analgesics and antipsychotics, were prepared For example, the hemifumarate of II was prepared in 17% yield by N-alkylation of 3-(1-piperazinyl)-1H-indazole, followed by acidification by fumaric acid.

The s.c. ED50 for II-hemifumarate for inhibition of writhing in mice was 0.07 mg/kg, vs. 3.9 mg/kg for propoxyphene (std). The antipsychotic activity of II was also demonstrated by the apomorphine climbing assay in mice.

ST indazole prepn analgesic antipsychotic; piperazinylindazole prepn analgesic antipsychotic

IT Analgesics
(indazole derivs.)

IT Psychotropics
(antipsychotics, indazole derivs.)

IT Tranquilizers and Neuroleptics
(major, indazole derivs.)

IT 74-88-4, Iodomethane, reactions 74-96-4, Ethyl bromide 103-63-9, (2-Bromoethyl)benzene 540-51-2, 2-Bromoethanol 1638-75-1, Chloromethyldimethylphosphine oxide 7051-34-5, (Bromomethyl)cyclopropane 62780-89-6 84243-02-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-alkylation by, in preparation of analgesics and antipsychotics)

IT 302-01-2, Hydrazine, reactions 556-89-8, Nitrourea
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation by, in preparation of analgesics and antipsychotics)

IT 506-68-3, Cyanogen bromide
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyanation by, in preparation of analgesics and antipsychotics)

IT 128520-83-2P 131633-85-7P 131633-87-9P 131633-88-0P 131633-89-1P
131633-90-4P **131633-91-5P** 131633-92-6P 131633-93-7P
131633-94-8P 131633-95-9P **131633-96-0P**
131633-97-1P **131633-98-2P** 131633-99-3P 131634-00-9P
131634-01-0P 131634-02-1P 131634-03-2P 131634-04-3P 131634-05-4P
131634-06-5P 131634-07-6P 131634-08-7P 131634-09-8P 131634-10-1P
131634-11-2P 131634-12-3P 131634-13-4P 131634-14-5P 131634-15-6P
131634-16-7P 131634-17-8P 131634-18-9P 131634-19-0P 131634-20-3P
131634-21-4P 131634-22-5P 131634-23-6P 131634-24-7P 131634-25-8P
131634-26-9P 131634-27-0P 131634-28-1P 131634-29-2P
131634-30-5P **131634-31-6P** 131634-32-7P 131634-33-8P
131634-34-9P **131634-35-0P** **131634-36-1P** 131634-37-2P
131634-38-3P 131634-39-4P **131634-40-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as analgesic and antipsychotic)

IT 5814-06-2P, 2,4-Dichlorobenzoic acid hydrazide 102908-67-8P
124673-62-7P 131634-41-8P 131634-42-9P 131634-43-0P
131634-44-1P 131634-45-2P 131634-46-3P 131634-47-4P 131634-48-5P
131634-49-6P 131634-50-9P 131634-51-0P 131634-52-1P 131634-53-2P
131634-54-3P 131634-55-4P 131634-56-5P 131634-57-6P
131634-58-7P 131634-59-8P 131634-60-1P 131634-61-2P 131634-62-3P
131634-63-4P **131634-64-5P** 131634-65-6P 131634-66-7P
131634-67-8P 131634-68-9P 131634-69-0P 131634-70-3P 131651-17-7P
131651-18-8P 131651-19-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for analgesics and antipsychotics)

IT 21098-10-2 29418-67-5, 2-Bromobenzoic acid hydrazide 56882-52-1, Ethyl 2,4-dichlorobenzoate 67487-35-8, 2,5-Dichlorobenzoic hydrazide 84231-39-0 112584-40-4, 2-Bromo-5-methoxybenzoic acid hydrazide 123614-86-8, 2-Chloro-4-fluorobenzoic acid hydrazide 131634-71-4, 5-Bromo-2-chlorobenzoic acid hydrazide 131634-72-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of analgesics and antipsychotics)

IT 109-01-3, N-Methylpiperazine
RL: RCT (Reactant); RACT (Reactant or reagent)
(substitution by, in preparation of analgesics and antipsychotics)

IT 98-09-9, Benzenesulfonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(sulfonylation by, of hydrazide derivative, in preparation of analgesics and

antipsychotics)
IT **131633-91-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as analgesic and antipsychotic)
RN 131633-91-5 HCAPLUS
CN 1H-Indazole, 5-bromo-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L57 ANSWER 25 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:216936 HCAPLUS
DN 112:216936
ED Entered STN: 09 Jun 1990
TI Preparation of pyrazolo[1,2-a]indazolium compounds as antiasthmatics
IN Grayshan, Roger; French, Andrew McKinnon; Al-Khammees, Hamad; De Boos, Gareth Andrew
PA National Research Development Corp., UK
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D487-04
ICS A61K031-435; C07D401-04
ICI C07D487-04, C07D231-00; C07D487-04, C07D237-00, C07D231-00
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8910924	A1	19891116	WO 1989-GB517	19890512 <--
	W: JP, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	JP 03504242	T2	19910919	JP 1989-505608	19890512 <--
PRAI	GB 1988-11299		19880512	<--	
	WO 1989-GB517		19890512	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 8910924	ICM	C07D487-04
	ICS	A61K031-435; C07D401-04
	ICI	C07D487-04, C07D231-00; C07D487-04, C07D237-00, C07D231-00

OS MARPAT 112:216936
GI



AB Title compds. I [R1 = (un)substituted 6-membered N-heterocyclyl bound to a C to the indazole ring; R2 = H, HO, C1-6 alkyl, C1-6 alkoxy; R3, R4 = H, HO, halo, C1-6 alkyl, -alkoxy, O2N, cyano, H2NCO, RNHCO; R = C1-3 alkyl; R5 = H, halo; X = pharmaceutically acceptable anion; n = 1,2] useful as antiasthmatics (no data), are prepared 3-(1-Methyl-1,2,5,6-tetrahydro-4-pyridyl)indazole (preparation given) in DMF was added to NaH in DMF, and the mixture added to Br(CH2)3Br in DMF to give 2,3-dihydro-9-(1,2,5,6 tetrahydro-1-methyl-4-pyridyl)pyrazole[1,2-a]indazolium bromide which was taken up in BuOH and aqueous HCl to give the bromide-HCl.

ST pyrazoloindalozium prepn antiasthmatic

IT Bronchodilators
(antiasthmatics, pyrazoloindazolium compds.)

IT 37885-56-6P 37885-57-7P 55556-42-8P 91973-39-6P 98294-53-2P 99878-53-2P 126971-79-7P 126971-80-0P 126971-81-1P 126971-82-2P 126971-83-3P 126971-84-4P 126971-85-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiasthmatic pyrazoloindazolium compds.)

IT 126971-74-2P 126971-75-3P 126971-76-4P 126971-77-5P 126971-78-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiasthmatic)

IT 68-12-2, reactions 95-20-5, 2-Methylindole 109-64-8, 1,3-Dibromopropane 302-01-2, Hydrazine, reactions 872-85-5, 4-Pyridinecarboxaldehyde 1445-73-4 6625-74-7 114995-70-9 **126971-86-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antiasthmatic pyrazoloindazolium compds.)

IT **126971-86-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antiasthmatic pyrazoloindazolium compds.)

RN 126971-86-6 HCAPLUS

CN 1H-Indazole, 5-chloro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L57 ANSWER 26 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:178964 HCAPLUS

DN 112:178964

ED Entered STN: 12 May 1990

TI Preparation of 5-amino-3-morpholinoindazole as an antiinflammatory agent
IN Wrzeciono, Urszula; Stochla, Krystyna; Linkowska, Ewa
PA Akademia Medyczna, Poznan, Pol.
SO Pol., 2 pp.
CODEN: POXXA7
DT Patent
LA Polish
IC ICM C07D413-04
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI PL 143965	B1	19880331	PL 1985-252039	19850219 <--
PRAI PL 1985-252039		19850219 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
PL 143965	ICM	C07D413-04

OS CASREACT 112:178964
GI



I

AB The title compound (I.2HCl; R = H), having antiinflammatory activity equal to that of benzidamine (with significantly lower toxicity) is prepared by hydrolysis of I (R = Ac) in refluxing EtOH containing HCl.
ST aminomorpholinoindazole prepn antiinflammatory; indazole aminomorpholino prepn antiinflammatory
IT Inflammation inhibitors
(amino(morpholino)indazole)
IT 126596-48-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of, in preparation of antiinflammatory agent)
IT **126596-47-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory agent)
IT **126596-47-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory agent)
RN 126596-47-2 HCAPLUS
CN 1H-Indazol-5-amine, 3-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L57 ANSWER 27 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:55915 HCAPLUS
DN 112:55915
ED Entered STN: 17 Feb 1990
TI Preparation of 5-chloro-3-(N-methylpiperazino)indazole and its monohydrochloride, useful as antiinflammatories
IN Wrzeciono, Urszula; Stochla, Krystyna; Majewska, Krystyna
PA Akademia Medyczna, Poznan, Pol.
SO Pol., 3 pp.
CODEN: POXXA7
DT Patent
LA Polish
IC ICM C07D403-04
ICA C07D231-54; C07D231-56
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI PL 145960	B1	19881231	PL 1985-252040	19850219 <--
PRAI PL 1985-252040		19850219 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
PL 145960	ICM	C07D403-04
	ICA	C07D231-54; C07D231-56

GI



I



II

AB Chloro(methylpiperazino)indazole I, with antiinflammatory activity, is prepared by reaction of chloronitroindazole II with N-methylpiperazine (III). Thus, 6.4 g II reacted over 3 h with 7.1 mL III in THF. Distillation, extraction, and acidification with HCl in MeOH gave I.2HCl, which was crystallized from MeOH (3.7 g). Dissoln. in H2O and alkalization with NH4OH gave I, which was crystallized from MeOH (2.3 g). I.HCl was 3-fold as strong as benzydamine in the carrageenin test for antiinflammatory activity in rats;

it was also less toxic than benzydamine to mice.

ST chloromethylpiperazinoindazole prepn antiinflammatory; piperazinoindazole chloromethyl prepn antiinflammatory; indazole chloromethylpiperazino prepn antiinflammatory

IT Inflammation inhibitors
(chloro(methylpiperazino)indazole and monohydrochloride)

IT **124673-64-9P**, 5-Chloro-3-(N-methylpiperazino)indazole dihydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and neutralization of, in preparation of antiinflammatories)

IT **124673-62-7P**, 5-Chloro-3-(N-methylpiperazino)indazole
124673-63-8P, 5-Chloro-3-(N-methylpiperazino)indazole monohydrochloride
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiinflammatory)

IT 109-01-3, N-Methylpiperazine
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloronitroindazole, chloro(methylpiperazino)indazole from)

IT 98083-45-5, 5-Chloro-2-nitro-2H-indazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methylpiperazine, chloro(methylpiperazino)indazole from)

IT **124673-64-9P**, 5-Chloro-3-(N-methylpiperazino)indazole dihydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); **THU (Therapeutic use)**
(preparation and neutralization of, in preparation of antiinflammatories)

RN 124673-64-9 HCAPLUS

CN 1H-Indazole, 5-chloro-3-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L57 ANSWER 28 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1987:598158 HCAPLUS

DN 107:198158

ED Entered STN: 27 Nov 1987

TI Synthesis and pharmacological activities of 3-phenylindazole derivatives

AU Fujimura, Yasuo; Ikeda, Yugo; Matsunaga, Isao

CS Cent. Res. Lab., Chugai Pharm. Co., Ltd., Tokyo, 171, Japan

SO Yakugaku Zasshi (**1986**), 106(11), 995-1001
CODEN: YKKZAJ; ISSN: 0031-6903

DT Journal

LA Japanese

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1
OS CASREACT 107:198158
GI



I II

AB 3-Phenylindazoles I [R = H, Cl, Br, Me; R1 = NH2, NHMe, NMe2, NEt2, NCH2CH:CH2)2, piperidino, morpholino, 4-methylpiperazino; n = 2,3] were prepared by diazotization and cyclization of benzophenones II. I (n = 3, R = Me, R1 = NHMe; n = 3, R = H, Me, Br, R1 = NMe2) were as effective in preventing reserpine-induced hypothermia as imipramine.

ST aminopropylphenylindazole prepn antidepresant; indazole aminoalkylphenyl

IT Antidepressants
((aminoalkyl)phenylindazoles)

IT 719-59-5, 2-Amino-5-chlorobenzophenone 2835-77-0, 2-Aminobenzophenone 17852-28-7, 2-Amino-5-methylbenzophenone 39859-36-4, 2-Amino-5-bromobenzophenone
RL: RCT (Reactant); RACT (Reactant or reagent)
(diazotization and cyclization of)

IT 61308-31-4P 61308-32-5P 111016-40-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and amidation of, with methylamine)

IT 63380-50-7P 63380-51-8P 63380-53-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and aminolysis of)

IT 57614-23-0P 57614-47-8P 57614-50-3P 57614-59-2P 57614-60-5P
57614-62-7P 61365-76-2P 61365-77-3P 61365-78-4P 63380-30-3P
63380-31-4P 63380-32-5P 63380-33-6P 63380-34-7P 63380-35-8P
63380-36-9P 63380-37-0P 63380-38-1P 63380-39-2P 63380-40-5P
63380-41-6P 63380-42-7P 63380-43-8P 63380-44-9P 63380-45-0P
63380-47-2P 63380-48-3P 63406-72-4P 63406-73-5P 63406-75-7P
63406-76-8P 63406-77-9P 63406-78-0P 63426-89-1P 63426-90-4P
63426-91-5P 111016-25-2P 111016-26-3P 111016-27-4P 111016-28-5P
111016-29-6P 111016-30-9P 111016-31-0P 111016-32-1P 111016-33-2P
111016-34-3P 111016-35-4P 111016-36-5P 111016-37-6P 111016-38-7P
111016-41-2P 111016-42-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidepressant activity of)

IT 57614-44-5P 57614-45-6P 57639-17-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrazinolysis of)

IT 63585-12-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitrosation of)

IT 42251-84-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with dimethylaminopropyl chloride)

IT 57614-46-7P 57614-49-0P 57614-52-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
IT 63585-15-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ring closure of)
IT 13097-01-3P, 3-Phenylindazole **13097-03-5P**, 5-Chloro-3-phenylindazole 57614-16-1P, 5-Methyl-3-phenylindazole **57639-16-4P**, 5-Bromo-3-phenylindazole
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and N-substitution of)
IT 111016-39-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 100-35-6, 2-Diethylaminoethyl chloride 104-16-5, 3-(4-Methylpiperazino)propyl chloride 104-77-8, 3-Diethylaminopropyl chloride 106-93-4, 1,2-Dibromoethane 107-99-3, 2-Dimethylaminoethyl chloride 109-54-6, 3-Dimethylaminopropyl chloride 142-28-9, 1,3-Dichloropropane 539-74-2, Ethyl 3-bromopropionate 1458-63-5, 3-Piperidinopropyl chloride 7357-67-7, 3-Morpholinopropyl chloride 57614-33-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with phenylindazoles)
IT **13097-03-5P**, 5-Chloro-3-phenylindazole
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and N-substitution of)
RN 13097-03-5 HCAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



L57 ANSWER 29 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1982:616169 HCAPLUS
DN 97:216169
ED Entered STN: 12 May 1984
TI Pyrazoloindazole derivatives and pharmaceutical composition containing them
IN Fujimura, Yasuo; Tanaka, Sadao; Matsunaga, Isao; Shiraki, Yasuyuki; Ikeda, Yugo; Yamazaki, Tamotsu; Ohba, Yasuhiro; Sakai, Kazushige; Hata, Shunichi; Shindo, Minoru
PA Chugai Pharmaceutical Co., Ltd. , Japan
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA English
IC C07D487-04; A61K031-415
ICA C07D231-56
ICI C07D487-04, C07D231-00
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 55450	A1	19820707	EP 1981-110654	19811221 <--

EP 55450	B1	19841205			
R: AT, BE, CH, DE, FR, GB, IT, NL, SE					
JP 57109787	A2	19820708	JP 1980-184106	19801226	<--
US 4415569	A	19831115	US 1981-331896	19811217	<--
DK 8105647	A	19820627	DK 1981-5647	19811218	<--
CA 1175826	A1	19841009	CA 1981-392734	19811218	<--
AT 10634	E	19841215	AT 1981-110654	19811221	<--
ZA 8108867	A	19821229	ZA 1981-8867	19811222	<--
HU 25092	O	19830530	HU 1981-3903	19811222	<--
HU 182636	B	19840228			
PRAI JP 1980-184106		19801226	<--		
EP 1981-110654		19811221	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 55450	IC	C07D487-04IC A61K031-415
	ICA	C07D231-56
	ICI	C07D487-04, C07D231-00

OS CASREACT 97:216169

GI



I

AB Pyrazolo[1,2-a]indazolium compds. I [R = cyano, CO2H, CO2H (metal salt), carbalkoxy, (un)substituted carbamoyl; X = Br, Cl], which showed bronchodilator activity, were prepared 1-(3-Bromopropyl)-5-cyano-3-phenylindazole was heated at 120° to give I (R = cyano, X = Br).

ST pyrazoloindazolium halide prepn bronchodilator

IT Bronchodilators and Antiasthmatics
(pyrazoloindazolium bromides)

IT 106-49-0, reactions 109-89-7, reactions 110-91-8, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation by, of pyrazoloindazolecarboxylic acid derivative)

IT **65642-56-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(oximation of, and dehydration of product from)

IT 83684-56-4P 83684-57-5P 83684-59-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and bronchodilator activity of)

IT 83684-58-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and esterification and amidation reactions of)

IT 83684-55-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and intramol. quaternization of)

IT **83684-54-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-alkylation of, by dibromopropane)

IT 83684-60-0P 83684-61-1P 83684-62-2P 83684-63-3P 83684-64-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 109-64-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-alkylation by, of indazole derivative)
IT **65642-56-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(oximation of, and dehydration of product from)
RN 65642-56-0 HCAPLUS
CN 1H-Indazole-5-carboxaldehyde, 3-phenyl- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:36:39 ON 07 OCT 2004)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 14:36:54 ON 07 OCT 2004
L1 1 S (US20040077877 OR US20020103229)/PN

FILE 'REGISTRY' ENTERED AT 14:37:27 ON 07 OCT 2004

FILE 'HCAPLUS' ENTERED AT 14:37:28 ON 07 OCT 2004
SET SMARTSELECT ON
L2 SEL L1 1- RN : 1161 TERMS
SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 14:37:28 ON 07 OCT 2004
L3 1161 S L2
L4 37 S L3 AND N2C3-C6/ES AND NC5/ES AND N2CNC/ES AND 46.150.18/RID
L5 27 S L4 AND 5/NR
L6 1 S L5 AND C22H24N6O
E C2H24N6O/MF
E C22H24N6O/MF
L7 1 S E3 AND 5/NR AND N2C3-C6/ES AND NC5/ES AND N2CNC/ES AND 46.150
L8 1 S L6,L7
SEL RN
L9 0 S E1/CRN

FILE 'HCAOLD' ENTERED AT 14:39:09 ON 07 OCT 2004
L10 0 S L8

FILE 'USPATFULL, USPAT2' ENTERED AT 14:39:15 ON 07 OCT 2004
L11 3 S L8

FILE 'HCAPLUS' ENTERED AT 14:39:18 ON 07 OCT 2004
L12 2 S L8

FILE 'REGISTRY' ENTERED AT 14:39:33 ON 07 OCT 2004

FILE 'USPATFULL, USPAT2' ENTERED AT 14:39:44 ON 07 OCT 2004

FILE 'HCAPLUS' ENTERED AT 14:39:52 ON 07 OCT 2004

```
     FILE 'REGISTRY' ENTERED AT 14:40:15 ON 07 OCT 2004
L13                STR
                   E 333.161.31/RID
L14          28038 S E3
                   E N2C3-C6/ES
L15          49149 S E3
L16          49149 S L14,L15
L17             50 S L13 CSS SAM SUB=L16
L18           2354 S L13 CSS FUL SUB=L16
                   SAV L18 JKIM673/A
L19            675 S L3 AND L18
L20           1679 S L18 NOT L19,L8
L21            674 S L19 NOT L8

     FILE 'HCAPLUS' ENTERED AT 14:47:48 ON 07 OCT 2004
L22             52 S L21

     FILE 'REGISTRY' ENTERED AT 14:49:10 ON 07 OCT 2004
L23              3 S 155215-87-5 OR 289899-93-0 OR 291756-39-3
L24            103 S KINASE(L)PHOSPHORYLATING(L)C()JUN (L) N()TERMINAL (L) GENE
L25              8 S L24 NOT SQL/FA
L26              8 S L23,L25

     FILE 'HCAPLUS' ENTERED AT 14:50:13 ON 07 OCT 2004
L27           5990 S L26
L28              7 S L22 AND L27
L29            220 S L20
L30              2 S L27 AND L29
L31              8 S L28,L30

     FILE 'REGISTRY' ENTERED AT 14:51:02 ON 07 OCT 2004
L32             95 S L24 NOT L26

     FILE 'HCAPLUS' ENTERED AT 14:51:05 ON 07 OCT 2004
L33             49 S L32
L34              0 S L22 AND L33
L35              0 S L29 AND L33
L36              8 S L22,L29 AND JNK
L37              8 S L31,L36
L38              2 S L37 AND (PD<=20000731 OR PRD<=20000731 OR AD<=20000731)
L39              2 S L1,L38
L40            197 S L22,L29 AND (PD<=20000731 OR PRD<=20000731 OR AD<=20000731)
L41              8 S L21 (L) (THU OR PKT OR PAC OR DMA)/RL
L42             85 S L20 (L) (THU OR PKT OR PAC OR DMA)/RL
L43              2 S L41 AND L40
L44             49 S L42 AND L40
L45              2 S L39,L43
L46             45 S L44 AND P/DT
L47              9 S L46 AND US/PC.B
                   SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 14:58:26 ON 07 OCT 2004
L48             44 S E1-E44
L49                STR L13
L50             43 S L49 SAM SUB=L20
L51           1039 S L49 FUL SUB=L20
                   SAV L51 JKIM673A/A
                   SAV L19 JKIM673B/A
L52              0 S L48 AND L51

     FILE 'HCAPLUS' ENTERED AT 15:00:17 ON 07 OCT 2004
L53             82 S L51
```

```
L54           59 S L53 AND (PD<=20000731 OR PRD<=20000731 OR AD<=20000731)
L55           10 S L51 (L) (THU OR PAC OR PKT OR DMA)/RL AND L54
L56           29 S L54 AND (PHARMACEUT? OR PHARMACOL?)/SC,SX
L57           29 S L55,L56
                 SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 15:01:48 ON 07 OCT 2004
L58          204 S E45-E248
L59          204 S L58 AND L14

     FILE 'REGISTRY' ENTERED AT 15:02:30 ON 07 OCT 2004

     FILE 'HCAPLUS' ENTERED AT 15:02:43 ON 07 OCT 2004

     FILE 'REGISTRY' ENTERED AT 15:03:24 ON 07 OCT 2004

     FILE 'HCAPLUS' ENTERED AT 15:03:47 ON 07 OCT 2004

=>
```

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 14:39:33 ON 07 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 OCT 2004  HIGHEST RN 757927-15-4
DICTIONARY FILE UPDATES:   6 OCT 2004  HIGHEST RN 757927-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d l8 ide can

L8   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   395104-30-0  REGISTRY
CN   1H-Indazole, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-
     yl)- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-
     piperidinoethoxy)benzene
FS   3D CONCORD
MF   C22 H24 N6 O
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               2 REFERENCES IN FILE CA (1907 TO DATE)
               2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE   1:  141:89085

REFERENCE   2:  136:151163

=> d his l8-
```

```
     (FILE 'REGISTRY' ENTERED AT 14:37:28 ON 07 OCT 2004)
L8             1 S L6,L7
                 SEL RN
L9             0 S E1/CRN

     FILE 'HCAOLD' ENTERED AT 14:39:09 ON 07 OCT 2004
L10            0 S L8

     FILE 'USPATFULL, USPAT2' ENTERED AT 14:39:15 ON 07 OCT 2004
L11            3 S L8

     FILE 'HCAPLUS' ENTERED AT 14:39:18 ON 07 OCT 2004
L12            2 S L8

     FILE 'REGISTRY' ENTERED AT 14:39:33 ON 07 OCT 2004

=> fil uspatall
FILE 'USPATFULL' ENTERED AT 14:39:44 ON 07 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:39:44 ON 07 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l11 bib abs hitstr tot

L11  ANSWER 1 OF 3  USPATFULL on STN
AN     2004:166046  USPATFULL
TI     Methods for treating an inflammatory condition or inhibiting JNK
IN     Bhagwat, Shripad S., San Diego, CA, UNITED STATES
       Satoh, Yoshitaka, San Diego, CA, UNITED STATES
       Sakata, Steven T., San Diego, CA, UNITED STATES
       Buhr, Chris A., Redwood City, CA, UNITED STATES
       Albers, Ronald, La Jolla, CA, UNITED STATES
       Sapienza, John, Chula Vista, CA, UNITED STATES
       Plantevin, Veronique, San Diego, CA, UNITED STATES
       Chao, Qi, San Diego, CA, UNITED STATES
       Sahasrabudhe, Kiran, San Diego, CA, UNITED STATES
       Ferri, Rachel, San Diego, CA, UNITED STATES
PI     US 2004127536      A1   20040701
AI     US 2003-414839     A1   20030416 (10)
RLI    Continuation-in-part of Ser. No. US 2001-910950, filed on 23 Jul 2001,
       PENDING
PRAI   US 2000-221799P     20000731 (60)
DT     Utility
FS     APPLICATION
LREP   JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
CLMN   Number of Claims: 71
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 13807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     This invention is generally directed to Indazole Derivatives having the
       following structure:   ##STR1##

       or pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2
       and A are as defined herein. Such compounds have utility in the
       treatment of a wide range of diseases and disorders that are responsive
       to JNK inhibition, such as an inflammatory disease or disorder. Thus,
       methods of treating such diseases and disorders are also disclosed, as
       are pharmaceutical compositions containing one or more compounds of the
       above compounds.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **395104-30-0P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene
(preparation of indazole derivs. as JNK enzyme inhibitors)
RN 395104-30-0 USPATFULL
CN 1H-Indazole, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 3 USPATFULL on STN
AN 2004:102007 USPATFULL
TI Indazole derivatives as JNK inhibitors and compositions and methods related thereto
IN Bhagwat, Shripad S., San Diego, CA, UNITED STATES
Satoh, Yoshitaka, San Diego, CA, UNITED STATES
Sakata, Steven T., San Diego, CA, UNITED STATES
Buhr, Chris A., Redwood City, CA, UNITED STATES
Albers, Ronald, La Jolla, CA, UNITED STATES
Sapienza, John, Chula Vista, CA, UNITED STATES
Plantevin, Veronique, San Diego, CA, UNITED STATES
Chao, Qi, San Diego, CA, UNITED STATES
Sahasrabudhe, Kiran, San Diego, CA, UNITED STATES
Ferri, Rachel, San Diego, CA, UNITED STATES
PA Signal Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004077877 A1 20040422
AI US 2003-673121 A1 20030926 (10)
RLI Continuation of Ser. No. US 2001-910950, filed on 23 Jul 2001, PENDING
PRAI US 2000-221799P 20000731 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST STREET, NEW YORK, NY, 10017
CLMN Number of Claims: 87
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12630
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: ##STR1##

wherein R.sub.1, R.sub.2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **395104-30-0P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene
(preparation of indazole derivs. as JNK enzyme inhibitors)
RN 395104-30-0 USPATFULL
CN 1H-Indazole, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



L11 ANSWER 3 OF 3 USPATFULL on STN
AN 2002:192157 USPATFULL
TI Indazole derivatives as JNK inhibitors and compositions and methods related thereto
IN Bhagwat, Shripad S., San Diego, CA, UNITED STATES
Satoh, Yoshitaka, San Diego, CA, UNITED STATES
Sakata, Steven T., San Diego, CA, UNITED STATES
Buhr, Chris A., Redwood City, CA, UNITED STATES
Albers, Ronald, La Jolla, CA, UNITED STATES
Sapienza, John, Chula Vista, CA, UNITED STATES
Plantevin, Veronique, San Diego, CA, UNITED STATES
Chao, Qi, San Diego, CA, UNITED STATES
Sahasrabudhe, Kiran, San Diego, CA, UNITED STATES
Ferri, Rachel, San Diego, CA, UNITED STATES
PI US 2002103229 A1 20020801
AI US 2001-910950 A1 20010723 (9)
PRAI US 2000-221799P 20000731 (60)
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 87
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: ##STR1##

wherein R.sub.1, R.sub.2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **395104-30-0P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene
(preparation of indazole derivs. as JNK enzyme inhibitors)
RN 395104-30-0 USPATFULL
CN 1H-Indazole, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:39:52 ON 07 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d l12 all hitstr tot

L12 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:533982 HCAPLUS
DN 141:89085
ED Entered STN: 02 Jul 2004
TI Preparation of indazole derivatives as JNK enzyme inhibitors
IN Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.; Buhr, Chris A.; Albers, Ronald; Sapienza, John; Plantevin, Veronique; Chao, Qi; Sahasrabudhe, Kiran; Ferri, Rachel
PA USA
SO U.S. Pat. Appl. Publ., 275 pp., Cont.-in-part of U.S. Ser. No. 910,950.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-416
ICS C07D231-56
NCL 514406000; 548362100
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004127536	A1	20040701	US 2003-414839	20030416
	US 2002103229	A1	20020801	US 2001-910950	20010723
	US 2004077877	A1	20040422	US 2003-673121	20030926
PRAI	US 2000-221799P	P	20000731		

US 2001-910950 A2 20010723

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004127536	ICM	A61K031-416
	ICS	C07D231-56
	NCL	514406000; 548362100
US 2004127536	ECLA	C07D231/56B; C07D405/14; C07D405/14; C07D409/04; C07D409/12; C07D409/14; C07D409/14; C07D413/04; C07D417/12; C07D401/04; C07D401/06; C07D401/12; C07D401/14; C07D; C07D403/04; C07D403/04; C07D403/04; C07D403/04; C07D403/06; C07D403/14; C07D405/04; C07D405/04; C07D040/12; C07D405/14
US 2004077877	ECLA	C07D231/56B; C07D401/14; C07D401/14; C07D403/04; C07D403/04; C07D403/04; C07D403/04; C07D403/06; C07D403/14; C07D405/04; C07D405/12; C07D405/14; C07D405/1; C07D405/14; C07D409/04; C07D409/12; C07D409/14; C07D409/14; C07D413/04; C07D417/12; C07D401/04; C07D401/06; C07D401/12

OS MARPAT 141:89085

GI



I

AB Indazole derivs. I [A = a bond, (CH2)a, (CH2)bCH:CH(CH2)c, (CH2)bC.tplbond.C(CH2)c; R1 = (un)substituted aryl, heteroaryl or heterocycle fused to Ph; R2 = R3, R4, (CH2)bC(O)R5, (CH2)bC(:O)OR5, (CH2)bC(O)NR5R6, (CH2)bC(O)NR5(CH2)cC(O)R6, (CH2)bNR5C(O)R6, (CH2)bNR5C(O)NR6R7, (CH2)bNR5R6, (CH2)bOR5, (CH2)bSOdR5 or (CH2)bSO2NR5R6; a = 1-6; b, c = 0-4; d = 0-2; R3 = halo, OH, CO2H, carboxy, etc.; R4 = (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, or R4 = halo or OH; R5-R7 = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl; with the provisos] having activity as selective inhibitors of JNK, are disclosed. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds. Many of the claimed compds. have IC50 values ≤0.5 μM in the JNK2 assay, e.g. 5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole. Although the methods of preparation are not claimed, >400 example prepns. are included.

ST indazole prepn Jun N terminal kinase JNK inhibitor antiinflammatory

IT AIDS (disease)
(AIDS dementia complex; preparation of indazole derivs. as JNK enzyme inhibitors)

IT Mental disorder
(AIDS dementia; preparation of indazole derivs. as JNK enzyme inhibitors)

IT Intestine, disease
(Crohn's; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)

IT Respiratory distress syndrome
(acute; preparation of indazole derivs. as JNK enzyme inhibitors)

IT Nose, disease

(allergic rhinitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Bronchi, disease
(bronchitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Lung, disease
(chronic obstructive; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Intestine, disease
(colitis, mucous; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Esophagus, disease
(esophagitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Obesity
(exogenous; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Lung, disease
(fibrosis, treating pulmonary interstitial fibrosis; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Kidney, disease
Liver, disease
(fibrosis; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Drug delivery systems
(for indazole derivs. useful as JNK enzyme inhibitors)
IT Stomach, disease
(gastritis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Obesity
(genetic; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Intestine, disease
(inflammatory; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Reperfusion
(injury; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Diabetes mellitus
(insulin-dependent; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Intestine, disease
(irritable bowel syndrome; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Hearing
(loss; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Heterocyclic compounds
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nitrogen, five-membered, indazoles; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Diabetes mellitus
(non-insulin-dependent; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Ear, disease
(otitis media, treating acute otitis media; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Ear, disease
(otitis, otitis externa; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Pancreas, disease
(pancreatitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Peritoneum, disease
(peritonitis; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Allergy

Allergy inhibitors
Anti-inflammatory agents
Antiobesity agents
Asthma
Diabetes insipidus
Gout
Inflammation
Kidney, disease
Multiple sclerosis
Osteoarthritis
Rheumatoid arthritis
Wound healing
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT Anti-ischemic agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antirheumatic agents
(preparation of indazole derivs. as JNK enzyme inhibitors useful as)

IT Burn
Cystic fibrosis
Dermatitis
Eczema
Lupus erythematosus
Psoriasis
Transplant rejection
(preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)

IT Shock (circulatory collapse)
(septic; preparation of indazole derivs. as JNK enzyme inhibitors)

IT Spinal column, disease
(spondylitis, rheumatoid; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)

IT Anti-AIDS agents
(treating AIDS dementia complex; preparation of indazole derivs. as JNK enzyme inhibitors)

IT Diabetes mellitus
(treating diabetes mellitus, malnutrition-related diabetes, ketosis-prone diabetes or ketosis-resistant diabetes; preparation of indazole derivs. as JNK enzyme inhibitors)

IT Obesity
(treating hormone related obesity or obesity related to the administration of medication; preparation of indazole derivs. as JNK enzyme inhibitors)

IT Intestine, disease
(ulcerative colitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)

IT 716321-04-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(del b,sprepn. of indazole derivs. as JNK enzyme inhibitors)

IT 155215-87-5, JNK 289899-93-0, JNK2 291756-39-3, JNK3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of indazole derivs. as JNK enzyme inhibitors)

IT 293758-67-5P, 5-Nitro-3-phenyl-1H-indazole 395099-05-5P, 5-Amino-3-phenyl-1H-indazole 395099-16-8P, Methyl 4-[N-(3-phenyl-1H-indazol-5-yl)carbamoyl]benzoate 395099-28-2P, 3-(4-Methoxyphenyl)-5-nitro-1H-indazole 395099-32-8P, 3-(3,4-Dimethoxyphenyl)-5-nitro-1H-indazole 395099-59-9P, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid 395099-86-2P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-hydroxybenzamide 395099-88-4P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-pyridinecarboxamide 395099-89-5P, N-[3-(4-Fluorophenyl)-1H-

indazol-5-yl]-3-pyridinecarboxamide 395100-10-4P, 3-(4-Fluorophenyl)-1H-indazole-5-carboxylic acid 395100-21-7P, Methyl 4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzoate 395100-32-0P, 3-[[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]propanoic acid 395100-33-1P, N-(3-Nitrophenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-76-2P, N-(Phenylmethoxy)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-93-3P, N-[(tert-Butoxy)carbonylamino]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-95-5P, N-Amino-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395101-17-4P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(4-nitrophenyl)-4H-1,2,4-triazole 395101-18-5P, 1-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]-4-methoxybenzene 395101-19-6P, Ethyl 2-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]acetate 395101-25-4P, 3-(4-Fluorophenyl)-5-(2-phenylethynyl)-1H-indazole 395101-30-1P, 5-((1E)-2-Phenylvinyl)-3-(4-fluorophenyl)-1H-indazole 395101-32-3P, 5-[(1E)-2-(2-Pyridyl)vinyl]-3-(4-fluorophenyl)-1H-indazole 395101-36-7P, 4-[(1E)-2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]vinyl]benzoic acid 395101-38-9P, 5-[(1E)-2-(3-Nitrophenyl)vinyl]-3-(4-fluorophenyl)-1H-indazole 395101-52-7P, Ethyl (2E)-3-[3-(4-fluorophenyl)-1H-indazol-5-yl]prop-2-enoate 395101-66-3P, 3-(4-Methoxyphenyl)-1H-indazole-5-carboxamide 395101-72-1P, 3-(4-Hydroxyphenyl)-1H-indazole-5-carboxamide 395101-78-7P, 3-(2-Naphthyl)-1H-indazole-5-carboxamide 395101-82-3P, Methyl 3-benzo[b]thiophen-2-yl-1H-indazole-5-carboxylate 395101-92-5P, 3-(Benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395101-97-0P, 3-[4-(Dimethylamino)phenyl]-1H-indazole-5-carboxamide 395102-02-0P, 3-(2-Phenylethynyl)-1H-indazole-5-carboxamide 395102-08-6P, 3-[4-[2-(Dimethylamino)ethoxy]phenyl]-1H-indazole-5-carboxamide 395102-09-7P, 1-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-2-methoxybenzene 395102-46-2P, 1-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-3-methoxybenzene 395103-58-9P, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]ethan-1-one 395103-83-0P, Ethyl 3-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propanoate 395104-41-3P 395107-78-5P 395107-84-3P, 3-(3-Quinolyl)-1H-indazole-5-carboxamide 395107-88-7P, 3-(6-Methoxy-2-naphthyl)-1H-indazole-5-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of indazole derivs. as JNK enzyme inhibitors)

IT 55-85-6P, N-Amino-2-(dimethylamino)acetamide 770-17-2P, N-Amino-2-(morpholin-4-yl)acetamide 2644-33-9P, N-Amino-2-(diethylamino)acetamide 7408-09-5P, N-Amino-2-piperidinoacetamide 22636-79-9P, N-Amino-3-(dimethylamino)propanamide 24534-93-8P, 3-Hydroxybutyric acid hydrazide 24632-72-2P, 2-(4-Acetylpiperazino)-N-aminoacetamide 37115-47-2P, N-Amino-2-(methylamino)acetamide 40598-94-5P, 3-Bromo-1H-indazole 59776-89-5P, N-Amino-2-(2-oxopyrrolidinyl)acetamide 66544-68-1P 67400-25-3P, 3-Bromo-5-nitro-1H-indazole 74626-47-4P, 1H-Indazole-5-carbonitrile 146137-79-3P, 4-Fluoro-3-formylbenzenecarbonitrile 395098-99-4P, 3-Bromo-1-[(2-methoxyethoxy)methyl]-1H-indazole 395099-00-0P, 1-[(2-Methoxyethoxy)methyl]-3-(4-methoxyphenyl)-1H-indazole 395099-02-2P, 1-[(2-Methoxyethoxy)methyl]-3-(2-methoxyphenyl)-1H-indazole 395099-03-3P, 3-(4-Fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazole 395099-07-7P, N-[2-(Phenylcarbonyl)-4-(phenylmethoxy)phenyl]benzamide 395099-09-9P, 2-Amino-5-(phenylmethoxy)phenyl phenyl ketone 395099-14-6P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)-2-pyridinecarboxamide 395099-17-9P, Methyl 4-[N-(1-acetyl-3-phenyl-1H-indazol-5-yl)carbamoyl]benzoate 395099-20-4P, 2-[N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)carbamoyl]phenyl acetate 395099-21-5P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)acetamide 395099-24-8P, N-[1-Acetyl-3-phenyl-1H-indazol-5-yl]-4-nitrobenzamide 395099-25-9P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)-4-aminobenzamide 395099-27-1P, N-[1-Acetyl-3-phenyl-1H-indazol-5-yl]-3-nitrobenzamide 395099-29-3P, 3-Bromo-1-[(2-methoxyethoxy)methyl]-5-nitro-

1H-indazole 395099-30-6P, 1-[(2-Methoxyethoxy)methyl]-3-(4-methoxyphenyl)-5-nitro-1H-indazole 395099-33-9P, 3-(3,4-Dimethoxyphenyl)-1-[(2-methoxyethoxy)methyl]-5-nitro-1H-indazole 395099-35-1P, 1-[(2-Methoxyethoxy)methyl]-5-nitro-3-(3-nitrophenyl)-1H-indazole 395099-62-4P, Methyl 4-[N-[3-(4-fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazol-5-yl]carbamoyl]benzoate 395099-63-5P, Methyl 4-[N-[3-(4-fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazol-5-yl]-N-methylcarbamoyl]benzoate 395099-66-8P, Methyl 3-[N-[3-(4-fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-72-6P, 4-Methoxy-1-[5-nitro-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzene 395099-74-8P, 3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-ylamine 395099-75-9P, Methyl 4-[N-[3-(4-methoxyphenyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-76-0P, Methyl 4-[N-[3-(4-methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-78-2P, 2-[5-Nitro-3-(4-pyridyl)-1H-indazol-1-yl]perhydro-2H-pyran 395099-79-3P, 1-(Perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazol-5-ylamine 395099-80-6P, Methyl 4-[N-[1-(perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-81-7P, Methyl 4-[N-[3-(4-pyridyl)-1H-indazol-5-yl]carbamoyl]benzoate 395100-00-2P, 1-Acetyl-3-(4-fluorophenyl)-1H-indazole-5-carbonyl chloride 395100-11-5P, 4-Fluoro-3-[(4-fluorophenyl)carbonyl]benzenecarbonitrile 395100-12-6P, 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile 395100-39-7P, Methyl 4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoate 395100-41-1P, Methyl 4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoate 395100-43-3P, N-(3-Nitrophenyl)-1-acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-48-8P 395100-52-4P, Methyl 4-[[[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]methyl]benzoate 395100-56-8P, N-(4-Pyridylmethyl)-1-acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-59-1P, Ethyl 2-[4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetate 395100-60-4P, Ethyl 2-[4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetate 395100-66-0P, N-[2-[(tert-Butoxy)carbonylamino]ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-69-3P, N-[3-[(tert-Butoxy)carbonylamino]propyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-73-9P, tert-Butyl 4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]piperazine-1-carboxylate 395100-74-0P, 1-Acetyl-3-(4-fluorophenyl)-5-(1-piperazinylcarbonyl)-1H-indazole 395100-84-2P, 1-Acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxylic acid 395100-98-8P, tert-Butyl 3-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]propanoate 395101-04-9P, N-[(1-Iminoethyl)amino]-3-(4-fluorophenyl)indene-5-carboxamide 395101-06-1P, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine hydrochloride 395101-26-5P, 2-Amino-5-bromo-4'-fluorobenzophenone 395101-27-6P, 5-Bromo-3-(4-fluorophenyl)-1H-indazole 395101-28-7P, 5-Bromo-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-29-8P, 3-(4-Fluorophenyl)-5-(2-phenylethynyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-31-2P, 5-((1E)-2-Phenylvinyl)-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-34-5P, 5-[(1E)-2-(2-Pyridyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-37-8P, 4-[(1E)-2-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]vinyl]benzoic acid 395101-44-7P, 5-[(1E)-2-(4-Aminophenyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-46-9P, 5-[(1E)-2-(4-Pyridyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-50-5P, Ethyl (2E)-3-[3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]prop-2-enoate 395101-61-8P, 1-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-2-phenylethan-1-ol 395101-64-1P, 1-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-2-phenylethan-1-one 395101-67-4P, 3-Bromo-1H-indazole-5-carbonitrile 395101-69-6P, 3-Bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-70-9P, 3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-71-0P, 3-(4-Methoxyphenyl)-1H-indazole-5-

carbonitrile 395101-74-3P, 3-(4-Hydroxyphenyl)-1-perhydro-2H-pyran-2-yl-1H-indazole-5-carbonitrile 395101-77-6P, 3-(4-Hydroxyphenyl)-1H-indazole-5-carbonitrile 395101-79-8P, 3-(2-Naphthyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-80-1P, 3-(2-Naphthyl)-1H-indazole-5-carbonitrile 395101-84-5P, 3-Bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395101-85-6P, 3-Benzo[b]thiophen-2-yl-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395101-89-0P, 3-Benzo[b]thiophen-2-yl-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-91-4P, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carbonitrile 395101-94-7P, 3-(Benzo[d]furan-2-yl)-1-perhydro-2H-pyran-2-yl-1H-indazole-5-carbonitrile 395101-95-8P, 3-(Benzo[d]furan-2-yl)-1H-indazole-5-carbonitrile 395101-98-1P, 3-[4-(Dimethylamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-00-8P, 3-[4-(Dimethylamino)phenyl]-1H-indazole-5-carbonitrile 395102-04-2P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-phenylethynyl)-1H-indazole-5-carbonitrile 395102-06-4P, 3-(2-Phenylethynyl)-1H-indazole-5-carbonitrile 395102-11-1P, 3-(2-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-12-2P, 3-(2-Methoxyphenyl)-1H-indazole-5-carbonitrile 395102-14-4P, 3-((1E)-2-Phenylvinyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-15-5P, 3-((1E)-2-Phenylvinyl)-1H-indazole-5-carbonitrile 395102-19-9P, 1-(Perhydro-2H-pyran-2-yl)-3-(3-pyridyl)-1H-indazole-5-carbonitrile 395102-20-2P, 3-(3-Pyridyl)-1H-indazole-5-carbonitrile 395102-22-4P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-thienyl)-1H-indazole-5-carbonitrile 395102-24-6P, 3-[4-Isopropylphenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-27-9P, 3-(2-Furyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-29-1P, 3-(3-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-31-5P, 3-(2H-Benzo[d]-1,3-dioxolan-5-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-32-6P, 3-(2H-Benzo[d]-1,3-dioxolan-5-yl)-1H-indazole-5-carbonitrile 395102-34-8P, 1-(Perhydro-2H-pyran-2-yl)-3-(3-thienyl)-1H-indazole-5-carbonitrile 395102-38-2P, 3-[4-(2-Methylpropoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-40-6P, 3-[4-(2-Methylpropoxy)phenyl]-1H-indazole-5-carbonitrile 395102-44-0P, 3-(4-Chlorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-47-3P, 3-(3-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-50-8P, 1-(Perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazole-5-carbonitrile 395102-60-0P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-phenylethyl)-1H-indazole-5-carbonitrile 395102-75-7P, 3-(1-Naphthyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-77-9P, 3-(1-Naphthyl)-1H-indazole-5-carbonitrile 395102-79-1P, 3-(1-Naphthyl)-1H-indazole-5-carboxamide 395102-89-3P, 3-(3,4-Dichlorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-96-2P, (2E)-2-Aza-3-(dimethylamino)-1-[3-bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]prop-2-en-1-one 395102-97-3P, 2-[5-(1H-1,2,4-Triazol-3-yl)-3-bromo-1H-indazol-1-yl]perhydro-2H-pyran 395102-98-4P 395102-99-5P, 2-[3-(4-Methylphenyl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-03-4P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenylamine 395103-09-0P, 1-[(1E)-2-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]vinyl]-4-methoxybenzene 395103-13-6P, 2-[3-[(1E)-2-(4-Chlorophenyl)vinyl]-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-17-0P, 4-Methylthio-1-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzene 395103-19-2P, 2-[3-[(1E)-2-(4-Methylphenyl)vinyl]-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-23-8P, 5-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane 395103-31-8P, (Methylsulfonyl)[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]amine 395103-35-2P, 2-Methoxy-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395103-40-9P,

N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395103-42-1P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-44-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395103-52-3P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-3-bromo-1H-indazolyl]perhydro-2H-pyran 395103-53-4P, 2-[3-Bromo-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazolyl]perhydro-2H-pyran 395103-54-5P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazol-3-yl]phenylamine 395103-56-7P, 2-Methoxy-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazol-3-yl]phenyl]acetamide 395103-60-3P, 1-[3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]ethan-1-one 395103-65-8P, 3-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]-1H-indazole-5-carbonitrile 395103-71-6P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395103-73-8P, 3-(3,4-Dimethoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395103-74-9P, 3-(3,4-Dimethoxyphenyl)-1H-indazole-5-carbonitrile 395103-77-2P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-(1-piperidyl)propanamide 395103-80-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-82-9P, 3-(3-Hydroxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395103-87-4P, Ethyl 3-(N-aminocarbamoyl)propanoate 395103-88-5P, Ethyl 4-(N-aminocarbamoyl)butanoate 395103-92-1P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-methoxypropanamide 395103-94-3P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazole-3-yl]phenyl]-3-pyridinecarboxamide 395103-98-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide 395104-11-7P, 3-[4-[3-(Dimethylamino)propoxy]phenyl]-1H-indazole-5-carbonitrile 395104-14-0P, 3-[3-[3-(Dimethylamino)propoxy]phenyl]-1H-indazole-5-carbonitrile 395104-16-2P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenol 395104-26-4P, 3-[4-[2-(Dimethylamino)ethoxy]phenyl]-1H-indazole-5-carbonitrile 395104-34-4P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(2-piperazinoethoxy)benzene 395104-50-4P, 4-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenylamine 395104-53-7P, Methyl 3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzoate 395104-55-9P, N-Benzyl-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-61-7P 395104-65-1P, N-(2,2-Dimethylpropyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-68-4P, N-(Cyclopropylmethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-72-0P, N-(3-Pyridylmethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-76-4P, N-[(4-Fluorophenyl)methyl]-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-78-6P, N-(Indan-2-yl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-81-1P, N-((1R)-Indanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-83-3P, N-((1S)-Indanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-85-5P, N-((1S,2R)-2-Hydroxyindanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazole-3-yl]benzamide 395104-87-7P, N-((1R,2S)-2-Hydroxyindanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-89-9P, N-(1-Methyl-1-phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-91-3P, N-(tert-Butyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazole-3-yl]benzamide

395104-93-5P, N-((1R)-1-Phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-94-6P, N-((1S)-1-Phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-96-8P, Isoindolin-2-yl 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl ketone 395105-01-8P, Ethyl 3-(benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylate 395105-03-0P, 3-(Benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylic acid 395105-04-1P, N-Isopropyl-3-(benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-13-2P, N-Amino-2-(4-hydroxypiperidyl)acetamide 395105-17-6P, (1S)-1-[N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-20-1P, 1-(Perhydro-2H-pyran-2-yl)-3-[3-(3-pyridylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-22-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-piperidylpropanamide 395105-25-6P, 1-[N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-27-8P, 3-(3-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-28-9P, 3-[3-(2-Methoxyacetamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-30-3P, tert-Butyl 4-[N-[3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]piperidine-1-carboxylate 395105-31-4P, tert-Butyl 4-[N-[3-(5-carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)phenyl]carbamoyl]piperidine-1-carboxylate 395105-33-6P, (1S)-1-[N-[3-[5-Carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-35-8P, 3-[3-[(2-Methoxyethyl)amino]phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-37-0P, 1-(Perhydro-2H-pyran-2-yl)-3-[3-(3-piperidylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395105-39-2P, 3-[3-(2-Furylcarbonylamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-41-6P, 2-(Dimethylamino)-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-44-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]butanamide 395105-46-1P, (2E)-N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-phenylprop-2-enamide 395105-48-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395105-51-8P, 3-[3-[2-(Dimethylamino)acetylamino]phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-54-1P, 3,3-Dimethyl-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]butanamide 395105-56-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]cyclopropanecarboxamide 395105-58-5P, 2-(Indol-3-yl)-2-oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-61-0P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-6-chloro-3-pyridinecarboxamide 395105-64-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]cyclopentanecarboxamide 395105-66-5P, Methyl[N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]formate 395105-69-8P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]benzo[b]thiophene-2-carboxamide 395105-72-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-pyridinecarboxamide 395105-74-5P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-furancarboxamide 395105-76-7P, [N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]phenylmethyl acetate 395105-79-0P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]isoxazole-5-carboxamide 395105-81-4P,

N-((1S)-1-Phenylethyl)-3-[5-(1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395105-82-5P, 2-(2-Furyl)-2-oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-84-7P, 2-Oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395105-86-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]pentanamide 395105-88-1P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-4-pyridinecarboxamide 395105-91-6P, 2-Cyclohexyl-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-93-8P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-phenylpropanamide 395105-95-0P

, 2-(4-Fluorophenyl)-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-97-2P 395106-03-3P, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine 395106-23-7P, N-Amino-2-(dimethylamino)propanamide 395106-25-9P, (1R)-[N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]phenylmethyl acetate 395106-27-1P, (2R)-N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide hydrochloride 395106-31-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide 395106-32-8P, N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide hydrochloride 395106-36-2P 395106-38-4P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-methylbutanamide 395106-39-5P, N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide hydrochloride 395106-70-4P, 3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395106-71-5P, 3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395106-79-3P, N-[(4-Fluorophenyl)methyl]-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-80-6P, N-[(4-Fluorophenyl)methyl]-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-82-8P, N-(tert-Butyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-83-9P, N-(tert-Butyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenylcarboxamide 395106-85-1P, N-((1R)-Indanyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-86-2P, N-((1R)-Indanyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-88-4P, [[3-[3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-91-9P, [[3-[3-(2H-Benzo[d]-1,3-dioxol-5-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-94-2P, [3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl](hydroxyimino)methylamine 395106-96-4P, 2-Amino-1-aza-2-[3-(4-fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]vinyl ethoxyformate 395106-97-5P, 3-[3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1,2,4-oxadiazolin-5-one 395106-99-7P, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl](phenylmethoxy)methane 395107-03-6P, N-(2-Piperidinoethyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395107-05-8P, N-(2-Piperidinoethyl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide trihydrochloride 395107-08-1P 395107-11-6P, N-Phenyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indazole derivs. as JNK enzyme inhibitors)

IT 395107-13-8P, N-(4-Fluorophenyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395107-15-0P, N-(4-Fluorophenyl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-17-2P, N-(Indan-2-yl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-

indazol-3-yl]benzamide 395107-18-3P, N-(Indan-2-yl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-20-7P, N-Cyclopropyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395107-22-9P, N-Cyclopropyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-25-2P, N-Cyclobutyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395107-26-3P, N-Cyclobutyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-28-5P, 3-(4-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395107-29-6P, N-[4-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395107-30-9P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]-3-(2-methoxyethoxy)benzene 395107-46-7P, Methyl 3-(5-carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoate 395107-80-9P 395107-86-5P, 3-(1,1-Dimethyl-1-stannaethyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395107-90-1P, 3-(6-Methoxy-2-naphthyl)-1H-indazole-5-carbonitrile 395107-96-7P, 3-(2,3-Dihydrobenzo[b]furan-5-yl)-1H-indazole-5-carbonitrile 395108-15-3P, Ethoxy[3-(6-methoxy-2-naphthyl)-1H-indazol-5-yl]methanimine 395108-20-0P, N-Phenyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide 395108-21-1P, N-Phenyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395108-24-4P 395108-25-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indazole derivs. as JNK enzyme inhibitors)

IT 395100-29-5P, tert-Butyl 3-[[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]propanoate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 57614-16-1P, 5-Methyl-3-phenyl-1H-indazole 57614-63-8P, 5-Fluoro-3-phenyl-1H-indazole 395099-04-4P, 3-Phenyl-5-trifluoromethyl-1H-indazole 395099-06-6P, 3-Phenyl-5-(phenylmethoxy)-1H-indazole 395099-10-2P, 3-Phenyl-1H-indazol-5-ol 395099-11-3P, N-(3-Phenyl-1H-indazol-5-yl)benzamide 395099-12-4P, N-(3-Phenyl-1H-indazol-5-yl)-2-pyridinecarboxamide 395099-18-0P, 4-[N-(3-Phenyl-1H-indazol-5-yl)carbamoyl]benzoic acid 395099-19-1P, N-(3-Phenyl-1H-indazol-5-yl)-2-Hydroxybenzamide 395099-22-6P, N-[3-Phenyl-1H-indazol-5-yl]acetamide 395099-23-7P, N-(3-Phenyl-1H-indazol-5-yl)-4-aminobenzamide 395099-26-0P, N-(3-Phenyl-1H-indazol-5-yl)-3-aminobenzamide 395099-31-7P, 5-Nitro-3-[3-(trifluoromethyl)phenyl]-1H-indazole 395099-34-0P, 5-Nitro-3-(3-nitrophenyl)-1H-indazole 395099-36-2P, 3-(1-Naphthyl)-5-nitro-1H-indazole 395099-37-3P, 3-(2-Naphthyl)-5-nitro-1H-indazole 395099-38-4P, 3-(5-Nitro-1H-indazol-3-yl)furan 395099-39-5P, 3-Ethoxy-1-(5-nitro-1H-indazol-3-yl)benzene 395099-40-8P, 3-[3-Isopropylphenyl]-5-nitro-1H-indazole 395099-41-9P, 3-[4-Isopropylphenyl]-5-nitro-1H-indazole 395099-42-0P, 5-Nitro-3-(3-phenylphenyl)-1H-indazole 395099-43-1P, 5-Nitro-3-(4-phenylphenyl)-1H-indazole 395099-45-3P, 5-Amino-3-(3,4-dimethoxyphenyl)-1H-indazole mono(trifluoroacetate) 395099-46-4P, 5-Amino-3-(4-methoxyphenyl)-1H-indazole monohydrochloride 395099-47-5P, 3-[3-(Trifluoromethyl)phenyl]-1H-indazol-5-ylamine 395099-48-6P, 3-(4-Fluorophenyl)-1H-indazol-5-ylamine 395099-50-0P, Ethyl[3-(4-fluorophenyl)-1H-indazol-5-yl]amine 395099-51-1P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methylbenzamide 395099-53-3P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methoxybenzamide 395099-54-4P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-phenylbenzamide 395099-55-5P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]benzo[b]thiophene-2-carboxamide 395099-56-6P, [3-(4-Fluorophenyl)-1H-indazol-5-yl](phenylsulfonyl)amine 395099-57-7P, Methyl 4-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-58-8P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-pyridinecarboxamide 395099-60-2P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]cyclopropanecarboxamide 395099-61-3P, Methyl 4-[N-[3-(4-

fluorophenyl)-1H-indazol-5-yl]-N-methylcarbamoyl]benzoate 395099-64-6P, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-N-methylcarbamoyl]benzoic acid 395099-65-7P, Methyl 3-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-68-0P, 3-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid 395099-69-1P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-(N-methylcarbamoyl)benzamide 395099-70-4P, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzamide 395099-71-5P, 4-[N-[3-(4-Methoxyphenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid 395099-77-1P, 4-[N-(3-(4-Pyridyl)-1H-indazol-5-yl)carbamoyl]benzoic acid 395099-82-8P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]benzamide 395099-83-9P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3,5-Bis(trifluoromethyl)benzamide 395099-84-0P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-furancarboxamide 395099-85-1P 395099-87-3P, [2-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]phenyl]methyl benzoate 395099-90-8P, [3-(4-Fluorophenyl)-1H-indazol-5-yl](4-pyridylmethyl)amine 395099-91-9P, [3-(4-Fluorophenyl)-1H-indazol-5-yl](3-pyridylmethyl)amine 395099-92-0P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-thiophenecarboxamide 395099-94-2P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]morpholine-4-carboxamide 395099-96-4P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl][(4-fluorophenyl)amino]carboxamide 395099-99-7P, 3-(4-Fluorophenyl)-1H-indazole-5-carboxamide 395100-02-4P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole 395100-04-6P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395100-06-8P, 3-(4-Fluorophenyl)-5-imidazol-2-yl-1H-indazole 395100-08-0P, 3-(4-Fluorophenyl)-5-pyrazol-3-yl-1H-indazole 395100-13-7P, Ethyl 3-(4-fluorophenyl)-1H-indazole-5-carboxylate 395100-14-8P, 5-Benzimidazol-2-yl-3-(4-fluorophenyl)-1H-indazole 395100-16-0P, N-Phenyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-18-2P, N-[2-(Dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-19-3P, Ethyl 1-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]piperidine-4-carboxylate 395100-22-8P, 4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzoic acid 395100-23-9P, 4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzamide 395100-25-1P, 1-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonyl]piperidine-4-carboxylicaci 395100-26-2P, N-(2-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-27-3P, N-(3-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-28-4P, N-(4-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-30-8P, N-(3-Hydroxyphenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-35-3P 395100-37-5P, 4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoic acid 395100-42-2P, N-(3-Aminophenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-44-4P, 2-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]acetic acid 395100-46-6P, 5-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]pentanoic acid 395100-50-2P, 4-[[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]methyl]benzoic acid 395100-54-6P, N-(4-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-58-0P, 2-[4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetic acid 395100-62-6P, N,N-Dimethyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-63-7P, N-Methyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-65-9P, N-(2-Aminoethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-68-2P, N-(3-Aminopropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-70-6P, 3-(4-Fluorophenyl)-1H-indazol-5-yl 1-pyrrolidinyl ketone 395100-72-8P, 3-(4-Fluorophenyl)-1H-indazol-5-yl 1-piperazinyl ketone 395100-78-4P, N-(2-Hydroxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-79-5P, 3-(4-Fluorophenyl)-1H-indazole-5-carbohydroxamic acid 395100-81-9P, N-(2H-1,2,3,4-Tetrazol-5-yl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-83-1P, N-(3-(Morpholin-4-yl)propyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-86-4P, N-(3-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-88-6P 395100-89-7P, N-[2-(1-Methylimidazol-5-yl)ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-91-1P, N-(2-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-

carboxamide 395100-97-7P, N-(2-Carbamoylethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395101-00-5P, N-(3-Carbamoylpropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395101-02-7P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-methyl-4H-1,2,4-triazole 395101-05-0P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-isopropyl-4H-1,2,4-triazole 395101-07-2P, 1-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propan-2-ol 395101-10-7P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-phenyl-4H-1,2,4-triazole 395101-12-9P, 2-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]furan 395101-13-0P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(4-pyridyl)-4H-1,2,4-triazole 395101-14-1P, 3-(4-Chlorophenyl)-5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazole 395101-15-2P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-propyl-4H-1,2,4-triazole 395101-20-9P, 4-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]phenylamine 395101-21-0P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-benzyl-4H-1,2,4-triazole 395101-23-2P, 2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-phenyl-1,3,4-oxadiazole 395101-24-3P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methyl-1,3,4-oxadiazole 395101-40-3P, 5-((1Z)-2-Phenylvinyl)-3-(4-fluorophenyl)-1H-indazole 395101-42-5P, 5-[(1E)-2-(4-Aminophenyl)vinyl]-3-(4-fluorophenyl)-1H-indazole 395101-45-8P, 5-[(1E)-2-(4-Pyridyl)vinyl]-3-(4-fluorophenyl)-1H-indazole 395101-48-1P, (2E)-3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]prop-2-enoic acid 395101-53-8P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]propanoic acid 395101-55-0P, 5-[2-(3-Aminophenyl)ethyl]-3-(4-fluorophenyl)-1H-indazole 395101-57-2P, 4-[2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]ethyl]benzoic acid 395101-58-3P, 3-(4-Fluorophenyl)-5-[2-(2-pyridyl)ethyl]-1H-indazole 395101-59-4P, 3-(4-Fluorophenyl)-5-(2-phenylethyl)-1H-indazole 395101-60-7P, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-phenylethan-1-ol 395101-62-9P, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-phenylethan-1-one 395101-86-7P, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxylic acid 395101-88-9P, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxamide 395101-96-9P, 3-[3-Isopropylphenyl]-1H-indazole-5-carboxamide 395102-01-9P, 3-(3-Furyl)-1H-indazole-5-carboxamide 395102-13-3P, 5-[3-((1E)-2-Phenylvinyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole 395102-17-7P, 5-[3-(3-Pyridyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole 395102-21-3P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]thiophene 395102-23-5P, 5-[3-[4-Isopropylphenyl]-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole 395102-26-8P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]furan 395102-28-0P, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenylamine 395102-30-4P, 5-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane 395102-33-7P, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]thiophene 395102-35-9P, 5-[3-(2-Naphthyl)-1H-indazol-5-yl]-1H-1,2,3,4-tetrazole 395102-36-0P, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-methoxybenzene 395102-37-1P, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-(2-methylpropoxy)benzene 395102-42-8P, 5-[3-(4-Chlorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole 395102-48-4P, 5-[3-(4-Pyridyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole 395102-52-0P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]benzo[b]furan 395102-55-3P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenol 395102-56-4P, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenol 395102-57-5P, 5-[3-(2-Phenylethynyl)-1H-indazol-5-yl]-1H-1,2,3,4-tetrazole 395102-59-7P, 5-[3-(2-Phenylethyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole 395102-61-1P, 5-[3-[3-Isopropylphenyl]-1H-indazol-5-yl]-1H-1,2,4-triazole 395102-63-3P, 4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenol 395102-64-4P, [4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl]dimethylamine 395102-66-6P, 3-[3-((E)-2-Phenylvinyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395102-68-8P, [2-[4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine 395102-70-2P, 3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]furan 395102-72-4P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-methoxybenzene 395102-73-5P, 5-(3-(1-Naphthyl)-1H-indazol-5-yl)-1H-1,2,4-triazole 395102-80-4P, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]thiophene 395102-83-7P, 5-[3-(2-Naphthyl)-1H-indazol-

5-yl]-1H-1,2,4-triazole 395102-85-9P, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenylamine 395102-87-1P, 3-[3-(3,4-Dichlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395102-91-7P, 3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzo[b]thiophene 395102-95-1P, 3-[3-(4-Methylphenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395103-01-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]acetamide 395103-05-6P, 5-[3-(3-Chlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395103-07-8P, 1-[(1E)-2-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]vinyl]-4-methoxybenzene 395103-11-4P, 3-[3-[(1E)-2-(4-Chlorophenyl)vinyl]-1H-indazol-5-yl]-1H-1,2,4-triazole 395103-15-8P, 2-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzo[b]furan 395103-16-9P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-(methylsulfonyl)benzene 395103-18-1P, 3-[3-[(1E)-2-(4-Methylphenyl)vinyl]-1H-indazol-5-yl]-1H-1,2,4-triazole 395103-20-5P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-(methylsulfinyl)benzene 395103-21-6P, 5-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane 395103-25-0P, 4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenylamine 395103-27-2P, 5-[3-[4-(Trifluoromethyl)phenyl]-1H-indazol-5-yl]-1H-1,2,4-triazole 395103-29-4P, [3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl](methylsulfonyl)amine 395103-33-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide 395103-37-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395103-41-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-43-2P, 5-[3-(2-Phenylethynyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395103-45-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395103-46-5P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(3-pyridyl)-4H-1,2,4-triazole 395103-47-6P, 4-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]phenol 395103-48-7P, 2-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]aceticaci 395103-50-1P, 1-[5-[3-(4-Fluorophenyl)1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]ethan-1-ol 395103-51-2P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide 395103-61-4P, 2-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]benzo[b]thiophene 395103-63-6P, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-(2-(morpholin-4-yl)ethoxy)benzene 395103-67-0P, 4-[3-(4-Fluorophenyl)-1H-indazol-5-yl]pyrimidine-2-ylamine 395103-69-2P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395103-72-7P, 3-(3,4-Dimethoxyphenyl)-1H-indazole-5-carboxamide 395103-76-1P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-(1-piperidyl)propanamide 395103-78-3P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-81-8P, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene 395103-85-2P, Ethyl 4-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]butanoate 395103-90-9P, 4-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-1,2-dimethoxybenzene 395103-91-0P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-methoxypropanamide 395103-93-2P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395103-96-5P, 3-(3-Aminophenyl)-1H-indazole-5-carboxamide 395104-02-6P, 3-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propanoic acid 395104-04-8P, 3-[2H-Benzo[d]-1,3-dioxol-5-yl]-1H-indazole-5-carboxamide 395104-06-0P, 5-Methyl-3-(4-fluorophenyl)-1H-indazole 395104-09-3P, [3-[4-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine trifluoroacetate 395104-13-9P, [3-[3-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine trifluoroacetate 395104-15-1P, [3-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine 395104-19-5P, [2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine 395104-21-9P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene 395104-24-2P, [2-[3-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine mono(trifluoroacetate)

395104-28-6P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-pyrrolidinoethoxy)benzene **395104-30-0P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene 395104-32-2P, 1-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]pyrrolidin-2-one 395104-35-5P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperazinylethoxy)benzene bis(trifluoroacetate) 395104-37-7P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(3-piperidinopropoxy)benzene 395104-38-8P, 4-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]-1-acetylpiperazine 395104-43-5P, 2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethylamine mono(trifluoroacetate) 395104-45-7P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-cyclohexylethoxy)benzene 395104-47-9P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-hexahydroazepinoethoxy)benzene 395104-49-1P, N-[4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395104-51-5P, N-Benzyl-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-57-1P, N-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]acetamide 395104-59-3P, 5-[3-(2-Chlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395104-63-9P, N-(2,2-Dimethylpropyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-67-3P, N-(Cyclopropylmethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-70-8P, N-(3-Pyridylmethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-74-2P, [3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl] 4-methyl-1-piperazinyl ketone 395104-75-3P, N-[(4-Fluorophenyl)methyl]-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-77-5P, N-(Indan-2-yl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-79-7P, N-((1R)-1-Indanyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-82-2P, N-((1S)-Indanyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-84-4P, N-((1S,2R)-2-Hydroxyindanyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-86-6P, N-((2S,1R)-2-Hydroxyindanyl)3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-88-8P, N-(1-Methyl-1-phenylethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-90-2P, N-(tert-Butyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-92-4P, N-((1R)-1-Phenylethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-95-7P, [3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl] isoindolin-2-yl ketone 395104-97-9P, N-[2-(Dimethylamino)ethyl]-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-98-0P, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]amine 395104-99-1P, [[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]methyl]dimethylamine 395105-00-7P, N-Isopropyl-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-05-2P, N-(2-Methoxyethyl)-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-06-3P, N-[2-(Dimethylamino)ethyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-07-4P, N-[4-(Dimethylamino)butyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-08-5P, N-[3-(Dimethylamino)propyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-10-9P, N-(2-Methylpropyl)-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-11-0P, N-Methyl-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-12-1P, 1-[[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]methyl]piperidin-4-ol

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 395105-14-3P, 1-Acetyl-4-[[5-[3-(4-fluorophenyl)-1H-indazol-5-yl](4H-1,2,4-triazol-3-yl)]methyl]piperazine 395105-15-4P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-(2S)-2-hydroxypropanamide 395105-16-5P, (1S)-1-[N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-19-8P, 3-[3-(3-Pyridylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-21-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-

piperidylpropanamide 395105-23-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-hydroxypropanamide 395105-26-7P, 3-[3-(2-Methoxyacetylamino)phenyl]-1H-indazole-5-carboxamide 395105-29-0P, 3-[3-(4-Piperidylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-32-5P, (1S)-1-[N-[3-(5-Carbamoyl-1H-indazol-3-yl)phenyl]carbamoyl]ethyl acetate 395105-34-7P, 3-[3-[(2-Methoxyethyl)amino]phenyl]-1H-indazole-5-carboxamide 395105-36-9P, 3-[3-(3-Piperidylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395105-38-1P, 3-[3-(2-Furylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-40-5P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(dimethylamino)acetamide 395105-43-8P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]butanamide 395105-45-0P, (2E)-N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-phenylprop-2-enamide 395105-47-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395105-50-7P, 3-[3-[2-(Dimethylamino)acetylamino]phenyl]-1H-indazole-5-carboxamide 395105-53-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide 395105-55-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]cyclopropanecarboxamide 395105-57-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-indol-3-yl-2-oxoacetamide 395105-59-6P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-6-chloro-3-pyridinecarboxamide 395105-63-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]cyclopentanecarboxamide 395105-65-4P, [N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]carbamoyl]formic acid 395105-68-7P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]benzo[b]thiophen-2-carboxamide 395105-71-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-pyridinecarboxamide 395105-73-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-furancarboxamide 395105-75-6P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide 395105-78-9P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]isoxazole-5-carboxamide 395105-80-3P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(2-furyl)-2-oxoacetamide 395105-83-6P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-oxo-2-phenylacetamide 395105-85-8P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]pentanamide 395105-87-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-pyridinecarboxamide 395105-90-5P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-cyclohexylacetamide 395105-92-7P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-phenylpropanamide 395105-94-9P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(4-fluorophenyl)acetamide 395105-96-1P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-(2R)-2-hydroxy-2-phenylacetamide 395105-98-3P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-(2S)-2-hydroxy-2-phenylacetamide 395106-01-1P, [2-[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl](1H-1,2,4-triazol-5-yl)]ethyl]dimethylamine 395106-04-4P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-(piperidinomethyl)-1H-1,2,4-triazole 395106-12-4P, Diethyl[[3-[3-(4-fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]amine 395106-13-5P, 4-[[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]morpholine 395106-16-8P, 4-[[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1,3,4-oxadiazol-2-yl]methyl]morpholine 395106-17-9P, 1-[[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]pyrrolidin-2-one 395106-20-4P, [[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]methylamine 395106-21-5P, [1-[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]ethyl]dimethylamine 395106-24-8P, (2R)-N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide 395106-29-3P, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide 395106-34-0P 395106-35-1P, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-methylbutanamide 395106-37-3P, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-

pyridinecarboxamide 395106-40-8P, 3-[3-(2-Phenylacetylamino)phenyl]-1H-indazole-5-carboxamide 395106-41-9P, 3-[3-[2-(4-Methoxyphenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-43-1P, 3-[3-[2-(2-Methyl-1,3-thiazol-5-yl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-46-4P, 3-[3-(Oxolan-3-ylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395106-48-6P, 3-[3-[2-(3-Thienyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-50-0P, 3-[3-(2-Thienylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395106-51-1P, 3-[3-[2-(4-Pyridyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-52-2P, 3-[3-[2-(2-Pyridyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-54-4P, 3-[3-[2-(4-Fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-55-5P, 3-[3-(Cyclopropylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395106-56-6P, 3-[3-[(3-Hydroxyphenyl)carbonylamino]phenyl]-1H-indazole-5-carboxamide 395106-57-7P, 3-[3-[2-(2,4-Dichlorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-58-8P, 3-[3-[2-[4-(Trifluoromethyl)phenyl]acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-59-9P, 3-[3-[2-[4-(Dimethylamino)phenyl]acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-60-2P, 3-[3-[2-(2-Chloro-4-fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-62-4P, 3-[3-[2-(4-Chlorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-63-5P, 3-[3-(3-Phenylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395106-64-6P, 3-[3-[3-(4-Fluorophenyl)propanoylamino]phenyl]-1H-indazole-5-carboxamide 395106-65-7P, 3-[3-[2-(3,4-Difluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-66-8P, 3-[3-[2-(2-Fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-68-0P, 3-[3-(2-Phenylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395106-69-1P, 3-[3-(2-Piperidinoethoxy)phenyl]-1H-indazole-5-carboxamide 395106-73-7P, N-Ethyl-3-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]propanamide 395106-74-8P, N-[(4-Fluorophenyl)methyl]-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395106-81-7P, N-tert-Butyl-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395106-84-0P, N-((1R)-Indanyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395106-87-3P, [[3-[3-(4-Methoxyphenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-90-8P, [[3-[3-(2H-Benzo[d]-1,3-dioxol-5-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-92-0P, N-(3-Methoxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395106-93-1P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1,2,4-oxadiazolin-5-one 395106-98-6P, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]methan-1-ol 395107-01-4P, N-(2-Piperidinoethyl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide 395107-07-0P, [[5-[3-(Benzo[d]furan-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]methyl]dimethylamine 395107-09-2P, N-Phenyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide 395107-12-7P, N-(4-Fluorophenyl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide dihydrochloride 395107-16-1P, N-(Indan-2-yl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide 395107-19-4P, N-Cyclopropyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide 395107-24-1P, N-Cyclobutyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide dihydrochloride 395107-27-4P, N-[4-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395107-32-1P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(2-methoxyethoxy)benzene 395107-33-2P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(3-pyridylmethoxy)benzene 395107-34-3P, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]benzoic acid 395107-35-4P, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395107-36-5P, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395107-37-6P, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide

395107-38-7P, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(dimethylamino)acetamide 395107-39-8P, [4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl](methylsulfonyl)amine 395107-40-1P, N-(2-Methoxyethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-42-3P, N-Phenyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-43-4P, N-(2-Phenethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-44-5P, N-(2-Piperidylethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-45-6P, 3-[3-[N-(2-Piperidinoethyl)carbamoyl]phenyl]-1H-indazole-5-carboxamide 395107-47-8P, N-[2-(Morpholin-4-yl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-48-9P, N-Cyclohexyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-49-0P, N-Cyclopentyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-51-4P, N-(4-Fluorophenyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-53-6P, N-[2-(1-Benzyl-4-piperidyl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-55-8P 395107-57-0P, N-Cyclopropyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-59-2P, N-(3-Pyridyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-61-6P, N-(5,6,7,8-Tetrahydronaphthyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-63-8P, N-[1-Benzyl-4-piperidyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-65-0P, N-[1-Benzylpyrrolidin-3-yl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-67-2P, N-Isopropyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-69-4P, N-Cyclobutyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-70-7P, N-(4-Pyridyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-72-9P, N-(2-Hydroxyethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395107-73-0P, N-(3-Hydroxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395107-74-1P, N-(2-Methoxyethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395107-76-3P, N-[(Oxolan-2-yl)methyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395107-82-1P 395107-91-2P, 6-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-2-methoxynaphthalene 395107-92-3P, 3-[3-(3-Quinolyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395107-94-5P, 3-[2,3-Dihydrobenzo[b]furan-5-yl]-1H-indazole-5-carboxamide 395107-98-9P, 5-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-2,3-dihydrobenzo[b]furan 395107-99-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]benzamide 395108-01-7P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2,4-dichlorobenzamide 395108-03-9P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-methoxybenzamide 395108-05-1P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-methylbenzamide 395108-06-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-chlorobenzamide 395108-07-3P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methylpropanamide 395108-08-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-methylbutanamide 395108-10-8P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(morpholin-4-yl)acetamide 395108-11-9P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(4-methylpiperazino)acetamide 395108-12-0P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-[(4-pyrrolidinopiperidino)methyl]-1H-1,2,4-triazole 395108-14-2P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole 395108-16-4P, [[3-[3-(6-Methoxy-2-naphthyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395108-17-5P, 2-Methoxy-6-[5-[5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]naphthalene 395108-19-7P, N-Phenyl-3-[5-[5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395108-23-3P 395108-26-6P, N-(3-Oxo-3-pyrrolidinopropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395108-28-8P, 3-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]-N-methylpropanamide 395108-29-9P, 3-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]-N,N-dimethylpropanamide 395108-30-2P 716320-95-5P 716320-96-6P 716320-98-8P 716320-99-9P 716321-00-5P 716321-01-6P 716321-02-7P 716321-03-8P 716321-05-0P 716321-06-1P 716321-07-2P 716321-08-3P 716321-09-4P 716321-10-7P 716321-11-8P 716321-12-9P

716321-13-0P 716321-14-1P 716321-15-2P 716321-16-3P 716321-17-4P
716321-18-5P 716321-19-6P 716321-20-9P 716321-21-0P 716321-22-1P
716321-23-2P 716321-24-3P 716321-25-4P 716321-26-5P 716321-27-6P
716321-28-7P 716321-29-8P 716321-30-1P 716321-31-2P 716321-32-3P
716321-33-4P 716321-34-5P 716321-35-6P 716321-36-7P 716321-37-8P
716321-38-9P 716321-39-0P 716321-40-3P 716321-41-4P 716321-42-5P
716321-43-6P 716321-44-7P 716321-45-8P 716321-46-9P 716321-47-0P
716321-48-1P 716321-49-2P 716321-50-5P 716321-51-6P 716321-52-7P
716321-53-8P 716321-54-9P 716321-55-0P 716321-56-1P 716321-57-2P
716321-58-3P 716321-59-4P 716321-60-7P 716321-61-8P 716321-62-9P
716321-63-0P 716321-64-1P 716321-65-2P 716321-66-3P 716321-67-4P
716321-68-5P 716321-69-6P 716321-70-9P 716321-71-0P 716321-72-1P
716321-73-2P 716321-74-3P 716321-75-4P 716321-76-5P 716321-77-6P
716321-78-7P 716321-79-8P 716321-80-1P 716321-81-2P 716321-82-3P
716321-83-4P 716321-84-5P 716321-85-6P 716321-86-7P 716321-87-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 716321-88-9P 716321-89-0P 716321-90-3P 716321-91-4P 716321-92-5P
716321-93-6P 716321-94-7P 716321-95-8P 716321-96-9P 716321-97-0P
716321-98-1P 716321-99-2P 716322-00-8P 716322-01-9P 716322-02-0P
716322-03-1P 716322-04-2P 716322-05-3P 716322-06-4P 716322-07-5P
716322-08-6P 716322-09-7P 716322-10-0P 716322-11-1P 716322-12-2P
716322-13-3P 716322-14-4P 716322-15-5P 716322-16-6P 716322-17-7P
716322-18-8P 716322-19-9P 716322-20-2P 716321-21-3P 716322-22-4P
716322-23-5P 716322-24-6P 716322-25-7P 716322-26-8P 716322-27-9P
716322-28-0P 716322-29-1P 716322-30-4P 716322-31-5P 716322-32-6P
716322-33-7P 716322-34-8P 716322-35-9P 716322-36-0P 716322-37-1P
716322-38-2P 716322-39-3P 716322-40-6P 716322-41-7P 716322-42-8P
716322-43-9P 716322-44-0P 716322-45-1P 716322-46-2P 716322-47-3P
716322-48-4P 716322-49-5P 716322-50-8P 716321-51-9P 716322-52-0P
716322-53-1P 716322-54-2P 716322-55-3P 716322-56-4P 716322-57-5P
716322-62-2P 716322-63-3P 716322-64-4P 716322-65-5P 716322-66-6P
716322-67-7P 716322-68-8P 716322-69-9P 716322-70-2P 716322-71-3P
716322-72-4P 716322-73-5P 716322-76-8P 716322-77-9P 716322-78-0P
716322-79-1P 716322-80-4P 716322-81-5P 716322-82-6P 716322-83-7P
716322-84-8P 716322-85-9P 716322-86-0P 716322-87-1P 716322-88-2P
716322-89-3P 716322-90-6P 716322-91-7P 716322-92-8P 716322-93-9P
716322-94-0P 716322-95-1P 716322-96-2P 716322-97-3P 716322-98-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 556-24-1 595-37-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 5856-77-9P 24310-18-7P 716320-97-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 13097-01-3P, 3-Phenyl-1H-indazole 55271-06-2P, 3-(4-Methoxyphenyl)-1H-indazole 155590-27-5P, 3-(4-Fluorophenyl)-1H-indazole 395098-98-3P, 3-(4-Hydroxyphenyl)-1H-indazole 395099-01-1P, 3-(2-Methoxyphenyl)-1H-indazole
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 54-85-3, Isonicotinic acid hydrazide 64-04-0, Phenethylamine 67-51-6, 3,5-Dimethylpyrazole 75-31-0, Isopropylamine, reactions 75-64-9, tert-Butylamine, reactions 76-83-5, Triphenylmethyl chloride 78-77-3, 1-Bromo-2-methylpropane 78-81-9, Isobutylamine 78-96-6, 1-Amino-2-propanol 79-30-1, 2-Methylpropanoyl chloride 88-74-4, 2-Nitroaniline 89-75-8, 2,4-Dichlorobenzoyl chloride 96-32-2, Methyl

bromoacetate 98-09-9, Phenylsulfonyl chloride 98-88-4, Benzoyl chloride 99-06-9, 3-Hydroxybenzoic acid, reactions 99-09-2, 3-Nitroaniline 100-07-2, 4-Methoxybenzoyl chloride 100-20-9, Terephthalic acid chloride 100-42-5, Styrene, reactions 100-43-6, 4-Vinylpyridine 100-55-0, 3-Pyridylcarbinol 100-69-6, 2-Vinylpyridine 103-80-0, Phenylacetyl chloride 103-82-2, Phenylacetic acid, reactions 104-01-8, 4-Methoxyphenylacetic acid 104-58-5, 3-Piperidinopropanol 106-40-1, 4-Bromoaniline 108-00-9, N,N-Dimethylethylenediamine 108-01-0, N,N-Dimethylethanolamine 108-12-3, 3-Methylbutanoyl chloride 108-91-8, Cyclohexylamine, reactions 109-01-3, N-Methylpiperazine 109-55-7, 3-Dimethylaminopropylamine 109-85-3, 2-Methoxyethylamine 121-90-4, 3-Nitrobenzoyl chloride 122-01-0, 4-Chlorobenzoyl chloride 122-04-3 122-78-1, Phenylacetaldehyde 123-00-2, 4-(3-Aminopropyl)morpholine 123-75-1, Pyrrolidine, reactions 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl acrylate 141-75-3, Butanoyl chloride 142-26-7, 2-N-Acetylaminoethanol 156-87-6, 3-Amino-1-propanol 271-44-3, 1H-Indazole 342-24-5, 2-Fluorobenzophenone 371-40-4, 4-Fluoroaniline 403-43-0, 4-Fluorobenzoyl chloride 405-50-5, 2-(4-Fluorophenyl)acetic acid 451-82-1, 2-Fluorophenylacetic acid 459-31-4, 3-(4-Fluorophenyl)propanoic acid 462-08-8, 3-Aminopyridine 488-93-7, Furan-3-carboxylic acid 492-37-5, 2-Phenylpropionic acid 496-12-8, Isoindoline 501-52-0, Hydrocinnamic acid 504-24-5, 4-Aminopyridine 504-29-0, 2-Aminopyridine 527-69-5, 2-Furoyl chloride 527-72-0, 2-Thiophenecarboxylic acid 535-17-1, 2-Acetoxypropionic acid 536-40-3, 4-Chlorobenzoic hydrazide 536-74-3, Phenylacetylene 547-64-8, Methyl lactate 553-53-7, Nicotinic hydrazide 585-32-0, Cumylamine 586-39-0, 3-Nitrostyrene 591-27-5, 3-Aminophenol 611-73-4, 2-Oxo-2-phenylacetic acid 613-94-5, Benzoic hydrazide 619-45-4, Methyl 4-aminobenzoate 622-40-2, 4-(2-Hydroxyethyl)morpholine 636-97-5, 4-Nitrobenzoic hydrazide 638-29-9, Pentanoyl chloride 644-42-8, 3-Methylhistamine 645-45-4, 3-Phenylpropanoyl chloride 658-93-5, 3,4-Difluorophenylacetic acid 661-69-8, Hexamethylditin 765-30-0, Cyclopropylamine 785-56-8, 3,5-Bis(trifluoromethyl)benzoyl chloride 870-46-2, tert-Butyl carbazate 874-60-2, 4-Methylbenzoyl chloride 937-39-3, Phenylacetic hydrazide 940-31-8, 2-Phenoxypropionic acid 1003-03-8, Cyclopentylamine 1075-49-6, 4-Vinylbenzoic acid 1126-09-6, Ethyl 4-piperidinecarboxylate 1194-02-1, 4-Fluorobenzonitrile 1195-45-5, 4-Fluorophenyl isocyanate 1423-26-3, 3-Trifluoromethylphenylboronic acid 1467-70-5, 2-(2-Furyl)-2-oxoacetic acid 1520-21-4, 4-Vinylaniline 1679-18-1, 4-Chlorophenylboronic acid 1679-64-7, Terephthalic acid monomethyl ester 1692-15-5, 4-Pyridylboronic acid 1692-25-7, 3-Pyridylboronic acid 1759-53-1, Cyclopropanecarboxylic acid 1765-93-1, 4-Fluorophenylboronic acid 1877-71-0, Isophthalic acid monomethyl ester 1986-47-6, trans-2-Phenylcyclopropylamine hydrochloride 2008-75-5, 1-(2-Chloroethyl)piperidine monohydrochloride 2038-03-1, 4-(2-Aminoethyl)morpholine 2133-40-6 2208-07-3, Ethyl acetimidate hydrochloride 2217-40-5, 1,2,3,4-Tetrahydro-1-naphthylamine 2338-18-3, 2-Aminoindan hydrochloride 2491-06-7, N,N-Dimethylglycine hydrochloride 2516-34-9, Cyclobutylamine 2516-47-4, Cyclopropylmethylamine 2544-06-1, 3-Methoxypropionic acid 2627-86-3, (S)-(-)-α-Methylbenzylamine 2835-68-9, 4-Aminobenzamide 2955-88-6, 2-Pyrrolidinoethanol 2975-41-9, 2-Aminoindane 3024-72-4, 3,4-Dichlorobenzoyl chloride 3040-44-6, 2-Piperidinoethanol 3179-63-3, 3-N,N-Dimethylaminopropanol 3290-99-1, 4-Methoxybenzhydrazide 3326-71-4, 2-Furoic acid hydrazide 3445-11-2, 1-(2-Hydroxyethyl)pyrrolidin-2-one 3529-10-0, 4-Dimethylaminobutylamine 3538-65-6, Butyric acid hydrazide 3619-17-8, Isobutyric acid hydrazide 3731-51-9, 2-Aminomethylpyridine 3731-52-0, 3-Aminomethylpyridine 3731-53-1, 4-(Aminomethyl)pyridine 3853-06-3, Methyl 3-(dimethylamino)propanoate 3886-69-9, (R)-(+)-α-Methylbenzylamine 3900-89-8, 2-Chlorophenylboronic acid 3970-21-6, (2-Methoxyethoxy)methyl chloride 4023-34-1, Cyclopropylcarbonyl chloride 4442-79-9,

2-(Cyclohexyl)ethanol 4524-93-0, Cyclopentanecarbonyl chloride 4795-29-3, Tetrahydrofurfurylamine 5122-94-1, 4-Phenylphenylboronic acid 5122-95-2, 3-Phenylphenylboronic acid 5271-67-0, 2-Thiophenecarbonyl chloride 5292-21-7, 2-Cyclohexylacetic acid 5332-24-1, 3-Bromoquinoline 5332-73-0, 3-Methoxypropylamine 5382-16-1, 4-Hydroxypiperidine 5401-94-5, 5-Nitro-1H-indazole 5405-41-4, Ethyl 3-hydroxybutyrate 5438-70-0, Ethyl (4-aminophenyl)acetate 5445-17-0, Methyl 2-bromopropanoate 5538-51-2, Acetyl salicyloyl chloride 5691-09-8, trans-2-Aminomethyl-1-cyclohexanol 5720-05-8, 4-Methylphenylboronic acid 5720-06-9, 2-Methoxyphenylboronic acid 5720-07-0, 4-Methoxyphenylboronic acid 5781-53-3, Methyl (chlorocarbonyl)formate 5813-64-9, 2,2-Dimethylpropylamine 6034-46-4, (S)-(-)-2-Acetoxypropionic acid 6165-68-0, 2-Thiopheneboronic acid 6165-69-1, 3-Thiopheneboronic acid 6456-74-2, tert-Butyl glycinate 6482-24-2, 2-Bromo-1-methoxyethane 6622-91-9, 4-Pyridylacetic acid hydrochloride 6783-05-7, trans-2-Phenylethenylboronic acid 6964-21-2, 3-Thiopheneacetic acid 7065-46-5, 3,3-Dimethylbutanoyl chloride 7171-96-2, N-Amino-2-pyrrolidinoacetamide 7322-88-5, (2S)-2-Acetyloxy-2-phenylacetic acid 7377-26-6, Methyl 4-carboxybenzoyl chloride 10277-74-4, (R)-(-)-1-Aminoindane 10365-98-7, 3-Methoxyphenylboronic acid 10400-19-8, Pyridine-3-carbonyl chloride 13031-60-2, Methyl 4-aminobutyrate hydrochloride 13331-23-2, 2-Furanboronic acid 13331-27-6, 3-Nitrophenylboronic acid 13515-93-0, Methyl 2-(methylamino)acetate hydrochloride 13797-62-1, 2-(2-Methyl-1,3-thiazol-4-yl)acetic acid 13889-98-0, 1-Acetylpiperazine 13922-41-3, 1-Naphthylboronic acid 14002-51-8, 4-Phenylbenzoyl chloride 14794-31-1, Ethyl succinyl chloride 15159-40-7, Morpholine-4-carbonyl chloride 16152-51-5, 4-Isopropylphenylboronic acid 16179-97-8, 2-Pyridylacetic acid hydrochloride 17078-28-3, 4-(Dimethylamino)phenylacetic acid 17082-09-6, (2E)-3-Phenylprop-2-enoyl chloride 17852-28-7, 2-Amino-5-methylphenyl phenyl ketone 18469-52-8, Methyl 4-(aminomethyl)benzoate 18471-40-4, 1-Benzyl-3-aminopyrrolidine 18668-00-3, (R)-2-Acetoxypropionic acid 19335-11-6, 5-Aminoindazole 19719-28-9, 2,4-Dichlorophenylacetic acid 20260-53-1, Pyridine-3-carbonyl chloride hydrochloride 20603-00-3, 2-(Perhydroazepino)ethanol 21615-34-9, 2-Methoxybenzoyl chloride 22980-09-2, 2-(Indol-3-yl)-2-oxoacetyl chloride 26371-07-3, 1-Piperidinepropionic acid 27578-60-5, 1-(2-Aminoethyl)piperidine 28611-39-4, 4-(N,N-Dimethylamino)phenylboronic acid 29745-44-6, Pyridine-2-carbonyl chloride 30280-35-4, Methyl 2-(diethylamino)acetate 30418-59-8, 3-Aminophenylboronic acid 32316-92-0, 2-Naphthylboronic acid 32857-62-8, 4-(Trifluoromethyl)phenylacetic acid 34052-37-4, 2-Chloro-5-nitrobenzophenone 35855-10-8, Methyl 2-(morpholin-4-yl)acetate 38870-89-2, 2-Methoxyacetyl chloride 39178-35-3, Pyridine-4-carbonyl chloride hydrochloride 39256-35-4, N-Amino-2-(phenylmethoxy)acetamide 39827-11-7, 2-Benzo[b]thiophene-2-carbonyl chloride 39901-94-5, Picolinoyl chloride hydrochloride 50541-93-0, 4-Amino-1-benzylpiperidine 51019-43-3, (R)-2-Acetoxy-2-phenylacetic acid 55552-70-0, 3-Furanboronic acid 57260-71-6, tert-Butyl 1-piperazine carboxylate 57260-73-8, N-(2-Aminoethyl)carbamic acid tert-butyl ester 58249-87-9, [2-(Chlorocarbonyl)phenyl]methyl benzoate 58583-90-7, Methyl 2-piperidinoacetate 58620-93-2, H-β-Ala-O-tert-butyl hydrochloride 58757-38-3, 6-Chloropyridine-3-carbonyl chloride 59776-88-4, Methyl 2-(2-oxopyrrolidinyl)acetate 61341-86-4, (S)-(+)-1-Aminoindane 62348-13-4, Isoxazole-5-carbonyl chloride 63984-02-1, Methyl 5-aminovalerate 71597-85-8, 4-Hydroxybenzeneboronic acid 72316-18-8 75178-96-0 76652-88-5, (S)-2-Acetylpropionic acid 77279-24-4, 2-[4-(tert-Butyloxycarbonyl)piperazino]ethanol 77987-49-6, 2-[N-(Benzyloxycarbonyl)amino]ethanol 84358-13-4, 1-[(tert-Butyl)oxycarbonyl]piperidine-4-carboxylic acid 85068-36-6, 2,5-Difluorobenzophenone 86945-25-7, 4-(2-Aminoethyl)-1-benzylpiperidine 87199-18-6, 3-Hydroxyphenylboronic acid 88443-78-1, 3-

Acetoxyphenylacetyl chloride 89364-31-8, Tetrahydro-3-furoic acid 89415-43-0, 4-Aminophenylboronic acid 90555-66-1, 3-Ethoxyphenylboronic acid 91713-56-3, 2-Amino-5-methylphenyl 4-fluorophenyl ketone 94839-07-3, 3,4-(Methylenedioxy)phenylboronic acid 98431-09-5, Ethyl glutaryl chloride 98437-23-1, Benzo[b]thiophene-2-boronic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of indazole derivs. as JNK enzyme inhibitors)

IT 98437-24-2 98546-51-1, 4-(Methylthio)phenylboronic acid 99769-19-4, 3-(Carbomethoxy)phenylboronic acid 122775-35-3, 3,4-Dimethoxyphenylboronic acid 126456-43-7, (1S,2R)-(-)-cis-1-Amino-2-indanol 128796-39-4, 4-Trifluoromethylphenylboronic acid 136030-00-7, (1R,2S)-(+)-cis-1-Amino-2-indanol 151169-75-4, 3,4-Dichlorophenylboronic acid 154230-29-2, trans-2-(4-Chlorophenyl)ethenylboronic acid 156641-98-4, 6-Methoxynaphthalene-2-boronic acid 164014-95-3 177985-32-9, 2-Chloro-4-fluorophenylacetic acid 199292-40-5, 2-Fluoro-5-trifluoromethylbenzophenone 214360-73-3, 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 216019-28-2, 3-Isopropylphenylboronic acid 227305-69-3, 2,3-Dihydrobenzo[b]furan-5-boronic acid 395099-08-8, N-[4-Hydroxy-2-(phenylcarbonyl)phenyl]benzamide 395099-15-7, 1-Acetyl-5-amino-3-phenyl-1H-indazole 395099-49-7, 1-[[3-(4-Fluorophenyl)-5-nitro-1H-indazol-1-yl]methoxy]-2-methoxyethane 395099-52-2, 1-[[3-(4-Fluorophenyl)-5-amino-1H-indazol-1-yl]methoxy]-2-methoxyethane 395099-67-9, 2-[3-(4-Fluorophenyl)-5-amino-1H-indazol-1-yl]perhydro-2H-pyran 395099-73-7, 2-(3-Bromo-5-nitro-1H-indazol-1-yl)perhydro-2H-pyran 395099-97-5, 3-(4-Fluorophenyl)-1-(2-methoxyethoxy)-1H-indazol-5-ylamine 395100-09-1, 3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-81-5, 3-(3-Thienyl)-1H-indazole-5-carboxamide 395102-93-9, 3-(Benzo[b]thiophen-3-yl)-1H-indazole-5-carboxamide 395103-84-1, Ethoxy[[3-(4-fluorophenyl)-1H-indazol-5-yl]methyl]amine monohydrochloride 395105-02-9, Ethyl 3-bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylate 395106-75-9, Methyl 3-(5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoate 395106-77-1, 3-(5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoic acid 395107-00-3, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine dihydrochloride 395107-31-0, 3-[5-(1H-1,2,4-Triazol-3-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenol 395108-13-1, Methyl 2-(4-pyrrolidinopiperidino)acetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of indazole derivs. as JNK enzyme inhibitors)

IT **395104-30-0P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as JNK enzyme inhibitors)

RN 395104-30-0 HCAPLUS
CN 1H-Indazole, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:107318 HCAPLUS
DN 136:151163

ED Entered STN: 10 Feb 2002
TI Preparation of indazole derivatives as JNK enzyme inhibitors
IN Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 412 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D231-00
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010137	A2	20020207	WO 2001-US23890	20010730
	WO 2002010137	C2	20030206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1313711	A2	20030528	EP 2001-957332	20010730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004513882	T2	20040513	JP 2002-516269	20010730
	NZ 524045	A	20040730	NZ 2001-524045	20010730
PRAI	US 2000-221799P	P	20000731		
	WO 2001-US23890	W	20010730		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002010137	ICM	C07D231-00
JP 2004513882	FTERM	4C063/AA01; 4C063/AA03; 4C063/BB01; 4C063/BB02; 4C063/BB03; 4C063/BB09; 4C063/CC22; 4C063/CC25; 4C063/CC26; 4C063/CC29; 4C063/CC41; 4C063/CC47; 4C063/CC51; 4C063/CC58; 4C063/CC62; 4C063/CC75; 4C063/CC76; 4C063/CC81; 4C063/CC82; 4C063/CC92; 4C063/CC94; 4C063/DD10; 4C063/DD12; 4C063/DD14; 4C063/DD22; 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC37; 4C086/BC38; 4C086/BC39; 4C086/BC42; 4C086/BC50; 4C086/BC60; 4C086/BC62; 4C086/BC67; 4C086/BC71; 4C086/BC73; 4C086/BC82; 4C086/GA02; 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA09; 4C086/GA10; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA02; 4C086/ZA06; 4C086/ZA15; 4C086/ZA16; 4C086/ZA36; 4C086/ZA40; 4C086/ZA45; 4C086/ZA59; 4C086/ZA66; 4C086/ZA68; 4C086/ZA75; 4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB05; 4C086/ZB07; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB26; 4C086/ZB27; 4C086/ZC31; 4C086/ZC35; 4C086/ZC54

OS MARPAT 136:151163
AB Indazole derivs., 3-R1A-5-R2-1H-indazoles (1), having activity as selective inhibitors of JNK are disclosed. In 1: A is a direct bond, -(CH2)a-, -(CH2)bCH:CH(CH2)c-, or -(CH2)bC.tplbond.C(CH2)c-; R1 is aryl, heteroaryl or heterocycle fused to Ph, each being optionally substituted with 1-4 R3; R2 is -R3, -R4, -(CH2)bC(O)R5, -(CH2)bC(:O)OR5, -(CH2)bC(O)NR5R6, -(CH2)bC(O)NR5(CH2)cC(O)R6, -(CH2)bNR5C(O)R6, -(CH2)bNR5C(O)NR6R7, -(CH2)bNR5R6, -(CH2)bOR5, -(CH2)bSOdR5 or

-(CH2)bSO2NR5R6. A is 1-6; b and c are the same or different and are 0-4; d is 0-2. R3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(O)OR8, -C(O)R8, -C(O)NR8R9, -C(O)NR8OR9, -SO2NR8R9, -NR8SO2R9, -CN, -NO2, -NR8R9, -NR8C(O)R9, -NR8C(O)(CH2)bOR9, -NR8C(O)(CH2)bR9, -O(CH2)bNR5R9, or heterocycle fused to Ph. R4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with 1-4 R3, or R4 is halogen or hydroxy. R5, R6and R7 are the same or different and are H, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R5, R6 and R7 are optionally substituted with 1-4 R3. R8 and R9 are the same or different and at each occurrence independently H, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R8 and R9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R8, R9, and R8 and R9 taken together to form a heterocycle are optionally substituted with 1-4 R3 with the proviso that: when A is a direct bond and R1 is Ph, R2 is not Me, methoxy, C(O)CH3 or C(O)H; when A is a direct bond and R1 is 4-Me-Ph, R2 is not Me; when A is a direct bond and R1 is 4-F-Ph, R2 is not trifluoromethyl; when A is a direct bond or -C.tplbond.C- and R1 is Ph, R2 is not -COOEt; and when A is a direct bond and R1 is 6,7-dimethoxyisoquinolin-1-yl, R2 is not hydroxy. Such compds. have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds. Many of the claimed compds. have IC50 values ≤0.5 μM in the JNK2 assay, e.g. 5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole. Although the methods of preparation are not claimed, >400 example prepns. are included.

ST indazole deriv prepn Jun N terminal kinase inhibitor; JNK enzyme inhibitor indazole deriv prepn

IT Intestine, disease
(Crohn's; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)

IT Nervous system, disease
(Huntington's chorea; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)

IT Antidiabetic agents
(Type II; preparation of indazole derivs. as JNK enzyme inhibitors useful as)

IT Nose, disease
(allergic rhinitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of indazole derivs. as JNK enzyme inhibitors useful as)

IT Antitumor agents
(bladder; preparation of indazole derivs. as JNK enzyme inhibitors useful as)

IT Antitumor agents
(blood; preparation of indazole derivs. as JNK enzyme inhibitors useful as)

IT Antitumor agents
(brain; preparation of indazole derivs. as JNK enzyme inhibitors useful as)

IT Antitumor agents
(bronchi; preparation of indazole derivs. as JNK enzyme inhibitors useful as)

IT Bronchi, disease
(bronchitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)

IT Uterus, neoplasm
(cervix, inhibitors; preparation of indazole derivs. as JNK enzyme inhibitors useful as)

IT Antitumor agents
(cervix; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Lung, disease
(chronic obstructive; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Intestine, disease
(colitis, mucous; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Intestine, neoplasm
(colon, inhibitors; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Antitumor agents
(colon; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Esophagus, disease
(esophagitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Antitumor agents
(esophagus; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Drug delivery systems
(for indazole derivs. useful as JNK enzyme inhibitors)
IT Stomach, disease
(gastritis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Transplant and Transplantation
(graft-vs.-host reaction; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Antitumor agents
(head; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Heart, disease
(infarction, therapeutic agents; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Intestine, disease
(inflammatory; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Brain, neoplasm
Kidney, neoplasm
Lung, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Skin, neoplasm
Stomach, neoplasm
Uterus, neoplasm
(inhibitors; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Intestine, disease
(irritable bowel syndrome; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Antitumor agents
(kidney; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Antitumor agents
(larynx tumor inhibitors; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Heart, disease
(left ventricle, hypertrophy; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Antitumor agents
(liver; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Antitumor agents
(lung; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Antitumor agents
(mouth; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Antitumor agents

(neck; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Bladder
Bronchi
Esophagus
Head
Mouth
Neck, anatomical
Prostate gland
(neoplasm, inhibitors; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Kidney, disease
(nephritis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Heterocyclic compounds
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nitrogen, five-membered, indazoles; preparation of indazole derivs. as JNK enzyme inhibitors)
IT Antitumor agents
(ovary; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Antitumor agents
(pancreas; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Pancreas, disease
(pancreatitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Antitumor agents
(pharynx; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Anticonvulsants
Antiparkinsonian agents
Antirheumatic agents
Antitumor agents
Cytotoxic agents
(preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Organ preservation
(preparation of indazole derivs. as JNK enzyme inhibitors useful for)
IT Burn
Cachexia
Cystic fibrosis
Dermatitis
Eczema
Hepatitis
Lupus erythematosus
Multiple organ failure
Psoriasis
Transplant rejection
(preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Antitumor agents
(prostate gland; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Intestine, neoplasm
(rectum, inhibitors; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Antitumor agents
(rectum; preparation of indazole derivs. as JNK enzyme inhibitors useful as)

IT Artery, disease
(restenosis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Shock (circulatory collapse)
(septic; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Antitumor agents
(skin; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Transplant and Transplantation
(skin; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Spinal column, disease
(spondylitis, rheumatoid; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Antitumor agents
(stomach; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Brain, disease
(stroke; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Multiple sclerosis
(therapeutic agents; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Skin
(transplant; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Larynx
(tumor inhibitors; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT Intestine, disease
(ulcerative colitis; preparation of indazole derivs. as JNK enzyme inhibitors useful in treating)
IT Antitumor agents
(uterus; preparation of indazole derivs. as JNK enzyme inhibitors useful as)
IT 155215-87-5, JNK 289899-93-0, JNK2 291756-39-3, JNK3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of indazole derivs. as JNK enzyme inhibitors)
IT 293758-67-5P, 5-Nitro-3-phenyl-1H-indazole 395099-05-5P, 5-Amino-3-phenyl-1H-indazole 395099-16-8P, Methyl 4-[N-(3-phenyl-1H-indazol-5-yl)carbamoyl]benzoate 395099-28-2P, 3-(4-Methoxyphenyl)-5-nitro-1H-indazole 395099-32-8P, 3-(3,4-Dimethoxyphenyl)-5-nitro-1H-indazole 395099-59-9P, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid 395099-86-2P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-hydroxybenzamide 395099-88-4P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-pyridinecarboxamide 395099-89-5P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-pyridinecarboxamide 395100-10-4P, 3-(4-Fluorophenyl)-1H-indazole-5-carboxylic acid 395100-21-7P, Methyl 4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzoate 395100-32-0P, 3-[[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]propanoic acid 395100-33-1P, N-(3-Nitrophenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-76-2P, N-(Phenylmethoxy)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-93-3P, N-[(tert-Butoxy)carbonylamino]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-95-5P, N-Amino-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395101-17-4P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(4-nitrophenyl)-4H-1,2,4-triazole 395101-18-5P, 1-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]-4-methoxybenzene 395101-19-6P, Ethyl 2-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]acetate 395101-25-4P, 3-(4-Fluorophenyl)-5-(2-phenylethynyl)-1H-indazole 395101-30-1P, 5-((1E)-2-Phenylvinyl)-3-(4-fluorophenyl)-1H-indazole 395101-32-3P, 5-[(1E)-2-(2-Pyridyl)vinyl]-3-(4-fluorophenyl)-1H-indazole 395101-36-7P, 4-[(1E)-2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]vinyl]benzoic acid 395101-38-9P, 5-[(1E)-2-(3-Nitrophenyl)vinyl]-3-(4-fluorophenyl)-1H-

indazole 395101-52-7P, Ethyl (2E)-3-[3-(4-fluorophenyl)-1H-indazol-5-yl]prop-2-enoate 395101-66-3P, 3-(4-Methoxyphenyl)-1H-indazole-5-carboxamide 395101-72-1P, 3-(4-Hydroxyphenyl)-1H-indazole-5-carboxamide 395101-78-7P, 3-(2-Naphthyl)-1H-indazole-5-carboxamide 395101-82-3P, Methyl 3-benzo[b]thiophen-2-yl-1H-indazole-5-carboxylate 395101-92-5P, 3-(Benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395101-97-0P, 3-[4-(Dimethylamino)phenyl]-1H-indazole-5-carboxamide 395102-02-0P, 3-(2-Phenylethynyl)-1H-indazole-5-carboxamide 395102-08-6P, 3-[4-[2-(Dimethylamino)ethoxy]phenyl]-1H-indazole-5-carboxamide 395102-09-7P, 1-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-2-methoxybenzene 395102-46-2P, 1-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-3-methoxybenzene 395103-58-9P, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]ethan-1-one 395103-83-0P, Ethyl 3-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propanoate 395104-41-3P 395107-78-5P 395107-84-3P, 3-(3-Quinolyl)-1H-indazole-5-carboxamide 395107-88-7P, 3-(6-Methoxy-2-naphthyl)-1H-indazole-5-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of indazole derivs. as JNK enzyme inhibitors)

IT 55-85-6P, N-Amino-2-(dimethylamino)acetamide 770-17-2P, N-Amino-2-(morpholin-4-yl)acetamide 2644-33-9P, N-Amino-2-(diethylamino)acetamide 7408-09-5P, N-Amino-2-piperidinoacetamide 22636-79-9P, N-Amino-3-(dimethylamino)propanamide 24534-93-8P, 3-Hydroxybutyric acid hydrazide 24632-72-2P, 2-(4-Acetylpiperazino)-N-aminoacetamide 37115-47-2P, N-Amino-2-(methylamino)acetamide 40598-94-5P, 3-Bromo-1H-indazole 59776-89-5P, N-Amino-2-(2-oxopyrrolidinyl)acetamide 66544-68-1P 67400-25-3P, 3-Bromo-5-nitro-1H-indazole 74626-47-4P, 1H-Indazole-5-carbonitrile 146137-79-3P, 4-Fluoro-3-formylbenzenecarbonitrile 395098-99-4P, 3-Bromo-1-[(2-methoxyethoxy)methyl]-1H-indazole 395099-00-0P, 1-[(2-Methoxyethoxy)methyl]-3-(4-methoxyphenyl)-1H-indazole 395099-02-2P, 1-[(2-Methoxyethoxy)methyl]-3-(2-methoxyphenyl)-1H-indazole 395099-03-3P, 3-(4-Fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazole 395099-07-7P, N-[2-(Phenylcarbonyl)-4-(phenylmethoxy)phenyl]benzamide 395099-09-9P, 2-Amino-5-(phenylmethoxy)phenyl phenyl ketone 395099-14-6P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)-2-pyridinecarboxamide 395099-17-9P, Methyl 4-[N-(1-acetyl-3-phenyl-1H-indazol-5-yl)carbamoyl]benzoate 395099-20-4P, 2-[N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)carbamoyl]phenyl acetate 395099-21-5P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)acetamide 395099-24-8P, N-[1-Acetyl-3-phenyl-1H-indazol-5-yl]-4-nitrobenzamide 395099-25-9P, N-(1-Acetyl-3-phenyl-1H-indazol-5-yl)-4-aminobenzamide 395099-27-1P, N-[1-Acetyl-3-phenyl-1H-indazol-5-yl]-3-nitrobenzamide 395099-29-3P, 3-Bromo-1-[(2-methoxyethoxy)methyl]-5-nitro-1H-indazole 395099-30-6P, 1-[(2-Methoxyethoxy)methyl]-3-(4-methoxyphenyl)-5-nitro-1H-indazole 395099-33-9P, 3-(3,4-Dimethoxyphenyl)-1-[(2-methoxyethoxy)methyl]-5-nitro-1H-indazole 395099-35-1P, 1-[(2-Methoxyethoxy)methyl]-5-nitro-3-(3-nitrophenyl)-1H-indazole 395099-62-4P, Methyl 4-[N-[3-(4-fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazol-5-yl]carbamoyl]benzoate 395099-63-5P, Methyl 4-[N-[3-(4-fluorophenyl)-1-[(2-methoxyethoxy)methyl]-1H-indazol-5-yl]-N-methylcarbamoyl]benzoate 395099-66-8P, Methyl 3-[N-[3-(4-fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-72-6P, 4-Methoxy-1-[5-nitro-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzene 395099-74-8P, 3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-ylamine 395099-75-9P, Methyl 4-[N-[3-(4-methoxyphenyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-76-0P, Methyl 4-[N-[3-(4-methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-78-2P, 2-[5-Nitro-3-(4-pyridyl)-1H-indazol-1-yl]perhydro-2H-pyran 395099-79-3P, 1-(Perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazol-5-ylamine 395099-80-6P, Methyl 4-[N-[1-(perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-81-7P, Methyl 4-[N-[3-(4-pyridyl)-1H-indazol-5-

yl]carbamoyl]benzoate 395100-00-2P, 1-Acetyl-3-(4-fluorophenyl)-1H-indazole-5-carbonyl chloride 395100-11-5P, 4-Fluoro-3-[(4-fluorophenyl)carbonyl]benzenecarbonitrile 395100-12-6P, 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile 395100-39-7P, Methyl 4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoate 395100-41-1P, Methyl 4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoate 395100-43-3P, N-(3-Nitrophenyl)-1-acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-48-8P 395100-52-4P, Methyl 4-[[[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]methyl]benzoate 395100-56-8P, N-(4-Pyridylmethyl)-1-acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-59-1P, Ethyl 2-[4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetate 395100-60-4P, Ethyl 2-[4-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetate 395100-66-0P, N-[2-[(tert-Butoxy)carbonylamino]ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-69-3P, N-[3-[(tert-Butoxy)carbonylamino]propyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-73-9P, tert-Butyl 4-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]piperazine-1-carboxylate 395100-74-0P, 1-Acetyl-3-(4-fluorophenyl)-5-(1-piperazinylcarbonyl)-1H-indazole 395100-84-2P, 1-Acetyl-3-(4-fluorophenyl)-1H-indazole-5-carboxylic acid 395100-98-8P, tert-Butyl 3-[[1-acetyl-3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]propanoate 395101-04-9P, N-[(1-Iminoethyl)amino]-3-(4-fluorophenyl)indene-5-carboxamide 395101-06-1P, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine hydrochloride 395101-26-5P, 2-Amino-5-bromo-4'-fluorobenzophenone 395101-27-6P, 5-Bromo-3-(4-fluorophenyl)-1H-indazole 395101-28-7P, 5-Bromo-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-29-8P, 3-(4-Fluorophenyl)-5-(2-phenylethynyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-31-2P, 5-((1E)-2-Phenylvinyl)-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-34-5P, 5-[(1E)-2-(2-Pyridyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-37-8P, 4-[(1E)-2-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]vinyl]benzoic acid 395101-44-7P, 5-[(1E)-2-(4-Aminophenyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-46-9P, 5-[(1E)-2-(4-Pyridyl)vinyl]-3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazole 395101-50-5P, Ethyl (2E)-3-[3-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]prop-2-enoate 395101-61-8P, 1-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-2-phenylethan-1-ol 395101-64-1P, 1-[3-(4-Fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-2-phenylethan-1-one 395101-67-4P, 3-Bromo-1H-indazole-5-carbonitrile 395101-69-6P, 3-Bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-70-9P, 3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-71-0P, 3-(4-Methoxyphenyl)-1H-indazole-5-carbonitrile 395101-74-3P, 3-(4-Hydroxyphenyl)-1-perhydro-2H-pyran-2-yl-1H-indazole-5-carbonitrile 395101-77-6P, 3-(4-Hydroxyphenyl)-1H-indazole-5-carbonitrile 395101-79-8P, 3-(2-Naphthyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-80-1P, 3-(2-Naphthyl)-1H-indazole-5-carbonitrile 395101-84-5P, 3-Bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395101-85-6P, 3-Benzo[b]thiophen-2-yl-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395101-89-0P, 3-Benzo[b]thiophen-2-yl-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395101-91-4P, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carbonitrile 395101-94-7P, 3-(Benzo[d]furan-2-yl)-1-perhydro-2H-pyran-2-yl-1H-indazole-5-carbonitrile 395101-95-8P, 3-(Benzo[d]furan-2-yl)-1H-indazole-5-carbonitrile 395101-98-1P, 3-[4-(Dimethylamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-00-8P, 3-[4-(Dimethylamino)phenyl]-1H-indazole-5-carbonitrile 395102-04-2P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-phenylethynyl)-1H-indazole-5-carbonitrile 395102-06-4P, 3-(2-Phenylethynyl)-1H-indazole-5-carbonitrile 395102-11-1P, 3-(2-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-12-2P, 3-(2-Methoxyphenyl)-1H-indazole-5-carbonitrile 395102-14-4P, 3-((1E)-2-Phenylvinyl)-1-(perhydro-2H-pyran-2-

yl)-1H-indazole-5-carbonitrile 395102-15-5P, 3-((1E)-2-Phenylvinyl)-1H-indazole-5-carbonitrile 395102-19-9P, 1-(Perhydro-2H-pyran-2-yl)-3-(3-pyridyl)-1H-indazole-5-carbonitrile 395102-20-2P, 3-(3-Pyridyl)-1H-indazole-5-carbonitrile 395102-22-4P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-thienyl)-1H-indazole-5-carbonitrile 395102-24-6P, 3-[4-Isopropylphenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-27-9P, 3-(2-Furyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-29-1P, 3-(3-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-31-5P, 3-(2H-Benzo[d]-1,3-dioxolan-5-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-32-6P, 3-(2H-Benzo[d]-1,3-dioxolan-5-yl)-1H-indazole-5-carbonitrile 395102-34-8P, 1-(Perhydro-2H-pyran-2-yl)-3-(3-thienyl)-1H-indazole-5-carbonitrile 395102-38-2P, 3-[4-(2-Methylpropoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-40-6P, 3-[4-(2-Methylpropoxy)phenyl]-1H-indazole-5-carbonitrile 395102-44-0P, 3-(4-Chlorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-47-3P, 3-(3-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-50-8P, 1-(Perhydro-2H-pyran-2-yl)-3-(4-pyridyl)-1H-indazole-5-carbonitrile 395102-60-0P, 1-(Perhydro-2H-pyran-2-yl)-3-(2-phenylethyl)-1H-indazole-5-carbonitrile 395102-75-7P, 3-(1-Naphthyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-77-9P, 3-(1-Naphthyl)-1H-indazole-5-carbonitrile 395102-79-1P, 3-(1-Naphthyl)-1H-indazole-5-carboxamide 395102-89-3P, 3-(3,4-Dichlorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-96-2P, (2E)-2-Aza-3-(dimethylamino)-1-[3-bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]prop-2-en-1-one 395102-97-3P, 2-[5-(1H-1,2,4-Triazol-3-yl)-3-bromo-1H-indazol-1-yl]perhydro-2H-pyran 395102-98-4P 395102-99-5P, 2-[3-(4-Methylphenyl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-03-4P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenylamine 395103-09-0P, 1-[(1E)-2-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]vinyl]-4-methoxybenzene 395103-13-6P, 2-[3-[(1E)-2-(4-Chlorophenyl)vinyl]-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-17-0P, 4-Methylthio-1-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzene 395103-19-2P, 2-[3-[(1E)-2-(4-Methylphenyl)vinyl]-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-1-yl]perhydro-2H-pyran 395103-23-8P, 5-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]-2H-benzo[d]-1,3-dioxolane 395103-31-8P, (Methylsulfonyl)[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]amine 395103-35-2P, 2-Methoxy-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395103-40-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395103-42-1P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-44-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395103-52-3P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-3-bromo-1H-indazolyl]perhydro-2H-pyran 395103-53-4P, 2-[3-Bromo-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazolyl]perhydro-2H-pyran 395103-54-5P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazol-3-yl]phenylamine 395103-56-7P, 2-Methoxy-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[2-(triphenylmethyl)-2H-1,2,3,4-tetrazol-5-yl]-1H-indazol-3-yl]phenyl]acetamide 395103-60-3P, 1-[3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]ethan-1-one 395103-65-8P, 3-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]-1H-indazole-5-carbonitrile 395103-71-6P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395103-73-8P, 3-(3,4-Dimethoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395103-74-9P, 3-(3,4-Dimethoxyphenyl)-1H-indazole-5-carbonitrile 395103-77-2P,

N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-(1-piperidyl)propanamide 395103-80-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-82-9P, 3-(3-Hydroxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395103-87-4P, Ethyl 3-(N-aminocarbamoyl)propanoate 395103-88-5P, Ethyl 4-(N-aminocarbamoyl)butanoate 395103-92-1P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-methoxypropanamide 395103-94-3P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazole-3-yl]phenyl]-3-pyridinecarboxamide 395103-98-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide 395104-11-7P, 3-[4-[3-(Dimethylamino)propoxy]phenyl]-1H-indazole-5-carbonitrile 395104-14-0P, 3-[3-[3-(Dimethylamino)propoxy]phenyl]-1H-indazole-5-carbonitrile 395104-16-2P, 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenol 395104-26-4P, 3-[4-[2-(Dimethylamino)ethoxy]phenyl]-1H-indazole-5-carbonitrile 395104-34-4P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(2-piperazinoethoxy)benzene 395104-50-4P, 4-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenylamine 395104-53-7P, Methyl 3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzoate 395104-55-9P, N-Benzyl-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-61-7P 395104-65-1P, N-(2,2-Dimethylpropyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-68-4P, N-(Cyclopropylmethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-72-0P, N-(3-Pyridylmethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-76-4P, N-[(4-Fluorophenyl)methyl]-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-78-6P, N-(Indan-2-yl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-81-1P, N-((1R)-Indanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-83-3P, N-((1S)-Indanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-85-5P, N-((1S,2R)-2-Hydroxyindanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazole-3-yl]benzamide 395104-87-7P, N-((1R,2S)-2-Hydroxyindanyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-89-9P, N-(1-Methyl-1-phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-91-3P, N-(tert-Butyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazole-3-yl]benzamide 395104-93-5P, N-((1R)-1-Phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-94-6P, N-((1S)-1-Phenylethyl)-3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395104-96-8P, Isoindolin-2-yl 3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl ketone 395105-01-8P, Ethyl 3-(benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylate 395105-03-0P, 3-(Benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylic acid 395105-04-1P, N-Isopropyl-3-(benzo[d]furan-2-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-13-2P, N-Amino-2-(4-hydroxypiperidyl)acetamide 395105-17-6P, (1S)-1-[N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-20-1P, 1-(Perhydro-2H-pyran-2-yl)-3-[3-(3-pyridylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-22-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-piperidylpropanamide 395105-25-6P, 1-[N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-27-8P, 3-(3-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-

carboxamide 395105-28-9P, 3-[3-(2-Methoxyacetamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-30-3P, tert-Butyl 4-[N-[3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]piperidine-1-carboxylate 395105-31-4P, tert-Butyl 4-[N-[3-(5-carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)phenyl]carbamoyl]piperidine-1-carboxylate 395105-33-6P, (1S)-1-[N-[3-[5-Carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-35-8P, 3-[3-[(2-Methoxyethyl)amino]phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-37-0P, 1-(Perhydro-2H-pyran-2-yl)-3-[3-(3-piperidylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395105-39-2P, 3-[3-(2-Furylcarbonylamino)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-41-6P, 2-(Dimethylamino)-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-44-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]butanamide 395105-46-1P, (2E)-N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-phenylprop-2-enamide 395105-48-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395105-51-8P, 3-[3-[2-(Dimethylamino)acetylamino]phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395105-54-1P

, 3,3-Dimethyl-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]butanamide 395105-56-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]cyclopropanecarboxamide 395105-58-5P, 2-(Indol-3-yl)-2-oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-61-0P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-6-chloro-3-pyridinecarboxamide 395105-64-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]cyclopentanecarboxamide 395105-66-5P, Methyl[N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]formate 395105-69-8P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]benzo[b]thiophene-2-carboxamide 395105-72-3P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-pyridinecarboxamide 395105-74-5P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-furancarboxamide 395105-76-7P, [N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]carbamoyl]phenylmethyl acetate 395105-79-0P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]isoxazole-5-carboxamide 395105-81-4P, N-((1S)-1-Phenylethyl)-3-[5-(1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395105-82-5P, 2-(2-Furyl)-2-oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-84-7P, 2-Oxo-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395105-86-9P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]pentanamide 395105-88-1P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-4-pyridinecarboxamide 395105-91-6P, 2-Cyclohexyl-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-93-8P, N-[3-[1-(Perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-phenylpropanamide 395105-95-0P, 2-(4-Fluorophenyl)-N-[3-[1-(perhydro-2H-pyran-2-yl)-5-[1-(triphenylmethyl)-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]acetamide 395105-97-2P 395106-03-3P, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine 395106-23-7P, N-Amino-2-(dimethylamino)propanamide 395106-25-9P, (1R)-[N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-

yl]phenyl]carbamoyl]phenylmethyl acetate 395106-27-1P, (2R)-N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide hydrochloride 395106-31-7P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide 395106-32-8P, N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide hydrochloride 395106-36-2P 395106-38-4P, N-[3-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-methylbutanamide 395106-39-5P, N-[3-[5-(Ethoxyiminomethyl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide hydrochloride 395106-70-4P, 3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395106-71-5P, 3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide 395106-79-3P, N-[(4-Fluorophenyl)methyl]-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-80-6P, N-[(4-Fluorophenyl)methyl]-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-82-8P, N-(tert-Butyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-83-9P, N-(tert-Butyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenylcarboxamide 395106-85-1P, N-((1R)-Indanyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-86-2P, N-((1R)-Indanyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395106-88-4P, [[3-[3-(4-Methoxyphenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-91-9P, [[3-[3-(2H-Benzo[d]-1,3-dioxol-5-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-94-2P, [3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl](hydroxyimino)methylamine 395106-96-4P, 2-Amino-1-aza-2-[3-(4-fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]vinyl ethoxyformate 395106-97-5P, 3-[3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-5-yl]-1,2,4-oxadiazolin-5-one 395106-99-7P, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl](phenylmethoxy)methane 395107-03-6P, N-(2-Piperidinoethyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395107-05-8P, N-(2-Piperidinoethyl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide trihydrochloride 395107-08-1P 395107-11-6P, N-Phenyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indazole derivs. as JNK enzyme inhibitors)

IT 395107-13-8P, N-(4-Fluorophenyl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395107-15-0P, N-(4-Fluorophenyl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-17-2P, N-(Indan-2-yl)-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395107-18-3P, N-(Indan-2-yl)-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-20-7P, N-Cyclopropyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395107-22-9P, N-Cyclopropyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-25-2P, N-Cyclobutyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395107-26-3P, N-Cyclobutyl-3-[5-(ethoxyiminomethyl)-1H-indazol-3-yl]benzamide dihydrochloride 395107-28-5P, 3-(4-Aminophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395107-29-6P, N-[4-[5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395107-30-9P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]-3-(2-methoxyethoxy)benzene 395107-46-7P, Methyl 3-(5-carbamoyl-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoate 395107-80-9P 395107-86-5P, 3-(1,1-Dimethyl-1-stannaethyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395107-90-1P, 3-(6-Methoxy-2-naphthyl)-1H-indazole-5-carbonitrile 395107-96-7P, 3-(2,3-Dihydrobenzo[b]furan-5-yl)-1H-indazole-5-carbonitrile 395108-15-3P, Ethoxy[3-(6-methoxy-2-naphthyl)-1H-indazol-5-yl]methanimine 395108-20-0P, N-Phenyl-3-[5-(ethoxyiminomethyl)-1H-

indazol-3-yl]benzamide 395108-21-1P, N-Phenyl-3-[5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]benzamide 395108-24-4P 395108-25-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indazole derivs. as JNK enzyme inhibitors)

IT 395100-29-5P, tert-Butyl 3-[[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]propanoate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 57614-16-1P, 5-Methyl-3-phenyl-1H-indazole 57614-63-8P, 5-Fluoro-3-phenyl-1H-indazole 395099-04-4P, 3-Phenyl-5-trifluoromethyl-1H-indazole 395099-06-6P, 3-Phenyl-5-(phenylmethoxy)-1H-indazole 395099-10-2P, 3-Phenyl-1H-indazol-5-ol 395099-11-3P, N-(3-Phenyl-1H-indazol-5-yl)benzamide 395099-12-4P, N-(3-Phenyl-1H-indazol-5-yl)-2-pyridinecarboxamide 395099-18-0P, 4-[N-(3-Phenyl-1H-indazol-5-yl)carbamoyl]benzoic acid 395099-19-1P, N-(3-Phenyl-1H-indazol-5-yl)-2-Hydroxybenzamide 395099-22-6P, N-[3-Phenyl-1H-indazol-5-yl]acetamide 395099-23-7P, N-(3-Phenyl-1H-indazol-5-yl)-4-aminobenzamide 395099-26-0P, N-(3-Phenyl-1H-indazol-5-yl)-3-aminobenzamide 395099-31-7P, 5-Nitro-3-[3-(trifluoromethyl)phenyl]-1H-indazole 395099-34-0P, 5-Nitro-3-(3-nitrophenyl)-1H-indazole 395099-36-2P, 3-(1-Naphthyl)-5-nitro-1H-indazole 395099-37-3P, 3-(2-Naphthyl)-5-nitro-1H-indazole 395099-38-4P, 3-(5-Nitro-1H-indazol-3-yl)furan 395099-39-5P, 3-Ethoxy-1-(5-nitro-1H-indazol-3-yl)benzene 395099-40-8P, 3-[3-Isopropylphenyl]-5-nitro-1H-indazole 395099-41-9P, 3-[4-Isopropylphenyl]-5-nitro-1H-indazole 395099-42-0P, 5-Nitro-3-(3-phenylphenyl)-1H-indazole 395099-43-1P, 5-Nitro-3-(4-phenylphenyl)-1H-indazole 395099-45-3P, 5-Amino-3-(3,4-dimethoxyphenyl)-1H-indazole mono(trifluoroacetate) 395099-46-4P, 5-Amino-3-(4-methoxyphenyl)-1H-indazole monohydrochloride 395099-47-5P, 3-[3-(Trifluoromethyl)phenyl]-1H-indazol-5-ylamine 395099-48-6P, 3-(4-Fluorophenyl)-1H-indazol-5-ylamine 395099-50-0P, Ethyl[3-(4-fluorophenyl)-1H-indazol-5-yl]amine 395099-51-1P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methylbenzamide 395099-53-3P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methoxybenzamide 395099-54-4P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-phenylbenzamide 395099-55-5P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]benzo[b]thiophene-2-carboxamide 395099-56-6P, [3-(4-Fluorophenyl)-1H-indazol-5-yl](phenylsulfonyl)amine 395099-57-7P, Methyl 4-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-58-8P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-pyridinecarboxamide 395099-60-2P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]cyclopropanecarboxamide 395099-61-3P, Methyl 4-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]-N-methylcarbamoyl]benzoate 395099-64-6P, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-N-methylcarbamoyl]benzoic acid 395099-65-7P, Methyl 3-[N-[3-(4-fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoate 395099-68-0P, 3-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid 395099-69-1P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4-(N-methylcarbamoyl)benzamide 395099-70-4P, 4-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]benzamide 395099-71-5P, 4-[N-[3-(4-Methoxyphenyl)-1H-indazol-5-yl]carbamoyl]benzoic acid 395099-77-1P, 4-[N-(3-(4-Pyridyl)-1H-indazol-5-yl)carbamoyl]benzoic acid 395099-82-8P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]benzamide 395099-83-9P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3,5-Bis(trifluoromethyl)benzamide 395099-84-0P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-furancarboxamide 395099-85-1P 395099-87-3P, [2-[N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbamoyl]phenyl]methyl benzoate 395099-90-8P, [3-(4-Fluorophenyl)-1H-indazol-5-yl](4-pyridylmethyl)amine 395099-91-9P, [3-(4-Fluorophenyl)-1H-indazol-5-yl](3-pyridylmethyl)amine 395099-92-0P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-thiophenecarboxamide 395099-94-2P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]morpholine-4-carboxamide 395099-96-4P, N-[3-(4-Fluorophenyl)-1H-

indazol-5-yl][(4-fluorophenyl)amino]carboxamide 395099-99-7P,
3-(4-Fluorophenyl)-1H-indazole-5-carboxamide 395100-02-4P,
5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole
395100-04-6P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole
395100-06-8P, 3-(4-Fluorophenyl)-5-imidazol-2-yl-1H-indazole
395100-08-0P, 3-(4-Fluorophenyl)-5-pyrazol-3-yl-1H-indazole
395100-13-7P, Ethyl 3-(4-fluorophenyl)-1H-indazole-5-carboxylate
395100-14-8P, 5-Benzimidazol-2-yl-3-(4-fluorophenyl)-1H-indazole
395100-16-0P, N-Phenyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide
395100-18-2P, N-[2-(Dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-19-3P, Ethyl 1-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]piperidine-4-carboxylate 395100-22-8P, 4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzoic acid 395100-23-9P,
4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]benzamide
395100-25-1P, 1-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonyl]piperidine-4-carboxylic acid 395100-26-2P, N-(2-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-27-3P, N-(3-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-28-4P, N-(4-Pyridyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-30-8P, N-(3-Hydroxyphenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-35-3P 395100-37-5P,
4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]butanoic acid
395100-42-2P, N-(3-Aminophenyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-44-4P, 2-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]acetic acid 395100-46-6P, 5-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]pentanoic acid 395100-50-2P,
4-[[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]methyl]benzoic acid
395100-54-6P, N-(4-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-58-0P, 2-[4-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]phenyl]acetic acid 395100-62-6P, N,N-Dimethyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-63-7P,
N-Methyl-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-65-9P,
N-(2-Aminoethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide
395100-68-2P, N-(3-Aminopropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-70-6P, 3-(4-Fluorophenyl)-1H-indazol-5-yl
1-pyrrolidinyl ketone 395100-72-8P, 3-(4-Fluorophenyl)-1H-indazol-5-yl
1-piperazinyl ketone 395100-78-4P, N-(2-Hydroxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-79-5P,
3-(4-Fluorophenyl)-1H-indazole-5-carbohydroxamic acid 395100-81-9P,
N-(2H-1,2,3,4-Tetrazol-5-yl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide
395100-83-1P, N-(3-(Morpholin-4-yl)propyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-86-4P, N-(3-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-88-6P 395100-89-7P, N-[2-(1-Methylimidazol-5-yl)ethyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide
395100-91-1P, N-(2-Pyridylmethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395100-97-7P, N-(2-Carbamoylethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395101-00-5P, N-(3-Carbamoylpropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395101-02-7P,
5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-methyl-4H-1,2,4-triazole
395101-05-0P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-isopropyl-4H-1,2,4-triazole 395101-07-2P, 1-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propan-2-ol 395101-10-7P,
5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-phenyl-4H-1,2,4-triazole
395101-12-9P, 2-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]furan 395101-13-0P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(4-pyridyl)-4H-1,2,4-triazole 395101-14-1P, 3-(4-Chlorophenyl)-5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazole 395101-15-2P,
5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-propyl-4H-1,2,4-triazole
395101-20-9P, 4-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]phenylamine 395101-21-0P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-benzyl-4H-1,2,4-triazole 395101-23-2P, 2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-phenyl-1,3,4-oxadiazole 395101-24-3P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-methyl-1,3,4-oxadiazole 395101-40-3P,
5-((1Z)-2-Phenylvinyl)-3-(4-fluorophenyl)-1H-indazole 395101-42-5P,

5-[(1E)-2-(4-Aminophenyl)vinyl]-3-(4-fluorophenyl)-1H-indazole
395101-45-8P, 5-[(1E)-2-(4-Pyridyl)vinyl]-3-(4-fluorophenyl)-1H-indazole
395101-48-1P, (2E)-3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]prop-2-enoic acid
395101-53-8P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]propanoic acid
395101-55-0P, 5-[2-(3-Aminophenyl)ethyl]-3-(4-fluorophenyl)-1H-indazole
395101-57-2P, 4-[2-[3-(4-Fluorophenyl)-1H-indazol-5-yl]ethyl]benzoic acid
395101-58-3P, 3-(4-Fluorophenyl)-5-[2-(2-pyridyl)ethyl]-1H-indazole
395101-59-4P, 3-(4-Fluorophenyl)-5-(2-phenylethyl)-1H-indazole
395101-60-7P, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-phenylethan-1-ol
395101-62-9P, 1-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-2-phenylethan-1-one
395101-86-7P, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxylic acid
395101-88-9P, 3-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxamide
395101-96-9P, 3-[3-Isopropylphenyl]-1H-indazole-5-carboxamide
395102-01-9P, 3-(3-Furyl)-1H-indazole-5-carboxamide 395102-13-3P,
5-[3-((1E)-2-Phenylvinyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole
395102-17-7P, 5-[3-(3-Pyridyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole
395102-21-3P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]thiophene
395102-23-5P, 5-[3-[4-Isopropylphenyl]-1H-indazol-5-yl]-2H-1,2,3,4-
tetrazole 395102-26-8P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-
yl]furan 395102-28-0P, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-
yl]phenylamine 395102-30-4P, 5-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-
3-yl]-2H-benzo[d]-1,3-dioxolane 395102-33-7P, 3-[5-(2H-1,2,3,4-Tetrazol-
5-yl)-1H-indazol-3-yl]thiophene 395102-35-9P, 5-[3-(2-Naphthyl)-1H-
indazol-5-yl]-1H-1,2,3,4-tetrazole 395102-36-0P, 1-[5-(1H-1,2,3,4-
Tetrazol-5-yl)-1H-indazol-3-yl]-4-methoxybenzene 395102-37-1P,
1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-(2-
methylpropoxy)benzene 395102-42-8P, 5-[3-(4-Chlorophenyl)-1H-indazol-5-
yl]-2H-1,2,3,4-tetrazole 395102-48-4P, 5-[3-(4-Pyridyl)-1H-indazol-5-yl]-
2H-1,2,3,4-tetrazole 395102-52-0P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-
indazol-3-yl]benzo[b]furan 395102-55-3P, 2-[5-(2H-1,2,3,4-Tetrazol-5-yl)-
1H-indazol-3-yl]phenol 395102-56-4P, 3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-
indazol-3-yl]phenol 395102-57-5P, 5-[3-(2-Phenylethynyl)-1H-indazol-5-
yl]-1H-1,2,3,4-tetrazole 395102-59-7P, 5-[3-(2-Phenylethyl)-1H-indazol-5-
yl]-2H-1,2,3,4-tetrazole 395102-61-1P, 5-[3-[3-Isopropylphenyl]-1H-
indazol-5-yl]-1H-1,2,4-triazole 395102-63-3P, 4-[5-(1H-1,2,4-Triazol-5-
yl)-1H-indazol-3-yl]phenol 395102-64-4P, [4-[5-(1H-1,2,4-Triazol-5-yl)-
1H-indazol-3-yl]phenyl]dimethylamine 395102-66-6P, 3-[3-((E)-2-
Phenylvinyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395102-68-8P,
[2-[4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-
yl]phenoxy]ethyl]dimethylamine 395102-70-2P, 3-[5-(1H-1,2,4-Triazol-5-
yl)-1H-indazol-3-yl]furan 395102-72-4P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-
indazol-3-yl]-4-methoxybenzene 395102-73-5P, 5-(3-(1-Naphthyl)-1H-
indazol-5-yl)-1H-1,2,4-triazole 395102-80-4P, 3-[5-(1H-1,2,4-Triazol-3-
yl)-1H-indazol-3-yl]thiophene 395102-83-7P, 5-[3-(2-Naphthyl)-1H-indazol-
5-yl]-1H-1,2,4-triazole 395102-85-9P, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-
indazol-3-yl]phenylamine 395102-87-1P, 3-[3-(3,4-Dichlorophenyl)-1H-
indazol-5-yl]-1H-1,2,4-triazole 395102-91-7P, 3-[5-(1H-1,2,4-Triazol-5-
yl)-1H-indazol-3-yl]benzo[b]thiophene 395102-95-1P, 3-[3-(4-
Methylphenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395103-01-2P,
N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]acetamide
395103-05-6P, 5-[3-(3-Chlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole
395103-07-8P, 1-[(1E)-2-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]vinyl]-
4-methoxybenzene 395103-11-4P, 3-[3-[(1E)-2-(4-Chlorophenyl)vinyl]-1H-
indazol-5-yl]-1H-1,2,4-triazole 395103-15-8P, 2-[5-(1H-1,2,4-Triazol-5-
yl)-1H-indazol-3-yl]benzo[b]furan 395103-16-9P, 1-[5-(1H-1,2,4-Triazol-5-
yl)-1H-indazol-3-yl]-4-(methylsulfonyl)benzene 395103-18-1P,
3-[3-[(1E)-2-(4-Methylphenyl)vinyl]-1H-indazol-5-yl]-1H-1,2,4-triazole
395103-20-5P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-4-
(methylsulfinyl)benzene 395103-21-6P, 5-[5-(1H-1,2,4-Triazol-5-yl)-1H-
indazol-3-yl]-2H-benzo[d]-1,3-dioxolane 395103-25-0P,
4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenylamine 395103-27-2P,
5-[3-[4-(Trifluoromethyl)phenyl]-1H-indazol-5-yl]-1H-1,2,4-triazole
395103-29-4P, [3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-

yl]phenyl](methylsulfonyl)amine 395103-33-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide 395103-37-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395103-41-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-43-2P, 5-[3-(2-Phenylethynyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395103-45-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395103-46-5P, 5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(3-pyridyl)-4H-1,2,4-triazole 395103-47-6P, 4-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]phenol 395103-48-7P, 2-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]acetic acid 395103-50-1P, 1-[5-[3-(4-Fluorophenyl)1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]ethan-1-ol 395103-51-2P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide 395103-61-4P, 2-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]benzo[b]thiophene 395103-63-6P, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-(2-(morpholin-4-yl)ethoxy)benzene 395103-67-0P, 4-[3-(4-Fluorophenyl)-1H-indazol-5-yl]pyrimidine-2-ylamine 395103-69-2P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395103-72-7P, 3-(3,4-Dimethoxyphenyl)-1H-indazole-5-carboxamide 395103-76-1P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-(1-piperidyl)propanamide 395103-78-3P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395103-81-8P, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene 395103-85-2P, Ethyl 4-[5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]butanoate 395103-90-9P, 4-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-1,2-dimethoxybenzene 395103-91-0P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-methoxypropanamide 395103-93-2P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395103-96-5P, 3-(3-Aminophenyl)-1H-indazole-5-carboxamide 395104-02-6P, 3-[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]propanoic acid 395104-04-8P, 3-[2H-Benzo[d]-1,3-dioxol-5-yl]-1H-indazole-5-carboxamide 395104-06-0P, 5-Methyl-3-(4-fluorophenyl)-1H-indazole 395104-09-3P, [3-[4-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine trifluoroacetate 395104-13-9P, [3-[3-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine trifluoroacetate 395104-15-1P, [3-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]propyl]dimethylamine 395104-19-5P, [2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine 395104-21-9P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene 395104-24-2P, [2-[3-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]dimethylamine mono(trifluoroacetate) 395104-28-6P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-pyrrolidinoethoxy)benzene **395104-30-0P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene 395104-32-2P, 1-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]pyrrolidin-2-one 395104-35-5P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperazinylethoxy)benzene bis(trifluoroacetate) 395104-37-7P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(3-piperidinopropoxy)benzene 395104-38-8P, 4-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]-1-acetylpiperazine 395104-43-5P, 2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethylamine mono(trifluoroacetate) 395104-45-7P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-cyclohexylethoxy)benzene 395104-47-9P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-hexahydroazepinoethoxy)benzene 395104-49-1P, N-[4-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl]-2-furancarboxamide 395104-51-5P, N-Benzyl-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-57-1P, N-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]acetamide 395104-59-3P, 5-[3-(2-Chlorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395104-63-9P, N-(2,2-Dimethylpropyl)-3-

[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-67-3P, N-(Cyclopropylmethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-70-8P, N-(3-Pyridylmethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-74-2P, [3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl] 4-methyl-1-piperazinyl ketone 395104-75-3P, N-[(4-Fluorophenyl)methyl]-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-77-5P
, N-(Indan-2-yl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-79-7P, N-((1R)-1-Indanyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-82-2P, N-((1S)-Indanyl)-3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-84-4P, N-((1S,2R)-2-Hydroxyindanyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-86-6P, N-((2S,1R)-2-Hydroxyindanyl)3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-88-8P, N-(1-Methyl-1-phenylethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-90-2P, N-(tert-Butyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-92-4P, N-((1R)-1-Phenylethyl)-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-95-7P, [3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenyl] isoindolin-2-yl ketone 395104-97-9P, N-[2-(Dimethylamino)ethyl]-3-[5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl]benzamide 395104-98-0P, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]amine 395104-99-1P, [[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]methyl]dimethylamine 395105-00-7P, N-Isopropyl-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-05-2P, N-(2-Methoxyethyl)-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-06-3P, N-[2-(Dimethylamino)ethyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-07-4P, N-[4-(Dimethylamino)butyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-08-5P, N-[3-(Dimethylamino)propyl]-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-10-9P, N-(2-Methylpropyl)-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-11-0P, N-Methyl-3-(benzo[d]furan-2-yl)-1H-indazole-5-carboxamide 395105-12-1P, 1-[[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-4H-1,2,4-triazol-3-yl]methyl]piperidin-4-ol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 395105-14-3P, 1-Acetyl-4-[[5-[3-(4-fluorophenyl)-1H-indazol-5-yl](4H-1,2,4-triazol-3-yl)]methyl]piperazine 395105-15-4P, N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-(2S)-2-hydroxypropanamide 395105-16-5P, (1S)-1-[N-[3-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]carbamoyl]ethyl acetate 395105-19-8P, 3-[3-(3-Pyridylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-21-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-piperidylpropanamide 395105-23-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-hydroxypropanamide 395105-26-7P, 3-[3-(2-Methoxyacetylamino)phenyl]-1H-indazole-5-carboxamide 395105-29-0P, 3-[3-(4-Piperidylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-32-5P, (1S)-1-[N-[3-(5-Carbamoyl-1H-indazol-3-yl)phenyl]carbamoyl]ethyl acetate 395105-34-7P, 3-[3-[(2-Methoxyethyl)amino]phenyl]-1H-indazole-5-carboxamide 395105-36-9P, 3-[3-(3-Piperidylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395105-38-1P, 3-[3-(2-Furylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395105-40-5P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(dimethylamino)acetamide 395105-43-8P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]butanamide 395105-45-0P, (2E)-N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-phenylprop-2-enamide 395105-47-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenoxypropanamide 395105-50-7P, 3-[3-[2-(Dimethylamino)acetylamino]phenyl]-1H-indazole-5-carboxamide 395105-53-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide 395105-55-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]cyclopropanecarboxamide 395105-57-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-

yl]phenyl]-2-indol-3-yl-2-oxoacetamide 395105-59-6P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-6-chloro-3-pyridinecarboxamide 395105-63-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]cyclopentanecarboxamide 395105-65-4P, [N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]carbamoyl]formic acid 395105-68-7P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]benzo[b]thiophen-2-carboxamide 395105-71-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-pyridinecarboxamide 395105-73-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-furancarboxamide 395105-75-6P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide 395105-78-9P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]isoxazole-5-carboxamide 395105-80-3P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(2-furyl)-2-oxoacetamide 395105-83-6P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-oxo-2-phenylacetamide 395105-85-8P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]pentanamide 395105-87-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-pyridinecarboxamide 395105-90-5P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-cyclohexylacetamide 395105-92-7P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-phenylpropanamide 395105-94-9P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(4-fluorophenyl)acetamide 395105-96-1P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-(2R)-2-hydroxy-2-phenylacetamide 395105-98-3P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-(2S)-2-hydroxy-2-phenylacetamide 395106-01-1P, [2-[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl](1H-1,2,4-triazol-5-yl)]ethyl]dimethylamine 395106-04-4P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-(piperidinomethyl)-1H-1,2,4-triazole 395106-12-4P, Diethyl[[3-[3-(4-fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]amine 395106-13-5P, 4-[[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]morpholine 395106-16-8P, 4-[[5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1,3,4-oxadiazol-2-yl]methyl]morpholine 395106-17-9P, 1-[[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]pyrrolidin-2-one 395106-20-4P, [[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]methylamine 395106-21-5P, [1-[3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]ethyl]dimethylamine 395106-24-8P, (2R)-N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-2-hydroxy-2-phenylacetamide 395106-29-3P, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3,3-dimethylbutanamide 395106-34-0P 395106-35-1P, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-methylbutanamide 395106-37-3P, N-[3-[5-[5-[(Dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395106-40-8P, 3-[3-(2-Phenylacetylamino)phenyl]-1H-indazole-5-carboxamide 395106-41-9P, 3-[3-[2-(4-Methoxyphenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-43-1P, 3-[3-[2-(2-Methyl-1,3-thiazol-5-yl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-46-4P, 3-[3-(Oxolan-3-ylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395106-48-6P, 3-[3-[2-(3-Thienyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-50-0P, 3-[3-(2-Thienylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395106-51-1P, 3-[3-[2-(4-Pyridyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-52-2P, 3-[3-[2-(2-Pyridyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-54-4P, 3-[3-[2-(4-Fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-55-5P, 3-[3-(Cyclopropylcarbonylamino)phenyl]-1H-indazole-5-carboxamide 395106-56-6P, 3-[3-[(3-Hydroxyphenyl)carbonylamino]phenyl]-1H-indazole-5-carboxamide 395106-57-7P, 3-[3-[2-(2,4-Dichlorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-58-8P, 3-[3-[2-[4-(Trifluoromethyl)phenyl]acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-59-9P, 3-[3-[2-[4-

(Dimethylamino)phenyl]acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-60-2P, 3-[3-[2-(2-Chloro-4-fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-62-4P, 3-[3-[2-(4-Chlorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-63-5P, 3-[3-(3-Phenylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395106-64-6P, 3-[3-[3-(4-Fluorophenyl)propanoylamino]phenyl]-1H-indazole-5-carboxamide 395106-65-7P, 3-[3-[2-(3,4-Difluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-66-8P, 3-[3-[2-(2-Fluorophenyl)acetylamino]phenyl]-1H-indazole-5-carboxamide 395106-68-0P, 3-[3-(2-Phenylpropanoylamino)phenyl]-1H-indazole-5-carboxamide 395106-69-1P, 3-[3-(2-Piperidinoethoxy)phenyl]-1H-indazole-5-carboxamide 395106-73-7P, N-Ethyl-3-[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonylamino]propanamide 395106-74-8P, N-[(4-Fluorophenyl)methyl]-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395106-81-7P, N-tert-Butyl-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395106-84-0P, N-((1R)-Indanyl)-3-[5-[5-[(dimethylamino)methyl]-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395106-87-3P, [[3-[3-(4-Methoxyphenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-90-8P, [[3-[3-(2H-Benzo[d]-1,3-dioxol-5-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395106-92-0P, N-(3-Methoxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395106-93-1P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1,2,4-oxadiazolin-5-one 395106-98-6P, [5-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]methan-1-ol 395107-01-4P, N-(2-Piperidinoethyl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide 395107-07-0P, [[5-[3-(Benzo[d]furan-2-yl)-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]methyl]dimethylamine 395107-09-2P, N-Phenyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide 395107-12-7P, N-(4-Fluorophenyl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide dihydrochloride 395107-16-1P, N-(Indan-2-yl)-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide 395107-19-4P, N-Cyclopropyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide 395107-24-1P, N-Cyclobutyl-3-[5-[3-[(dimethylamino)methyl]-1H-1,2,4-triazol-5-yl]-1H-indazol-3-yl]benzamide dihydrochloride 395107-27-4P, N-[4-[5-(2H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395107-32-1P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(2-methoxyethoxy)benzene 395107-33-2P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(3-pyridylmethoxy)benzene 395107-34-3P, 3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]benzoic acid 395107-35-4P, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-pyridinecarboxamide 395107-36-5P, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-phenylacetamide 395107-37-6P, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methoxyacetamide 395107-38-7P, N-[4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(dimethylamino)acetamide 395107-39-8P, [4-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl](methylsulfonyl)amine 395107-40-1P, N-(2-Methoxyethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-42-3P, N-Phenyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-43-4P, N-(2-Phenethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-44-5P, N-(2-Piperidylethyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-45-6P, 3-[3-[N-(2-Piperidinoethyl)carbamoyl]phenyl]-1H-indazole-5-carboxamide 395107-47-8P, N-[2-(Morpholin-4-yl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-48-9P, N-Cyclohexyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-49-0P, N-Cyclopentyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-51-4P, N-(4-Fluorophenyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-53-6P, N-[2-(1-Benzyl-4-piperidyl)ethyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-55-8P 395107-57-0P, N-Cyclopropyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide

395107-59-2P, N-(3-Pyridyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-61-6P, N-(5,6,7,8-Tetrahydronaphthyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-63-8P, N-[1-Benzyl-4-piperidyl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-65-0P, N-[1-Benzylpyrrolidin-3-yl]-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-67-2P, N-Isopropyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-69-4P, N-Cyclobutyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-70-7P, N-(4-Pyridyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide 395107-72-9P, N-(2-Hydroxyethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395107-73-0P, N-(3-Hydroxypropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395107-74-1P, N-(2-Methoxyethyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395107-76-3P, N-[(Oxolan-2-yl)methyl]-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395107-82-1P 395107-91-2P, 6-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-2-methoxynaphthalene 395107-92-3P, 3-[3-(3-Quinolyl)-1H-indazol-5-yl]-1H-1,2,4-triazole 395107-94-5P, 3-[2,3-Dihydrobenzo[b]furan-5-yl]-1H-indazole-5-carboxamide 395107-98-9P, 5-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-2,3-dihydrobenzo[b]furan 395107-99-0P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]benzamide 395108-01-7P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2,4-dichlorobenzamide 395108-03-9P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-methoxybenzamide 395108-05-1P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-methylbenzamide 395108-06-2P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-4-chlorobenzamide 395108-07-3P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-methylpropanamide 395108-08-4P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-3-methylbutanamide 395108-10-8P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(morpholin-4-yl)acetamide 395108-11-9P, N-[3-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]phenyl]-2-(4-methylpiperazino)acetamide 395108-12-0P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-[(4-pyrrolidinopiperidino)methyl]-1H-1,2,4-triazole 395108-14-2P, 3-[3-(4-Fluorophenyl)-1H-indazol-5-yl]-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole 395108-16-4P, [[3-[3-(6-Methoxy-2-naphthyl)-1H-indazol-5-yl]-1H-1,2,4-triazol-5-yl]methyl]dimethylamine 395108-17-5P, 2-Methoxy-6-[5-[5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]naphthalene 395108-19-7P, N-Phenyl-3-[5-[5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl]-1H-indazol-3-yl]benzamide 395108-23-3P 395108-26-6P, N-(3-Oxo-3-pyrrolidinopropyl)-3-(4-fluorophenyl)-1H-indazole-5-carboxamide 395108-28-8P, 3-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]-N-methylpropanamide 395108-29-9P, 3-[[3-(4-Fluorophenyl)-1H-indazol-5-yl]carbonylamino]-N,N-dimethylpropanamide 395108-30-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 13097-01-3P, 3-Phenyl-1H-indazole 55271-06-2P, 3-(4-Methoxyphenyl)-1H-indazole 155590-27-5P, 3-(4-Fluorophenyl)-1H-indazole 395098-98-3P, 3-(4-Hydroxyphenyl)-1H-indazole 395099-01-1P, 3-(2-Methoxyphenyl)-1H-indazole
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of indazole derivs. as JNK enzyme inhibitors)

IT 54-85-3, Isonicotinic acid hydrazide 64-04-0, Phenethylamine 67-51-6, 3,5-Dimethylpyrazole 75-31-0, Isopropylamine, reactions 75-64-9, tert-Butylamine, reactions 76-83-5, Triphenylmethyl chloride 78-77-3, 1-Bromo-2-methylpropane 78-81-9, Isobutylamine 78-96-6, 1-Amino-2-propanol 79-30-1, 2-Methylpropanoyl chloride 88-74-4, 2-Nitroaniline 89-75-8, 2,4-Dichlorobenzoyl chloride 96-32-2, Methyl bromoacetate 98-09-9, Phenylsulfonyl chloride 98-88-4, Benzoyl chloride 99-06-9, 3-Hydroxybenzoic acid, reactions 99-09-2, 3-Nitroaniline 100-07-2, 4-Methoxybenzoyl chloride 100-20-9, Terephthalic acid chloride 100-42-5, Styrene, reactions 100-43-6,

4-Vinylpyridine 100-55-0, 3-Pyridylcarbinol 100-69-6, 2-Vinylpyridine 103-80-0, Phenylacetyl chloride 103-82-2, Phenylacetic acid, reactions 104-01-8, 4-Methoxyphenylacetic acid 104-58-5, 3-Piperidinopropanol 106-40-1, 4-Bromoaniline 108-00-9, N,N-Dimethylethylenediamine 108-01-0, N,N-Dimethylethanolamine 108-12-3, 3-Methylbutanoyl chloride 108-91-8, Cyclohexylamine, reactions 109-01-3, N-Methylpiperazine 109-55-7, 3-Dimethylaminopropylamine 109-85-3, 2-Methoxyethylamine 121-90-4, 3-Nitrobenzoyl chloride 122-01-0, 4-Chlorobenzoyl chloride 122-04-3 122-78-1, Phenylacetaldehyde 123-00-2, 4-(3-Aminopropyl)morpholine 123-75-1, Pyrrolidine, reactions 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl acrylate 141-75-3, Butanoyl chloride 142-26-7, 2-N-Acetylaminoethanol 156-87-6, 3-Amino-1-propanol 271-44-3, 1H-Indazole 342-24-5, 2-Fluorobenzophenone 371-40-4, 4-Fluoroaniline 403-43-0, 4-Fluorobenzoyl chloride 405-50-5, 2-(4-Fluorophenyl)acetic acid 451-82-1, 2-Fluorophenylacetic acid 459-31-4, 3-(4-Fluorophenyl)propanoic acid 462-08-8, 3-Aminopyridine 488-93-7, Furan-3-carboxylic acid 492-37-5, 2-Phenylpropionic acid 496-12-8, Isoindoline 501-52-0, Hydrocinnamic acid 504-24-5, 4-Aminopyridine 504-29-0, 2-Aminopyridine 527-69-5, 2-Furoyl chloride 527-72-0, 2-Thiophenecarboxylic acid 535-17-1, 2-Acetoxypropionic acid 536-40-3, 4-Chlorobenzoic hydrazide 536-74-3, Phenylacetylene 547-64-8, Methyl lactate 553-53-7, Nicotinic hydrazide 585-32-0, Cumylamine 586-39-0, 3-Nitrostyrene 591-27-5, 3-Aminophenol 611-73-4, 2-Oxo-2-phenylacetic acid 613-94-5, Benzoic hydrazide 619-45-4, Methyl 4-aminobenzoate 622-40-2, 4-(2-Hydroxyethyl)morpholine 636-97-5, 4-Nitrobenzoic hydrazide 638-29-9, Pentanoyl chloride 644-42-8, 3-Methylhistamine 645-45-4, 3-Phenylpropanoyl chloride 658-93-5, 3,4-Difluorophenylacetic acid 661-69-8, Hexamethylditin 765-30-0, Cyclopropylamine 785-56-8, 3,5-Bis(trifluoromethyl)benzoyl chloride 870-46-2, tert-Butyl carbazate 874-60-2, 4-Methylbenzoyl chloride 937-39-3, Phenylacetic hydrazide 940-31-8, 2-Phenoxypropionic acid 1003-03-8, Cyclopentylamine 1075-49-6, 4-Vinylbenzoic acid 1126-09-6, Ethyl 4-piperidinecarboxylate 1194-02-1, 4-Fluorobenzonitrile 1195-45-5, 4-Fluorophenyl isocyanate 1423-26-3, 3-Trifluoromethylphenylboronic acid 1467-70-5, 2-(2-Furyl)-2-oxoacetic acid 1520-21-4, 4-Vinylaniline 1679-18-1, 4-Chlorophenylboronic acid 1679-64-7, Terephthalic acid monomethyl ester 1692-15-5, 4-Pyridylboronic acid 1692-25-7, 3-Pyridylboronic acid 1759-53-1, Cyclopropanecarboxylic acid 1765-93-1, 4-Fluorophenylboronic acid 1877-71-0, Isophthalic acid monomethyl ester 1986-47-6, trans-2-Phenylcyclopropylamine hydrochloride 2008-75-5, 1-(2-Chloroethyl)piperidine monohydrochloride 2038-03-1, 4-(2-Aminoethyl)morpholine 2133-40-6 2208-07-3, Ethyl acetimidate hydrochloride 2217-40-5, 1,2,3,4-Tetrahydro-1-naphthylamine 2338-18-3, 2-Aminoindan hydrochloride 2491-06-7, N,N-Dimethylglycine hydrochloride 2516-34-9, Cyclobutylamine 2516-47-4, Cyclopropylmethylamine 2544-06-1, 3-Methoxypropionic acid 2627-86-3, (S)-(-)-α-Methylbenzylamine 2835-68-9, 4-Aminobenzamide 2955-88-6, 2-Pyrrolidinoethanol 2975-41-9, 2-Aminoindane 3024-72-4, 3,4-Dichlorobenzoyl chloride 3040-44-6, 2-Piperidinoethanol 3179-63-3, 3-N,N-Dimethylaminopropanol 3290-99-1, 4-Methoxybenzhydrazide 3326-71-4, 2-Furoic acid hydrazide 3445-11-2, 1-(2-Hydroxyethyl)pyrrolidin-2-one 3529-10-0, 4-Dimethylaminobutylamine 3538-65-6, Butyric acid hydrazide 3619-17-8, Isobutyric acid hydrazide 3731-51-9, 2-Aminomethylpyridine 3731-52-0, 3-Aminomethylpyridine 3731-53-1, 4-(Aminomethyl)pyridine 3853-06-3, Methyl 3-(dimethylamino)propanoate 3886-69-9, (R)-(+)-α-Methylbenzylamine 3900-89-8, 2-Chlorophenylboronic acid 3970-21-6, (2-Methoxyethoxy)methyl chloride 4023-34-1, Cyclopropylcarbonyl chloride 4442-79-9, 2-(Cyclohexyl)ethanol 4524-93-0, Cyclopentanecarbonyl chloride 4795-29-3, Tetrahydrofurfurylamine 5122-94-1, 4-Phenylphenylboronic acid 5122-95-2, 3-Phenylphenylboronic acid 5271-67-0, 2-Thiophenecarbonyl chloride 5292-21-7, 2-Cyclohexylacetic acid 5332-24-1,

3-Bromoquinoline 5332-73-0, 3-Methoxypropylamine 5382-16-1, 4-Hydroxypiperidine 5401-94-5, 5-Nitro-1H-indazole 5405-41-4, Ethyl 3-hydroxybutyrate 5438-70-0, Ethyl (4-aminophenyl)acetate 5445-17-0, Methyl 2-bromopropanoate 5538-51-2, Acetyl salicyloyl chloride 5691-09-8, trans-2-Aminomethyl-1-cyclohexanol 5720-05-8, 4-Methylphenylboronic acid 5720-06-9, 2-Methoxyphenylboronic acid 5720-07-0, 4-Methoxyphenylboronic acid 5781-53-3, Methyl (chlorocarbonyl)formate 5813-64-9, 2,2-Dimethylpropylamine 6034-46-4, (S)-(-)-2-Acetoxypropionic acid 6165-68-0, 2-Thiopheneboronic acid 6165-69-1, 3-Thiopheneboronic acid 6456-74-2, tert-Butyl glycinate 6482-24-2, 2-Bromo-1-methoxyethane 6622-91-9, 4-Pyridylacetic acid hydrochloride 6783-05-7, trans-2-Phenylethenylboronic acid 6964-21-2, 3-Thiopheneacetic acid 7065-46-5, 3,3-Dimethylbutanoyl chloride 7171-96-2, N-Amino-2-pyrrolidinoacetamide 7322-88-5, (2S)-2-Acetyloxy-2-phenylacetic acid 7377-26-6, Methyl 4-carboxybenzoyl chloride 10277-74-4, (R)-(-)-1-Aminoindane 10365-98-7, 3-Methoxyphenylboronic acid 10400-19-8, Pyridine-3-carbonyl chloride 13031-60-2, Methyl 4-aminobutyrate hydrochloride 13331-23-2, 2-Furanboronic acid 13331-27-6, 3-Nitrophenylboronic acid 13515-93-0, Methyl 2-(methylamino)acetate hydrochloride 13797-62-1, 2-(2-Methyl-1,3-thiazol-4-yl)acetic acid 13889-98-0, 1-Acetylpiperazine 13922-41-3, 1-Naphthylboronic acid 14002-51-8, 4-Phenylbenzoyl chloride 14794-31-1, Ethyl succinyl chloride 15159-40-7, Morpholine-4-carbonyl chloride 16152-51-5, 4-Isopropylphenylboronic acid 16179-97-8, 2-Pyridylacetic acid hydrochloride 17078-28-3, 4-(Dimethylamino)phenylacetic acid 17082-09-6, (2E)-3-Phenylprop-2-enoyl chloride 17852-28-7, 2-Amino-5-methylphenyl phenyl ketone 18469-52-8, Methyl 4-(aminomethyl)benzoate 18471-40-4, 1-Benzyl-3-aminopyrrolidine 18668-00-3, (R)-2-Acetoxypropionic acid 19335-11-6, 5-Aminoindazole 19719-28-9, 2,4-Dichlorophenylacetic acid 20260-53-1, Pyridine-3-carbonyl chloride hydrochloride 20603-00-3, 2-(Perhydroazepino)ethanol 21615-34-9, 2-Methoxybenzoyl chloride 22980-09-2, 2-(Indol-3-yl)-2-oxoacetyl chloride 26371-07-3, 1-Piperidinepropionic acid 27578-60-5, 1-(2-Aminoethyl)piperidine 28611-39-4, 4-(N,N-Dimethylamino)phenylboronic acid 29745-44-6, Pyridine-2-carbonyl chloride 30280-35-4, Methyl 2-(diethylamino)acetate 30418-59-8, 3-Aminophenylboronic acid 32316-92-0, 2-Naphthylboronic acid 32857-62-8, 4-(Trifluoromethyl)phenylacetic acid 34052-37-4, 2-Chloro-5-nitrobenzophenone 35855-10-8, Methyl 2-(morpholin-4-yl)acetate 38870-89-2, 2-Methoxyacetyl chloride 39178-35-3, Pyridine-4-carbonyl chloride hydrochloride 39256-35-4, N-Amino-2-(phenylmethoxy)acetamide 39827-11-7, 2-Benzo[b]thiophene-2-carbonyl chloride 39901-94-5, Picolinoyl chloride hydrochloride 50541-93-0, 4-Amino-1-benzylpiperidine 51019-43-3, (R)-2-Acetoxy-2-phenylacetic acid 55552-70-0, 3-Furanboronic acid 57260-71-6, tert-Butyl 1-piperazine carboxylate 57260-73-8, N-(2-Aminoethyl)carbamic acid tert-butyl ester 58249-87-9, [2-(Chlorocarbonyl)phenyl]methyl benzoate 58583-90-7, Methyl 2-piperidinoacetate 58620-93-2, H-β-Ala-O-tert-butyl hydrochloride 58757-38-3, 6-Chloropyridine-3-carbonyl chloride 59776-88-4, Methyl 2-(2-oxopyrrolidinyl)acetate 61341-86-4, (S)-(+)-1-Aminoindane 62348-13-4, Isoxazole-5-carbonyl chloride 63984-02-1, Methyl 5-aminovalerate 71597-85-8, 4-Hydroxybenzeneboronic acid 72316-18-8 75178-96-0 76652-88-5, (S)-2-Acetylpropionic acid 77279-24-4, 2-[4-(tert-Butyloxycarbonyl)piperazino]ethanol 77987-49-6, 2-[N-(Benzyloxycarbonyl)amino]ethanol 84358-13-4, 1-[(tert-Butyl)oxycarbonyl]piperidine-4-carboxylic acid 85068-36-6, 2,5-Difluorobenzophenone 86945-25-7, 4-(2-Aminoethyl)-1-benzylpiperidine 87199-18-6, 3-Hydroxyphenylboronic acid 88443-78-1, 3-Acetoxyphenylacetyl chloride 89364-31-8, Tetrahydro-3-furoic acid 89415-43-0, 4-Aminophenylboronic acid 90555-66-1, 3-Ethoxyphenylboronic acid 91713-56-3, 2-Amino-5-methylphenyl 4-fluorophenyl ketone 94839-07-3, 3,4-(Methylenedioxy)phenylboronic acid 98431-09-5, Ethyl

glutaryl chloride 98437-23-1, Benzo[b]thiophene-2-boronic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of indazole derivs. as JNK enzyme inhibitors)

IT 98437-24-2 98546-51-1, 4-(Methylthio)phenylboronic acid 99769-19-4, 3-(Carbomethoxy)phenylboronic acid 122775-35-3, 3,4-Dimethoxyphenylboronic acid 126456-43-7, (1S,2R)-(-)-cis-1-Amino-2-indanol 128796-39-4, 4-Trifluoromethylphenylboronic acid 136030-00-7, (1R,2S)-(+)-cis-1-Amino-2-indanol 151169-75-4, 3,4-Dichlorophenylboronic acid 154230-29-2, trans-2-(4-Chlorophenyl)ethenylboronic acid 156641-98-4, 6-Methoxynaphthalene-2-boronic acid 164014-95-3 177985-32-9, 2-Chloro-4-fluorophenylacetic acid 199292-40-5, 2-Fluoro-5-trifluoromethylbenzophenone 214360-73-3, 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 216019-28-2, 3-Isopropylphenylboronic acid 227305-69-3, 2,3-Dihydrobenzo[b]furan-5-boronic acid 395099-08-8, N-[4-Hydroxy-2-(phenylcarbonyl)phenyl]benzamide 395099-15-7, 1-Acetyl-5-amino-3-phenyl-1H-indazole 395099-49-7, 1-[[3-(4-Fluorophenyl)-5-nitro-1H-indazol-1-yl]methoxy]-2-methoxyethane 395099-52-2, 1-[[3-(4-Fluorophenyl)-5-amino-1H-indazol-1-yl]methoxy]-2-methoxyethane 395099-67-9, 2-[3-(4-Fluorophenyl)-5-amino-1H-indazol-1-yl]perhydro-2H-pyran 395099-73-7, 2-(3-Bromo-5-nitro-1H-indazol-1-yl)perhydro-2H-pyran 395099-97-5, 3-(4-Fluorophenyl)-1-(2-methoxyethoxy)-1H-indazol-5-ylamine 395100-09-1, 3-(4-Fluorophenyl)-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395102-81-5, 3-(3-Thienyl)-1H-indazole-5-carboxamide 395102-93-9, 3-(Benzo[b]thiophen-3-yl)-1H-indazole-5-carboxamide 395103-84-1, Ethoxy[[3-(4-fluorophenyl)-1H-indazol-5-yl]methyl]amine monohydrochloride 395105-02-9, Ethyl 3-bromo-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxylate 395106-75-9, Methyl 3-(5-cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoate 395106-77-1, 3-(5-Cyano-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzoic acid 395107-00-3, Ethoxy[3-(4-fluorophenyl)-1H-indazol-5-yl]methanimine dihydrochloride 395107-31-0, 3-[5-(1H-1,2,4-Triazol-3-yl)-1-(perhydro-2H-pyran-2-yl)-1H-indazol-3-yl]phenol 395108-13-1, Methyl 2-(4-pyrrolidinopiperidino)acetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of indazole derivs. as JNK enzyme inhibitors)

IT **395104-30-0P**, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as JNK enzyme inhibitors)

RN 395104-30-0 HCAPLUS
CN 1H-Indazole, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



=> => fil reg
FILE 'REGISTRY' ENTERED AT 15:02:30 ON 07 OCT 2004

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **293758-67-5** REGISTRY
CN 1H-Indazole, 5-nitro-3-phenyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-Nitro-3-phenyl-1H-indazole
FS 3D CONCORD
MF C13 H9 N3 O2
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **259876-53-4** REGISTRY
CN 1H-Indazole, 5-nitro-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H8 N4 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **307328-34-3** REGISTRY
CN 4-Quinazolinamine, N-[3-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-(3-Fluorobenzyl-1H-indazol-5-yl)[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine
FS 3D CONCORD
MF C31 H27 F N6 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **178971-64-7** REGISTRY
CN 1H-Indazole, 5-nitro-3-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H10 N4 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **13097-03-5** REGISTRY
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-Chloro-3-phenylindazole
FS 3D CONCORD
MF C13 H9 Cl N2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

16 REFERENCES IN FILE CA (1907 TO DATE)
16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **154458-84-1** REGISTRY
CN 1H-Indazol-5-ol, 3-(6,7-dimethoxy-1-isoquinolinyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H15 N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **141071-17-2** REGISTRY
CN 1,3'-Bi-1H-indazole, 5,5'-difluoro-3-nitro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H7 F2 N5 O2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **126971-86-6** REGISTRY
CN 1H-Indazole, 5-chloro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H8 Cl N3
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Patent
RL.P Roles from patents: RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **83684-54-2** REGISTRY
CN 1H-Indazole-5-carbonitrile, 3-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H9 N3
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **98083-49-9** REGISTRY
CN 1,3'-Bi-1H-indazole, 5,5'-dichloro-3-nitro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H7 Cl2 N5 O2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **57614-63-8** REGISTRY
CN 1H-Indazole, 5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-Fluoro-3-phenyl-1H-indazole
CN 5-Fluoro-3-phenylindazole
FS 3D CONCORD
MF C13 H9 F N2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **82616-92-0** REGISTRY
CN 1H-Indazole, 5-bromo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H8 Br N3
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **65092-57-1** REGISTRY
CN 1H-Indazole, 3-(1H-imidazol-1-yl)-5-nitro-, monohydrochloride (9CI) (CA INDEX NAME)
MF C10 H7 N5 O2 . Cl H
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **57639-16-4** REGISTRY
CN 1H-Indazole, 5-bromo-3-phenyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Phenyl-5-bromoindazole
CN 5-Bromo-3-phenylindazole
FS 3D CONCORD
MF C13 H9 Br N2
LC STN Files: CA, CAPLUS, CASREACT, IFICDB, IFIPAT, IFIUDB, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: RACT (Reactant or reagent)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **55076-04-5** REGISTRY
CN Phenol, 2-(5-chloro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H9 Cl N2 O
LC STN Files: CA, CAPLUS, CASREACT
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **13097-05-7** REGISTRY
CN 1H-Indazole, 5-methoxy-3-phenyl- (8CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H12 N2 O
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation)
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **307328-34-3** REGISTRY
CN 4-Quinazolinamine, N-[3-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-(3-Fluorobenzyl-1H-indazol-5-yl)[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine
FS 3D CONCORD
MF C31 H27 F N6 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **13097-03-5** REGISTRY
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-Chloro-3-phenylindazole
FS 3D CONCORD
MF C13 H9 Cl N2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

16 REFERENCES IN FILE CA (1907 TO DATE)
16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **154458-84-1** REGISTRY
CN 1H-Indazol-5-ol, 3-(6,7-dimethoxy-1-isoquinolinyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H15 N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **126971-86-6** REGISTRY
CN 1H-Indazole, 5-chloro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H8 Cl N3
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Patent
RL.P Roles from patents: RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L21 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **83684-54-2** REGISTRY
CN 1H-Indazole-5-carbonitrile, 3-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H9 N3
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **57614-63-8** REGISTRY
CN 1H-Indazole, 5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-Fluoro-3-phenyl-1H-indazole
CN 5-Fluoro-3-phenylindazole
FS 3D CONCORD
MF C13 H9 F N2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **82616-92-0** REGISTRY
CN 1H-Indazole, 5-bromo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H8 Br N3
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L24 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **57639-16-4** REGISTRY
CN 1H-Indazole, 5-bromo-3-phenyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Phenyl-5-bromoindazole
CN 5-Bromo-3-phenylindazole
FS 3D CONCORD
MF C13 H9 Br N2
LC STN Files: CA, CAPLUS, CASREACT, IFICDB, IFIPAT, IFIUDB, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: RACT (Reactant or reagent)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L25 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **55076-04-5** REGISTRY
CN Phenol, 2-(5-chloro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H9 Cl N2 O
LC STN Files: CA, CAPLUS, CASREACT
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L26 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **13097-05-7** REGISTRY
CN 1H-Indazole, 5-methoxy-3-phenyl- (8CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H12 N2 O
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation)
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)